US20160256440A1 - Multisubstituted aromatic compounds as inhibitors of thrombin - Google Patents
Multisubstituted aromatic compounds as inhibitors of thrombin Download PDFInfo
- Publication number
- US20160256440A1 US20160256440A1 US15/155,954 US201615155954A US2016256440A1 US 20160256440 A1 US20160256440 A1 US 20160256440A1 US 201615155954 A US201615155954 A US 201615155954A US 2016256440 A1 US2016256440 A1 US 2016256440A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- unsubstituted
- pyridin
- triazol
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000190 Thrombin Proteins 0.000 title abstract description 71
- 229960004072 thrombin Drugs 0.000 title abstract description 69
- 150000001491 aromatic compounds Chemical class 0.000 title abstract description 5
- 239000003112 inhibitor Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 232
- 238000000034 method Methods 0.000 claims abstract description 174
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 100
- 201000010099 disease Diseases 0.000 claims abstract description 57
- 238000011282 treatment Methods 0.000 claims abstract description 47
- 208000035475 disorder Diseases 0.000 claims abstract description 43
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 125000001425 triazolyl group Chemical group 0.000 claims abstract description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 135
- 125000000217 alkyl group Chemical group 0.000 claims description 103
- 125000003118 aryl group Chemical group 0.000 claims description 100
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 70
- 125000001072 heteroaryl group Chemical group 0.000 claims description 69
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 65
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 55
- 230000015572 biosynthetic process Effects 0.000 claims description 49
- 125000001424 substituent group Chemical group 0.000 claims description 49
- 125000002947 alkylene group Chemical group 0.000 claims description 46
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 37
- 229940002612 prodrug Drugs 0.000 claims description 33
- 239000000651 prodrug Substances 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 208000005189 Embolism Diseases 0.000 claims description 29
- 210000001367 artery Anatomy 0.000 claims description 28
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 28
- 238000002560 therapeutic procedure Methods 0.000 claims description 28
- 208000001435 Thromboembolism Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 22
- 208000010125 myocardial infarction Diseases 0.000 claims description 22
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 21
- 150000002148 esters Chemical class 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 21
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 18
- 230000015271 coagulation Effects 0.000 claims description 18
- 238000005345 coagulation Methods 0.000 claims description 18
- 230000002093 peripheral effect Effects 0.000 claims description 18
- 208000004043 venous thromboembolism Diseases 0.000 claims description 18
- 206010014522 Embolism venous Diseases 0.000 claims description 17
- 239000003146 anticoagulant agent Substances 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 15
- 208000006011 Stroke Diseases 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 12
- 230000001269 cardiogenic effect Effects 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 11
- 208000019622 heart disease Diseases 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 210000003462 vein Anatomy 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 10
- 206010047249 Venous thrombosis Diseases 0.000 claims description 10
- 230000000747 cardiac effect Effects 0.000 claims description 10
- 230000004761 fibrosis Effects 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 9
- 210000004556 brain Anatomy 0.000 claims description 9
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 9
- 125000003107 substituted aryl group Chemical group 0.000 claims description 9
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 8
- 206010038563 Reocclusion Diseases 0.000 claims description 8
- 210000003709 heart valve Anatomy 0.000 claims description 8
- 230000000306 recurrent effect Effects 0.000 claims description 8
- 208000037803 restenosis Diseases 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 7
- 230000003143 atherosclerotic effect Effects 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 6
- 230000000302 ischemic effect Effects 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010021143 Hypoxia Diseases 0.000 claims description 5
- 238000002399 angioplasty Methods 0.000 claims description 5
- 238000013176 antiplatelet therapy Methods 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 229910052710 silicon Inorganic materials 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000007814 Unstable Angina Diseases 0.000 claims description 4
- 206010003119 arrhythmia Diseases 0.000 claims description 4
- 238000007887 coronary angioplasty Methods 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 4
- 208000030613 peripheral artery disease Diseases 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 230000002537 thrombolytic effect Effects 0.000 claims description 4
- 208000020446 Cardiac disease Diseases 0.000 claims description 3
- 206010014513 Embolism arterial Diseases 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 339
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 192
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 165
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 156
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 150
- -1 4-chlorobutyl Chemical group 0.000 description 138
- 238000002360 preparation method Methods 0.000 description 127
- 239000000203 mixture Substances 0.000 description 121
- 239000000543 intermediate Substances 0.000 description 113
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 112
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- 238000004809 thin layer chromatography Methods 0.000 description 107
- 238000001819 mass spectrum Methods 0.000 description 98
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 78
- 238000005160 1H NMR spectroscopy Methods 0.000 description 77
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 76
- 239000000243 solution Substances 0.000 description 75
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 68
- 229920006395 saturated elastomer Polymers 0.000 description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 238000003756 stirring Methods 0.000 description 48
- 239000007832 Na2SO4 Substances 0.000 description 47
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 47
- 229910052938 sodium sulfate Inorganic materials 0.000 description 47
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000012267 brine Substances 0.000 description 38
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 38
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 38
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 36
- 239000007787 solid Substances 0.000 description 36
- 239000003868 thrombin inhibitor Substances 0.000 description 35
- 239000003480 eluent Substances 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- 238000004440 column chromatography Methods 0.000 description 33
- 239000012044 organic layer Substances 0.000 description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 32
- 239000000741 silica gel Substances 0.000 description 32
- 229910002027 silica gel Inorganic materials 0.000 description 32
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 31
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 29
- 229940122388 Thrombin inhibitor Drugs 0.000 description 28
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 27
- 239000002904 solvent Substances 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 26
- 125000001544 thienyl group Chemical group 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 239000013058 crude material Substances 0.000 description 23
- 125000004076 pyridyl group Chemical group 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 20
- 125000003566 oxetanyl group Chemical group 0.000 description 20
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 125000002541 furyl group Chemical group 0.000 description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 16
- 125000002757 morpholinyl group Chemical group 0.000 description 16
- 125000001624 naphthyl group Chemical group 0.000 description 16
- 125000002098 pyridazinyl group Chemical group 0.000 description 16
- 125000000714 pyrimidinyl group Chemical group 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- BVMXWVUHUWOSJA-UHFFFAOYSA-N 2-pyridin-2-yl-1,2,4-triazol-3-amine Chemical compound NC1=NC=NN1C1=CC=CC=N1 BVMXWVUHUWOSJA-UHFFFAOYSA-N 0.000 description 13
- 125000003368 amide group Chemical group 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- JSIAIROWMJGMQZ-UHFFFAOYSA-N 2h-triazol-4-amine Chemical compound NC1=CNN=N1 JSIAIROWMJGMQZ-UHFFFAOYSA-N 0.000 description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- 229940127219 anticoagulant drug Drugs 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 9
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 229920000669 heparin Polymers 0.000 description 9
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 229960005080 warfarin Drugs 0.000 description 9
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 9
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 9
- 229960001522 ximelagatran Drugs 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 8
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 8
- PHYOJNNPPUPKEA-UHFFFAOYSA-N 5-pyridin-4-yl-1h-1,2,4-triazol-3-amine Chemical compound NC1=NNC(C=2C=CN=CC=2)=N1 PHYOJNNPPUPKEA-UHFFFAOYSA-N 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 7
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 208000034158 bleeding Diseases 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- DXMNCYUUVKTZHP-UHFFFAOYSA-N (5-amino-1,2,4-triazol-1-yl)-thiophen-3-ylmethanone Chemical compound NC1=NC=NN1C(=O)C1=CSC=C1 DXMNCYUUVKTZHP-UHFFFAOYSA-N 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- VPTQEOQBSABCKV-UHFFFAOYSA-N 5-pyridin-2-yl-1h-1,2,4-triazol-3-amine Chemical compound NC1=NNC(C=2N=CC=CC=2)=N1 VPTQEOQBSABCKV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 6
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 229960000288 dabigatran etexilate Drugs 0.000 description 6
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 125000001207 fluorophenyl group Chemical group 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 239000002808 molecular sieve Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 5
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 5
- KDAANJYILKBKSI-UHFFFAOYSA-N 2-pyridin-2-ylpyrazol-3-amine Chemical compound NC1=CC=NN1C1=CC=CC=N1 KDAANJYILKBKSI-UHFFFAOYSA-N 0.000 description 5
- HCMGEILTAKUCRR-UHFFFAOYSA-N 3-pyridin-3-yl-1,2,4-triazole-1-carboxamide Chemical compound NC(=O)N1C=NC(C=2C=NC=CC=2)=N1 HCMGEILTAKUCRR-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 5
- 102000007625 Hirudins Human genes 0.000 description 5
- 108010007267 Hirudins Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000010100 anticoagulation Effects 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 5
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 5
- 229940006607 hirudin Drugs 0.000 description 5
- 229940127215 low-molecular weight heparin Drugs 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940019333 vitamin k antagonists Drugs 0.000 description 5
- CIJLZEGCWFVSBW-UHFFFAOYSA-N (5-amino-1,2,4-triazol-1-yl)-thiophen-2-ylmethanone Chemical compound NC1=NC=NN1C(=O)C1=CC=CS1 CIJLZEGCWFVSBW-UHFFFAOYSA-N 0.000 description 4
- VKGQPUZNCZPZKI-UHFFFAOYSA-N (diaminomethylideneamino)azanium;sulfate Chemical compound NN=C(N)N.NN=C(N)N.OS(O)(=O)=O VKGQPUZNCZPZKI-UHFFFAOYSA-N 0.000 description 4
- 0 *.[1*]CC.[2*]CC.[3*]CC.[4*]CC Chemical compound *.[1*]CC.[2*]CC.[3*]CC.[4*]CC 0.000 description 4
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 4
- WLSHISKNXJLHCQ-UHFFFAOYSA-N 2-(2h-triazol-4-yl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CNN=N1 WLSHISKNXJLHCQ-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108090000317 Chymotrypsin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010080805 Factor XIa Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NUAYIVQHSZUJKS-UHFFFAOYSA-N N1=CC(=CC=C1)OC(=O)N1N=CN=C1 Chemical compound N1=CC(=CC=C1)OC(=O)N1N=CN=C1 NUAYIVQHSZUJKS-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000004781 alginic acids Chemical class 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000002393 azetidinyl group Chemical group 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229960002376 chymotrypsin Drugs 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 229960003850 dabigatran Drugs 0.000 description 4
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 239000011147 inorganic material Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- YGDGZDGRCWHDOU-UHFFFAOYSA-N methyl 4-[[5-chloro-4-(2-hydroxyphenyl)thiophen-2-yl]sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC(C=2C(=CC=CC=2)O)=C(Cl)S1 YGDGZDGRCWHDOU-UHFFFAOYSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 125000005475 oxolanyl group Chemical group 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 3
- LJVQHXICFCZRJN-UHFFFAOYSA-N 1h-1,2,4-triazole-5-carboxylic acid Chemical compound OC(=O)C1=NC=NN1 LJVQHXICFCZRJN-UHFFFAOYSA-N 0.000 description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- ITUTZIKPUKFTAI-UHFFFAOYSA-N 2-pyridin-2-ylpyrazole-3-carboxamide Chemical compound NC(=O)C1=CC=NN1C1=CC=CC=N1 ITUTZIKPUKFTAI-UHFFFAOYSA-N 0.000 description 3
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 3
- RJFHMLHZCNZQMA-UHFFFAOYSA-N 5-pyridin-2-yl-1h-pyrazol-3-amine Chemical compound N1N=C(N)C=C1C1=CC=CC=N1 RJFHMLHZCNZQMA-UHFFFAOYSA-N 0.000 description 3
- USTVEFNDQUIZNC-UHFFFAOYSA-N 5-pyridin-3-yl-1h-1,2,4-triazol-3-amine Chemical compound NC1=NNC(C=2C=NC=CC=2)=N1 USTVEFNDQUIZNC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101710183811 Glia-derived nexin Proteins 0.000 description 3
- 102100033299 Glia-derived nexin Human genes 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 208000024248 Vascular System injury Diseases 0.000 description 3
- 208000012339 Vascular injury Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 3
- 239000012964 benzotriazole Substances 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- PYFSLJVSCGXYAJ-UHFFFAOYSA-N methyl 2-hydroxy-4-[[3-(2-hydroxyphenyl)phenyl]sulfonylamino]benzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC=CC(C=2C(=CC=CC=2)O)=C1 PYFSLJVSCGXYAJ-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000009861 stroke prevention Effects 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZUHBIVLGBDHHSW-UHFFFAOYSA-N 1-pyridin-2-ylpyrazole-3-carboxamide Chemical compound N1=C(C(=O)N)C=CN1C1=CC=CC=N1 ZUHBIVLGBDHHSW-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- SCIBJNGDHDWFHX-UHFFFAOYSA-N 1-thiophen-2-yl-1,2,4-triazole Chemical compound C1=CSC(N2N=CN=C2)=C1 SCIBJNGDHDWFHX-UHFFFAOYSA-N 0.000 description 2
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 2
- APHHSQSNBPTMEA-UHFFFAOYSA-N 2,2-dimethyl-1-pyrazol-1-ylpropan-1-one Chemical compound CC(C)(C)C(=O)N1C=CC=N1 APHHSQSNBPTMEA-UHFFFAOYSA-N 0.000 description 2
- PVMLJDLTWMGZAH-UHFFFAOYSA-N 2-(1h-1,2,4-triazol-5-yl)pyridine Chemical compound N1C=NC(C=2N=CC=CC=2)=N1 PVMLJDLTWMGZAH-UHFFFAOYSA-N 0.000 description 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 2
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- RYDOQJPDRXMRRP-UHFFFAOYSA-N 2-methylpropan-1-one Chemical compound CC(C)[C]=O RYDOQJPDRXMRRP-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- DQSRVWNGCNSDNE-UHFFFAOYSA-N 3-(pyridin-3-ylamino)propyl 4-[[3-(5-fluoro-2-hydroxyphenyl)phenyl]sulfonylamino]-2-hydroxybenzoate Chemical compound OC1=CC=C(F)C=C1C1=CC=CC(S(=O)(=O)NC=2C=C(O)C(C(=O)OCCCNC=3C=NC=CC=3)=CC=2)=C1 DQSRVWNGCNSDNE-UHFFFAOYSA-N 0.000 description 2
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 2
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 2
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 2
- PWSZRRFDVPMZGM-UHFFFAOYSA-N 5-phenyl-1h-pyrazol-3-amine Chemical compound N1N=C(N)C=C1C1=CC=CC=C1 PWSZRRFDVPMZGM-UHFFFAOYSA-N 0.000 description 2
- XMLRXJVRTGHHIJ-UHFFFAOYSA-N 5-thiophen-2-yl-1h-1,2,4-triazol-3-amine Chemical compound NC1=NNC(C=2SC=CC=2)=N1 XMLRXJVRTGHHIJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005157 alkyl carboxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 2
- 229960003856 argatroban Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000009426 cardioembolic effect Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 231100000012 chronic liver injury Toxicity 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000006623 intrinsic pathway Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
- 229960000899 nadroparin Drugs 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QFLNTQDOVCLQKW-UHFFFAOYSA-N (1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC(C)(C(F)(F)F)C(F)(F)F)=CC=C1CC1=C(O)C2=CC=CC=C2OC1=O QFLNTQDOVCLQKW-UHFFFAOYSA-N 0.000 description 1
- AZEVOYBDTTVOSA-UHFFFAOYSA-N (2-methoxyphenyl)-(1h-pyrazol-5-yl)methanol Chemical compound COC1=CC=CC=C1C(O)C1=CC=NN1 AZEVOYBDTTVOSA-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 1
- MUQWDYYIYNYBQD-OFHININYSA-N (2s,3s,4s,5r,6r)-3-[(2r,3r,4r,5s,6r)-3-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]-4,5-dimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxy-4,5-dimethoxy- Chemical compound OS(=O)(=O)O[C@@H]1[C@@H](OS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS(O)(=O)=O)O4)NC(=O)CCCCCNC(=O)CCCC[C@H]4[C@H]5NC(=O)N[C@H]5CS4)[C@H](O3)C(O)=O)OC)[C@@H](COS(O)(=O)=O)O2)OS(O)(=O)=O)[C@H](C(O)=O)O1 MUQWDYYIYNYBQD-OFHININYSA-N 0.000 description 1
- VWLHBPNUOYUTOR-UHFFFAOYSA-N (4-fluorophenyl)methylcarbamic acid Chemical compound OC(=O)NCC1=CC=C(F)C=C1 VWLHBPNUOYUTOR-UHFFFAOYSA-N 0.000 description 1
- FJFZGHKNZAAYRL-UHFFFAOYSA-N (5-amino-1-ethylsulfonyl-1,2,4-triazol-3-yl)-morpholin-4-ylmethanone Chemical compound N1=C(N)N(S(=O)(=O)CC)N=C1C(=O)N1CCOCC1 FJFZGHKNZAAYRL-UHFFFAOYSA-N 0.000 description 1
- JNMNSFSYFYFBCU-UHFFFAOYSA-N (5-amino-1-methylsulfonyl-1,2,4-triazol-3-yl)-morpholin-4-ylmethanone Chemical compound N1=C(N)N(S(=O)(=O)C)N=C1C(=O)N1CCOCC1 JNMNSFSYFYFBCU-UHFFFAOYSA-N 0.000 description 1
- XFOFNRPAKUBICP-UHFFFAOYSA-N (5-amino-3-phenyl-1,2,4-triazol-1-yl)-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(N)=NC(C=2C=CC=CC=2)=N1 XFOFNRPAKUBICP-UHFFFAOYSA-N 0.000 description 1
- FGPIRFBZOFBCBD-UHFFFAOYSA-N (5-amino-3-phenyl-1,2,4-triazol-1-yl)-phenylmethanone Chemical compound NC1=NC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 FGPIRFBZOFBCBD-UHFFFAOYSA-N 0.000 description 1
- XPLXNIULKANSNN-UHFFFAOYSA-N (5-amino-3-phenylpyrazol-1-yl)-phenylmethanone Chemical compound NC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 XPLXNIULKANSNN-UHFFFAOYSA-N 0.000 description 1
- MZENMOWZUBHLGT-UHFFFAOYSA-N (5-amino-3-pyridin-2-yl-1,2,4-triazol-1-yl)-phenylmethanone Chemical compound NC1=NC(C=2N=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 MZENMOWZUBHLGT-UHFFFAOYSA-N 0.000 description 1
- YLUMVCNEFHTQHD-UHFFFAOYSA-N (5-amino-3-pyridin-3-yl-1,2,4-triazol-1-yl)-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(N)=NC(C=2C=NC=CC=2)=N1 YLUMVCNEFHTQHD-UHFFFAOYSA-N 0.000 description 1
- BIEYFOHSWAIQDF-UHFFFAOYSA-N (5-amino-3-pyridin-3-yl-1,2,4-triazol-1-yl)-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(N)=NC(C=2C=NC=CC=2)=N1 BIEYFOHSWAIQDF-UHFFFAOYSA-N 0.000 description 1
- OTIFHPVRAWSQPU-UHFFFAOYSA-N (5-amino-3-pyridin-3-yl-1,2,4-triazol-1-yl)-phenylmethanone Chemical compound NC1=NC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 OTIFHPVRAWSQPU-UHFFFAOYSA-N 0.000 description 1
- XPDWJFJAQWNCEU-UHFFFAOYSA-N (5-amino-3-pyridin-3-ylpyrazol-1-yl)-phenylmethanone Chemical compound NC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 XPDWJFJAQWNCEU-UHFFFAOYSA-N 0.000 description 1
- HPBCTRCLXUKZBM-UHFFFAOYSA-N (5-amino-3-pyridin-4-yl-1,2,4-triazol-1-yl)-phenylmethanone Chemical compound NC1=NC(C=2C=CN=CC=2)=NN1C(=O)C1=CC=CC=C1 HPBCTRCLXUKZBM-UHFFFAOYSA-N 0.000 description 1
- PHIJWRCGPUBPFF-UHFFFAOYSA-N (5-amino-3-thiophen-2-yl-1,2,4-triazol-1-yl)-phenylmethanone Chemical compound NC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 PHIJWRCGPUBPFF-UHFFFAOYSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- ZPQOPVIELGIULI-UHFFFAOYSA-N 1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1 ZPQOPVIELGIULI-UHFFFAOYSA-N 0.000 description 1
- CABHXTNYNGUYFF-UHFFFAOYSA-N 1-(1h-pyrazol-5-yl)ethanol Chemical compound CC(O)C1=CC=NN1 CABHXTNYNGUYFF-UHFFFAOYSA-N 0.000 description 1
- BHTZCIGVYSJBQB-UHFFFAOYSA-N 1-(1h-pyrazol-5-yl)ethanone Chemical compound CC(=O)C=1C=CNN=1 BHTZCIGVYSJBQB-UHFFFAOYSA-N 0.000 description 1
- MEZNZVQFHZIVOI-UHFFFAOYSA-N 1-(1h-pyrazol-5-yl)propan-1-ol Chemical compound CCC(O)C1=CC=NN1 MEZNZVQFHZIVOI-UHFFFAOYSA-N 0.000 description 1
- GXMZKSUWPJHWHY-UHFFFAOYSA-N 1-(1h-pyrazol-5-yl)propan-1-one Chemical compound CCC(=O)C1=CC=NN1 GXMZKSUWPJHWHY-UHFFFAOYSA-N 0.000 description 1
- FLRUNCJXOVYWDH-UHFFFAOYSA-N 1-(2-bromoethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCBr)C=C1 FLRUNCJXOVYWDH-UHFFFAOYSA-N 0.000 description 1
- RQHSWRBINVYJKM-UHFFFAOYSA-N 1-(triazol-1-yl)propan-1-one Chemical compound CCC(=O)N1C=CN=N1 RQHSWRBINVYJKM-UHFFFAOYSA-N 0.000 description 1
- DZSKWFGKGSLTTF-UHFFFAOYSA-N 1-[3-(4-chlorophenyl)-5-[(4-fluorophenyl)methylamino]-1,2,4-triazol-1-yl]-2-methoxyethanone Chemical compound COCC(=O)N1N=C(C=2C=CC(Cl)=CC=2)N=C1NCC1=CC=C(F)C=C1 DZSKWFGKGSLTTF-UHFFFAOYSA-N 0.000 description 1
- BPZBMHZXZDGNSA-UHFFFAOYSA-N 1-[3-(furan-2-yl)-5-methylsulfanyl-1,2,4-triazol-1-yl]propan-1-one Chemical compound N1=C(SC)N(C(=O)CC)N=C1C1=CC=CO1 BPZBMHZXZDGNSA-UHFFFAOYSA-N 0.000 description 1
- QKXZUZXEOPIKGT-UHFFFAOYSA-N 1-[5-(benzylamino)-3-(4-fluorophenyl)-1,2,4-triazol-1-yl]propan-1-one Chemical compound CCC(=O)N1N=C(C=2C=CC(F)=CC=2)N=C1NCC1=CC=CC=C1 QKXZUZXEOPIKGT-UHFFFAOYSA-N 0.000 description 1
- ZWPFBNNFMYRPEV-UHFFFAOYSA-N 1-[5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-2-phenylethanone Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)CC1=CC=CC=C1 ZWPFBNNFMYRPEV-UHFFFAOYSA-N 0.000 description 1
- UUVZUHRYPGSMRA-UHFFFAOYSA-N 1-[5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-3-methylbutan-1-one Chemical compound CC(C)CC(=O)N1N=C(C=2OC=CC=2)N=C1NCC1=CC=CC=C1 UUVZUHRYPGSMRA-UHFFFAOYSA-N 0.000 description 1
- YPVYDTVVOGJILC-UHFFFAOYSA-N 1-[5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2OC=CC=2)N=C1NCC1=CC=CC=C1 YPVYDTVVOGJILC-UHFFFAOYSA-N 0.000 description 1
- FHFAROUFCVIIBW-UHFFFAOYSA-N 1-[5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]propan-1-one Chemical compound CCC(=O)N1N=C(C=2OC=CC=2)N=C1NCC1=CC=CC=C1 FHFAROUFCVIIBW-UHFFFAOYSA-N 0.000 description 1
- UVTGFYXMKJBLAE-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-2-methylpropan-1-one Chemical compound CC(C)C(=O)N1N=C(C=2C=CC=CC=2)N=C1NCC1=CC=CC=C1 UVTGFYXMKJBLAE-UHFFFAOYSA-N 0.000 description 1
- HZYZFFQVFCWWKO-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-2-phenylethanone Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)CC1=CC=CC=C1 HZYZFFQVFCWWKO-UHFFFAOYSA-N 0.000 description 1
- FIUSCULNIGAZAB-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-3-methylbutan-1-one Chemical compound CC(C)CC(=O)N1N=C(C=2C=CC=CC=2)N=C1NCC1=CC=CC=C1 FIUSCULNIGAZAB-UHFFFAOYSA-N 0.000 description 1
- ONDQYXCHTLQKBK-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-3-phenylpropan-1-one Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)CCC1=CC=CC=C1 ONDQYXCHTLQKBK-UHFFFAOYSA-N 0.000 description 1
- BTWLINKOZLNYAW-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]butan-1-one Chemical compound CCCC(=O)N1N=C(C=2C=CC=CC=2)N=C1NCC1=CC=CC=C1 BTWLINKOZLNYAW-UHFFFAOYSA-N 0.000 description 1
- XXMUBFQNJKIVHE-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2C=CC=CC=2)N=C1NCC1=CC=CC=C1 XXMUBFQNJKIVHE-UHFFFAOYSA-N 0.000 description 1
- UFHRQHSRIANHJQ-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]propan-1-one Chemical compound CCC(=O)N1N=C(C=2C=CC=CC=2)N=C1NCC1=CC=CC=C1 UFHRQHSRIANHJQ-UHFFFAOYSA-N 0.000 description 1
- GBCMCRKUEAHZOI-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenylpyrazol-1-yl]-2-methylpropan-1-one Chemical compound CC(C)C(=O)N1N=C(C=2C=CC=CC=2)C=C1NCC1=CC=CC=C1 GBCMCRKUEAHZOI-UHFFFAOYSA-N 0.000 description 1
- IPJARJGTFQJSPR-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenylpyrazol-1-yl]-2-phenylethanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)CC1=CC=CC=C1 IPJARJGTFQJSPR-UHFFFAOYSA-N 0.000 description 1
- IUFFNHUZILYOTE-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenylpyrazol-1-yl]-3-methylbutan-1-one Chemical compound CC(C)CC(=O)N1N=C(C=2C=CC=CC=2)C=C1NCC1=CC=CC=C1 IUFFNHUZILYOTE-UHFFFAOYSA-N 0.000 description 1
- HYYJGPYLHCHXIU-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenylpyrazol-1-yl]-3-phenylpropan-1-one Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)CCC1=CC=CC=C1 HYYJGPYLHCHXIU-UHFFFAOYSA-N 0.000 description 1
- DCFIYHDEQTYOIO-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenylpyrazol-1-yl]butan-1-one Chemical compound CCCC(=O)N1N=C(C=2C=CC=CC=2)C=C1NCC1=CC=CC=C1 DCFIYHDEQTYOIO-UHFFFAOYSA-N 0.000 description 1
- SVEMNUUYAWUYOS-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenylpyrazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2C=CC=CC=2)C=C1NCC1=CC=CC=C1 SVEMNUUYAWUYOS-UHFFFAOYSA-N 0.000 description 1
- BHJBQLPTGCLDES-UHFFFAOYSA-N 1-[5-(benzylamino)-3-phenylpyrazol-1-yl]propan-1-one Chemical compound CCC(=O)N1N=C(C=2C=CC=CC=2)C=C1NCC1=CC=CC=C1 BHJBQLPTGCLDES-UHFFFAOYSA-N 0.000 description 1
- AKBVCUXJTDCNGV-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2N=CC=CC=2)N=C1NCC1=CC=CC=C1 AKBVCUXJTDCNGV-UHFFFAOYSA-N 0.000 description 1
- ACZAQEMEHLWTMO-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2C=NC=CC=2)N=C1NCC1=CC=CC=C1 ACZAQEMEHLWTMO-UHFFFAOYSA-N 0.000 description 1
- MKACFBYRQPQGRJ-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazol-1-yl]propan-1-one Chemical compound CCC(=O)N1N=C(C=2C=NC=CC=2)N=C1NCC1=CC=CC=C1 MKACFBYRQPQGRJ-UHFFFAOYSA-N 0.000 description 1
- AVELKDGLDKBGGP-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-2-methylpropan-1-one Chemical compound CC(C)C(=O)N1N=C(C=2C=NC=CC=2)C=C1NCC1=CC=CC=C1 AVELKDGLDKBGGP-UHFFFAOYSA-N 0.000 description 1
- HXDJOYRYQKJSTB-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-2-phenylethanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)CC1=CC=CC=C1 HXDJOYRYQKJSTB-UHFFFAOYSA-N 0.000 description 1
- BNNOIUZXALBJJM-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-3-methylbutan-1-one Chemical compound CC(C)CC(=O)N1N=C(C=2C=NC=CC=2)C=C1NCC1=CC=CC=C1 BNNOIUZXALBJJM-UHFFFAOYSA-N 0.000 description 1
- BNFVLSXZUFYSGY-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-3-phenylpropan-1-one Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)CCC1=CC=CC=C1 BNFVLSXZUFYSGY-UHFFFAOYSA-N 0.000 description 1
- AIPBHGOXTMBALY-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]butan-1-one Chemical compound CCCC(=O)N1N=C(C=2C=NC=CC=2)C=C1NCC1=CC=CC=C1 AIPBHGOXTMBALY-UHFFFAOYSA-N 0.000 description 1
- LYAGMWSRMFLHHF-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2C=NC=CC=2)C=C1NCC1=CC=CC=C1 LYAGMWSRMFLHHF-UHFFFAOYSA-N 0.000 description 1
- JLJGMHNLCBQZMM-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]propan-1-one Chemical compound CCC(=O)N1N=C(C=2C=NC=CC=2)C=C1NCC1=CC=CC=C1 JLJGMHNLCBQZMM-UHFFFAOYSA-N 0.000 description 1
- PSJLZCSHFAPQDP-UHFFFAOYSA-N 1-[5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2C=CN=CC=2)N=C1NCC1=CC=CC=C1 PSJLZCSHFAPQDP-UHFFFAOYSA-N 0.000 description 1
- DIZRXPDYXPQHJL-UHFFFAOYSA-N 1-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-2-methylpropan-1-one Chemical compound CC(C)C(=O)N1N=C(C=2SC=CC=2)N=C1NCC1=CC=CC=C1 DIZRXPDYXPQHJL-UHFFFAOYSA-N 0.000 description 1
- UHBRRMVZMXGYJA-UHFFFAOYSA-N 1-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-2-phenylethanone Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)CC1=CC=CC=C1 UHBRRMVZMXGYJA-UHFFFAOYSA-N 0.000 description 1
- DXQKWPGMIXFZDF-UHFFFAOYSA-N 1-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-3-methylbutan-1-one Chemical compound CC(C)CC(=O)N1N=C(C=2SC=CC=2)N=C1NCC1=CC=CC=C1 DXQKWPGMIXFZDF-UHFFFAOYSA-N 0.000 description 1
- QENCSBPZGFZUFX-UHFFFAOYSA-N 1-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-3-phenylpropan-1-one Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)CCC1=CC=CC=C1 QENCSBPZGFZUFX-UHFFFAOYSA-N 0.000 description 1
- QWKFDJWBQWNVTE-UHFFFAOYSA-N 1-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]butan-1-one Chemical compound CCCC(=O)N1N=C(C=2SC=CC=2)N=C1NCC1=CC=CC=C1 QWKFDJWBQWNVTE-UHFFFAOYSA-N 0.000 description 1
- PSXMFEVNIWMIGG-UHFFFAOYSA-N 1-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C=2SC=CC=2)N=C1NCC1=CC=CC=C1 PSXMFEVNIWMIGG-UHFFFAOYSA-N 0.000 description 1
- JEJXBHJOLJMBDT-UHFFFAOYSA-N 1-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]propan-1-one Chemical compound CCC(=O)N1N=C(C=2SC=CC=2)N=C1NCC1=CC=CC=C1 JEJXBHJOLJMBDT-UHFFFAOYSA-N 0.000 description 1
- VZNCSZQPNIEEMN-UHFFFAOYSA-N 1-fluoro-2-isocyanatobenzene Chemical compound FC1=CC=CC=C1N=C=O VZNCSZQPNIEEMN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BQQFSUKXGGGGLV-UHFFFAOYSA-N 1-phenylpyrazol-3-amine Chemical compound N1=C(N)C=CN1C1=CC=CC=C1 BQQFSUKXGGGGLV-UHFFFAOYSA-N 0.000 description 1
- WEKRISLAKIQYBQ-UHFFFAOYSA-N 1-pyridin-2-yl-1,2,4-triazol-3-amine Chemical compound N1=C(N)N=CN1C1=CC=CC=N1 WEKRISLAKIQYBQ-UHFFFAOYSA-N 0.000 description 1
- QVGXRFZGRDFKDS-UHFFFAOYSA-N 1-pyridin-2-ylpyrazole-4-carboxamide Chemical compound C1=C(C(=O)N)C=NN1C1=CC=CC=N1 QVGXRFZGRDFKDS-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical compound CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- KGOWPIDHJBDPEN-UHFFFAOYSA-N 2-(1h-1,2,4-triazol-5-yl)propanamide Chemical compound NC(=O)C(C)C1=NC=NN1 KGOWPIDHJBDPEN-UHFFFAOYSA-N 0.000 description 1
- FBBAKYJYWFXPGK-UHFFFAOYSA-N 2-(2-fluorophenyl)pyrazol-3-amine Chemical compound NC1=CC=NN1C1=CC=CC=C1F FBBAKYJYWFXPGK-UHFFFAOYSA-N 0.000 description 1
- PZPIDYGFBLVMTA-UHFFFAOYSA-N 2-(4-fluorophenyl)ethylhydrazine Chemical compound NNCCC1=CC=C(F)C=C1 PZPIDYGFBLVMTA-UHFFFAOYSA-N 0.000 description 1
- GHWMKHGYNCADMV-UHFFFAOYSA-N 2-(benzenesulfonyl)-5-pyridin-3-yl-1,2,4-triazol-3-amine Chemical compound NC1=NC(C=2C=NC=CC=2)=NN1S(=O)(=O)C1=CC=CC=C1 GHWMKHGYNCADMV-UHFFFAOYSA-N 0.000 description 1
- XYTVHCKWWOXECK-UHFFFAOYSA-N 2-(thiophen-2-ylmethyl)-1,2,4-triazol-3-amine Chemical compound NC1=NC=NN1CC1=CC=CS1 XYTVHCKWWOXECK-UHFFFAOYSA-N 0.000 description 1
- KFEVMOCBDLBBKX-UHFFFAOYSA-N 2-(thiophen-2-ylmethyl)pyrazol-3-amine Chemical compound NC1=CC=NN1CC1=CC=CS1 KFEVMOCBDLBBKX-UHFFFAOYSA-N 0.000 description 1
- IYXUKWQGESUKSC-UHFFFAOYSA-N 2-(thiophen-3-ylmethyl)-1,2,4-triazol-3-amine Chemical compound NC1=NC=NN1CC1=CSC=C1 IYXUKWQGESUKSC-UHFFFAOYSA-N 0.000 description 1
- NDWSUFOXJFBUHN-UHFFFAOYSA-N 2-(thiophen-3-ylmethyl)pyrazol-3-amine Chemical compound NC1=CC=NN1CC1=CSC=C1 NDWSUFOXJFBUHN-UHFFFAOYSA-N 0.000 description 1
- AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical compound CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 description 1
- ADODRSVGNHNKAT-UHFFFAOYSA-N 2-Chlorophenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1Cl ADODRSVGNHNKAT-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- GSJKXXAUWPDFLL-UHFFFAOYSA-N 2-[5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1C#N GSJKXXAUWPDFLL-UHFFFAOYSA-N 0.000 description 1
- QPFUAAFBWSVGIX-UHFFFAOYSA-N 2-[5-(benzylamino)-3-phenyl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1C#N QPFUAAFBWSVGIX-UHFFFAOYSA-N 0.000 description 1
- BUZIQLNIFXFVAO-UHFFFAOYSA-N 2-[5-(benzylamino)-3-phenylpyrazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1C#N BUZIQLNIFXFVAO-UHFFFAOYSA-N 0.000 description 1
- HBGURODONFCQQD-UHFFFAOYSA-N 2-[5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1C#N HBGURODONFCQQD-UHFFFAOYSA-N 0.000 description 1
- LOVOIGZGQRTFSF-UHFFFAOYSA-N 2-[5-(benzylamino)-3-pyridin-3-ylpyrazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1C#N LOVOIGZGQRTFSF-UHFFFAOYSA-N 0.000 description 1
- WQHIWSFAJRYNGW-UHFFFAOYSA-N 2-[5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1C#N WQHIWSFAJRYNGW-UHFFFAOYSA-N 0.000 description 1
- QQQBJDVBCCMKBG-UHFFFAOYSA-N 2-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1C#N QQQBJDVBCCMKBG-UHFFFAOYSA-N 0.000 description 1
- NNIDTERILXPJJX-UHFFFAOYSA-N 2-[[(2-benzoyl-5-phenyl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C(=CC=CC=2)C#N)N1C(=O)C1=CC=CC=C1 NNIDTERILXPJJX-UHFFFAOYSA-N 0.000 description 1
- BSFTUYBWRIAQDB-UHFFFAOYSA-N 2-[[(2-benzoyl-5-phenylpyrazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C(=CC=CC=2)C#N)N1C(=O)C1=CC=CC=C1 BSFTUYBWRIAQDB-UHFFFAOYSA-N 0.000 description 1
- UGYCVZRIZYPNBO-UHFFFAOYSA-N 2-[[(2-benzoyl-5-pyridin-3-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C(=CC=CC=2)C#N)N1C(=O)C1=CC=CC=C1 UGYCVZRIZYPNBO-UHFFFAOYSA-N 0.000 description 1
- DZQSRMIAPQUOHD-UHFFFAOYSA-N 2-[[(2-benzoyl-5-pyridin-3-ylpyrazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C(=CC=CC=2)C#N)N1C(=O)C1=CC=CC=C1 DZQSRMIAPQUOHD-UHFFFAOYSA-N 0.000 description 1
- FBMRHEMEVJOPJG-UHFFFAOYSA-N 2-[[(2-benzoyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C(=CC=CC=2)C#N)N1C(=O)C1=CC=CC=C1 FBMRHEMEVJOPJG-UHFFFAOYSA-N 0.000 description 1
- DJAFNXAUCYYCDY-UHFFFAOYSA-N 2-[[(2-benzoyl-5-thiophen-2-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C(=CC=CC=2)C#N)N1C(=O)C1=CC=CC=C1 DJAFNXAUCYYCDY-UHFFFAOYSA-N 0.000 description 1
- DFFXKILPXMDZKK-UHFFFAOYSA-N 2-[[[2-benzoyl-5-(furan-2-yl)-1,2,4-triazol-3-yl]amino]methyl]benzonitrile Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C(=CC=CC=2)C#N)N1C(=O)C1=CC=CC=C1 DFFXKILPXMDZKK-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 1
- ZOZQSVBPKHTXKO-UHFFFAOYSA-N 2-fluoro-n-[5-(furan-2-yl)-1h-1,2,4-triazol-3-yl]benzamide Chemical compound FC1=CC=CC=C1C(=O)NC1=NNC(C=2OC=CC=2)=N1 ZOZQSVBPKHTXKO-UHFFFAOYSA-N 0.000 description 1
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
- MNWSGMTUGXNYHJ-UHFFFAOYSA-N 2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(N)=O MNWSGMTUGXNYHJ-UHFFFAOYSA-N 0.000 description 1
- RZNHSEZOLFEFGB-UHFFFAOYSA-N 2-methoxybenzoyl chloride Chemical compound COC1=CC=CC=C1C(Cl)=O RZNHSEZOLFEFGB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- KBSOLQCTJCJDMI-UHFFFAOYSA-N 2-pyridazin-3-yl-1,2,4-triazol-3-amine Chemical compound NC1=NC=NN1C1=CC=CN=N1 KBSOLQCTJCJDMI-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- AYNOTZBOYPKSQF-UHFFFAOYSA-N 2-pyrimidin-2-yl-1,2,4-triazol-3-amine Chemical compound NC1=NC=NN1C1=NC=CC=N1 AYNOTZBOYPKSQF-UHFFFAOYSA-N 0.000 description 1
- NPMRNHCMGVPNSF-UHFFFAOYSA-N 2-pyrimidin-4-yl-1,2,4-triazol-3-amine Chemical compound NC1=NC=NN1C1=CC=NC=N1 NPMRNHCMGVPNSF-UHFFFAOYSA-N 0.000 description 1
- JSBBSDIGOGGYIR-UHFFFAOYSA-N 2-pyrimidin-5-yl-1,2,4-triazol-3-amine Chemical compound N1=CN=CC(=C1)N1N=CN=C1N JSBBSDIGOGGYIR-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LWXUEBXGMVANMO-UHFFFAOYSA-N 3-[5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC(C#N)=C1 LWXUEBXGMVANMO-UHFFFAOYSA-N 0.000 description 1
- XWAXCKRIMIAHOL-UHFFFAOYSA-N 3-[5-(benzylamino)-3-phenyl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC(C#N)=C1 XWAXCKRIMIAHOL-UHFFFAOYSA-N 0.000 description 1
- NSOALSBIWKQVHQ-UHFFFAOYSA-N 3-[5-(benzylamino)-3-phenylpyrazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC(C#N)=C1 NSOALSBIWKQVHQ-UHFFFAOYSA-N 0.000 description 1
- SJQKMMQVNCKQOD-UHFFFAOYSA-N 3-[5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC(C#N)=C1 SJQKMMQVNCKQOD-UHFFFAOYSA-N 0.000 description 1
- YIKJYHDHPNZCQK-UHFFFAOYSA-N 3-[5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC(C#N)=C1 YIKJYHDHPNZCQK-UHFFFAOYSA-N 0.000 description 1
- DAHPEMISQRABOB-UHFFFAOYSA-N 3-[5-(benzylamino)-3-pyridin-3-ylpyrazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC(C#N)=C1 DAHPEMISQRABOB-UHFFFAOYSA-N 0.000 description 1
- LWMGIRJBZSUCDJ-UHFFFAOYSA-N 3-[5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC(C#N)=C1 LWMGIRJBZSUCDJ-UHFFFAOYSA-N 0.000 description 1
- OTNIMZPBNKEFBR-UHFFFAOYSA-N 3-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC(C#N)=C1 OTNIMZPBNKEFBR-UHFFFAOYSA-N 0.000 description 1
- QJHVPUXTBJWRSY-UHFFFAOYSA-N 3-[[(2-benzoyl-5-phenyl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=C(C=CC=2)C#N)N1C(=O)C1=CC=CC=C1 QJHVPUXTBJWRSY-UHFFFAOYSA-N 0.000 description 1
- CNHAWDZXKAISSW-UHFFFAOYSA-N 3-[[(2-benzoyl-5-phenylpyrazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=C(C=CC=2)C#N)N1C(=O)C1=CC=CC=C1 CNHAWDZXKAISSW-UHFFFAOYSA-N 0.000 description 1
- FFCQUCAINZXETN-UHFFFAOYSA-N 3-[[(2-benzoyl-5-pyridin-2-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2C=C(C=CC=2)C#N)N1C(=O)C1=CC=CC=C1 FFCQUCAINZXETN-UHFFFAOYSA-N 0.000 description 1
- SOELWZCECZOIPO-UHFFFAOYSA-N 3-[[(2-benzoyl-5-pyridin-3-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=C(C=CC=2)C#N)N1C(=O)C1=CC=CC=C1 SOELWZCECZOIPO-UHFFFAOYSA-N 0.000 description 1
- WFZPXKQZAIOKKR-UHFFFAOYSA-N 3-[[(2-benzoyl-5-pyridin-3-ylpyrazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=C(C=CC=2)C#N)N1C(=O)C1=CC=CC=C1 WFZPXKQZAIOKKR-UHFFFAOYSA-N 0.000 description 1
- YHYFVKXDFMPDNB-UHFFFAOYSA-N 3-[[(2-benzoyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=C(C=CC=2)C#N)N1C(=O)C1=CC=CC=C1 YHYFVKXDFMPDNB-UHFFFAOYSA-N 0.000 description 1
- BRUJGTOOXLBBAY-UHFFFAOYSA-N 3-[[(2-benzoyl-5-thiophen-2-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=C(C=CC=2)C#N)N1C(=O)C1=CC=CC=C1 BRUJGTOOXLBBAY-UHFFFAOYSA-N 0.000 description 1
- FNROTVQYKKIWGZ-UHFFFAOYSA-N 3-[[[2-benzoyl-5-(furan-2-yl)-1,2,4-triazol-3-yl]amino]methyl]benzonitrile Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=C(C=CC=2)C#N)N1C(=O)C1=CC=CC=C1 FNROTVQYKKIWGZ-UHFFFAOYSA-N 0.000 description 1
- MVRGLMCHDCMPKD-UHFFFAOYSA-N 3-amino-1h-1,2,4-triazole-5-carboxylic acid Chemical compound NC1=NNC(C(O)=O)=N1 MVRGLMCHDCMPKD-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- AMIONCYUULHEKQ-UHFFFAOYSA-N 3-methyl-1-pyridin-2-ylpyrazole-4-carboxamide Chemical compound C1=C(C(N)=O)C(C)=NN1C1=CC=CC=N1 AMIONCYUULHEKQ-UHFFFAOYSA-N 0.000 description 1
- OOHPFUUSZUFJHA-UHFFFAOYSA-N 3-phenylpropan-1-one Chemical compound O=[C]CCC1=CC=CC=C1 OOHPFUUSZUFJHA-UHFFFAOYSA-N 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 1
- YCMDXUKBVNNWPK-UHFFFAOYSA-N 4-[5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=C(C#N)C=C1 YCMDXUKBVNNWPK-UHFFFAOYSA-N 0.000 description 1
- FTRUQPJZIZIWBX-UHFFFAOYSA-N 4-[5-(benzylamino)-3-phenyl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=C(C#N)C=C1 FTRUQPJZIZIWBX-UHFFFAOYSA-N 0.000 description 1
- ZPBQNZJYXNFSKZ-UHFFFAOYSA-N 4-[5-(benzylamino)-3-phenylpyrazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=C(C#N)C=C1 ZPBQNZJYXNFSKZ-UHFFFAOYSA-N 0.000 description 1
- GUPWOJREWBJKLH-UHFFFAOYSA-N 4-[5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=C(C#N)C=C1 GUPWOJREWBJKLH-UHFFFAOYSA-N 0.000 description 1
- JKPJYNRGUHJHQN-UHFFFAOYSA-N 4-[5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=C(C#N)C=C1 JKPJYNRGUHJHQN-UHFFFAOYSA-N 0.000 description 1
- XRXXPCWCIHNLTB-UHFFFAOYSA-N 4-[5-(benzylamino)-3-pyridin-3-ylpyrazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=C(C#N)C=C1 XRXXPCWCIHNLTB-UHFFFAOYSA-N 0.000 description 1
- NMKDVXQYOKQXNK-UHFFFAOYSA-N 4-[5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=C(C#N)C=C1 NMKDVXQYOKQXNK-UHFFFAOYSA-N 0.000 description 1
- ZSXSHSYIXAOLDP-UHFFFAOYSA-N 4-[5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazole-1-carbonyl]benzonitrile Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=C(C#N)C=C1 ZSXSHSYIXAOLDP-UHFFFAOYSA-N 0.000 description 1
- CYXSRHSLZFWJEE-UHFFFAOYSA-N 4-[[(2-benzoyl-5-phenyl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC(=CC=2)C#N)N1C(=O)C1=CC=CC=C1 CYXSRHSLZFWJEE-UHFFFAOYSA-N 0.000 description 1
- UAFNFAMVUFXUBW-UHFFFAOYSA-N 4-[[(2-benzoyl-5-phenylpyrazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC(=CC=2)C#N)N1C(=O)C1=CC=CC=C1 UAFNFAMVUFXUBW-UHFFFAOYSA-N 0.000 description 1
- YFGHIRFEMMXDHK-UHFFFAOYSA-N 4-[[(2-benzoyl-5-pyridin-2-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2C=CC(=CC=2)C#N)N1C(=O)C1=CC=CC=C1 YFGHIRFEMMXDHK-UHFFFAOYSA-N 0.000 description 1
- KAUYRZAZMPKPEP-UHFFFAOYSA-N 4-[[(2-benzoyl-5-pyridin-3-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=CC(=CC=2)C#N)N1C(=O)C1=CC=CC=C1 KAUYRZAZMPKPEP-UHFFFAOYSA-N 0.000 description 1
- FOEVXJLKLKOKCR-UHFFFAOYSA-N 4-[[(2-benzoyl-5-pyridin-3-ylpyrazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC(=CC=2)C#N)N1C(=O)C1=CC=CC=C1 FOEVXJLKLKOKCR-UHFFFAOYSA-N 0.000 description 1
- HTVRAYWZWARZJL-UHFFFAOYSA-N 4-[[(2-benzoyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=CC(=CC=2)C#N)N1C(=O)C1=CC=CC=C1 HTVRAYWZWARZJL-UHFFFAOYSA-N 0.000 description 1
- IBENODYRFNRAIY-UHFFFAOYSA-N 4-[[(2-benzoyl-5-thiophen-2-yl-1,2,4-triazol-3-yl)amino]methyl]benzonitrile Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC(=CC=2)C#N)N1C(=O)C1=CC=CC=C1 IBENODYRFNRAIY-UHFFFAOYSA-N 0.000 description 1
- CLWXKOLVXAHLQR-UHFFFAOYSA-N 4-[[[2-benzoyl-5-(furan-2-yl)-1,2,4-triazol-3-yl]amino]methyl]benzonitrile Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CC(=CC=2)C#N)N1C(=O)C1=CC=CC=C1 CLWXKOLVXAHLQR-UHFFFAOYSA-N 0.000 description 1
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- PXCDIRKSCUAMKA-UHFFFAOYSA-N 5-(furan-2-yl)-1h-1,2,4-triazol-3-amine Chemical compound NC1=NNC(C=2OC=CC=2)=N1 PXCDIRKSCUAMKA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000011682 Mitral valve disease Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000032626 PAR-1 Receptor Human genes 0.000 description 1
- 108010070519 PAR-1 Receptor Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- NTUPOKHATNSWCY-JYJNAYRXSA-N Phe-Pro-Arg Chemical group C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=CC=C1 NTUPOKHATNSWCY-JYJNAYRXSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000033012 Postpartum state Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108010039286 S 2238 Proteins 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- VCIKRACWPGFDRG-UHFFFAOYSA-N [3-(furan-2-yl)-5-(pyridin-2-ylmethylamino)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2N=CC=CC=2)N1C(=O)C1=CC=CC=C1 VCIKRACWPGFDRG-UHFFFAOYSA-N 0.000 description 1
- XNFVVZMKCYZHNH-UHFFFAOYSA-N [3-(furan-2-yl)-5-(pyridin-3-ylmethylamino)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=NC=CC=2)N1C(=O)C1=CC=CC=C1 XNFVVZMKCYZHNH-UHFFFAOYSA-N 0.000 description 1
- CWTXNWNXPAEGOV-UHFFFAOYSA-N [3-(furan-2-yl)-5-(pyridin-4-ylmethylamino)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CN=CC=2)N1C(=O)C1=CC=CC=C1 CWTXNWNXPAEGOV-UHFFFAOYSA-N 0.000 description 1
- VTAZRPSRSGDLGT-UHFFFAOYSA-N [3-(furan-2-yl)-5-[(2-methylphenyl)methylamino]-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC=C1CNC1=NC(C=2OC=CC=2)=NN1C(=O)C1=CC=CC=C1 VTAZRPSRSGDLGT-UHFFFAOYSA-N 0.000 description 1
- RDLXUMBHGVHICL-UHFFFAOYSA-N [3-(furan-2-yl)-5-[(3-methoxyphenyl)methylamino]-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC(CNC=2N(N=C(N=2)C=2OC=CC=2)C(=O)C=2C=CC=CC=2)=C1 RDLXUMBHGVHICL-UHFFFAOYSA-N 0.000 description 1
- MZJYHUXIBCBXNA-UHFFFAOYSA-N [3-(furan-2-yl)-5-[(3-methylphenyl)methylamino]-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC(CNC=2N(N=C(N=2)C=2OC=CC=2)C(=O)C=2C=CC=CC=2)=C1 MZJYHUXIBCBXNA-UHFFFAOYSA-N 0.000 description 1
- YULXCTDNSPDRDY-UHFFFAOYSA-N [5-(benzylamino)-3-(2-fluorophenyl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC=C1C1=NN(C(=O)C=2C=CC=CC=2)C(NCC=2C=CC=CC=2)=N1 YULXCTDNSPDRDY-UHFFFAOYSA-N 0.000 description 1
- YYHQTXSLEFEZHI-UHFFFAOYSA-N [5-(benzylamino)-3-(2-methylphenyl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC=C1C1=NN(C(=O)C=2C=CC=CC=2)C(NCC=2C=CC=CC=2)=N1 YYHQTXSLEFEZHI-UHFFFAOYSA-N 0.000 description 1
- NARPLLBXDOLMLQ-UHFFFAOYSA-N [5-(benzylamino)-3-(3-fluorophenyl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC(C2=NN(C(NCC=3C=CC=CC=3)=N2)C(=O)C=2C=CC=CC=2)=C1 NARPLLBXDOLMLQ-UHFFFAOYSA-N 0.000 description 1
- RANOVBFZNXOICY-UHFFFAOYSA-N [5-(benzylamino)-3-(3-methylphenyl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC(C2=NN(C(NCC=3C=CC=CC=3)=N2)C(=O)C=2C=CC=CC=2)=C1 RANOVBFZNXOICY-UHFFFAOYSA-N 0.000 description 1
- ZGWPXYJANUJAQL-UHFFFAOYSA-N [5-(benzylamino)-3-(4-fluorophenyl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(F)=CC=C1C1=NN(C(=O)C=2C=CC=CC=2)C(NCC=2C=CC=CC=2)=N1 ZGWPXYJANUJAQL-UHFFFAOYSA-N 0.000 description 1
- OKRIWGGLXHBTAS-UHFFFAOYSA-N [5-(benzylamino)-3-(4-methylphenyl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(C)=CC=C1C1=NN(C(=O)C=2C=CC=CC=2)C(NCC=2C=CC=CC=2)=N1 OKRIWGGLXHBTAS-UHFFFAOYSA-N 0.000 description 1
- PSXKKFCAWMPYSN-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-(2-fluorophenyl)methanone Chemical compound FC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2OC=CC=2)=N1 PSXKKFCAWMPYSN-UHFFFAOYSA-N 0.000 description 1
- QVPWAQRNLXPWQK-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2C(=NC(=N2)C=2OC=CC=2)NCC=2C=CC=CC=2)=C1 QVPWAQRNLXPWQK-UHFFFAOYSA-N 0.000 description 1
- KGTWONJEEZWIIO-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C(=NC(=N2)C=2OC=CC=2)NCC=2C=CC=CC=2)=C1 KGTWONJEEZWIIO-UHFFFAOYSA-N 0.000 description 1
- UARLTAITULFKIZ-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-(4-chlorophenyl)methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2OC=CC=2)=N1 UARLTAITULFKIZ-UHFFFAOYSA-N 0.000 description 1
- ZAKZUZIDHNPYIP-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2OC=CC=2)=N1 ZAKZUZIDHNPYIP-UHFFFAOYSA-N 0.000 description 1
- CVPRRNMICYCDME-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-[2-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2OC=CC=2)=N1 CVPRRNMICYCDME-UHFFFAOYSA-N 0.000 description 1
- FROXDBVEQDIMCG-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(=N2)C=2OC=CC=2)NCC=2C=CC=CC=2)=C1 FROXDBVEQDIMCG-UHFFFAOYSA-N 0.000 description 1
- KCAVPNLGRHHQFH-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2OC=CC=2)=N1 KCAVPNLGRHHQFH-UHFFFAOYSA-N 0.000 description 1
- XDEIYFXSGYNEAV-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1 XDEIYFXSGYNEAV-UHFFFAOYSA-N 0.000 description 1
- HENNBZMDJZHFEP-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-pyridin-2-ylmethanone Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=N1 HENNBZMDJZHFEP-UHFFFAOYSA-N 0.000 description 1
- KPQFUQWDWJVTIB-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-pyridin-3-ylmethanone Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CN=C1 KPQFUQWDWJVTIB-UHFFFAOYSA-N 0.000 description 1
- COHFQOJOHVYGQG-UHFFFAOYSA-N [5-(benzylamino)-3-(furan-2-yl)-1,2,4-triazol-1-yl]-pyridin-4-ylmethanone Chemical compound N1=C(C=2OC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=NC=C1 COHFQOJOHVYGQG-UHFFFAOYSA-N 0.000 description 1
- OBABAPXXCXIRFJ-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-(2-chlorophenyl)methanone Chemical compound ClC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 OBABAPXXCXIRFJ-UHFFFAOYSA-N 0.000 description 1
- RMEGCGAQEBMQAC-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-(2-fluorophenyl)methanone Chemical compound FC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 RMEGCGAQEBMQAC-UHFFFAOYSA-N 0.000 description 1
- PKWACHXXVDVRRT-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 PKWACHXXVDVRRT-UHFFFAOYSA-N 0.000 description 1
- AKHGYQPRZSPUHO-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-(3-chlorophenyl)methanone Chemical compound ClC1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 AKHGYQPRZSPUHO-UHFFFAOYSA-N 0.000 description 1
- MUMZTOIIXXCDJY-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 MUMZTOIIXXCDJY-UHFFFAOYSA-N 0.000 description 1
- BAGHSHAKJHMCKB-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 BAGHSHAKJHMCKB-UHFFFAOYSA-N 0.000 description 1
- UIOZBHJHKIVNTK-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 UIOZBHJHKIVNTK-UHFFFAOYSA-N 0.000 description 1
- DLGBPNWRAWYLML-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-(4-chlorophenyl)methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 DLGBPNWRAWYLML-UHFFFAOYSA-N 0.000 description 1
- CIXWORJELSTFNE-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 CIXWORJELSTFNE-UHFFFAOYSA-N 0.000 description 1
- HDKUMDVLMRCVPB-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-[2-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 HDKUMDVLMRCVPB-UHFFFAOYSA-N 0.000 description 1
- HFKQJCTXLDDRRS-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 HFKQJCTXLDDRRS-UHFFFAOYSA-N 0.000 description 1
- NCVAEEHVANBZLK-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 NCVAEEHVANBZLK-UHFFFAOYSA-N 0.000 description 1
- RIBAOPQQLBGRDT-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1 RIBAOPQQLBGRDT-UHFFFAOYSA-N 0.000 description 1
- MGPMDBJNGMUTFK-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-pyridin-2-ylmethanone Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=N1 MGPMDBJNGMUTFK-UHFFFAOYSA-N 0.000 description 1
- LWFGXMUHZZCMSA-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-pyridin-3-ylmethanone Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CN=C1 LWFGXMUHZZCMSA-UHFFFAOYSA-N 0.000 description 1
- NLBHBIYRVYPTGU-UHFFFAOYSA-N [5-(benzylamino)-3-phenyl-1,2,4-triazol-1-yl]-pyridin-4-ylmethanone Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=NC=C1 NLBHBIYRVYPTGU-UHFFFAOYSA-N 0.000 description 1
- IQWQWSMTPXISPX-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(2-chlorophenyl)methanone Chemical compound ClC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 IQWQWSMTPXISPX-UHFFFAOYSA-N 0.000 description 1
- VOVJUEYZEMFTBP-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(2-fluorophenyl)methanone Chemical compound FC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 VOVJUEYZEMFTBP-UHFFFAOYSA-N 0.000 description 1
- XVWWXTBRZMLQCR-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 XVWWXTBRZMLQCR-UHFFFAOYSA-N 0.000 description 1
- VLVXEYBWIYPMTQ-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 VLVXEYBWIYPMTQ-UHFFFAOYSA-N 0.000 description 1
- IWBUUQYKMDZGBO-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(3-chlorophenyl)methanone Chemical compound ClC1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 IWBUUQYKMDZGBO-UHFFFAOYSA-N 0.000 description 1
- FHLKTYCODBZRKU-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 FHLKTYCODBZRKU-UHFFFAOYSA-N 0.000 description 1
- KYIALRNUZJLUEW-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 KYIALRNUZJLUEW-UHFFFAOYSA-N 0.000 description 1
- AXJDQRCNSSEOOR-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 AXJDQRCNSSEOOR-UHFFFAOYSA-N 0.000 description 1
- GNLGUQBTJCZJSM-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(4-chlorophenyl)methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 GNLGUQBTJCZJSM-UHFFFAOYSA-N 0.000 description 1
- ZOYFHOMTGPXIHQ-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 ZOYFHOMTGPXIHQ-UHFFFAOYSA-N 0.000 description 1
- LEOSNGTYXOFDLK-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 LEOSNGTYXOFDLK-UHFFFAOYSA-N 0.000 description 1
- OZXNECZEEBNRAI-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 OZXNECZEEBNRAI-UHFFFAOYSA-N 0.000 description 1
- MIRWMJCRDQXZKV-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-(furan-2-yl)methanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CO1 MIRWMJCRDQXZKV-UHFFFAOYSA-N 0.000 description 1
- GKKIPQHUXDNYHH-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-[2-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 GKKIPQHUXDNYHH-UHFFFAOYSA-N 0.000 description 1
- AEXKCSBCWMEAFV-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=CC=CC=2)NCC=2C=CC=CC=2)=C1 AEXKCSBCWMEAFV-UHFFFAOYSA-N 0.000 description 1
- PXPIPRNPIGDDEH-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=CC=CC=2)=N1 PXPIPRNPIGDDEH-UHFFFAOYSA-N 0.000 description 1
- KEMCQKUJAQRURH-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1 KEMCQKUJAQRURH-UHFFFAOYSA-N 0.000 description 1
- UICCSIFGBJUZQD-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-pyridin-2-ylmethanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=N1 UICCSIFGBJUZQD-UHFFFAOYSA-N 0.000 description 1
- FBKKEDXGOQANNS-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-pyridin-3-ylmethanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CN=C1 FBKKEDXGOQANNS-UHFFFAOYSA-N 0.000 description 1
- UIVINGGDOKTKLL-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-pyridin-4-ylmethanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=NC=C1 UIVINGGDOKTKLL-UHFFFAOYSA-N 0.000 description 1
- KHBLSBHRQQFJNW-UHFFFAOYSA-N [5-(benzylamino)-3-phenylpyrazol-1-yl]-thiophen-2-ylmethanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CS1 KHBLSBHRQQFJNW-UHFFFAOYSA-N 0.000 description 1
- HVUIQSCCFAHPNI-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazol-1-yl]-(3-chlorophenyl)methanone Chemical compound ClC1=CC=CC(C(=O)N2C(=NC(=N2)C=2N=CC=CC=2)NCC=2C=CC=CC=2)=C1 HVUIQSCCFAHPNI-UHFFFAOYSA-N 0.000 description 1
- YSYFCBPNMSSRGZ-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(=N2)C=2N=CC=CC=2)NCC=2C=CC=CC=2)=C1 YSYFCBPNMSSRGZ-UHFFFAOYSA-N 0.000 description 1
- LERSCROHHAXVRO-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 LERSCROHHAXVRO-UHFFFAOYSA-N 0.000 description 1
- FLVKSGBPRWEIFU-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(=N2)C=2N=CC=CC=2)NCC=2C=CC=CC=2)=C1 FLVKSGBPRWEIFU-UHFFFAOYSA-N 0.000 description 1
- FALBXQQMBCOWCM-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 FALBXQQMBCOWCM-UHFFFAOYSA-N 0.000 description 1
- WOCJGOHSQJGJOZ-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazol-1-yl]-pyridin-2-ylmethanone Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=N1 WOCJGOHSQJGJOZ-UHFFFAOYSA-N 0.000 description 1
- PWPBWKSZFQDDRX-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazol-1-yl]-pyridin-3-ylmethanone Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CN=C1 PWPBWKSZFQDDRX-UHFFFAOYSA-N 0.000 description 1
- QEUADNRNGSGJKI-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-2-yl-1,2,4-triazol-1-yl]-pyridin-4-ylmethanone Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=NC=C1 QEUADNRNGSGJKI-UHFFFAOYSA-N 0.000 description 1
- KIOKZACCLFQDOT-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazol-1-yl]-[2-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=NC=CC=2)=N1 KIOKZACCLFQDOT-UHFFFAOYSA-N 0.000 description 1
- SZWKOBDNFXXXPH-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=NC=CC=2)NCC=2C=CC=CC=2)=C1 SZWKOBDNFXXXPH-UHFFFAOYSA-N 0.000 description 1
- VXOJVLQQHRPCKE-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=NC=CC=2)=N1 VXOJVLQQHRPCKE-UHFFFAOYSA-N 0.000 description 1
- SJCHCRXOJRIKTP-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazol-1-yl]-pyridin-2-ylmethanone Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=N1 SJCHCRXOJRIKTP-UHFFFAOYSA-N 0.000 description 1
- IAWYRYFLLIQWBQ-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazol-1-yl]-pyridin-3-ylmethanone Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CN=C1 IAWYRYFLLIQWBQ-UHFFFAOYSA-N 0.000 description 1
- GGVUDTYJBHJWPQ-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-yl-1,2,4-triazol-1-yl]-pyridin-4-ylmethanone Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=NC=C1 GGVUDTYJBHJWPQ-UHFFFAOYSA-N 0.000 description 1
- DLZDTDABXWHFSC-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(2-chlorophenyl)methanone Chemical compound ClC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 DLZDTDABXWHFSC-UHFFFAOYSA-N 0.000 description 1
- WSYQZELRKGQHRN-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(2-fluorophenyl)methanone Chemical compound FC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 WSYQZELRKGQHRN-UHFFFAOYSA-N 0.000 description 1
- IJXUSNMHQCGZSE-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(2-methoxyphenyl)methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 IJXUSNMHQCGZSE-UHFFFAOYSA-N 0.000 description 1
- UMDCTKGULMQLSZ-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 UMDCTKGULMQLSZ-UHFFFAOYSA-N 0.000 description 1
- BQYHJBQIZIKWTF-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(3-chlorophenyl)methanone Chemical compound ClC1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=NC=CC=2)NCC=2C=CC=CC=2)=C1 BQYHJBQIZIKWTF-UHFFFAOYSA-N 0.000 description 1
- CCNCFSYUAJOFGZ-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=NC=CC=2)NCC=2C=CC=CC=2)=C1 CCNCFSYUAJOFGZ-UHFFFAOYSA-N 0.000 description 1
- QXJNGPNVNROUPI-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=NC=CC=2)NCC=2C=CC=CC=2)=C1 QXJNGPNVNROUPI-UHFFFAOYSA-N 0.000 description 1
- UURDCDNKTOKDTO-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=NC=CC=2)NCC=2C=CC=CC=2)=C1 UURDCDNKTOKDTO-UHFFFAOYSA-N 0.000 description 1
- GBKFISLFGQLEPI-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(4-chlorophenyl)methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 GBKFISLFGQLEPI-UHFFFAOYSA-N 0.000 description 1
- LLGHDEWHODDFSG-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 LLGHDEWHODDFSG-UHFFFAOYSA-N 0.000 description 1
- DGGRQBYRYHXWBZ-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 DGGRQBYRYHXWBZ-UHFFFAOYSA-N 0.000 description 1
- FTUOEOAJYXZSCD-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 FTUOEOAJYXZSCD-UHFFFAOYSA-N 0.000 description 1
- ODYFAEBBKXYPPH-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-(furan-2-yl)methanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CO1 ODYFAEBBKXYPPH-UHFFFAOYSA-N 0.000 description 1
- MUBXPQSXYKIHFP-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-[2-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 MUBXPQSXYKIHFP-UHFFFAOYSA-N 0.000 description 1
- WWGZHVCDOZKILO-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=CC(=N2)C=2C=NC=CC=2)NCC=2C=CC=CC=2)=C1 WWGZHVCDOZKILO-UHFFFAOYSA-N 0.000 description 1
- SFLUNOHBGACURV-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=CC(C=2C=NC=CC=2)=N1 SFLUNOHBGACURV-UHFFFAOYSA-N 0.000 description 1
- RTBJBMHJFHOVQU-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1 RTBJBMHJFHOVQU-UHFFFAOYSA-N 0.000 description 1
- BZONSCAGHCGEIC-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-pyridin-2-ylmethanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=N1 BZONSCAGHCGEIC-UHFFFAOYSA-N 0.000 description 1
- MAQWKTHMJSCARK-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-pyridin-3-ylmethanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CN=C1 MAQWKTHMJSCARK-UHFFFAOYSA-N 0.000 description 1
- JVQZHOAMDGUVPK-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-pyridin-4-ylmethanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=NC=C1 JVQZHOAMDGUVPK-UHFFFAOYSA-N 0.000 description 1
- XDBNBCUIQIEXIE-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-3-ylpyrazol-1-yl]-thiophen-2-ylmethanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CS1 XDBNBCUIQIEXIE-UHFFFAOYSA-N 0.000 description 1
- SFIKGLNJQLXGKM-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CN=CC=2)=N1 SFIKGLNJQLXGKM-UHFFFAOYSA-N 0.000 description 1
- GZZOBESYGBSSLP-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-(3-chlorophenyl)methanone Chemical compound ClC1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=CN=CC=2)NCC=2C=CC=CC=2)=C1 GZZOBESYGBSSLP-UHFFFAOYSA-N 0.000 description 1
- TWWGJXGGNGHHND-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=CN=CC=2)NCC=2C=CC=CC=2)=C1 TWWGJXGGNGHHND-UHFFFAOYSA-N 0.000 description 1
- VDSDCKKVKMLYOE-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=CN=CC=2)NCC=2C=CC=CC=2)=C1 VDSDCKKVKMLYOE-UHFFFAOYSA-N 0.000 description 1
- GGZXBNJPRPPJCC-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CN=CC=2)=N1 GGZXBNJPRPPJCC-UHFFFAOYSA-N 0.000 description 1
- ZYLZQTSXCBLVPM-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CN=CC=2)=N1 ZYLZQTSXCBLVPM-UHFFFAOYSA-N 0.000 description 1
- DDLMPTDCDBVATR-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-[2-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CN=CC=2)=N1 DDLMPTDCDBVATR-UHFFFAOYSA-N 0.000 description 1
- SMYQEPUCXCORQC-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC(C(=O)N2C(=NC(=N2)C=2C=CN=CC=2)NCC=2C=CC=CC=2)=C1 SMYQEPUCXCORQC-UHFFFAOYSA-N 0.000 description 1
- MYMQZHKJVMGGHG-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2C=CN=CC=2)=N1 MYMQZHKJVMGGHG-UHFFFAOYSA-N 0.000 description 1
- RPSLDSLZZSJSDB-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-pyridin-2-ylmethanone Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=N1 RPSLDSLZZSJSDB-UHFFFAOYSA-N 0.000 description 1
- ZMOCYGQNBZGDIK-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-pyridin-3-ylmethanone Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CN=C1 ZMOCYGQNBZGDIK-UHFFFAOYSA-N 0.000 description 1
- WOAHPKCTLFFZFZ-UHFFFAOYSA-N [5-(benzylamino)-3-pyridin-4-yl-1,2,4-triazol-1-yl]-pyridin-4-ylmethanone Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=NC=C1 WOAHPKCTLFFZFZ-UHFFFAOYSA-N 0.000 description 1
- FAMBHWGJGQXSEI-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(2-fluorophenyl)methanone Chemical compound FC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2SC=CC=2)=N1 FAMBHWGJGQXSEI-UHFFFAOYSA-N 0.000 description 1
- FECGZISLAQOMFW-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2SC=CC=2)=N1 FECGZISLAQOMFW-UHFFFAOYSA-N 0.000 description 1
- RITPATICVSFVJD-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(3-chlorophenyl)methanone Chemical compound ClC1=CC=CC(C(=O)N2C(=NC(=N2)C=2SC=CC=2)NCC=2C=CC=CC=2)=C1 RITPATICVSFVJD-UHFFFAOYSA-N 0.000 description 1
- OEUOJZSPSYEZNS-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2C(=NC(=N2)C=2SC=CC=2)NCC=2C=CC=CC=2)=C1 OEUOJZSPSYEZNS-UHFFFAOYSA-N 0.000 description 1
- KULOVZJGXFLUBE-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2C(=NC(=N2)C=2SC=CC=2)NCC=2C=CC=CC=2)=C1 KULOVZJGXFLUBE-UHFFFAOYSA-N 0.000 description 1
- AWBWGPUHBFUAFP-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2C(=NC(=N2)C=2SC=CC=2)NCC=2C=CC=CC=2)=C1 AWBWGPUHBFUAFP-UHFFFAOYSA-N 0.000 description 1
- HLHZBPCSURQICQ-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(4-chlorophenyl)methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2SC=CC=2)=N1 HLHZBPCSURQICQ-UHFFFAOYSA-N 0.000 description 1
- FBUFMILYJNCLEM-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2SC=CC=2)=N1 FBUFMILYJNCLEM-UHFFFAOYSA-N 0.000 description 1
- RCUMTKBQOZKZFD-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2SC=CC=2)=N1 RCUMTKBQOZKZFD-UHFFFAOYSA-N 0.000 description 1
- CSNDKBWAOGINDS-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2SC=CC=2)=N1 CSNDKBWAOGINDS-UHFFFAOYSA-N 0.000 description 1
- VZFDVVOOLPVPJK-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-[2-(dimethylamino)phenyl]methanone Chemical compound CN(C)C1=CC=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2SC=CC=2)=N1 VZFDVVOOLPVPJK-UHFFFAOYSA-N 0.000 description 1
- VBQIKXAWYOAUSV-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1C(NCC=2C=CC=CC=2)=NC(C=2SC=CC=2)=N1 VBQIKXAWYOAUSV-UHFFFAOYSA-N 0.000 description 1
- CJWHTXLDDZVDPU-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=C1 CJWHTXLDDZVDPU-UHFFFAOYSA-N 0.000 description 1
- VUCBWOBNCDCMOG-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-pyridin-2-ylmethanone Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CC=N1 VUCBWOBNCDCMOG-UHFFFAOYSA-N 0.000 description 1
- OLSJCQYLLIQXCV-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-pyridin-3-ylmethanone Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=CN=C1 OLSJCQYLLIQXCV-UHFFFAOYSA-N 0.000 description 1
- MMOXUCHVYAVBDK-UHFFFAOYSA-N [5-(benzylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]-pyridin-4-ylmethanone Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CC=CC=2)N1C(=O)C1=CC=NC=C1 MMOXUCHVYAVBDK-UHFFFAOYSA-N 0.000 description 1
- LMVOXXXTVHKGCF-UHFFFAOYSA-N [5-[(2-chlorophenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC=C1CNC1=NC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 LMVOXXXTVHKGCF-UHFFFAOYSA-N 0.000 description 1
- NSWFFMBNOYKFCD-UHFFFAOYSA-N [5-[(2-chlorophenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 NSWFFMBNOYKFCD-UHFFFAOYSA-N 0.000 description 1
- DLCTYPQKSCHYJZ-UHFFFAOYSA-N [5-[(2-chlorophenyl)methylamino]-3-pyridin-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC=C1CNC1=NC(C=2N=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 DLCTYPQKSCHYJZ-UHFFFAOYSA-N 0.000 description 1
- OELUMOPLEGPIJV-UHFFFAOYSA-N [5-[(2-chlorophenyl)methylamino]-3-pyridin-3-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC=C1CNC1=NC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 OELUMOPLEGPIJV-UHFFFAOYSA-N 0.000 description 1
- DTYUHPACHCGVJT-UHFFFAOYSA-N [5-[(2-chlorophenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 DTYUHPACHCGVJT-UHFFFAOYSA-N 0.000 description 1
- RVEOGVRFKIDPJF-UHFFFAOYSA-N [5-[(2-chlorophenyl)methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC=C1CNC1=NC(C=2C=CN=CC=2)=NN1C(=O)C1=CC=CC=C1 RVEOGVRFKIDPJF-UHFFFAOYSA-N 0.000 description 1
- YQPRKSQBYBVKQQ-UHFFFAOYSA-N [5-[(2-chlorophenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 YQPRKSQBYBVKQQ-UHFFFAOYSA-N 0.000 description 1
- URCJZBOBECCCAJ-UHFFFAOYSA-N [5-[(2-fluorophenyl)methylamino]-3-(furan-2-yl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC=C1CNC1=NC(C=2OC=CC=2)=NN1C(=O)C1=CC=CC=C1 URCJZBOBECCCAJ-UHFFFAOYSA-N 0.000 description 1
- ABEGZDCDKRZABL-UHFFFAOYSA-N [5-[(2-fluorophenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC=C1CNC1=NC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 ABEGZDCDKRZABL-UHFFFAOYSA-N 0.000 description 1
- GYNCWOCCFLLAMX-UHFFFAOYSA-N [5-[(2-fluorophenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 GYNCWOCCFLLAMX-UHFFFAOYSA-N 0.000 description 1
- ZMXUGSGQEATKMP-UHFFFAOYSA-N [5-[(2-fluorophenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 ZMXUGSGQEATKMP-UHFFFAOYSA-N 0.000 description 1
- APDYQNYEIHNBQY-UHFFFAOYSA-N [5-[(2-fluorophenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 APDYQNYEIHNBQY-UHFFFAOYSA-N 0.000 description 1
- CEJOWWYNSICSFW-UHFFFAOYSA-N [5-[(2-methoxyphenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC=C1CNC1=NC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 CEJOWWYNSICSFW-UHFFFAOYSA-N 0.000 description 1
- BBKDXTZLIKZFIQ-UHFFFAOYSA-N [5-[(2-methoxyphenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 BBKDXTZLIKZFIQ-UHFFFAOYSA-N 0.000 description 1
- NADSMDWGSBXONP-UHFFFAOYSA-N [5-[(2-methoxyphenyl)methylamino]-3-pyridin-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC=C1CNC1=NC(C=2N=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 NADSMDWGSBXONP-UHFFFAOYSA-N 0.000 description 1
- NWPOROHJTHCDJT-UHFFFAOYSA-N [5-[(2-methoxyphenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 NWPOROHJTHCDJT-UHFFFAOYSA-N 0.000 description 1
- DPLBESABHRZYIN-UHFFFAOYSA-N [5-[(2-methoxyphenyl)methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC=C1CNC1=NC(C=2C=CN=CC=2)=NN1C(=O)C1=CC=CC=C1 DPLBESABHRZYIN-UHFFFAOYSA-N 0.000 description 1
- LICVPKCZUCOYEO-UHFFFAOYSA-N [5-[(2-methoxyphenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 LICVPKCZUCOYEO-UHFFFAOYSA-N 0.000 description 1
- HMZZUKYKCFWCNF-UHFFFAOYSA-N [5-[(2-methylphenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC=C1CNC1=NC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 HMZZUKYKCFWCNF-UHFFFAOYSA-N 0.000 description 1
- BJDAHOPTFPZIEY-UHFFFAOYSA-N [5-[(2-methylphenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 BJDAHOPTFPZIEY-UHFFFAOYSA-N 0.000 description 1
- GKJGNOXNUCIXRV-UHFFFAOYSA-N [5-[(2-methylphenyl)methylamino]-3-pyridin-3-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC=C1CNC1=NC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 GKJGNOXNUCIXRV-UHFFFAOYSA-N 0.000 description 1
- CCYSYKIFBPRIEJ-UHFFFAOYSA-N [5-[(2-methylphenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 CCYSYKIFBPRIEJ-UHFFFAOYSA-N 0.000 description 1
- JPEAANCMKXTLAP-UHFFFAOYSA-N [5-[(2-methylphenyl)methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC=C1CNC1=NC(C=2C=CN=CC=2)=NN1C(=O)C1=CC=CC=C1 JPEAANCMKXTLAP-UHFFFAOYSA-N 0.000 description 1
- LVZLTVLHMALNEA-UHFFFAOYSA-N [5-[(2-methylphenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 LVZLTVLHMALNEA-UHFFFAOYSA-N 0.000 description 1
- GFQDNSYFWZNCGW-UHFFFAOYSA-N [5-[(3-chlorophenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC(CNC=2N(N=C(N=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 GFQDNSYFWZNCGW-UHFFFAOYSA-N 0.000 description 1
- TYUFLQODGMSXGR-UHFFFAOYSA-N [5-[(3-chlorophenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC(CNC=2N(N=C(C=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 TYUFLQODGMSXGR-UHFFFAOYSA-N 0.000 description 1
- HWILBTCOVGEICO-UHFFFAOYSA-N [5-[(3-chlorophenyl)methylamino]-3-pyridin-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC(CNC=2N(N=C(N=2)C=2N=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 HWILBTCOVGEICO-UHFFFAOYSA-N 0.000 description 1
- YIOSYCCWGFPUPV-UHFFFAOYSA-N [5-[(3-chlorophenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC(CNC=2N(N=C(C=2)C=2C=NC=CC=2)C(=O)C=2C=CC=CC=2)=C1 YIOSYCCWGFPUPV-UHFFFAOYSA-N 0.000 description 1
- OUXFTHKEKWPSNV-UHFFFAOYSA-N [5-[(3-chlorophenyl)methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC(CNC=2N(N=C(N=2)C=2C=CN=CC=2)C(=O)C=2C=CC=CC=2)=C1 OUXFTHKEKWPSNV-UHFFFAOYSA-N 0.000 description 1
- RPRUPXRQOGWCQV-UHFFFAOYSA-N [5-[(3-chlorophenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound ClC1=CC=CC(CNC=2N(N=C(N=2)C=2SC=CC=2)C(=O)C=2C=CC=CC=2)=C1 RPRUPXRQOGWCQV-UHFFFAOYSA-N 0.000 description 1
- ATIOWWWGPZHCPZ-UHFFFAOYSA-N [5-[(3-fluorophenyl)methylamino]-3-(furan-2-yl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC(CNC=2N(N=C(N=2)C=2OC=CC=2)C(=O)C=2C=CC=CC=2)=C1 ATIOWWWGPZHCPZ-UHFFFAOYSA-N 0.000 description 1
- JSOJOHGRSIWIEZ-UHFFFAOYSA-N [5-[(3-fluorophenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC(CNC=2N(N=C(N=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 JSOJOHGRSIWIEZ-UHFFFAOYSA-N 0.000 description 1
- PSKVITPFXWOALG-UHFFFAOYSA-N [5-[(3-fluorophenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC(CNC=2N(N=C(C=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 PSKVITPFXWOALG-UHFFFAOYSA-N 0.000 description 1
- FMZYYMAWVPVHDV-UHFFFAOYSA-N [5-[(3-fluorophenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC(CNC=2N(N=C(C=2)C=2C=NC=CC=2)C(=O)C=2C=CC=CC=2)=C1 FMZYYMAWVPVHDV-UHFFFAOYSA-N 0.000 description 1
- NTQXZPGIKYHGIJ-UHFFFAOYSA-N [5-[(3-fluorophenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound FC1=CC=CC(CNC=2N(N=C(N=2)C=2SC=CC=2)C(=O)C=2C=CC=CC=2)=C1 NTQXZPGIKYHGIJ-UHFFFAOYSA-N 0.000 description 1
- NBKXWUUJSZIMTM-UHFFFAOYSA-N [5-[(3-methoxyphenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC(CNC=2N(N=C(N=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 NBKXWUUJSZIMTM-UHFFFAOYSA-N 0.000 description 1
- MFQFGURGMXRDPG-UHFFFAOYSA-N [5-[(3-methoxyphenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC(CNC=2N(N=C(C=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 MFQFGURGMXRDPG-UHFFFAOYSA-N 0.000 description 1
- ADEALJKJVTWBCG-UHFFFAOYSA-N [5-[(3-methoxyphenyl)methylamino]-3-pyridin-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC(CNC=2N(N=C(N=2)C=2N=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 ADEALJKJVTWBCG-UHFFFAOYSA-N 0.000 description 1
- AJKNAFLMKWDTBI-UHFFFAOYSA-N [5-[(3-methoxyphenyl)methylamino]-3-pyridin-3-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC(CNC=2N(N=C(N=2)C=2C=NC=CC=2)C(=O)C=2C=CC=CC=2)=C1 AJKNAFLMKWDTBI-UHFFFAOYSA-N 0.000 description 1
- PBJQFHLECWAKCW-UHFFFAOYSA-N [5-[(3-methoxyphenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC(CNC=2N(N=C(C=2)C=2C=NC=CC=2)C(=O)C=2C=CC=CC=2)=C1 PBJQFHLECWAKCW-UHFFFAOYSA-N 0.000 description 1
- XLCWGBUAMYURNX-UHFFFAOYSA-N [5-[(3-methoxyphenyl)methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC(CNC=2N(N=C(N=2)C=2C=CN=CC=2)C(=O)C=2C=CC=CC=2)=C1 XLCWGBUAMYURNX-UHFFFAOYSA-N 0.000 description 1
- HUBYPKHHOOPIJS-UHFFFAOYSA-N [5-[(3-methoxyphenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound COC1=CC=CC(CNC=2N(N=C(N=2)C=2SC=CC=2)C(=O)C=2C=CC=CC=2)=C1 HUBYPKHHOOPIJS-UHFFFAOYSA-N 0.000 description 1
- YOSHMUAJHLLBKI-UHFFFAOYSA-N [5-[(3-methylphenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC(CNC=2N(N=C(N=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 YOSHMUAJHLLBKI-UHFFFAOYSA-N 0.000 description 1
- GKPWHOBQHRMTMR-UHFFFAOYSA-N [5-[(3-methylphenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC(CNC=2N(N=C(C=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 GKPWHOBQHRMTMR-UHFFFAOYSA-N 0.000 description 1
- LXIQKFXNVDQSIO-UHFFFAOYSA-N [5-[(3-methylphenyl)methylamino]-3-pyridin-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC(CNC=2N(N=C(N=2)C=2N=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 LXIQKFXNVDQSIO-UHFFFAOYSA-N 0.000 description 1
- YZBILJQGWRQSRQ-UHFFFAOYSA-N [5-[(3-methylphenyl)methylamino]-3-pyridin-3-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC(CNC=2N(N=C(N=2)C=2C=NC=CC=2)C(=O)C=2C=CC=CC=2)=C1 YZBILJQGWRQSRQ-UHFFFAOYSA-N 0.000 description 1
- HPWHUMWYCRPOEC-UHFFFAOYSA-N [5-[(3-methylphenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC(CNC=2N(N=C(C=2)C=2C=NC=CC=2)C(=O)C=2C=CC=CC=2)=C1 HPWHUMWYCRPOEC-UHFFFAOYSA-N 0.000 description 1
- PVBALADVPJCJSU-UHFFFAOYSA-N [5-[(3-methylphenyl)methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC(CNC=2N(N=C(N=2)C=2C=CN=CC=2)C(=O)C=2C=CC=CC=2)=C1 PVBALADVPJCJSU-UHFFFAOYSA-N 0.000 description 1
- CVAJACFIFFJYEM-UHFFFAOYSA-N [5-[(3-methylphenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CC1=CC=CC(CNC=2N(N=C(N=2)C=2SC=CC=2)C(=O)C=2C=CC=CC=2)=C1 CVAJACFIFFJYEM-UHFFFAOYSA-N 0.000 description 1
- BPHVSUNWIBUOMK-UHFFFAOYSA-N [5-[(4-chlorophenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(Cl)=CC=C1CNC1=NC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 BPHVSUNWIBUOMK-UHFFFAOYSA-N 0.000 description 1
- NCJDDFPJKGCASE-UHFFFAOYSA-N [5-[(4-chlorophenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(Cl)=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 NCJDDFPJKGCASE-UHFFFAOYSA-N 0.000 description 1
- BWJPGJFSKRHHNH-UHFFFAOYSA-N [5-[(4-chlorophenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(Cl)=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 BWJPGJFSKRHHNH-UHFFFAOYSA-N 0.000 description 1
- APUQPLNPGQDLET-UHFFFAOYSA-N [5-[(4-chlorophenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(Cl)=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 APUQPLNPGQDLET-UHFFFAOYSA-N 0.000 description 1
- AFJAORZPTPMWKX-UHFFFAOYSA-N [5-[(4-fluorophenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(F)=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 AFJAORZPTPMWKX-UHFFFAOYSA-N 0.000 description 1
- XOJMCWZAXITJSP-UHFFFAOYSA-N [5-[(4-fluorophenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(F)=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 XOJMCWZAXITJSP-UHFFFAOYSA-N 0.000 description 1
- CIPZSNVIFJMEOM-UHFFFAOYSA-N [5-[(4-fluorophenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(F)=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 CIPZSNVIFJMEOM-UHFFFAOYSA-N 0.000 description 1
- AKBBZROTVMXILH-UHFFFAOYSA-N [5-[(4-methoxyphenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(OC)=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 AKBBZROTVMXILH-UHFFFAOYSA-N 0.000 description 1
- OOOFRPSKNNJPNQ-UHFFFAOYSA-N [5-[(4-methoxyphenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(OC)=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 OOOFRPSKNNJPNQ-UHFFFAOYSA-N 0.000 description 1
- ANIKWUNUNVYVGW-UHFFFAOYSA-N [5-[(4-methoxyphenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(OC)=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 ANIKWUNUNVYVGW-UHFFFAOYSA-N 0.000 description 1
- UWNCZIAFWNTERM-UHFFFAOYSA-N [5-[(4-methylphenyl)methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(C)=CC=C1CNC1=NC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 UWNCZIAFWNTERM-UHFFFAOYSA-N 0.000 description 1
- VDSVKIXYLLCGCG-UHFFFAOYSA-N [5-[(4-methylphenyl)methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(C)=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 VDSVKIXYLLCGCG-UHFFFAOYSA-N 0.000 description 1
- LSXYWMOTZWSOOU-UHFFFAOYSA-N [5-[(4-methylphenyl)methylamino]-3-pyridin-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(C)=CC=C1CNC1=NC(C=2N=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 LSXYWMOTZWSOOU-UHFFFAOYSA-N 0.000 description 1
- XLNIKKLHNBAKJA-UHFFFAOYSA-N [5-[(4-methylphenyl)methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(C)=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 XLNIKKLHNBAKJA-UHFFFAOYSA-N 0.000 description 1
- PPBLFUPFDOHBOA-UHFFFAOYSA-N [5-[(4-methylphenyl)methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(C)=CC=C1CNC1=NC(C=2C=CN=CC=2)=NN1C(=O)C1=CC=CC=C1 PPBLFUPFDOHBOA-UHFFFAOYSA-N 0.000 description 1
- DIKCEXQEOLOZMZ-UHFFFAOYSA-N [5-[(4-methylphenyl)methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(C)=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 DIKCEXQEOLOZMZ-UHFFFAOYSA-N 0.000 description 1
- HOKVCULMXQCSLW-UHFFFAOYSA-N [5-[[2-(dimethylamino)phenyl]methylamino]-3-(furan-2-yl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC=C1CNC1=NC(C=2OC=CC=2)=NN1C(=O)C1=CC=CC=C1 HOKVCULMXQCSLW-UHFFFAOYSA-N 0.000 description 1
- SQJDLVVDZRLKSP-UHFFFAOYSA-N [5-[[2-(dimethylamino)phenyl]methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC=C1CNC1=NC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 SQJDLVVDZRLKSP-UHFFFAOYSA-N 0.000 description 1
- VIZFNANKMSXBHE-UHFFFAOYSA-N [5-[[2-(dimethylamino)phenyl]methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 VIZFNANKMSXBHE-UHFFFAOYSA-N 0.000 description 1
- ZVVJCUIWXCIQPJ-UHFFFAOYSA-N [5-[[2-(dimethylamino)phenyl]methylamino]-3-pyridin-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC=C1CNC1=NC(C=2N=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 ZVVJCUIWXCIQPJ-UHFFFAOYSA-N 0.000 description 1
- MOOMQNPXVVYZND-UHFFFAOYSA-N [5-[[2-(dimethylamino)phenyl]methylamino]-3-pyridin-3-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC=C1CNC1=NC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 MOOMQNPXVVYZND-UHFFFAOYSA-N 0.000 description 1
- GGGLBRUJTWQSLY-UHFFFAOYSA-N [5-[[2-(dimethylamino)phenyl]methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 GGGLBRUJTWQSLY-UHFFFAOYSA-N 0.000 description 1
- NGLRDUNWPWNZJS-UHFFFAOYSA-N [5-[[2-(dimethylamino)phenyl]methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC=C1CNC1=NC(C=2C=CN=CC=2)=NN1C(=O)C1=CC=CC=C1 NGLRDUNWPWNZJS-UHFFFAOYSA-N 0.000 description 1
- WZKXIBDDNLXLNM-UHFFFAOYSA-N [5-[[2-(dimethylamino)phenyl]methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 WZKXIBDDNLXLNM-UHFFFAOYSA-N 0.000 description 1
- KCNZRCRFCWDMRQ-UHFFFAOYSA-N [5-[[3-(dimethylamino)phenyl]methylamino]-3-(furan-2-yl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC(CNC=2N(N=C(N=2)C=2OC=CC=2)C(=O)C=2C=CC=CC=2)=C1 KCNZRCRFCWDMRQ-UHFFFAOYSA-N 0.000 description 1
- METLTSQVBHMAHP-UHFFFAOYSA-N [5-[[3-(dimethylamino)phenyl]methylamino]-3-phenyl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC(CNC=2N(N=C(N=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 METLTSQVBHMAHP-UHFFFAOYSA-N 0.000 description 1
- UYDKRCNMUIPWML-UHFFFAOYSA-N [5-[[3-(dimethylamino)phenyl]methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC(CNC=2N(N=C(C=2)C=2C=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 UYDKRCNMUIPWML-UHFFFAOYSA-N 0.000 description 1
- HKEDEBXPWUZFRQ-UHFFFAOYSA-N [5-[[3-(dimethylamino)phenyl]methylamino]-3-pyridin-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC(CNC=2N(N=C(N=2)C=2N=CC=CC=2)C(=O)C=2C=CC=CC=2)=C1 HKEDEBXPWUZFRQ-UHFFFAOYSA-N 0.000 description 1
- ZZLVTVVLHYAESU-UHFFFAOYSA-N [5-[[3-(dimethylamino)phenyl]methylamino]-3-pyridin-3-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC(CNC=2N(N=C(N=2)C=2C=NC=CC=2)C(=O)C=2C=CC=CC=2)=C1 ZZLVTVVLHYAESU-UHFFFAOYSA-N 0.000 description 1
- PWIVZNNDTJAJIJ-UHFFFAOYSA-N [5-[[3-(dimethylamino)phenyl]methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC(CNC=2N(N=C(C=2)C=2C=NC=CC=2)C(=O)C=2C=CC=CC=2)=C1 PWIVZNNDTJAJIJ-UHFFFAOYSA-N 0.000 description 1
- XXHJYXRAQNODBH-UHFFFAOYSA-N [5-[[3-(dimethylamino)phenyl]methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC(CNC=2N(N=C(N=2)C=2C=CN=CC=2)C(=O)C=2C=CC=CC=2)=C1 XXHJYXRAQNODBH-UHFFFAOYSA-N 0.000 description 1
- CHBVABQORUHJMT-UHFFFAOYSA-N [5-[[3-(dimethylamino)phenyl]methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound CN(C)C1=CC=CC(CNC=2N(N=C(N=2)C=2SC=CC=2)C(=O)C=2C=CC=CC=2)=C1 CHBVABQORUHJMT-UHFFFAOYSA-N 0.000 description 1
- OPCXBAOIOVHIOZ-UHFFFAOYSA-N [5-[[4-(dimethylamino)phenyl]methylamino]-3-phenylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(N(C)C)=CC=C1CNC1=CC(C=2C=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 OPCXBAOIOVHIOZ-UHFFFAOYSA-N 0.000 description 1
- VJLJKKLAKSAWFK-UHFFFAOYSA-N [5-[[4-(dimethylamino)phenyl]methylamino]-3-pyridin-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(N(C)C)=CC=C1CNC1=NC(C=2N=CC=CC=2)=NN1C(=O)C1=CC=CC=C1 VJLJKKLAKSAWFK-UHFFFAOYSA-N 0.000 description 1
- YQKCSBGCVLUUPO-UHFFFAOYSA-N [5-[[4-(dimethylamino)phenyl]methylamino]-3-pyridin-3-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(N(C)C)=CC=C1CNC1=NC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 YQKCSBGCVLUUPO-UHFFFAOYSA-N 0.000 description 1
- FGEDBJNKLUHQFG-UHFFFAOYSA-N [5-[[4-(dimethylamino)phenyl]methylamino]-3-pyridin-3-ylpyrazol-1-yl]-phenylmethanone Chemical compound C1=CC(N(C)C)=CC=C1CNC1=CC(C=2C=NC=CC=2)=NN1C(=O)C1=CC=CC=C1 FGEDBJNKLUHQFG-UHFFFAOYSA-N 0.000 description 1
- XQQOINUBEKCYEL-UHFFFAOYSA-N [5-[[4-(dimethylamino)phenyl]methylamino]-3-pyridin-4-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(N(C)C)=CC=C1CNC1=NC(C=2C=CN=CC=2)=NN1C(=O)C1=CC=CC=C1 XQQOINUBEKCYEL-UHFFFAOYSA-N 0.000 description 1
- LUZKAOFZOIGTGJ-UHFFFAOYSA-N [5-[[4-(dimethylamino)phenyl]methylamino]-3-thiophen-2-yl-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound C1=CC(N(C)C)=CC=C1CNC1=NC(C=2SC=CC=2)=NN1C(=O)C1=CC=CC=C1 LUZKAOFZOIGTGJ-UHFFFAOYSA-N 0.000 description 1
- WRIPQWKFOPCBDA-UHFFFAOYSA-N [5-amino-1-(benzenesulfonyl)-1,2,4-triazol-3-yl]-morpholin-4-ylmethanone Chemical compound NC1=NC(C(=O)N2CCOCC2)=NN1S(=O)(=O)C1=CC=CC=C1 WRIPQWKFOPCBDA-UHFFFAOYSA-N 0.000 description 1
- IGCDDPNPYAFVCA-UHFFFAOYSA-N [5-amino-3-(furan-2-yl)-1,2,4-triazol-1-yl]-phenylmethanone Chemical compound NC1=NC(C=2OC=CC=2)=NN1C(=O)C1=CC=CC=C1 IGCDDPNPYAFVCA-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000003698 antivitamin K Substances 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005165 aryl thioxy group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940098003 aspirin 325 mg Drugs 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 230000004712 cancer cell adhesion Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000006641 cyclooctyl carbonyl group Chemical group 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940018872 dalteparin sodium Drugs 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 229960000622 edoxaban Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- HKGDZONGAAYKHU-NTUHNPAUSA-N ethyl 3-[(e)-pyridin-3-ylmethylideneamino]-1h-1,2,4-triazole-5-carboxylate Chemical compound CCOC(=O)C1=NNC(\N=C\C=2C=NC=CC=2)=N1 HKGDZONGAAYKHU-NTUHNPAUSA-N 0.000 description 1
- ZCYCGRXZBNHEBZ-UHFFFAOYSA-N ethyl 5-amino-3-(4-chlorophenyl)pyrazole-1-carboxylate Chemical compound C1=C(N)N(C(=O)OCC)N=C1C1=CC=C(Cl)C=C1 ZCYCGRXZBNHEBZ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960002137 melagatran Drugs 0.000 description 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- GODGFUUWJVTOLR-UHFFFAOYSA-N methyl 3-(2,2-dimethylpropanoylamino)-1h-1,2,4-triazole-5-carboxylate Chemical compound COC(=O)C1=NC(NC(=O)C(C)(C)C)=NN1 GODGFUUWJVTOLR-UHFFFAOYSA-N 0.000 description 1
- JRZFDBVGXNBRIS-UHFFFAOYSA-N methyl 3-(pyridin-3-ylmethylideneamino)-1h-1,2,4-triazole-5-carboxylate Chemical compound N1C(C(=O)OC)=NC(N=CC=2C=NC=CC=2)=N1 JRZFDBVGXNBRIS-UHFFFAOYSA-N 0.000 description 1
- BIYWUQHRRGKCSA-UHFFFAOYSA-N methyl 3-[(2-methylfuran-3-carbonyl)amino]-1h-1,2,4-triazole-5-carboxylate Chemical compound COC(=O)C1=NNC(NC(=O)C2=C(OC=C2)C)=N1 BIYWUQHRRGKCSA-UHFFFAOYSA-N 0.000 description 1
- UNZHCCBJXDGPDN-UHFFFAOYSA-N methyl 3-[3-(4-methylphenyl)propanoylamino]-1h-1,2,4-triazole-5-carboxylate Chemical compound COC(=O)C1=NNC(NC(=O)CCC=2C=CC(C)=CC=2)=N1 UNZHCCBJXDGPDN-UHFFFAOYSA-N 0.000 description 1
- OSZNPKRMPBUQLB-UHFFFAOYSA-N methyl 3-amino-1h-1,2,4-triazole-5-carboxylate Chemical compound COC(=O)C1=NC(N)=NN1 OSZNPKRMPBUQLB-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- KHVTXXKCNDNRCK-UHFFFAOYSA-N n-(2,4-dichlorophenyl)-5-(1,2,4-triazol-1-ylmethyl)-1h-1,2,4-triazole-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1NC(=O)C1=NNC(CN2N=CN=C2)=N1 KHVTXXKCNDNRCK-UHFFFAOYSA-N 0.000 description 1
- PLIAVRYEEFDVAK-UHFFFAOYSA-N n-(2-chlorophenyl)-3-(1,2,4-triazol-4-yl)-1h-1,2,4-triazole-5-carboxamide Chemical compound ClC1=CC=CC=C1NC(=O)C1=NC(N2C=NN=C2)=NN1 PLIAVRYEEFDVAK-UHFFFAOYSA-N 0.000 description 1
- OEALSIWRKHXKLH-UHFFFAOYSA-N n-(4-bromophenyl)-3-(1,2,4-triazol-4-yl)-1h-1,2,4-triazole-5-carboxamide Chemical compound C1=CC(Br)=CC=C1NC(=O)C1=NC(N2C=NN=C2)=NN1 OEALSIWRKHXKLH-UHFFFAOYSA-N 0.000 description 1
- YHEWSWBQMVBRCR-UHFFFAOYSA-N n-[3-(benzylamino)-1h-1,2,4-triazol-5-yl]acetamide Chemical compound N1C(NC(=O)C)=NC(NCC=2C=CC=CC=2)=N1 YHEWSWBQMVBRCR-UHFFFAOYSA-N 0.000 description 1
- USQMBFQATPPSPV-UHFFFAOYSA-N n-[5-(furan-2-yl)-1h-1,2,4-triazol-3-yl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(N=1)=NNC=1C1=CC=CO1 USQMBFQATPPSPV-UHFFFAOYSA-N 0.000 description 1
- RACVYURBPHPGSA-UHFFFAOYSA-N n-benzyl-5-(furan-2-yl)-1h-1,2,4-triazol-3-amine Chemical compound C=1C=CC=CC=1CNC(NN=1)=NC=1C1=CC=CO1 RACVYURBPHPGSA-UHFFFAOYSA-N 0.000 description 1
- RTUVBNBPMODREQ-UHFFFAOYSA-N n-benzyl-5-pyridin-2-yl-1h-1,2,4-triazol-3-amine Chemical compound C=1C=CC=CC=1CNC(NN=1)=NC=1C1=CC=CC=N1 RTUVBNBPMODREQ-UHFFFAOYSA-N 0.000 description 1
- HYSNROIMGSZTHD-UHFFFAOYSA-N n-benzyl-5-pyridin-3-yl-1h-1,2,4-triazol-3-amine Chemical compound C=1C=CC=CC=1CNC(NN=1)=NC=1C1=CC=CN=C1 HYSNROIMGSZTHD-UHFFFAOYSA-N 0.000 description 1
- UPVSNLDXOUWEDP-UHFFFAOYSA-N n-benzyl-5-pyridin-4-yl-1h-1,2,4-triazol-3-amine Chemical compound C=1C=CC=CC=1CNC(NN=1)=NC=1C1=CC=NC=C1 UPVSNLDXOUWEDP-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DLMMQHNYEBTUFT-UHFFFAOYSA-N n-ethoxypropan-1-amine Chemical compound CCCNOCC DLMMQHNYEBTUFT-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940124707 pain therapeutics Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000004675 pentylcarbonyl group Chemical group C(CCCC)C(=O)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- BHMHWSUTXMJHOQ-UHFFFAOYSA-N phenyl-[3-phenyl-5-(pyridin-2-ylmethylamino)pyrazol-1-yl]methanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2N=CC=CC=2)N1C(=O)C1=CC=CC=C1 BHMHWSUTXMJHOQ-UHFFFAOYSA-N 0.000 description 1
- DUSQTWCHVCBXBZ-UHFFFAOYSA-N phenyl-[3-phenyl-5-(pyridin-3-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2C=CC=CC=2)N=C(NCC=2C=NC=CC=2)N1C(=O)C1=CC=CC=C1 DUSQTWCHVCBXBZ-UHFFFAOYSA-N 0.000 description 1
- BRBPFCYUDJCSNZ-UHFFFAOYSA-N phenyl-[3-phenyl-5-(pyridin-3-ylmethylamino)pyrazol-1-yl]methanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=NC=CC=2)N1C(=O)C1=CC=CC=C1 BRBPFCYUDJCSNZ-UHFFFAOYSA-N 0.000 description 1
- UUUGETNUQDMRHI-UHFFFAOYSA-N phenyl-[3-phenyl-5-(pyridin-4-ylmethylamino)pyrazol-1-yl]methanone Chemical compound N1=C(C=2C=CC=CC=2)C=C(NCC=2C=CN=CC=2)N1C(=O)C1=CC=CC=C1 UUUGETNUQDMRHI-UHFFFAOYSA-N 0.000 description 1
- FETBUPMLDYCFKH-UHFFFAOYSA-N phenyl-[3-pyridin-2-yl-5-(pyridin-2-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2N=CC=CC=2)N1C(=O)C1=CC=CC=C1 FETBUPMLDYCFKH-UHFFFAOYSA-N 0.000 description 1
- JQSCHDSPIRYJCT-UHFFFAOYSA-N phenyl-[3-pyridin-2-yl-5-(pyridin-3-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2C=NC=CC=2)N1C(=O)C1=CC=CC=C1 JQSCHDSPIRYJCT-UHFFFAOYSA-N 0.000 description 1
- BLCYUMJLWYNNGU-UHFFFAOYSA-N phenyl-[3-pyridin-2-yl-5-(pyridin-4-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2N=CC=CC=2)N=C(NCC=2C=CN=CC=2)N1C(=O)C1=CC=CC=C1 BLCYUMJLWYNNGU-UHFFFAOYSA-N 0.000 description 1
- UZQPKNWFXGLEMM-UHFFFAOYSA-N phenyl-[3-pyridin-3-yl-5-(pyridin-2-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2N=CC=CC=2)N1C(=O)C1=CC=CC=C1 UZQPKNWFXGLEMM-UHFFFAOYSA-N 0.000 description 1
- MJKOFYJXGHAPKK-UHFFFAOYSA-N phenyl-[3-pyridin-3-yl-5-(pyridin-2-ylmethylamino)pyrazol-1-yl]methanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2N=CC=CC=2)N1C(=O)C1=CC=CC=C1 MJKOFYJXGHAPKK-UHFFFAOYSA-N 0.000 description 1
- OVFMRLCBKXDUHF-UHFFFAOYSA-N phenyl-[3-pyridin-3-yl-5-(pyridin-3-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=NC=CC=2)N1C(=O)C1=CC=CC=C1 OVFMRLCBKXDUHF-UHFFFAOYSA-N 0.000 description 1
- FKMUSLMUNFAGHL-UHFFFAOYSA-N phenyl-[3-pyridin-3-yl-5-(pyridin-3-ylmethylamino)pyrazol-1-yl]methanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=NC=CC=2)N1C(=O)C1=CC=CC=C1 FKMUSLMUNFAGHL-UHFFFAOYSA-N 0.000 description 1
- XUKOSJXJRXHVEK-UHFFFAOYSA-N phenyl-[3-pyridin-3-yl-5-(pyridin-4-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2C=NC=CC=2)N=C(NCC=2C=CN=CC=2)N1C(=O)C1=CC=CC=C1 XUKOSJXJRXHVEK-UHFFFAOYSA-N 0.000 description 1
- WMOFBCIPCBWQSO-UHFFFAOYSA-N phenyl-[3-pyridin-3-yl-5-(pyridin-4-ylmethylamino)pyrazol-1-yl]methanone Chemical compound N1=C(C=2C=NC=CC=2)C=C(NCC=2C=CN=CC=2)N1C(=O)C1=CC=CC=C1 WMOFBCIPCBWQSO-UHFFFAOYSA-N 0.000 description 1
- GQAHWKYBHYZWJA-UHFFFAOYSA-N phenyl-[3-pyridin-4-yl-5-(pyridin-2-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2N=CC=CC=2)N1C(=O)C1=CC=CC=C1 GQAHWKYBHYZWJA-UHFFFAOYSA-N 0.000 description 1
- POWOBSIWYKEPCI-UHFFFAOYSA-N phenyl-[3-pyridin-4-yl-5-(pyridin-3-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=NC=CC=2)N1C(=O)C1=CC=CC=C1 POWOBSIWYKEPCI-UHFFFAOYSA-N 0.000 description 1
- ZWOQMHNQURHKDN-UHFFFAOYSA-N phenyl-[3-pyridin-4-yl-5-(pyridin-4-ylmethylamino)-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2C=CN=CC=2)N=C(NCC=2C=CN=CC=2)N1C(=O)C1=CC=CC=C1 ZWOQMHNQURHKDN-UHFFFAOYSA-N 0.000 description 1
- STBHFPJPGBCPNX-UHFFFAOYSA-N phenyl-[5-(pyridin-2-ylmethylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2N=CC=CC=2)N1C(=O)C1=CC=CC=C1 STBHFPJPGBCPNX-UHFFFAOYSA-N 0.000 description 1
- HFAAPEZBRDCYBU-UHFFFAOYSA-N phenyl-[5-(pyridin-3-ylmethylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=NC=CC=2)N1C(=O)C1=CC=CC=C1 HFAAPEZBRDCYBU-UHFFFAOYSA-N 0.000 description 1
- GCQFIJAGODWGPE-UHFFFAOYSA-N phenyl-[5-(pyridin-4-ylmethylamino)-3-thiophen-2-yl-1,2,4-triazol-1-yl]methanone Chemical compound N1=C(C=2SC=CC=2)N=C(NCC=2C=CN=CC=2)N1C(=O)C1=CC=CC=C1 GCQFIJAGODWGPE-UHFFFAOYSA-N 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- NWELCUKYUCBVKK-UHFFFAOYSA-N pyridin-2-ylhydrazine Chemical compound NNC1=CC=CC=N1 NWELCUKYUCBVKK-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- FOVRZAGACROHCK-UHFFFAOYSA-N pyrimidine-2-carbonyl chloride Chemical compound ClC(=O)C1=NC=CC=N1 FOVRZAGACROHCK-UHFFFAOYSA-N 0.000 description 1
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 description 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229950008248 tecarfarin Drugs 0.000 description 1
- YTZKOQUCBOVLHL-UHFFFAOYSA-N tert-butylbenzene Chemical compound CC(C)(C)C1=CC=CC=C1 YTZKOQUCBOVLHL-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229940064689 tinzaparin sodium Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011541 total hip replacement Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- FDQJRYXHNYJHIN-UHFFFAOYSA-N triazole-1,4-dicarboxamide Chemical compound NC(=O)C1=CN(C(N)=O)N=N1 FDQJRYXHNYJHIN-UHFFFAOYSA-N 0.000 description 1
- BDTOTMBOHYUNSQ-UHFFFAOYSA-N triazole-1-carboxylic acid Chemical compound OC(=O)N1C=CN=N1 BDTOTMBOHYUNSQ-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000005065 undecenyl group Chemical group C(=CCCCCCCCCC)* 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present disclosure relates to compounds, e.g., multisubstituted aromatic compounds, which exhibit biological activity, e.g., inhibitory action, against thrombin (activated blood-coagulation factor II; EC 3.4.21.5).
- biological activity e.g., inhibitory action, against thrombin (activated blood-coagulation factor II; EC 3.4.21.5).
- the cascade includes the Extrinsic and Intrinsic pathways, involving the activation of at least 13 interconnected factors and a variety of co-factors and other regulatory proteins.
- plasma factor VII interacts with exposed Tissue Factor (TF), and the resultant TF-fVIIa complex initiates a complex series of events.
- Factor fXa is produced directly ‘downstream’ from the TF-fVIIa complex, and amplified manifold via the Intrinsic Pathway.
- FXa then serves as the catalyst for formation of thrombin (fIIa), which in turn is the direct precursor to fibrinolysis.
- the outcome is a fibrinolytic clot, which stops the bleeding. Fibrinolysis of the polymeric clot into fibrin monomers leads to dissolution and a return of the system to the pre-clot state.
- the cascade is a complex balance of factors and co-factors and is tightly regulated.
- heparin the naturally-occurring polysaccharide that activates AT III, the endogenous inhibitor of many of the factors in the coagulation cascade.
- thrombin is a central protein in the coagulation process, which is activated and amplified upon vascular injury. Thrombin generation prompts a cascade in various factors in the coagulation cascade, ultimately depositing fibrin, the framework for a clot. The clot causes cessation of the bleeding event accompanying the vascular injury. Thrombin and associated protein ultimately cause dissolution of the clot through ‘fibrinolysis’, returning the system back to the pre-injury state. In a ‘normal’ state of injury, this thrombin generation and clot deposition is desired.
- clot deposition In a disease state, clot deposition is undesired.
- General thrombotic events are the clinical result of clot deposition and accumulation in the arteries, veins or within the heart. Eventual break-off of the accumulated clot structure into the vascular system can cause the clot to travel to the brain and/or lungs, resulting in a stroke, myocardial infarction (heart attack), pulmonary embolism, paralysis and consequent death.
- Compounds that inhibit thrombin have been shown in the literature to be useful as anticoagulants in vitro and in vivo, and such compounds can fulfill a critically unmet medical need for patients in the clinic.
- DTIs direct thrombin inhibitors
- DTIs direct thrombin inhibitors
- the use of DTIs is very well precedented, such as with the hirudin-based anticoagulants, and thus there is strong interest in the discovery and development of novel DTIs, particularly those with selectivity for inhibiting thrombin over other related serine proteases.
- Ring A is substituted or unsubstituted pyrazolyl, or substituted or unsubstituted triazolyl.
- L 1 , L 2 and L 3 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —.
- L 4 is absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —.
- R 1 , R 2 and R 3 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- R 4 is absent, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that when L 4 is absent, then R 4 is absent.
- R 5 is independently hydrogen, or substituted or unsubstituted alkyl. It has been discovered that compounds described herein are useful for the inhibition of thrombin.
- a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient.
- the compound is a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, or a compound as set forth in any of Tables A, B or C herein, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof.
- a method for treating a disease or disorder in a subject includes administering a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, compound as set forth in any of Tables A, B or C herein, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical composition thereof, to a subject in need thereof in an amount effective to treat the disease or disorder.
- a method for preventing a disease or disorder in a subject includes administering a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, compound as set forth in any of Tables A, B or C herein, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical composition thereof, to a subject in need thereof in an amount effective to prevent the disease or disorder.
- Embodiments of the invention encompass methods for treating and/or preventing a disease or disorder in a subject, comprising administering a compound to a subject in need thereof in an amount effective to treat or prevent said disease or disorder, wherein the compound has the following formula:
- ring A is substituted or unsubstituted pyrazolyl, or substituted or unsubstituted triazolyl
- L 1 , L 2 and L 3 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —
- L 4 is absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —
- R 1 ; R 2 and R 3 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubsti
- the compound can have the following formula:
- L 1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —NHSO 2 —, or —NR 5 —;
- L 2 is a bond;
- L 3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;
- L 4 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;
- R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalky
- the disease or disorder can be a thrombotic disorder and/or can involve a blood clot thrombus or the potential formation of a blood clot thrombus.
- the thrombotic disorder can include acute coronary syndrome, thromboembolism, and/or thrombosis.
- the thromboembolism can include venous thromboembolism, arterial thromboembolism, and/or cardiogenic thromboembolism.
- the venous thromboembolism can include deep vein thrombosis and/or pulmonary embolism.
- the deep vein thrombosis and/or pulmonary embolism can occur following a medical procedure.
- the thrombotic disorder can involve dysfunctional coagulation or disseminated intravascular coagulation.
- the subject can be undergoing percutaneous coronary intervention (PCI).
- PCI percutaneous coronary intervention
- the thrombotic disease or disorder can involve a blood clot thrombus or the potential formation of a blood clot thrombus and can further involve stroke and/or one or more transient ischemic attacks (TIA).
- TIA transient ischemic attacks
- the thrombotic disease or disorder involving a blood clot thrombus or the potential formation of a blood clot thrombus can further involves stroke and wherein the subject can have non-valvular atrial fibrillation.
- the thrombotic disease or disorder can involve a blood clot thrombus or the potential formation of a blood clot thrombus and can further involve pulmonary hypertension.
- the pulmonary hypertension can be caused by one or more left heart disorder and/or chronic thromboembolic disease.
- the pulmonary hypertension can be associated with one or more lung disease, including pulmonary fibrosis (idiopathic or otherwise), and/or hypoxia.
- the disease or disorder can include fibrosis, Alzheimer's Disease, multiple sclerosis, pain, cancer, inflammation, and/or Type I diabetes mellitus.
- the disease or disorder can involve recurrent cardiac events after myocardial infarction.
- the venous thromboembolism can be associated with formation of a thrombus within a vein associated with one or more acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus.
- the one or more risk factors can include a previous venous thromboembolism.
- the cardiogenic thromboembolism can be due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, and/or embolism of peripheral arteries caused by a detached thrombus.
- the detached thrombus can be in the brain (ischemic stroke).
- the detached thrombus can cause a transient ischemic attack (TIA).
- TIA transient ischemic attack
- the cardiogenic thromboembolism can be due to non-valvular atrial fibrillation.
- the thrombosis can be arterial thrombosis.
- the arterial thrombosis can be due to one or more underlying atherosclerotic processes in the arteries.
- the one or more underlying atherosclerotic processes in the arteries can obstruct or occlude an artery, cause myocardial ischemia (angina pectoris, acute coronary syndrome), cause myocardial infarction, obstruct or occlude a peripheral artery (ischemic peripheral artery disease), and/or obstruct or occlude the artery after a procedure on a blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries).
- the treatment or prevention can include an adjunct therapy.
- the subject can have myocardial infarction, and the adjunct therapy can be in conjunction with thrombolytic therapy.
- the subject can have unstable angina pectoris, thrombosis, and/or heparin-induced thrombocytopenia, and the adjunct therapy can be in combination with antiplatelet therapy.
- the subject can have non-valvular atrial fibrillation, and the adjunct therapy can be in conjunction with other therapies.
- substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., —CH 2 O— is equivalent to —OCH 2 —.
- the term “attached” signifies a stable covalent bond, certain preferred points of attachment being apparent to those of ordinary skill in the art.
- halogen or “halo” include fluorine, chlorine, bromine, and iodine. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl.
- halo(C 1 -C 4 )alkyl includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
- alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched chain, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e., C 1 -C 10 means one to ten carbons).
- saturated hydrocarbon radicals include, but are not limited to, groups such as methyl (Me), ethyl (Et), propyl (Pr, including n-propyl, isopropyl), butyl (Bu, including n-butyl, t-butyl, isobutyl, sec-butyl), (cyclohexyl)methyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and the like, including homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and so forth, and the like.
- An unsaturated alkyl group is one having one or more double bonds or triple bonds.
- unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
- alkyl can refer to C 1 -C 16 straight chain saturated, C 1 -C 16 branched saturated, C 3 -C 8 cyclic saturated, C 3 -C 8 cyclic unsaturated, and C 1 -C 16 straight chain or branched saturated or unsaturated aliphatic hydrocarbon groups substituted with C 3 -C 8 cyclic saturated or unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms, and the like.
- cyclic alkyl groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopropylmethyl, and the like.
- alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a branched or unbranched, saturated or unsaturated alkyl, as defined above and as exemplified, but not limited by, —CH 2 CH 2 CH 2 CH 2 —, and the like.
- an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the compounds disclosed herein.
- a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
- heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, consisting of at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
- the heteroatom(s) O, N, P, S, and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule.
- heteroalkyl group can be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of atoms designated. Accordingly, the term “heteroalkyl” can refer to saturated or unsaturated straight or branched chains containing two through 16 atoms along the chain, cyclic saturated or unsaturated groups containing 3-8 atoms in the cycle, and the like.
- Examples include, but are not limited to: —CH 2 —CH 2 —O—CH 3 , —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —N(CH 3 )—CH 3 , CH 2 —S—CH 2 —CH 3 , —CH 2 —CH 2 , —S(O)—CH 3 , —CH 2 —CH 2 —S(O) 2 —CH 3 , —CH ⁇ CH—O—CH 3 , —Si(CH 3 ) 3 , —CH 2 —CH ⁇ N—OCH 3 , —CH ⁇ CH—N(CH 3 )—CH 3 , —O—CH 3 , —O—CH— 2 —CH 3 , —CN, and the like. Up to two heteroatoms may be consecutive, such as, for example, —CH 2 —NH—OCH 3 .
- heteroalkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as defined above and as exemplified, but not limited by, —CH 2 —CH 2 —S—CH 2 —CH 2 — and —CH 2 —S—CH 2 —CH 2 —NH—CH 2 —, and the like.
- heteroalkylene groups heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).
- heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as —C(O)R′, —C(O)NR′, —NR′R′′, —OR′, —SR′, and/or —SO 2 R′.
- heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as —NR′R′′ or the like, it will be understood that the terms heteroalkyl and —NR′R′′ are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as —NR′R′′ or the like.
- cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
- heterocycloalkyl examples include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
- a “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.
- alkenyl includes C 2 -C 16 straight chain unsaturated, C 2 -C 11 branched unsaturated, C 5 -C 8 unsaturated cyclic, and C 2 -C 16 straight chain or branched unsaturated aliphatic hydrocarbon groups substituted with C 3 -C 8 cyclic saturated and unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Double bonds may occur in any stable point along the chain and the carbon-carbon double bonds may have either the cis or trans configuration.
- this definition shall include but is not limited to ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, 1,5-octadienyl, 1,4,7-nonatrienyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, ethylcyclohexenyl, butenylcyclopentyl, 1-pentenyl-3-cyclohexenyl, and the like.
- heteroalkenyl refers to heteroalkyl having one or more double bonds, wherein heteroalkyl is as defined above.
- alkynyl refers in the customary sense to alkyl, as defined above, additionally having one or more triple bonds.
- cycloalkenyl refers to cycloalkyl, as defined above, additionally having one or more double bonds.
- heterocycloalkenyl refers to heterocycloalkyl additionally having one or more double bonds.
- acyl means, unless otherwise stated, —C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently, wherein each ring contains between 4-20 atoms, and preferably between 5-10 atoms.
- a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring.
- heteroaryl refers to aryl groups (or rings), as defined above, that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- heteroaryl includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring).
- a 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
- Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinoly
- aryl when used in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above.
- arylalkyl e.g., benzyl, phenethyl, pyridylmethyl, and the like
- alkyl group e.g., benzyl, phenethyl, pyridylmethyl, and the like
- alkyl groups e.g., benzyl, phenethyl, pyridylmethyl, and the like
- an oxygen atom e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like
- sulfur atom e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like
- arylalkyl e.g. (4-hydroxyphenyl)ethyl, (2-aminonaphthyl)hexyl, pyridylcyclopentyl
- arylalkyl represents an aryl group as defined above attached through an alkyl group as defined above having the indicated number of carbon atoms.
- R′, R′′, R′′′, and R′′′′ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups.
- each of the R groups is independently selected as are each R′, R′′, R′′′, and R′′′′ group when more than one of these groups is present.
- substituents for the aryl and heteroaryl groups are varied and are selected from, for example: —OR′, —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R, —C(O)R′, —CO 2 R′, —CONR′R′′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′—C(O)NR′′R′′′, —NR′′C(O) 2 R′, —NR—C(NR′R′′R′′′) ⁇ NR′′′′, —NR—C(NR′R′′) ⁇ NR′′′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R′′, —NRSO 2 R′, —CN, —NO 2 , —R′, —N 3 , —CH(Ph)
- Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)—(CRR′) q —U—, wherein T and U are independently —NR—, —O—, —CRR′—, or a single bond, and q is an integer of from 0 to 3.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r —B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 NR′—, or a single bond, and r is an integer of from 1 to 4.
- One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
- R, R′, R′′, and R′′′ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- heteroatom or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
- alkyloxy (e.g. methoxy, ethoxy, propyloxy, allyloxy, cyclohexyloxy) represents an alkyl group as defined above having the indicated number of carbon atoms attached through an oxygen bridge (—O—).
- alkylthio (e.g. methylthio, ethylthio, propylthio, cyclohexylthio and the like) represents an alkyl group as defined above having the indicated number of carbon atoms attached through a sulfur bridge (—S—).
- alkylaminoalkyl represents an alkylamino group attached through an alkyl group as defined above having the indicated number of carbon atoms.
- alkylcarbonyl e.g. cyclooctylcarbonyl, pentylcarbonyl, 3-hexylcarbonyl
- alkylcarbonyl represents an alkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group.
- alkylcarboxy e.g. heptylcarboxy, cyclopropylcarboxy, 3-pentenylcarboxy
- alkylcarboxy represents an alkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen.
- alkylcarboxyalkyl represents an alkylcarboxy group attached through an alkyl group as defined above having the indicated number of carbon atoms.
- alkylcarbonylamino e.g. hexylcarbonylamino, cyclopentylcarbonylaminomethyl, methylcarbonylaminophenyl
- alkylcarbonylamino represents an alkylcarbonyl group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of an amino group.
- the nitrogen group may itself be substituted with an alkyl or aryl group.
- oxo means an oxygen that is double bonded to a carbon atom.
- alkylsulfonyl means a moiety having the formula —S(O 2 )—R′, where R′ is an alkyl group as defined above. R′ may have a specified number of carbons (e.g., “C 1 -C 4 alkylsulfonyl”).
- carbonyloxy represents a carbonyl group attached through an oxygen bridge.
- alkyl and “alkenyl” may be used interchangeably in so far as a stable chemical entity is formed, as would be apparent to those skilled in the art.
- linker refers to attachment groups, e.g., L 1 , L 2 , L 3 and L 4 described herein.
- the linkers are interposed between substituents, e.g., R 1 , R 2 , R 3 or R 4 described herein which are generically referred to as below, and the group which is substituted, e.g., “ring A” in Formula (Ia).
- the linker includes amido (—CONH—R n or —NHCO—R n ), thioamido (—CSNH—R n or —NHCS—R n ), carboxyl (—CO 2 —R n or —OCOR n ), carbonyl (—CO—R n ), urea (—NHCONH—R n ), thiourea (—NHCSNH—R n ), sulfonamido (—NHSO 2 —R n or —SO 2 NH—R n ), ether (—O—R n ), sulfonyl (—SO 2 —R n ), sulfoxyl (—SO—R n ), carbamoyl (—NHCO 2 —R n or —OCONH—R n ), or amino (—NHR n ) linking moieties.
- a “substituent group,” as used herein, means a group selected from the following moieties:
- a “size-limited substituent” or “size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 4 -C 8 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 4 to 8 membered heterocycloalkyl.
- a “lower substituent” or “lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 5 -C 7 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 5 to 7 membered heterocycloalkyl.
- Ring A is substituted or unsubstituted pyrazolyl, or substituted or unsubstituted triazolyl.
- L 1 , L 2 and L 3 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —.
- L 4 is absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —.
- R 1 , R 2 and R 3 are independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, or substituted, unsubstituted heteroaryl, or substituted or unsubstituted fused ring aryl.
- R 4 is absent, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that when L 4 is absent, then R 4 is absent.
- R 5 is independently hydrogen, or substituted or unsubstituted alkyl.
- the compound is a pharmaceutically acceptable salt, ester, solvate, or prodrug of a compound of Formula (Ia). In some embodiments, the compound is not an ester, not a solvate, and not a prodrug.
- L 4 and R 4 are absent, providing a compound with structure of Formula (Ib) following.
- the compound has the structure of Formula (IIa), wherein L 3 is a bond, and R 3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- the pendant heteroaryl R 3 is substituted or unsubstituted pyridyl, thienyl, or furyl.
- the R 3 is unsubstituted pyridyl, thienyl, or furyl.
- R 3 is unsubstituted aryl, preferably phenyl.
- R 3 is substituted aryl, preferably halogen-substituted phenyl.
- a compound is provided with structure of Formula (IIa), wherein L 3 is a bond, substituted or unsubstituted alkylene, and R 3 is substituted or unsubstituted aryl, or substituted or unsubstituted heterocycloalkyl.
- the compound has the structure of Formula (IIa), wherein L 3 is —C(O)O—, and R 3 is substituted or unsubstituted alkyl, preferably unsubstituted alkyl, more preferably unsubstituted lower alkyl.
- the compound has the structure of Formula (IIa), wherein L 3 is —C(O)NR 5 —, R 5 is hydrogen or alkyl, and R 3 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.
- L 1 is —S—, —NR 5 —, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene
- R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- L 1 is —NC(O)—.
- R 3 is substituted or unsubstituted aryl.
- R 3 is unsubstituted aryl.
- L 2 is a bond. In some embodiments, L 2 is a bond and R 2 is hydrogen.
- L 2 is substituted or unsubstituted alkylene or —C(O)—
- R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- the compound of Formula (IIa) has the structure of Formula (IIc) following, wherein L 1 is —NH—(CH 2 ) n —, n is 0 to 6, preferably 1, and R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- L 1 is —NHCH 2 — or —NH(CH 2 ) 2 —, and R 1 is substituted or unsubstituted aryl.
- R 1 is unsubstituted aryl.
- R 1 is aryl, preferably phenyl, substituted with halogen, —CN or alkyloxy, preferably methoxy.
- R 1 is unsubstituted alkyl, preferably lower alkyl, more preferably methyl or ethyl.
- n is 0, and R 1 is hydrogen.
- the compound of Formula (IIa) has the structure of Formula (IId) following, wherein L 1 is a bond, and R 1 is unsubstituted alkyl, or substituted or unsubstituted aryl. In some embodiments, R 1 is unsubstituted alkyl, preferably lower alkyl. In some embodiments, R 1 is substituted aryl, preferably halogen-substituted phenyl.
- the compound has the structure of Formula (IIIa).
- L 3 is a bond or substituted or unsubstituted alkylene
- R 3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl.
- R 3 is substituted or unsubstituted phenyl, or substituted or unsubstituted pyridyl.
- R 3 is unsubstituted phenyl.
- R 3 is unsubstituted pyridyl. In some embodiments, R 3 is substituted or unsubstituted heteroalkyl. In some embodiments, R 3 is substituted or unsubstituted cycloalkyl. In some embodiments, R 3 is substituted or unsubstituted cyclohexyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cycloheptyl. In some embodiments, R 3 is substituted or unsubstituted cycloalkenyl. In some embodiments, R 3 is substituted or unsubstituted cyclohexenyl.
- R 3 is substituted or unsubstituted heterocycloalkyl. In some embodiments, R 3 is substituted or unsubstituted piperidinyl. In some embodiments, R 3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R 3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R 3 is substituted or unsubstituted azetidinyl. In some embodiments, R 3 is substituted or unsubstituted oxetanyl. In some embodiments, R 3 is substituted or unsubstituted oxolanyl. In some embodiments, R 3 is substituted or unsubstituted oxanyl.
- the compound has the structure of Formula (IIIa) wherein L 3 is —C(O)O—, and R 3 is substituted or unsubstituted alkyl.
- the compound has the structure of Formula (IIIa) wherein L 3 is —C(O)NR 6 , R 6 is hydrogen or alkyl, and R 3 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.
- L 1 is —S—, —NR 5 —, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene
- R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- R 1 is an R 1 is unsubstituted phenyl.
- R 1 is a substituted or unsubstituted pyridyl.
- R 1 is a substituted or unsubstituted pyridazinyl. In some embodiments, R 1 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R 1 is a substituted or unsubstituted thienyl. In some embodiments, R 1 is a substituted or unsubstituted furyl. In some embodiments, R 1 is an unsubstituted pyridyl. In some embodiments, R 1 is an unsubstituted pyridazinyl. In some embodiments, R 1 is an unsubstituted pyrimidinyl. In some embodiments, R 1 is an unsubstituted thienyl.
- R 1 is a chloro-substituted thienyl. In some embodiments, R 1 is an unsubstituted furyl. In some embodiments, R 1 is a substituted or unsubstituted morpholinyl. In some embodiments, R 1 is a substituted or unsubstituted oxanyl. In some embodiments, R 1 is a substituted or unsubstituted oxetanyl. In some embodiments, R 1 is an unsubstituted morpholinyl. In some embodiments, R 1 is an unsubstituted oxanyl. In some embodiments, R 1 is an unsubstituted oxetanyl.
- R 1 is substituted or unsubstituted benzodioxinyl. In some embodiments, R 1 is substituted or unsubstituted naphthyl. In some embodiments, R 1 is unsubstituted benzodioxinyl. In some embodiments, R 1 is unsubstituted naphthyl.
- L 2 is bond, —S—, —O—, —NR 5 —, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
- L 2 is —C(O)—.
- R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl.
- L 2 is a bond.
- L 2 is unsubstituted alkylene.
- L 2 is substituted alkylene.
- L 2 is a bond and R 2 is hydrogen.
- R 2 is unsubstituted alkyl. In some embodiments, R 2 is unsubstituted aryl. In some embodiments, R 2 is substituted alkyl. In some embodiments, R 2 is substituted aryl. In some embodiments, R 2 is substituted or unsubstituted phenyl. In some embodiments, R 2 is unsubstituted phenyl. In some embodiments, R 2 is a substituted or unsubstituted pyridyl. In some embodiments, R 2 is a substituted or unsubstituted pyridazinyl. In some embodiments, R 2 is a substituted or unsubstituted pyrimidinyl.
- R 2 is a substituted or unsubstituted thienyl. In some embodiments, R 2 is a substituted or unsubstituted furyl. In some embodiments, R 2 is an unsubstituted pyridyl. In some embodiments, R 2 is an unsubstituted pyridazinyl. In some embodiments, R 2 is an unsubstituted pyrimidinyl. In some embodiments, R 2 is an unsubstituted thienyl. In some embodiments, R 2 is a chloro-substituted thienyl. In some embodiments, R 2 is an unsubstituted furyl.
- R 2 is a substituted or unsubstituted morpholinyl. In some embodiments, R 2 is a substituted or unsubstituted oxanyl. In some embodiments, R 2 is a substituted or unsubstituted oxetanyl. In some embodiments, R 2 is an unsubstituted morpholinyl. In some embodiments, R 2 is an unsubstituted oxanyl. In some embodiments, R 2 is an unsubstituted oxetanyl. In some embodiments, R 2 is substituted or unsubstituted benzodioxinyl. In some embodiments, R 2 is substituted or unsubstituted naphthyl. In some embodiments, R 2 is unsubstituted benzodioxinyl. In some embodiments, R 2 is unsubstituted naphthyl.
- the compound has the structure of Formula (IIIb).
- L 2 is a bond, substituted or unsubstituted alkylene or —C(O)—. In some embodiments, L 2 is a bond. In some embodiments, L 2 is unsubstituted alkylene. In some embodiments, L 2 is substituted alkylene. In some embodiments, R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- R 2 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl. In some embodiments, R 2 is unsubstituted alkyl. In some embodiments, R 2 is unsubstituted aryl. In some embodiments, R 2 is substituted alkyl. In some embodiments, R 2 is substituted aryl.
- the compound has the structure of Formula (IIIc).
- L 3 is a bond or substituted or unsubstituted alkylene
- R 3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl.
- R 3 is substituted or unsubstituted phenyl, or substituted or unsubstituted pyridyl.
- R 3 is unsubstituted phenyl.
- R 3 is unsubstituted pyridyl. In some embodiments, R 3 is substituted or unsubstituted heteroalkyl. In some embodiments, R 3 is substituted or unsubstituted cycloalkyl. In some embodiments, R 3 is substituted or unsubstituted cyclohexyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cycloheptyl. In some embodiments, R 3 is substituted or unsubstituted cycloalkenyl. In some embodiments, R 3 is substituted or unsubstituted cyclohexenyl.
- R 3 is substituted or unsubstituted heterocycloalkyl. In some embodiments, R 3 is substituted or unsubstituted piperidinyl. In some embodiments, R 3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R 3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R 3 is substituted or unsubstituted azetidinyl. In some embodiments, R 3 is substituted or unsubstituted oxetanyl. In some embodiments, R 3 is substituted or unsubstituted oxolanyl. In some embodiments, R 3 is substituted or unsubstituted oxanyl.
- the compound has the structure of Formula (IIIc) wherein L 3 is —C(O)O—, and R 3 is substituted or unsubstituted alkyl.
- the compound has the structure of Formula (IIIc) wherein L 3 is —C(O)NR 6 , R 6 is hydrogen or alkyl, and R 3 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.
- L 1 is —S—, —O—, —NR 5 —, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, where R 5 is as described in formula Ia, and R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- R 1 is substituted or unsubstituted phenyl.
- R 1 is unsubstituted phenyl. In some embodiments, R 1 is a substituted or unsubstituted pyridyl. In some embodiments, R 1 is a substituted or unsubstituted pyridazinyl. In some embodiments, R 1 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R 1 is a substituted or unsubstituted thienyl. In some embodiments, R 1 is a substituted or unsubstituted furyl. In some embodiments, R 1 is an unsubstituted pyridyl.
- R 1 is an unsubstituted pyridazinyl. In some embodiments, R 1 is an unsubstituted pyrimidinyl. In some embodiments, R 1 is an unsubstituted thienyl. In some embodiments, R 1 is a chloro-substituted thienyl. In some embodiments, R 1 is an unsubstituted furyl. In some embodiments, R 1 is a substituted or unsubstituted morpholinyl. In some embodiments, R 1 is a substituted or unsubstituted oxanyl. In some embodiments, R 1 is a substituted or unsubstituted oxetanyl.
- R 1 is an unsubstituted morpholinyl. In some embodiments, R 1 is an unsubstituted oxanyl. In some embodiments, R 1 is an unsubstituted oxetanyl. In some embodiments, R 1 is substituted or unsubstituted benzodioxinyl. In some embodiments, R 1 is substituted or unsubstituted naphthyl. In some embodiments, R 1 is unsubstituted benzodioxinyl. In some embodiments, R 1 is unsubstituted naphthyl.
- L 2 is bond, —S—, —O—, —NR 5 —, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
- L 2 is —C(O)—.
- R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl.
- L 2 is a bond.
- L 2 is a bond and R 2 is hydrogen.
- R 2 is unsubstituted alkyl.
- R 2 is unsubstituted aryl. In some embodiments, R 2 is substituted alkyl. In some embodiments, R 2 is substituted aryl. In some embodiments, R 2 is substituted or unsubstituted phenyl. In some embodiments, R 2 is unsubstituted phenyl. In some embodiments, R 2 is a substituted or unsubstituted pyridyl. In some embodiments, R 2 is a substituted or unsubstituted pyridazinyl. In some embodiments, R 2 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R 2 is a substituted or unsubstituted thienyl.
- R 2 is a substituted or unsubstituted furyl. In some embodiments, R 2 is an unsubstituted pyridyl. In some embodiments, R 2 is an unsubstituted pyridazinyl. In some embodiments, R 2 is an unsubstituted pyrimidinyl. In some embodiments, R 2 is an unsubstituted thienyl. In some embodiments, R 2 is a chloro-substituted thienyl. In some embodiments, R 2 is an unsubstituted furyl. In some embodiments, R 2 is a substituted or unsubstituted morpholinyl.
- R 2 is a substituted or unsubstituted oxanyl. In some embodiments, R 2 is a substituted or unsubstituted oxetanyl. In some embodiments, R 2 is an unsubstituted morpholinyl. In some embodiments, R 2 is an unsubstituted oxanyl. In some embodiments, R 2 is an unsubstituted oxetanyl. In some embodiments, R 2 is substituted or unsubstituted benzodioxinyl. In some embodiments, R 2 is substituted or unsubstituted naphthyl. In some embodiments, R 2 is unsubstituted benzodioxinyl. In some embodiments, R 2 is unsubstituted naphthyl.
- L 3 is a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, and R 3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- L 3 is a bond, —NH—, —NHCH 2 — or —NH(CH 2 ) 2 —.
- L 1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —C(O)—, —C(O)—NR 6 —.
- R 1 is hydrogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; substituted or unsubstituted heterocycloalkyl.
- R 6 is hydrogen, or substituted or unsubstituted alkyl.
- R 4 is halogen.
- R 4 is unsubstituted alkyl.
- L 3 is a bond or substituted or unsubstituted alkylene
- R 3 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl.
- R 3 is substituted or unsubstituted heteroalkyl.
- R 3 is substituted or unsubstituted cycloalkyl.
- R 3 is substituted or unsubstituted cyclohexyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cycloheptyl. In some embodiments, R 3 is substituted or unsubstituted cycloalkenyl. In some embodiments, R 3 is substituted or unsubstituted cyclohexenyl. In some embodiments, R 3 is substituted or unsubstituted heterocycloalkyl. In some embodiments, R 3 is substituted or unsubstituted piperidinyl. In some embodiments, R 3 is substituted or unsubstituted pyrrolidinyl.
- R 3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R 3 is substituted or unsubstituted azetidinyl. In some embodiments, R 3 is substituted or unsubstituted oxetanyl. In some embodiments, R 3 is substituted or unsubstituted oxolanyl. In some embodiments, R 3 is substituted or unsubstituted oxanyl.
- L 1 is —S—, —O—, —NR 5 —, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, where R 5 is as described in formula Ia, and R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- R 1 is substituted or unsubstituted phenyl.
- R 1 is unsubstituted phenyl. In some embodiments, R 1 is a substituted or unsubstituted pyridyl. In some embodiments, R 1 is a substituted or unsubstituted pyridazinyl. In some embodiments, R 1 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R 1 is a substituted or unsubstituted thienyl. In some embodiments, R 1 is a substituted or unsubstituted furyl. In some embodiments, R 1 is an unsubstituted pyridyl.
- R 1 is an unsubstituted pyridazinyl. In some embodiments, R 1 is an unsubstituted pyrimidinyl. In some embodiments, R 1 is an unsubstituted thienyl. In some embodiments, R 1 is a chloro-substituted thienyl. In some embodiments, R 1 is an unsubstituted furyl. In some embodiments, R 1 is a substituted or unsubstituted morpholinyl. In some embodiments, R 1 is a substituted or unsubstituted oxanyl. In some embodiments, R 1 is a substituted or unsubstituted oxetanyl.
- R 1 is an unsubstituted morpholinyl. In some embodiments, R 1 is an unsubstituted oxanyl. In some embodiments, R 1 is an unsubstituted oxetanyl. In some embodiments, R 1 is substituted or unsubstituted benzodioxinyl. In some embodiments, R 1 is substituted or unsubstituted naphthyl. In some embodiments, R 1 is unsubstituted benzodioxinyl. In some embodiments, R 1 is unsubstituted naphthyl. In some embodiments, L 2 and R 2 are absent. In some embodiments, L 2 is a bond. In some embodiments, L 2 is a bond and R 2 is hydrogen.
- L 2 is bond, —S—, —O—, —NR 5 —, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
- L 2 is —C(O)—, to give the structure of Formula (Vc).
- R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl.
- R 2 is substituted or unsubstituted phenyl.
- is an R 2 is unsubstituted phenyl.
- R 2 is a substituted or unsubstituted pyridyl. In some embodiments, R 2 is a substituted or unsubstituted pyridazinyl. In some embodiments, R 2 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R 2 is a substituted or unsubstituted thienyl. In some embodiments, R 2 is a substituted or unsubstituted furyl. In some embodiments, R 2 is an unsubstituted pyridyl. In some embodiments, R 2 is an unsubstituted pyridazinyl.
- R 2 is an unsubstituted pyrimidinyl. In some embodiments, R 2 is an unsubstituted thienyl. In some embodiments, R 2 is a chloro-substituted thienyl. In some embodiments, R 2 is an unsubstituted furyl. In some embodiments, R 2 is a substituted or unsubstituted morpholinyl. In some embodiments, R 2 is a substituted or unsubstituted oxanyl. In some embodiments, R 2 is a substituted or unsubstituted oxetanyl. In some embodiments, R 2 is an unsubstituted morpholinyl.
- R 2 is an unsubstituted oxanyl. In some embodiments, R 2 is an unsubstituted oxetanyl. In some embodiments, R 2 is substituted or unsubstituted benzodioxinyl. In some embodiments, R 2 is substituted or unsubstituted naphthyl. In some embodiments, R 2 is unsubstituted benzodioxinyl. In some embodiments, R 2 is unsubstituted naphthyl.
- R 4 is halogen.
- R 4 is unsubstituted alkyl.
- L 3 is a bond or substituted or unsubstituted alkylene, and R 3 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl.
- R 3 is substituted or unsubstituted heteroalkyl.
- R 3 is substituted or unsubstituted cycloalkyl.
- R 3 is substituted or unsubstituted cyclohexyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cycloheptyl. In some embodiments, R 3 is substituted or unsubstituted cycloalkenyl. In some embodiments, R 3 is substituted or unsubstituted cyclohexenyl. In some embodiments, R 3 is substituted or unsubstituted heterocycloalkyl. In some embodiments, R 3 is substituted or unsubstituted piperidinyl. In some embodiments, R 3 is substituted or unsubstituted pyrrolidinyl.
- R 3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R 3 is substituted or unsubstituted azetidinyl. In some embodiments, R 3 is substituted or unsubstituted oxetanyl. In some embodiments, R 3 is substituted or unsubstituted oxolanyl. In some embodiments, R 3 is substituted or unsubstituted oxanyl.
- L 1 is —S—, —O—, —NR 5 —, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, where R 5 is as described in formula Ia, and R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- R 1 is substituted or unsubstituted phenyl.
- R 1 is unsubstituted phenyl. In some embodiments, R 1 is a substituted or unsubstituted pyridyl. In some embodiments, R 1 is a substituted or unsubstituted pyridazinyl. In some embodiments, R 1 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R 1 is a substituted or unsubstituted thienyl. In some embodiments, R 1 is a substituted or unsubstituted furyl. In some embodiments, R 1 is an unsubstituted pyridyl.
- R 1 is an unsubstituted pyridazinyl. In some embodiments, R 1 is an unsubstituted pyrimidinyl. In some embodiments, R 1 is an unsubstituted thienyl. In some embodiments, R 1 is a chloro-substituted thienyl. In some embodiments, R 1 is an unsubstituted furyl. In some embodiments, R 1 is a substituted or unsubstituted morpholinyl. In some embodiments, R 1 is a substituted or unsubstituted oxanyl. In some embodiments, R 1 is a substituted or unsubstituted oxetanyl.
- R 1 is an unsubstituted morpholinyl. In some embodiments, R 1 is an unsubstituted oxanyl. In some embodiments, R 1 is an unsubstituted oxetanyl. In some embodiments, R 1 is substituted or unsubstituted benzodioxinyl. In some embodiments, R 1 is substituted or unsubstituted naphthyl. In some embodiments, R 1 is unsubstituted benzodioxinyl. In some embodiments, R 1 is unsubstituted naphthyl. In some embodiments, L 2 and R 2 are absent. In some embodiments, L 2 is a bond. In some embodiments, L 2 is a bond and R 2 is hydrogen.
- L 2 is bond
- R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl.
- R 2 is substituted or unsubstituted phenyl.
- R 2 is unsubstituted phenyl. In some embodiments, R 2 is a substituted or unsubstituted pyridyl. In some embodiments, R 2 is a substituted or unsubstituted pyridazinyl. In some embodiments, R 2 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R 2 is a substituted or unsubstituted thienyl. In some embodiments, R 2 is a substituted or unsubstituted furyl. In some embodiments, R 2 is an unsubstituted pyridyl.
- R 2 is an unsubstituted pyridazinyl. In some embodiments, R 2 is an unsubstituted pyrimidinyl. In some embodiments, R 2 is an unsubstituted thienyl. In some embodiments, R 2 is a chloro-substituted thienyl. In some embodiments, R 2 is an unsubstituted furyl. In some embodiments, R 2 is a substituted or unsubstituted morpholinyl. In some embodiments, R 2 is a substituted or unsubstituted oxanyl. In some embodiments, R 2 is a substituted or unsubstituted oxetanyl.
- R 2 is an unsubstituted morpholinyl. In some embodiments, R 2 is an unsubstituted oxanyl. In some embodiments, R 2 is an unsubstituted oxetanyl. In some embodiments, R 2 is substituted or unsubstituted benzodioxinyl. In some embodiments, R 2 is substituted or unsubstituted naphthyl. In some embodiments, R 2 is unsubstituted benzodioxinyl. In some embodiments, R 2 is unsubstituted naphthyl.
- Exemplary compounds, e.g., multisubstituted aromatic compounds, in accordance with the present disclosure are provided herein.
- compound (Cmpd) number chemical name (i.e., International Union of Pure and Applied Chemistry [IUPAC] name)
- molecular weight MW calc calculated mass and MW meas measured mass
- biological activity i.e., inhibition activity in a thrombin assay
- the measured chemical species can be the protonated compound, e.g., [M+H] + , whereby the measured mass is 1 atomic unit greater than the calculated mass of the compound, as well known in the art.
- Compounds disclosed herein also include racemic mixtures, stereoisomers and mixtures of the compounds, including isotopically-labeled and radio-labeled compounds. See e.g., Goding, 1986, M ONOCLONAL A NTIBODIES P RINCIPLES AND P RACTICE ; Academic Press, p. 104. Such isomers can be isolated by standard resolution techniques, including e.g., fractional crystallization, chiral chromatography, and the like. See e.g., Eliel, E. L. & Wilen S. H., 1993, S TEREOCHEMISTRY IN O RGANIC C OMPOUNDS ; John Wiley & Sons, New York.
- compounds disclosed herein have asymmetric centers and may occur as racemates, racemic mixtures, and as individual enantiomers or diastereoisomers, with all isomeric forms as well as mixtures thereof being contemplated for use in the compounds and methods described herein.
- the compounds contemplated for use in the compounds and methods described herein do not include those that are known in the art to be too unstable to synthesize and/or isolate.
- the compounds disclosed herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds disclosed herein, whether radioactive or not, are encompassed within the contemplated scope.
- metabolites of the compounds disclosed herein are useful for the methods disclosed herein.
- prodrug refers to a compound that can be converted into a compound (e.g., a biologically active compound) described herein in vivo.
- Prodrugs can be useful for a variety of reason known in the art, including e.g., ease of administration due e.g., to enhanced bioavailability in oral administration, and the like.
- the prodrug may also have improved solubility in pharmaceutical compositions over the biologically active compounds.
- prodrug ester refers to derivatives of the compounds disclosed herein formed by the addition of any of a variety of ester-forming groups, e.g., groups known in the art, that are hydrolyzed under physiological conditions.
- ester-forming groups e.g., groups known in the art, that are hydrolyzed under physiological conditions.
- prodrug ester groups include pivaloyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art, including a (5-R-2-oxo-1,3-dioxolen-4-yl)methyl group.
- Other examples of prodrug ester groups can be found in, for example, T.
- prodrugs can be slowly converted to the compounds described herein useful for the methods described herein when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Certain compounds disclosed herein can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of contemplated compounds. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the compounds and methods contemplated herein and are intended to be within the scope disclosed herein.
- compounds described herein exhibit inhibitory activity against thrombin with activities 1 ⁇ M, e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 ⁇ M, or even greater.
- the compounds exhibit inhibitory activity against thrombin with activities between 0.1 ⁇ M and 1 ⁇ M, e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 ⁇ M.
- compounds described herein exhibit inhibitory activity against thrombin with activities 0.1 ⁇ M, e.g., about 1, 2, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nM. Ranges of values using a combination of any of the values recited herein as upper and/or lower limits are also contemplated, for example, but not limited to, 1-10 nM, 10-100 nM, 0.1-1 ⁇ M, 1-10 ⁇ M, 10-100 ⁇ M, 100-200 ⁇ M, 200-500 ⁇ M, or even 500-1000 ⁇ M.
- the inhibitory activity is in the range of about 1-10 nM, 10-100 nM, 0.1-1 ⁇ M, 1-10 ⁇ M, 10-100 ⁇ M, 100-200 ⁇ M, 200-500 ⁇ M, or even 500-1000 ⁇ M. It is understood that for purposes of quantification, the terms “activity,” “inhibitory activity,” “biological activity,” “thrombin activity” and the like in the context of an inhibitory compound disclosed herein can be quantified in a variety of ways known in the art. Unless indicated otherwise, as used herein such terms refer to IC 50 in the customary sense (i.e., concentration to achieve half-maximal inhibition).
- a dose or a therapeutically effective dose of a compound disclosed herein will be that which is sufficient to achieve a plasma concentration of the compound or its active metabolite(s) within a range set forth herein, e.g., about 1-10 nM, 10-100 nM, 0.1-1 ⁇ M, 1-10 ⁇ M, 10-100 ⁇ M, 100-200 ⁇ M, 200-500 ⁇ M, or even 500-1000 ⁇ M, preferably about 1-10 nM, 10-100 nM, or 0.1-1
- it is believe that such compounds are indicated in the treatment or management of thrombotic disorders.
- a dose or a therapeutically effective dose of a compound disclosed herein will be that which is sufficient to achieve a plasma concentration of the compound or its active metabolite(s) within a range set forth herein, e.g., about 1-10 nM, 10-100 nM, 0.1-1 ⁇ M, 1-10 ⁇ M, 10-100 ⁇ M, 100-200 ⁇ M, 200-500 ⁇ M, or even 500-1000 ⁇ M, preferably about 1-10 nM, 10-100 nM, or 0.1-1 ⁇ M.
- it is believe that such compounds are indicated in the treatment or management of diseases associated with thrombin.
- the compounds selectively inhibit thrombin over related serine proteases such as trypsin, chymotrypsin, factor XIIa, factor XIa, factor Xa, and factor VIIa.
- the compounds inhibit chymotrypsin with an IC 50 greater than 1 uM.
- the compounds inhibit chymotrypsin with an IC 50 greater than 10 uM.
- the compounds inhibit chymotrypsin with an IC 50 greater than 100 uM.
- the compounds inhibit Factor XIa with an IC 50 greater than 1 uM.
- the compounds inhibit Factor XIa with an IC 50 greater than 10 uM.
- the compounds inhibit Factor XIa with an IC 50 greater than 100 uM.
- the compounds persist in the blood plasma after intravenous infusion. In some embodiments, greater than 50% of the initial compound concentration persists in the blood plasma of mice 1 hour after intravenous injection. In some embodiments, greater than 50% of the initial compound concentration persists in the blood plasma of mice 3 hours or longer after intravenous injection.
- Thrombin-Related Diseases and Conditions e.g. Thrombosis
- Thrombotic diseases are the primary indications for thrombin inhibition, because of thrombin's location in the coagulation cascade and, in turn, the importance of the coagulation cascade in the progression of blood clotting processes.
- thrombin thrombin's location in the coagulation cascade and, in turn, the importance of the coagulation cascade in the progression of blood clotting processes.
- the coagulation cascade in general, and thrombin in particular is important in a variety other disease states.
- This inhibitory action is useful in the treatment of a variety of thrombotic disorders, such as, but not limited to, acute vascular diseases such as acute coronary syndromes; venous-, arterial- and cardiogenic thromboembolisms; the prevention of other states such as disseminated intravascular coagulation, or other conditions that involve the presence or the potential formation of a blood clot thrombus.
- acute vascular diseases such as acute coronary syndromes
- venous-, arterial- and cardiogenic thromboembolisms the prevention of other states such as disseminated intravascular coagulation, or other conditions that involve the presence or the potential formation of a blood clot thrombus.
- Other indications for methods described herein include the following.
- LMWHs low molecular weight heparins
- dabigatran etexilate treatment led to a 50% reduction in tumor volume at 4 weeks with no weight loss in treated mice. Dabigatran etexilate also reduced tumor cells in the blood and liver micrometastases by 50-60%. These investigators concluded that dabigatran etexilate may be beneficial in not only preventing thrombotic events in cancer patients, but also as adjunct therapy to treat malignant tumors.
- hirudin and the LMWH nadroparin dramatically reduced the number of lung metastases when administered prior to cancer cell inoculation. See e.g., Hu, L., et al., 2004 , Blood, 104:2746-51.
- the de novo thrombin inhibitor d-Arg-Oic-Pro-d-Ala-Phe(p-Me) has been found to block thrombin-stimulated invasion of prostate cancer cell line PC-3 in a concentration dependent manner. See e.g., Nieman, M. T., et al., 2008 , J Thromb Haemost, 6:837-845. A reduced rate of tumor growth was observed in mice dosed with the pentapeptide through their drinking water. The mice also showed reduced fold rate in tumor size and reduced overall tumor weight compared to untreated mice. Microscopic examination of treated tumors showed reduced number of large blood vessels thus concluding that the pentapeptide interfered with tumor angiogenesis. Nieman, M. T., et al., Thromb Haemost, 104:1044-8.
- anticoagulants affect tumor metastasis; that is, angiogenesis, cancer cell adhesion, migration and invasion processes. See e.g., Van Noorden, C. J., et al., 2010 , Thromb Res, 125 Suppl 2:S77-79.
- Fibrosis Fibrosis.
- Several studies have shown the utility of anticoagulant therapy in fibrotic disorders. For example, in a rat model of CCl 4 -induced chronic liver injury, the DTI SSR182289 decreased liver fibrogenesis significantly after 7 weeks of administration. Similar observations were made in other studies using the LMWHs nadroparin, tinzaparin, enoxaparin, and dalteparin sodium. See e.g., Duplantier, J. G., et al., 2004 , Gut, 53:1682-1687; Abdel-Salam, O.
- thrombin inhibitor as an anticoagulant can be useful in the treatment of fibrinolytic diseases.
- the DTI melagatran greatly reduced ischemia reperfusion injury in a kidney transplant model in the large white pig. This led to a drastically improved kidney graft survival at 3 months. See e.g., Favreau, F., et al., 2010 , Am J Transplant, 10:30-39.
- MS Multiple Sclerosis
- hirudin prevented the development of neuropathic pain and curbed pain responses for 7 days.
- the investigators found that following injury, neuropathic pain was mediated by thrombin generation, which in turn activated PAR-1 receptor in the spinal cord. Hirudin inhibited thrombin generation and ultimately led to pain relief. See e.g., Garcia, P. S., et al., 2010 , Thromb Haemost, 103:1145-1151; Narita, M., et al., 2005 , J Neurosci, 25:10000-10009.
- thrombin inhibitors have been reported to be useful in preventing stroke in individuals with atrial fibrillation.
- the selective thrombin inhibitor ximelagatran was studied in two phase III clinical trials ((SPORTIF III and SPORTIF V), which compared ximelagatran to warfarin for the prevention of cardioembolic events in patients with non-valvular atrial fibrillation.
- SPORTIF III phase III clinical trials
- the investigators for the SPORTIF III clinical trial found that ximelagatran, administered in a fixed dose without coagulation monitoring, protects high-risk patients with atrial fibrillation against thromboembolism at least as effectively as well-controlled warfarin, and is associated with less bleeding.
- thrombin inhibitors have been reported to be useful in the treatment and prevention of acute coronary syndrome (Clemens, A. et al. WIPO Patent Application WO/2008/009638).
- ACS is a group of symptoms that are caused by myocardial ischemia.
- the drug could be used as a prophylaxis for myocardial infarction, or at a certain time after the event (e.g. after myocardial infarction, post-MI; i.e. chronic therapy, secondary prevention).
- thrombin inhibitors have been reported to be useful in the prevention of recurrent cardiac events after myocardial infarction.
- the selective thrombin inhibitor ximelagatran was studied in a phase II clinical trial entitled ESTEEM, measuring the efficacy and safety of ximelagatran in patients with recent myocardial damage.
- the result of the ESTEEM trial supports the notion that long-term treatment with an oral direct thrombin inhibitor reduces arterial thrombotic events.
- Oral ximelagatran in combination with acetylsalicylic acid was more effective than acetylsalicylic acid alone in reducing the frequency of major cardiovascular events during 6 months of treatment in patients with a recent myocardial infarction. (Hirsh, J. et al. Blood 2005, 105 (2), 453-463.).
- thrombin inhibitors have been reported to be useful in post-operative prophylaxis of deep vein thrombosis.
- the selective thrombin inhibitor ximelagatran was found to be efficacious for the prevention of venous thromboembolism following a medical procedure like total hip or knee replacement (Francis, C. W. et al. Ann Intern Med 2002; 137:648-55; Heit, J. A. et al. Arch Intern Med 2001; 161: 2215-21; Eriksson B I et al. Thromb Haemost 2003; 89: 288-96).
- thrombin inhibition in general can be useful in post-operative prophylaxis of deep vein thrombosis.
- thrombin inhibitors such as, for example, dabigatran have been reported to be useful in long-term treatment of pulmonary embolism. (Robertson L, Kesteven P, McCaslin J E. Cochrane Database Syst Rev. 2015 Dec. 4; 12). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful in treating pulmonary embolism.
- thrombin inhibitors have been reported to be useful for the prevention of coagulation in patients undergoing percutaneous coronary intervention.
- Percutaneous coronary intervention PCI
- PCI Percutaneous coronary intervention
- HIT heparin-induced thrombocytopenia
- the endovascular disruption and the hypercoagulable state that characterized HIT means patients are put at risk of thrombosis during PCI.
- Dabigatran which had already been claimed as a thrombin inhibitor and a useful anticoagulant in the clinical setting, was also published as a secondary medication in percutaneous interventional cardiac catherization. (Reilly et al. WIPO Patent Application WO/2010/020602). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful in preventing coagulation in patients undergoing percutaneous coronary intervention.
- Dabigatran a selective thrombin inhibitor
- PAH pulmonary-arterial hypertension
- dabigatran had found use as a treatment of: (i); pulmonary hypertension caused by left heart disorders, (ii); pulmonary hypertension associated with lung diseases such as pulmonary fibroses, particularly idiopathic pulmonary fibrosis, and/or hypoxia, (iii); pulmonary hypertension caused by chronic thromboembolic diseases.
- thrombin inhibition in general can be useful for the treatment of pulmonary-arterial hypertension.
- thrombin inhibitors have been reported to be useful for the treatment of pulmonary-arterial hypertension caused by left heart disorders (Feuring, M. WIPO Patent Application WO/2010/020600). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of pulmonary-arterial hypertension caused by left heart disorders.
- thrombin inhibitors have been reported to be useful for the treatment of pulmonary-arterial hypertension associated with lung diseases such as pulmonary fibroses, particularly idiopathic pulmonary fibrosis, and/or hypoxia (Feuring, M. WIPO Patent Application WO/2010/020600). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of pulmonary-arterial hypertension associated with lung diseases.
- thrombin inhibitors have been reported to be useful for the treatment of pulmonary hypertension caused by chronic thromboembolic diseases (Feuring, M. WIPO Patent Application WO/2010/020600). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of pulmonary hypertension caused by chronic thromboembolic diseases.
- Non-valvular atrial fibrillation is a sustained cardiac disturbance often associated with heart disease.
- Known thrombin inhibitors like ximelagatran have been reported to be useful for stroke prevention in patients with non-valvular atrial fibrillation (Diener H.-C. Cerebrovasc Dis 2006; 21:279-293). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for stroke prevention in patients with non-valvular atrial fibrillation.
- TIA Transient Ischemic Attack
- TIA is an acute episode of temporary neurologic dysfunction that typically lasts less than an hour; results from focal cerebral, spinal cord, or retinal ischemia; and is not associated with acute tissue infarction.
- the incidence of subsequent stroke is as high as 11% over the next 7 days and 24-29% over the following 5 years.
- Stroke prevention medication typically recommended for cardioembolic TIA is as follows: For patients with atrial fibrillation after TIA, long-term anticoagulation with warfarin (aspirin 325 mg/day for those unable to take oral anticoagulants); In acute myocardial infarction (MI) with left ventricular thrombus, oral anticoagulation with warfarin; concurrent aspirin up to 162 mg/day for ischemic coronary artery disease [CAD]); In dilated cardiomyopathy, oral anticoagulation with warfarin or antiplatelet therapy; In rheumatic mitral valve disease, oral anticoagulation with warfarin.
- MI myocardial infarction
- CAD ischemic coronary artery disease
- VKAs vitamin K antagonists
- the direct thrombin inhibitor, dabigatran etexilate has shown efficacy over warfarin in a recent trial.
- Other new anticoagulants including the oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, the parenteral factor Xa inhibitor, idrabiotaparinux, and the novel VKA, tecarfarin, were being assessed in 2010.
- thrombin inhibitors have been reported to be useful for the treatment of venous thromboembolism due to formation of a thrombus within a vein (venous thrombosis) associated with acquired (prolonged bedrest, surgery, injury, malignancy, pregnancy and postpartum states) or inherited (deficiency of natural coagulation inhibitors) risk factors (Marsic, L. P. et al. WIPO Patent Application WO/2003/048155).
- thrombin inhibition in general can be useful for the treatment of venous thromboembolism due to formation of a thrombus within a vein associated with acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus.
- An example of an acquired risk factor would be a previous venous thromboembolism and/or embolism of peripheral veins caused by a detached thrombus.
- An example of an acquired risk factor would be a previous venous thromboembolism.
- thrombin inhibitors have been reported to be useful for the treatment of cardiogenic thromboembolism due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, embolism of peripheral arteries caused by a detached thrombus, most commonly in the brain (ischemic stroke). See Marsic, L. P. et al. WIPO Patent Application WO/2003/048155. Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of cardiogenic thromboembolism.
- thrombin inhibitors have been reported to be useful for the treatment of arterial thrombosis due to underlying atherosclerotic processes in the arteries which obstructs or occludes an artery and causes myocardial ischemia (angina pectoris, acute coronary syndrome) or myocardial infarction, obstructs or occludes a peripheral artery (ischemic peripheral artery disease) and obstructs or occludes the artery after a procedure on the blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries). See Marsic, L. P. et al. WIPO Patent Application WO/2003/048155. Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of arterial thrombosis.
- thrombin inhibitors have been reported to be useful for the treatment of disseminated intravascular coagulation in a number of states (e.g., in complications in pregnancy, in metastasing malignant diseases, after extensive injuries, in bacterial sepsis) when thrombogenic activation causes dysfunctional coagulation with widespread formation of thrombi within the vascular system. See Marsic, L. P. et al. WIPO Patent Application WO/2003/048155. Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of disseminated intravascular coagulation.
- thrombin inhibitors have been reported to be useful as an adjunct therapy in conjunction with thrombolytic therapy in recent myocardial infarction, in combination with aspirin in patients with unstable angina pectoris designed to undergo percutaneous transluminal angioplasty and in the treatment of patients with thrombosis and with heparin-induced thrombocytopenia (Marsic, L. P. et al. WIPO Patent Application WO/2003/048155). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful as an adjunct therapy with other antithrombotic therapies.
- thrombin inhibitors have been reported to be useful for the treatment of inflammation (Kirk, I. WIPO Patent Application WO/2000/041716), type I diabetes mellitus (Korsgren, O.; Nillson, B. WIPO Patent Application WO/2003/061682), cancer (Kakkar, A. K. et al. J Clin Oncol 2004, 22, (10), 1944-8; Hua, Y. et al. Acta Neurochir Suppl 2005, 95, 403-6; Nieman, M. T. et al. J Thromb Haemost, 6 (2008), 837-845; Van Ryn, J.; Clemens, A. WIPO Patent Application WO/2010/020601), fibrosis (Duplantier, J. G.
- LWHs low molecular weight heparins
- FAMOUS clinical trials that measured specifically the survival of cancer patients.
- thrombin inhibition in general can be useful for the treatment of thrombotic diseases or disorders and/or diseases or disorders which involve a blood clot thrombus or the potential formation of a blood clot thrombus and/or further involves stroke and/or one or more transient ischemic attacks (TIA) and/or pulmonary hypertension.
- TIA transient ischemic attacks
- Such conditions include, for example, acute coronary syndrome, thromboembolism, thrombosis, inflammation, diabetes mellitus, cancer, fibrosis, Alzheimer's Disease, multiple sclerosis, pain, recurrent cardiac events after myocardial infarction, or the like.
- a method for treating a disease or disorder in a subject in need thereof includes administering a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, a compound as set forth in any of Tables A, B or C, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical composition thereof, to a subject in need thereof in an amount effective to treat the disease or disorder.
- terapéuticaally effective amount refers to that amount of drug or pharmaceutical agent (e.g., compound or pharmaceutical composition disclosed herein) that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- drug or pharmaceutical agent e.g., compound or pharmaceutical composition disclosed herein
- Compounds useful for methods disclosed herein include the compounds set forth for Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), and (VI), and for the compounds set forth in Tables A and B above. Additionally, compounds useful for methods disclosed herein include the compounds set forth in Table C following. For Table C, the compounds were assayed for inhibition of the protease activity of thrombin as described for Table A.
- the disease or disorder to be treated can include one or more thrombotic diseases or disorders and/or can involve a blood clot thrombus or the potential formation of a blood clot thrombus.
- the thrombotic disease or disorder can be acute coronary syndrome, thromboembolism, and/or thrombosis.
- the thromboembolism can be venous thromboembolism, arterial thromboembolism and/or cardiogenic thromboembolism.
- the venous thromboembolism can include deep vein thrombosis and/or pulmonary embolism.
- the deep vein thrombosis and/or pulmonary embolism can occur following a medical procedure.
- the thrombotic disease or disorder can involve dysfunctional coagulation or disseminated intravascular coagulation.
- the subject with dysfunctional coagulation can be undergoing percutaneous coronary intervention (PCI).
- the thrombotic disease or disorder can involve a blood clot thrombus or the potential formation of a blood clot thrombus and further can involve stroke and/or one or more transient ischemic attacks (TIA).
- PCI percutaneous coronary intervention
- TIA transient ischemic attacks
- the thrombotic disease or disorder involving a blood clot thrombus or the potential formation of a blood clot thrombus can further involve stroke, wherein the subject can have non-valvular atrial fibrillation.
- the thrombotic disease or disorder can involve a blood clot thrombus or the potential formation of a blood clot thrombus and further can involve pulmonary hypertension.
- the pulmonary hypertension can be caused by one or more left heart disorder and/or chronic thromboembolic disease.
- the pulmonary hypertension can be associated with one or more lung disease, including pulmonary fibrosis (idiopathic or otherwise), and/or hypoxia.
- the venous thromboembolism can be associated with formation of a thrombus within a vein associated with one or more acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus.
- the one or more risk factors can include a previous venous thromboembolism.
- the cardiogenic thromboembolism can be due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, and/or embolism of peripheral arteries caused by a detached thrombus.
- the detached thrombus can be in the brain (ischemic stroke).
- the detached thrombus can cause a transient ischemic attack (TIA).
- TIA transient ischemic attack
- the cardiogenic thromboembolism can be due to non-valvular atrial fibrillation.
- the thrombosis can be arterial thrombosis.
- the arterial thrombosis can be due to one or more underlying atherosclerotic processes in the arteries.
- the one or more underlying atherosclerotic processes in the arteries can obstruct or occlude an artery, cause myocardial ischemia (angina pectoris, acute coronary syndrome), cause myocardial infarction, obstruct or occlude a peripheral artery (ischemic peripheral artery disease), and/or obstruct or occlude the artery after a procedure on a blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries).
- myocardial ischemia angina pectoris, acute coronary syndrome
- myocardial infarction obstruct or occlude a peripheral artery
- ischemic peripheral artery disease ischemic peripheral artery disease
- obstruct or occlude the artery after a procedure on a blood vessel reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenos
- the disease or disorder can include fibrosis, Alzheimer's Disease, multiple sclerosis, pain, cancer, inflammation, and/or Type I diabetes mellitus. In some embodiments, the disease or disorder can involve recurrent cardiac events after myocardial infarction.
- the treatment or prevention can include an adjunct therapy.
- the subject can have myocardial infarction, and the adjunct therapy can be in conjunction with thrombolytic therapy.
- the subject can have unstable angina pectoris, thrombosis, and/or heparin-induced thrombocytopenia, and the adjunct therapy can be in combination with antiplatelet therapy.
- the subject can have non-valvular atrial fibrillation, and the adjunct therapy can be in conjunction with one or more other therapies.
- the disease or disorder can be fibrosis. In some embodiments contemplating fibrosis, the method is directed to treating chronic liver injury. In some embodiments, the disease or disorder can be ischemia reperfusion injury. In some embodiments, the disease or disorder can be pulmonary fibrosis.
- the disease or disorder can be pain.
- the pain can be neuropathic pain.
- the disease or disorder is cancer.
- said type of cancer can be cervical-, testicular-, or non-small-cell lung adenocarcinoma.
- the cancer can be limited small cell lung cancer.
- the cancer can be a glioma.
- the cancer can be malignant breast cancer.
- the cancer can be a micrometastasis.
- the micrometastasis can be of the blood or liver.
- the cancer can be a lung metastasis.
- the cancer can be prostatic cancer.
- the disease or disorder can be an inflammatory condition
- said inflammatory condition can be sepsis, inflammatory bowel disease, systemic inflammatory response syndrome, inflammatory arthritis, or rheumatoid arthritis.
- a method for preventing a disease or disorder in a subject includes administering a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, compound as set forth in any of Tables A, B or C herein, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical composition thereof, to a subject in need thereof in an amount effective to prevent the disease or disorder.
- protease activity of a variety of proteins, e.g., thrombin.
- protease activity of a variety of proteins e.g., thrombin
- a chromophoric substrate e.g., a p-nitroanilide peptide substrate, which upon hydrolysis releases p-nitroanilide, which in turn gives rise to a color change which can be determined spectrophotometrically.
- the change in color can be monitored with a spectrophotometer at e.g., 405 nm to provide a signal which is directly proportional to the proteolytic activity of the enzyme.
- the thrombin activity reported herein was obtained as follows. Human thrombin was obtained from Haematologic Technologies Inc. The chromogenic substrate S-2238 was obtained from DiaPharma. Thrombin was assayed in buffer containing 0.05 M Tris (pH 7.4), 0.015 M NaCl and 0.01% PEG-8000. The final concentration of enzyme used was 3 nM thrombin. The final concentration of substrate used was 125 ⁇ M S-2238 for thrombin. All assays were performed in 96-well microtiter plates at room temperature (RT).
- Inhibitor IC 50 values were determined by adding test compound as ten point, three-fold serial dilutions in buffer solution, as known in the art. The plate was read at 10 minutes after substrate addition. The IC 50 was calculated by plotting the percent (%) inhibition against compound concentration and fitting the data to a constrained four parameter sigmoidal curve, as known in the art.
- a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient.
- the compound is a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, a compound as set forth in any of Tables A, B or C herein, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof.
- the compound is set forth in Table A herein.
- the compound is set forth in Table B herein.
- the compound is set forth in Table C herein.
- salts are meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic,
- salts such as with pharmaceutically acceptable acids. Accordingly, the compounds contemplated herein include such salts. Examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, ( ⁇ )-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in the art.
- the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
- esters can be employed, e. g., methyl, ethyl, tert-butyl, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
- the compounds disclosed herein may be administered orally as tablets, aqueous or oily suspensions, lozenges, troches, powders, granules, emulsions, capsules, syrups or elixirs.
- the composition for oral use may contain one or more agents selected from the group of sweetening agents, flavoring agents, coloring agents and preserving agents in order to produce pharmaceutically elegant and palatable preparations. Accordingly, there are also provided pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and one or more compounds disclosed herein.
- tablets contain the acting ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
- excipients may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate, carboxymethylcellulose, or sodium phosphate; (2) granulating and disintegrating agents, such as corn starch or alginic acid; (3) binding agents, such as starch, gelatin or acacia; and (4) lubricating agents, such as magnesium stearate, stearic acid or talc.
- These tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- a coating may also be performed using techniques known in the art.
- pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more substance that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- a compound disclosed herein, in the form of a free compound or a pharmaceutically-acceptable pro-drug, metabolite, analogue, derivative, solvate or salt can be administered, for in vivo application, parenterally by injection or by gradual perfusion over time. Administration may be intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally. For in vitro studies the compounds may be added or dissolved in an appropriate biologically acceptable buffer and added to a cell or tissue.
- the carrier is a finely divided solid in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from 5% to 70% of the active compound.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
- liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- admixtures for the compounds disclosed herein are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories.
- carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like. Ampoules are convenient unit dosages.
- the compounds disclosed herein can also be incorporated into liposomes or administered via transdermal pumps or patches.
- compositions and methods suitable for use in the pharmaceuticals compositions and methods disclosed herein include those described, for example, in P HARMACEUTICAL S CIENCES (17th Ed., Mack Pub. Co., Easton, Pa.) and WO 96/05309, the teachings of both of which are hereby incorporated by reference.
- preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- the pharmaceutical preparation is preferably in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component.
- the composition can, if desired, also contain other compatible therapeutic agents.
- co-solvents include: Polysorbate 20, 60, and 80; Pluronic F-68, F-84, and P-103; cyclodextrin; and polyoxyl 35 castor oil. Such co-solvents are typically employed at a level between about 0.01% and about 2% by weight.
- Viscosity greater than that of simple aqueous solutions may be desirable to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation, and/or otherwise to improve the formulation.
- Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose, chondroitin sulfate and salts thereof, hyaluronic acid and salts thereof, and combinations of the foregoing.
- Such agents are typically employed at a level between about 0.01% and about 2% by weight.
- compositions disclosed herein may additionally include components to provide sustained release and/or comfort.
- Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides, and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
- a subject having a wound or in need of tissue repair is treated at the site of the wound or damaged tissue or treated systemically, with a compound disclosed herein in the form of a free compound or a pharmaceutically-acceptable prodrug, metabolite, analogue, derivative, solvate or salt.
- the terms “treating”, “treatment” and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacologic and/or physiologic effect.
- the effect may be prophylactic in terms of completely or partially preventing a disease or disorder or sign or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure for a disorder and/or adverse effect attributable to it, e.g. pulmonary embolism following a medical procedure.
- Treating covers any treatment of, or prevention of a disease or disorder in a vertebrate, a mammal, particularly a human, and includes: (a) preventing the disease or disorder from occurring in a subject that may be predisposed to the disease or disorder, but has not yet been diagnosed as having it; (b) inhibiting the disease or disorder, i. e., arresting its development; or (c) relieving or ameliorating the disease or disorder, i. e., cause regression of the disease or disorder.
- compositions useful for ameliorating certain diseases and disorders are prepared by formulating a compound disclosed herein in the form of a free compound or a pharmaceutically-acceptable pro-drug, metabolite, analogue, derivative, solvate or salt, either alone or together with other pharmaceutical agents, suitable for administration to a subject using carriers, excipients and additives or auxiliaries.
- Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols.
- Intravenous vehicles include fluid and nutrient replenishers.
- Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases.
- Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing Co., 1405-1412, 1461-1487 (1975) and The National Formulary XIV., 14th ed. Washington: American Pharmaceutical Association (1975), the contents of which are hereby incorporated by reference.
- the pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See e.g., Goodman and Gilman (eds.), 1990, T HE P HARMACOLOGICAL B ASIS FOR T HERAPEUTICS (7th ed.).
- the pharmaceutical compositions are preferably prepared and administered in dose units.
- Solid dose units are tablets, capsules and suppositories.
- different daily doses can be used for treatment of a subject, depending on activity of the compound, manner of administration, nature and severity of the disease or disorder, age and body weight of the subject.
- the administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administrations of subdivided doses at specific intervals.
- compositions contemplated herein may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease or disorder and the weight and general state of the subject. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders.
- Dosages for parenteral administration of active pharmaceutical agents can be converted into corresponding dosages for oral administration by multiplying parenteral dosages by appropriate conversion factors.
- the parenteral dosage in mg/mL times 1.8 the corresponding oral dosage in milligrams (“mg”).
- the parenteral dosage in mg/mL times 1.6 the corresponding oral dosage in mg.
- An average adult weighs about 70 kg.
- the method by which the compound disclosed herein may be administered for oral use would be, for example, in a hard gelatin capsule wherein the active ingredient is mixed with an inert solid diluent, or soft gelatin capsule, wherein the active ingredient is mixed with a co-solvent mixture, such as PEG 400 containing Tween-20.
- a compound disclosed herein may also be administered in the form of a sterile injectable aqueous or oleaginous solution or suspension.
- the compound can generally be administered intravenously or as an oral dose of 0.1 ⁇ g to 20 mg/kg given, for example, every 3-24 hours.
- Formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin.
- the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspension.
- excipients may be (1) suspending agent such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; (2) dispersing or wetting agents which may be (a) naturally occurring phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; (c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylenoxycetanol; (d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as polyoxyethylene sorbitol monooleate, or (e) a condensation product of ethylene oxide with a
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
- This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
- the sterile injectable preparation may also a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- a compound disclosed herein may also be administered in the form of suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter and polyethylene glycols.
- Liposome delivery systems such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
- creams, ointments, jellies, solutions or suspensions, etc., containing the compounds disclosed herein are employed.
- solvates may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the methods contemplated herein.
- compositions provided herein include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
- a therapeutically effective amount i.e., in an amount effective to achieve its intended purpose.
- the actual amount effective for a particular application will depend, inter alia, on the condition being treated.
- such compositions when administered in methods to treat thrombosis, such compositions will contain an amount of active ingredient effective to achieve the desired result (such as, e.g., decreasing the extent of the thrombosis).
- the dosage and frequency (single or multiple doses) of compound administered can vary depending upon a variety of factors, including route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated (e.g., the disease responsive to inhibition of thrombin); presence of other diseases or other health-related problems; kind of concurrent treatment; and complications from any disease or treatment regimen.
- Other therapeutic regimens or agents can be used in conjunction with the methods and compounds disclosed herein.
- the therapeutically effective amount can be initially determined from a variety of techniques known in the art, e.g., biochemical characterization of inhibition of thrombin, cell culture assays, and the like.
- Target concentrations will be those concentrations of active compound(s) that are capable of decreasing thrombin enzymatic activity as measured, for example, using the methods described.
- Therapeutically effective amounts for use in humans may be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring thrombin inhibition and adjusting the dosage upwards or downwards, as described above.
- Dosages may be varied depending upon the requirements of the patient and the compound being employed.
- the dose administered to a patient should be sufficient to affect a beneficial therapeutic response in the patient over time.
- the size of the dose also will be determined by the existence, nature, and extent of any adverse side effects.
- treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
- the dosage range is 0.001% to 10% w/v. In some embodiments, the dosage range is 0.1% to 5% w/v.
- Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
- an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is entirely effective to treat the clinical symptoms demonstrated by the particular patient.
- This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration, and the toxicity profile of the selected agent.
- dosage levels of the compounds disclosed herein as used in the present methods are of the order of e.g., about 0.1 mg to about 1 mg, about 1 mg to about 10 mg, about 0.5 mg to about 20 mg per kilogram body weight, an average adult weighing 70 kilograms, with a preferred dosage range between about 0.1 mg to about 20 mg per kilogram body weight per day (from about 7.0 mg to about 1.4 gm per patient per day).
- the amount of the compound disclosed herein that may be combined with the carrier materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration.
- a formulation intended for oral administration to humans may contain about 5 ⁇ g to 1 g of a compound disclosed herein with an appropriate and convenient amount of carrier material that may vary from about 5 to 95 percent of the total composition.
- Dosage unit forms will generally contain between from about 0.1 mg to 500 mg of a compound disclosed herein.
- the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
- the ratio between toxicity and therapeutic effect for a particular compound is its therapeutic index and can be expressed as the ratio between LD 50 (the amount of compound lethal in 50% of the population) and ED 50 (the amount of compound effective in 50% of the population).
- LD 50 the amount of compound lethal in 50% of the population
- ED 50 the amount of compound effective in 50% of the population.
- Compounds that exhibit high therapeutic indices are preferred.
- Therapeutic index data obtained from in vitro assays, cell culture assays and/or animal studies can be used in formulating a range of dosages for use in humans.
- the dosage of such compounds preferably lies within a range of plasma concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. See, e.g.
- Phenylacetaldehyde (0.29 mL, 2.48 mmol, 2 eq), molecular sieves (4 ⁇ powder), AcOH (0.1 mL, 2.48 mmol, 2 eq), and Na(OAc) 3 BH (655 mg, 7.71 mmol, 6.2 eq) at 0° C. were added to a solution of Cmpd 1 (200 mg, 1.24 mmol) in DCE (10 mL) and stirred at RT for 18 h. The solvent was distilled-off and the residue was diluted with EtOAc (150 mL).
- Oxalyl chloride (2 mL, 23.3 mmol, 1.4 eq) was added to a solution of nicotinic acid (2 g, 16.3 mmol) in DCM followed by catalytic amount of DMF (0.5 mL) at 0° C. and stirred for 5 h at RT. The solvent was then evaporated to afford nicotinic acid chloride as a yellow solid. Nicotinic acid chloride (1.1 g, 7.93 mmol, 1.5 eq) was then added to a solution of Intermediate 11 (1 g, 5.29 mmol) in CHCl 3 (30 mL) followed by Et 3 N (0.7 mL, 5.29 mmol, 1 eq) at 0° C.
- 2-Thiophene carboxylic acid chloride (6.5 mL, 60.4 mmol) was added slowly portion-wise to a solution of thiosemicarbazide (5 g, 54.9 mmol, 1.1 eq) in pyridine (50 mL) at 0° C. over a period of 1 h and then allowed to stir at RT for 14 h.
- the reaction mixture was neutralized with saturated aqueous NaHCO 3 (50 mL) and extracted with t-BuOH (3 ⁇ 100 mL) and dried over Na 2 SO 4 , filtered and concentrated in vacuo.
- Oxalyl chloride (2.36 mL, 24.2 mmol, 1.5 eq) and a catalytic quantity of DMF were added to a solution of pyrimidine-2-carboxylic acid (2 g, 16.1 mmol) in dry DCM (30 mL) at 0° C.
- the resulting mixture was allowed to warm to RT and stir for 3 h.
- the volatiles were removed in vacuo and the residue was thoroughly dried to afford pyrimidine-2-carboxylic acid chloride (2.1 g, 14.8 mmol) as a black solid.
- the crude material was added portion-wise to a solution of aminoguanidine sulfate (5.5 g, 22.2 mmol, 1.5 eq) in pyridine (20 mL) at 0° C. The resulting mixture was allowed to warm to RT and stir for 14 h. The mixture was then neutralized with saturated aqueous NaHCO 3 , extracted with t-BuOH (5 ⁇ 50 mL), dried over Na 2 SO 4 , filtered and concentrated in vacuo. The crude material was dissolved in water (45 mL) and the resulting solution was heated to 100° C. for 24 h.
- N,O-Dimethylhydroxylamine hydrochloride (979 mg, 10.1 mmol, 1.5 eq) was added to a mixture of EDCI (2.0 g, 10.1 mmol, 1.5 eq), HOBt (3.1 g, 21.2 mmol, 3.2 eq), DIEA (3.5 mL, 20.2 mmol, 3 eq) and Cmpd 47 (2.1 g, 6.73 mmol) in DMF (30 mL). The resulting mixture was allowed to stir at RT for 16 h. The mixture was then diluted with water (50 mL) and extracted with EtOAc (100 mL).
- Lithium aluminum hydride (642 mg, 16.9 mmol) was added to a solution of Cmpd 48 (1.5 g, 4.22 mmol) in THF (20 mL) at ⁇ 40° C. The resulting mixture was allowed to warm to 0° C. and stir for 5 h. The mixture was then quenched with saturated aqueous NH 4 Cl (20 mL) and extracted with EtOAc (30 mL). The organic layer washed with water (2 ⁇ 50 mL), saturated aqueous NaHCO 3 (10 mL), brine (10 mL), dried over Na 2 SO 4 , filtered and concentrated in vacuo.
- Lithium hexamethyldisilazide (24.8 mL, 24.8 mmol, 1 eq, 1M in THF) was diluted with anhydrous Et 2 O (100 mL) and cooled to ⁇ 78° C. under an argon atmosphere. After 15 min, 2-acetylpyridine (3 g, 24.8 mmol) in Et 2 O (20 mL) was added to the cold mixture. After 30 min at ⁇ 78° C., diethyl oxalate (3.61 g, 24.8 mmol, 1 eq) in Et 2 O (25 mL) was added in a single portion and the resulting mixture was allowed to warm to RT and stir for 20 h. The resulting precipitate was collected by filtration and dried to afford Intermediate 44 (4 g, 74%) as the lithium salt. MS: 222 [M+H] + ; TLC: EtOAc: R f : 0.10.
- Lithium aluminum hydride (11 mg, 0.28 mmol) was added to a solution of Cmpd 53 (100 mg, 0.28 mmol) in THF (4 mL) at ⁇ 40° C. The resulting mixture was allowed to slowly warm to 0° C. and stir for 2 h. The mixture was then quenched with saturated aqueous NH 4 Cl (20 mL) and extracted with EtOAc (30 mL). The organic layer washed with water (10 mL), saturated aqueous NaHCO 3 (10 mL), brine (10 mL), dried over Na 2 SO 4 , filtered and concentrated in vacuo.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.
Description
- This application is a continuation-in-part of U.S. patent application Ser. No. 13/630,201, filed on Sep. 28, 2012, which is a continuation of International Application No. PCT/US2011/030585, filed on Mar. 30, 2011, which claims the benefit of U.S. Provisional Application No. 61/319,175, filed Mar. 30, 2010, all of which are incorporated by reference herein in their entireties and for all purposes.
- The present disclosure relates to compounds, e.g., multisubstituted aromatic compounds, which exhibit biological activity, e.g., inhibitory action, against thrombin (activated blood-coagulation factor II; EC 3.4.21.5).
- In mammalian systems, blood vessel injuries result in bleeding events, which are dealt with by the blood coagulation cascade. The cascade includes the Extrinsic and Intrinsic pathways, involving the activation of at least 13 interconnected factors and a variety of co-factors and other regulatory proteins. Upon vascular injury, plasma factor VII interacts with exposed Tissue Factor (TF), and the resultant TF-fVIIa complex initiates a complex series of events. Factor fXa is produced directly ‘downstream’ from the TF-fVIIa complex, and amplified manifold via the Intrinsic Pathway. FXa then serves as the catalyst for formation of thrombin (fIIa), which in turn is the direct precursor to fibrinolysis. The outcome is a fibrinolytic clot, which stops the bleeding. Fibrinolysis of the polymeric clot into fibrin monomers leads to dissolution and a return of the system to the pre-clot state. The cascade is a complex balance of factors and co-factors and is tightly regulated.
- In disease states, undesired up- or down-regulation of any factor leads to conditions such as bleeding or thrombosis. Historically, anticoagulants have been used in patients at risk of suffering from thrombotic complications, such as angina, stroke and heart attack. Warfarin has enjoyed dominance as a first-in-line anticoagulant therapeutic. Developed in the 1940s, it is a Vitamin K antagonist and inhibits factors II, VII, IX and X, amongst others. It is administered orally, but its ease of use is tempered by other effects: it has a very long half life (>2 days) and has serious drug-drug interactions. Importantly, since Vitamin K is a ubiquitous cofactor within the coagulation cascade, antagonism results in the simultaneous inhibition of many clotting factors and thus can lead to significant bleeding complications.
- Much attention has been focused on heparin, the naturally-occurring polysaccharide that activates AT III, the endogenous inhibitor of many of the factors in the coagulation cascade. The need for parenteral administration for the heparin-derived therapeutics, and the inconvenient requirements for close supervision for the orally available warfarin, has resulted in a drive to discover and develop orally available drugs with wide therapeutic windows for safety and efficacy.
- Indeed, the position of thrombin in the coagulation cascade has made it a popular target for drug discovery. Thrombin is a central protein in the coagulation process, which is activated and amplified upon vascular injury. Thrombin generation prompts a cascade in various factors in the coagulation cascade, ultimately depositing fibrin, the framework for a clot. The clot causes cessation of the bleeding event accompanying the vascular injury. Thrombin and associated protein ultimately cause dissolution of the clot through ‘fibrinolysis’, returning the system back to the pre-injury state. In a ‘normal’ state of injury, this thrombin generation and clot deposition is desired. In a disease state, clot deposition is undesired. General thrombotic events are the clinical result of clot deposition and accumulation in the arteries, veins or within the heart. Eventual break-off of the accumulated clot structure into the vascular system can cause the clot to travel to the brain and/or lungs, resulting in a stroke, myocardial infarction (heart attack), pulmonary embolism, paralysis and consequent death. Compounds that inhibit thrombin have been shown in the literature to be useful as anticoagulants in vitro and in vivo, and such compounds can fulfill a critically unmet medical need for patients in the clinic.
- A thorough discussion of thrombin and its roles in the coagulation process can be found in a variety of references, including the following which are incorporated herein by reference in their entireties and for all purposes: Wieland, H. A., et al., 2003, Curr Opin Investig Drugs, 4:264-71; Gross, P. L. & Weitz, J. I., 2008, Arterioscler Thromb Vasc Biol, 28:380-6; Hirsh, J., et al., 2005, Blood, 105:453-63; Prezelj, A., et al., 2007, Curr Pharm Des, 13:287-312. Without wishing to be bound by any theory, it is believed that the ultimate development of direct thrombin inhibitors (DTIs) is usefully based upon the classical D-Phe-Pro-Arg motif, a sequence that mimics fibrinogen, which is a natural substrate of thrombin. Without further wishing to be bound by any theory, it is believed that the use of DTIs is very well precedented, such as with the hirudin-based anticoagulants, and thus there is strong interest in the discovery and development of novel DTIs, particularly those with selectivity for inhibiting thrombin over other related serine proteases.
- In a first aspect, there is provided a compound with structure of Formula (Ia)
- or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof. Ring A is substituted or unsubstituted pyrazolyl, or substituted or unsubstituted triazolyl. L1, L2 and L3 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—. L4 is absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—. R1, R2 and R3 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. R4 is absent, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that when L4 is absent, then R4 is absent. R5 is independently hydrogen, or substituted or unsubstituted alkyl. It has been discovered that compounds described herein are useful for the inhibition of thrombin.
- In another aspect, there is provided a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient. The compound is a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, or a compound as set forth in any of Tables A, B or C herein, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof.
- In yet another aspect, there is provided a method for treating a disease or disorder in a subject. The method includes administering a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, compound as set forth in any of Tables A, B or C herein, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical composition thereof, to a subject in need thereof in an amount effective to treat the disease or disorder.
- In still another aspect, there is provided a method for preventing a disease or disorder in a subject. The method includes administering a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, compound as set forth in any of Tables A, B or C herein, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical composition thereof, to a subject in need thereof in an amount effective to prevent the disease or disorder.
- Embodiments of the invention encompass methods for treating and/or preventing a disease or disorder in a subject, comprising administering a compound to a subject in need thereof in an amount effective to treat or prevent said disease or disorder, wherein the compound has the following formula:
- or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof; wherein ring A is substituted or unsubstituted pyrazolyl, or substituted or unsubstituted triazolyl; L1, L2 and L3 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—; L4 is absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—; R1; R2 and R3 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R4 is absent, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that when L4 is absent, then R4 is absent; and R5 is independently hydrogen, or substituted or unsubstituted alkyl.
- In some embodiments of the methods, the compound can have the following formula:
- wherein L1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —NHSO2—, or —NR5—; L2 is a bond; L3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—; L4 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—; R1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl having at least one heteroatom selected from the group consisting of N, P, Si, and S, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl has a substituent group selected from the group consisting of —OH, —NH2, —SH, —CN, —CF3, —NO2, oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted fused ring aryl, or substituted heteroaryl has a substituent group selected from the group consisting of oxo, —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl; R3 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted aryl, or substituted or unsubstituted heteroaryl, and R5 is independently hydrogen, or substituted or unsubstituted alkyl.
- In some embodiments of the methods, the disease or disorder can be a thrombotic disorder and/or can involve a blood clot thrombus or the potential formation of a blood clot thrombus.
- In some embodiments, the thrombotic disorder can include acute coronary syndrome, thromboembolism, and/or thrombosis. In some embodiments, the thromboembolism can include venous thromboembolism, arterial thromboembolism, and/or cardiogenic thromboembolism. In some embodiments, the venous thromboembolism can include deep vein thrombosis and/or pulmonary embolism. In some embodiments, the deep vein thrombosis and/or pulmonary embolism can occur following a medical procedure.
- In some embodiments, the thrombotic disorder can involve dysfunctional coagulation or disseminated intravascular coagulation. In some embodiments, the subject can be undergoing percutaneous coronary intervention (PCI).
- In some embodiments, the thrombotic disease or disorder can involve a blood clot thrombus or the potential formation of a blood clot thrombus and can further involve stroke and/or one or more transient ischemic attacks (TIA). In some embodiments, the thrombotic disease or disorder involving a blood clot thrombus or the potential formation of a blood clot thrombus can further involves stroke and wherein the subject can have non-valvular atrial fibrillation.
- In some embodiments, the thrombotic disease or disorder can involve a blood clot thrombus or the potential formation of a blood clot thrombus and can further involve pulmonary hypertension. In some embodiments, the pulmonary hypertension can be caused by one or more left heart disorder and/or chronic thromboembolic disease. In some embodiments, the pulmonary hypertension can be associated with one or more lung disease, including pulmonary fibrosis (idiopathic or otherwise), and/or hypoxia.
- In some embodiments of the methods, the disease or disorder can include fibrosis, Alzheimer's Disease, multiple sclerosis, pain, cancer, inflammation, and/or Type I diabetes mellitus.
- In some embodiments of the methods, the disease or disorder can involve recurrent cardiac events after myocardial infarction.
- In some embodiments, the venous thromboembolism can be associated with formation of a thrombus within a vein associated with one or more acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus. In some embodiments, the one or more risk factors can include a previous venous thromboembolism.
- In some embodiments, the cardiogenic thromboembolism can be due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, and/or embolism of peripheral arteries caused by a detached thrombus. In some embodiments, the detached thrombus can be in the brain (ischemic stroke). In some embodiments, the detached thrombus can cause a transient ischemic attack (TIA). In some embodiments, the cardiogenic thromboembolism can be due to non-valvular atrial fibrillation.
- In some embodiments, the thrombosis can be arterial thrombosis. In some embodiments, the arterial thrombosis can be due to one or more underlying atherosclerotic processes in the arteries. In some embodiments, the one or more underlying atherosclerotic processes in the arteries can obstruct or occlude an artery, cause myocardial ischemia (angina pectoris, acute coronary syndrome), cause myocardial infarction, obstruct or occlude a peripheral artery (ischemic peripheral artery disease), and/or obstruct or occlude the artery after a procedure on a blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries).
- In some embodiments, the treatment or prevention can include an adjunct therapy. In some embodiments, the subject can have myocardial infarction, and the adjunct therapy can be in conjunction with thrombolytic therapy. In some embodiments, the subject can have unstable angina pectoris, thrombosis, and/or heparin-induced thrombocytopenia, and the adjunct therapy can be in combination with antiplatelet therapy. In some embodiments, the subject can have non-valvular atrial fibrillation, and the adjunct therapy can be in conjunction with other therapies.
- Not applicable.
- The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.
- Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., —CH2O— is equivalent to —OCH2—.
- As used herein, the term “attached” signifies a stable covalent bond, certain preferred points of attachment being apparent to those of ordinary skill in the art.
- The terms “halogen” or “halo” include fluorine, chlorine, bromine, and iodine. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “halo(C1-C4)alkyl” includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
- The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched chain, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e., C1-C10 means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl (Me), ethyl (Et), propyl (Pr, including n-propyl, isopropyl), butyl (Bu, including n-butyl, t-butyl, isobutyl, sec-butyl), (cyclohexyl)methyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and the like, including homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and so forth, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. Accordingly, the term “alkyl” can refer to C1-C16 straight chain saturated, C1-C16 branched saturated, C3-C8 cyclic saturated, C3-C8 cyclic unsaturated, and C1-C16 straight chain or branched saturated or unsaturated aliphatic hydrocarbon groups substituted with C3-C8 cyclic saturated or unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms, and the like. Examples of cyclic alkyl groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopropylmethyl, and the like.
- The term “alkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a branched or unbranched, saturated or unsaturated alkyl, as defined above and as exemplified, but not limited by, —CH2CH2CH2CH2—, and the like. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the compounds disclosed herein. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
- The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, consisting of at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N, P, S, and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. The heteroalkyl group can be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of atoms designated. Accordingly, the term “heteroalkyl” can refer to saturated or unsaturated straight or branched chains containing two through 16 atoms along the chain, cyclic saturated or unsaturated groups containing 3-8 atoms in the cycle, and the like. Examples include, but are not limited to: —CH2—CH2—O—CH3, —CH2—CH2—NH—CH3, —CH2—CH2—N(CH3)—CH3, CH2—S—CH2—CH3, —CH2—CH2, —S(O)—CH3, —CH2—CH2—S(O)2—CH3, —CH═CH—O—CH3, —Si(CH3)3, —CH2—CH═N—OCH3, —CH═CH—N(CH3)—CH3, —O—CH3, —O—CH—2—CH3, —CN, and the like. Up to two heteroatoms may be consecutive, such as, for example, —CH2—NH—OCH3.
- Similarly, the term “heteroalkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as defined above and as exemplified, but not limited by, —CH2—CH2—S—CH2—CH2— and —CH2—S—CH2—CH2—NH—CH2—, and the like. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula —C(O)2R′— represents both —C(O)2R′— and —R′C(O)2—. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as —C(O)R′, —C(O)NR′, —NR′R″, —OR′, —SR′, and/or —SO2R′. Where “heteroalkyl” is recited, followed by recitations of specific heteroalkyl groups, such as —NR′R″ or the like, it will be understood that the terms heteroalkyl and —NR′R″ are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as —NR′R″ or the like.
- The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. The “cycloalkyl” and “heterocycloalkyl” groups include, for example, monocyclic rings having 3-8 ring members, as well as bicyclic rings having 4-16 ring members, tricyclic rings having 5-24 ring members, and so on. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.
- The term “alkenyl” includes C2-C16 straight chain unsaturated, C2-C11 branched unsaturated, C5-C8 unsaturated cyclic, and C2-C16 straight chain or branched unsaturated aliphatic hydrocarbon groups substituted with C3-C8 cyclic saturated and unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Double bonds may occur in any stable point along the chain and the carbon-carbon double bonds may have either the cis or trans configuration. For example, this definition shall include but is not limited to ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, 1,5-octadienyl, 1,4,7-nonatrienyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, ethylcyclohexenyl, butenylcyclopentyl, 1-pentenyl-3-cyclohexenyl, and the like. Similarly, “heteroalkenyl” refers to heteroalkyl having one or more double bonds, wherein heteroalkyl is as defined above.
- The term “alkynyl” refers in the customary sense to alkyl, as defined above, additionally having one or more triple bonds. The term “cycloalkenyl” refers to cycloalkyl, as defined above, additionally having one or more double bonds. The term “heterocycloalkenyl” refers to heterocycloalkyl additionally having one or more double bonds.
- The term “acyl” means, unless otherwise stated, —C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently, wherein each ring contains between 4-20 atoms, and preferably between 5-10 atoms. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. The term “heteroaryl” refers to aryl groups (or rings), as defined above, that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. Thus, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl, and the like. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An “arylene” and a “heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. Accordingly, the term “aryl” can represent an unsubstituted, mono-, di- or trisubstituted monocyclic, polycyclic, biaryl and heterocyclic aromatic groups covalently attached at any ring position capable of forming a stable covalent bond, certain preferred points of attachment being apparent to those skilled in the art (e. g. 3-indolyl, 4-imidazolyl). The aryl substituents are independently selected from the group consisting of halo, nitro, cyano, trihalomethyl, C1-16alkyl, arylC1-16alkyl, C0-16alkyloxyC0-16alkyl, arylC0-16alkyloxyC0-16alkyl, C0-16alkylthioC0-16 alkyl, arylC0-16alkylthioC0-16alkyl, C0-16alkylaminoC0-16alkyl, arylC0-16alkylaminoC0-16 alkyl, di(arylC1-16alkyl)aminoC0-16alkyl, C1-16alkylcarbonylC0-16alkyl, arylC1-16alkylcarbonylC0-16alkyl, C1-16alkylcarboxyC0-16alkyl, arylC1-16alkylcarboxyC0-16alkyl, C1-16alkylcarbonylaminoC0-16alkyl, arylC1-16alkylcarbonylaminoC0-16alkyl, —C0-16alkylCOOR4, —C0-16alkylCONR5R6 wherein R4, R5 and R6 are independently selected from hydrogen, C1-C11alkyl, arylC0-C11alkyl, or R5 and R6 are taken together with the nitrogen to which they are attached forming a cyclic system containing 3 to 8 carbon atoms with or without one C1-16alkyl, arylC0-C16alkyl, or C0-C16alkylaryl substituent. Aryl includes but is not limited to pyrazolyl and triazolyl.
- For brevity, the term “aryl” when used in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the terms “arylalkyl,” “aralkyl” and the like are meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl, and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like), or a sulfur atom. Accordingly, the terms “arylalkyl” and the like (e.g. (4-hydroxyphenyl)ethyl, (2-aminonaphthyl)hexyl, pyridylcyclopentyl) represents an aryl group as defined above attached through an alkyl group as defined above having the indicated number of carbon atoms.
- Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “aryl,” and “heteroaryl”) includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided herein.
- Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, —OC(O)R, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O)2R′, —NR—C(NR′R″R′″)═NR″″, —NR—C(NR′R″)═NR′″, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —NRSO2R′, —CN, and —NO2 in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R′, R″, R′″, and R″″ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound disclosed herein includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, and R″″ group when more than one of these groups is present. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, —NR′R″ includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF3 and —CH2CF3) and acyl (e.g., —C(O)CH3, —C(O)CF3, —C(O)CH2OCH3, and the like).
- Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: —OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, —OC(O)R, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O)2R′, —NR—C(NR′R″R′″)═NR″″, —NR—C(NR′R″)═NR′″, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —NRSO2R′, —CN, —NO2, —R′, —N3, —CH(Ph)2, fluoro(C1-C4)alkoxy, and fluoro(C1-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R′, R″, R′″, and R″″ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound disclosed herein includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, and R″″ groups when more than one of these groups is present.
- Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the base structure.
- Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)—(CRR′)q—U—, wherein T and U are independently —NR—, —O—, —CRR′—, or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2)r—B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O)2—, —S(O)2NR′—, or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CRR′)s—X′—(C″R′″)d—, where s and d are independently integers of from 0 to 3, and X is —O—, —NR′—, —S—, —S(O)—, —S(O)2—, or —S(O)2NR′—. The substituents R, R′, R″, and R′″ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- As used herein, the terms “heteroatom” or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
- The term “alkyloxy” (e.g. methoxy, ethoxy, propyloxy, allyloxy, cyclohexyloxy) represents an alkyl group as defined above having the indicated number of carbon atoms attached through an oxygen bridge (—O—).
- The term “alkylthio” (e.g. methylthio, ethylthio, propylthio, cyclohexylthio and the like) represents an alkyl group as defined above having the indicated number of carbon atoms attached through a sulfur bridge (—S—).
- The term “alkylamino” represents one or two alkyl groups as defined above having the indicated number of carbon atoms attached through an amine bridge. The two alkyl groups can be taken together with the nitrogen to which they are attached forming a cyclic system containing 3 to 8 carbon atoms with or without one C1-C16alkyl, arylC0-C16alkyl, or C0-C16alkylaryl substituent.
- The term “alkylaminoalkyl” represents an alkylamino group attached through an alkyl group as defined above having the indicated number of carbon atoms.
- The term “alkyloxy(alkyl)amino” (e.g. methoxy(methyl)amine, ethoxy(propyl)amine) represents an alkyloxy group as defined above attached through an amino group, the amino group itself having an alkyl substituent.
- The term “alkylcarbonyl” (e.g. cyclooctylcarbonyl, pentylcarbonyl, 3-hexylcarbonyl) represents an alkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group.
- The term “alkylcarboxy” (e.g. heptylcarboxy, cyclopropylcarboxy, 3-pentenylcarboxy) represents an alkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen.
- The term “alkylcarboxyalkyl” represents an alkylcarboxy group attached through an alkyl group as defined above having the indicated number of carbon atoms.
- The term “alkylcarbonylamino” (e.g. hexylcarbonylamino, cyclopentylcarbonylaminomethyl, methylcarbonylaminophenyl) represents an alkylcarbonyl group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of an amino group.
- The nitrogen group may itself be substituted with an alkyl or aryl group.
- The term “oxo,” as used herein, means an oxygen that is double bonded to a carbon atom.
- The term “alkylsulfonyl,” as used herein, means a moiety having the formula —S(O2)—R′, where R′ is an alkyl group as defined above. R′ may have a specified number of carbons (e.g., “C1-C4 alkylsulfonyl”).
- The term “carbonyloxy” represents a carbonyl group attached through an oxygen bridge.
- In the above definitions, the terms “alkyl” and “alkenyl” may be used interchangeably in so far as a stable chemical entity is formed, as would be apparent to those skilled in the art.
- The terms “linker,” “linking moiety” and the like refer to attachment groups, e.g., L1, L2, L3 and L4 described herein. The linkers are interposed between substituents, e.g., R1, R2, R3 or R4 described herein which are generically referred to as below, and the group which is substituted, e.g., “ring A” in Formula (Ia). In some embodiments, the linker includes amido (—CONH—Rn or —NHCO—Rn), thioamido (—CSNH—Rn or —NHCS—Rn), carboxyl (—CO2—Rn or —OCORn), carbonyl (—CO—Rn), urea (—NHCONH—Rn), thiourea (—NHCSNH—Rn), sulfonamido (—NHSO2—Rn or —SO2NH—Rn), ether (—O—Rn), sulfonyl (—SO2—Rn), sulfoxyl (—SO—Rn), carbamoyl (—NHCO2—Rn or —OCONH—Rn), or amino (—NHRn) linking moieties.
- A “substituent group,” as used herein, means a group selected from the following moieties:
-
- (A) —OH, —NH2, —SH, —CN, —CF3, —NO2, oxo, halogen, —COOH, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
- (B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from:
- (i) oxo, —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
- (ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from:
- (a) oxo, —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
- (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, substituted with at least one substituent selected from: oxo, —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
- A “size-limited substituent” or “size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C4-C8 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 4 to 8 membered heterocycloalkyl.
- A “lower substituent” or “lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C5-C7 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 5 to 7 membered heterocycloalkyl.
- The term “about” used in the context of a numeric value indicates a range of +/−10% of the numeric value, unless expressly indicated otherwise.
- In one aspect, there is provided a compound with structure of Formula (Ia):
- or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof. Ring A is substituted or unsubstituted pyrazolyl, or substituted or unsubstituted triazolyl. L1, L2 and L3 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—. L4 is absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—. R1, R2 and R3 are independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, or substituted, unsubstituted heteroaryl, or substituted or unsubstituted fused ring aryl. R4 is absent, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that when L4 is absent, then R4 is absent. R5 is independently hydrogen, or substituted or unsubstituted alkyl.
- In some embodiments, the compound is a pharmaceutically acceptable salt, ester, solvate, or prodrug of a compound of Formula (Ia). In some embodiments, the compound is not an ester, not a solvate, and not a prodrug.
- In some embodiments, L4 and R4 are absent, providing a compound with structure of Formula (Ib) following.
- In some embodiments, there is provided a compound according to Formula (Ib) with structures of either of Formulae (IIa) or (IIb) following.
- In some embodiments, the compound has the structure of Formula (IIa), wherein L3 is a bond, and R3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, the pendant heteroaryl R3 is substituted or unsubstituted pyridyl, thienyl, or furyl. In some embodiments, the R3 is unsubstituted pyridyl, thienyl, or furyl. In some embodiments, R3 is unsubstituted aryl, preferably phenyl. In some embodiments, R3 is substituted aryl, preferably halogen-substituted phenyl.
- In some embodiments, a compound is provided with structure of Formula (IIa), wherein L3 is a bond, substituted or unsubstituted alkylene, and R3 is substituted or unsubstituted aryl, or substituted or unsubstituted heterocycloalkyl.
- In some embodiments, the compound has the structure of Formula (IIa), wherein L3 is —C(O)O—, and R3 is substituted or unsubstituted alkyl, preferably unsubstituted alkyl, more preferably unsubstituted lower alkyl.
- In some embodiments, the compound has the structure of Formula (IIa), wherein L3 is —C(O)NR5—, R5 is hydrogen or alkyl, and R3 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.
- Further to any embodiment above, in some embodiments L1 is —S—, —NR5—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, and R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, L1 is —NC(O)—. In some embodiments, R3 is substituted or unsubstituted aryl. In some embodiments, R3 is unsubstituted aryl. In some embodiments, L2 is a bond. In some embodiments, L2 is a bond and R2 is hydrogen.
- Further to any embodiment above, in some embodiments L2 is substituted or unsubstituted alkylene or —C(O)—, and R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- In some embodiments, the compound of Formula (IIa) has the structure of Formula (IIc) following, wherein L1 is —NH—(CH2)n—, n is 0 to 6, preferably 1, and R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
- In some embodiments of the compound of Formula (IIc), L1 is —NHCH2— or —NH(CH2)2—, and R1 is substituted or unsubstituted aryl. In some embodiments, R1 is unsubstituted aryl. In some embodiments, R1 is aryl, preferably phenyl, substituted with halogen, —CN or alkyloxy, preferably methoxy. In some embodiments, R1 is unsubstituted alkyl, preferably lower alkyl, more preferably methyl or ethyl. In some embodiments, n is 0, and R1 is hydrogen.
- In some embodiments, the compound of Formula (IIa) has the structure of Formula (IId) following, wherein L1 is a bond, and R1 is unsubstituted alkyl, or substituted or unsubstituted aryl. In some embodiments, R1 is unsubstituted alkyl, preferably lower alkyl. In some embodiments, R1 is substituted aryl, preferably halogen-substituted phenyl.
- In some embodiments, there is provided a compound with structure of Formula (IIb). In some embodiments, L2 is a bond, or substituted or unsubstituted alkylene. In some embodiments, L2 is a bond, and R2 is alkyl, preferably lower alkyl. In some embodiments, L2 is a substituted alkylene. In some embodiments, L2 is an unsubstituted alkylene, preferably methylene or ethylene. In some embodiments, L2 is an unsubstituted alkylene, and R2 is unsubstituted aryl, preferably phenyl. In some embodiments, R2 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.
- In some embodiments, there is provided a compound according to Formula (Ib) with structure of either of Formulae (IIIa), (IIIb), or (IIIc) following.
- In some embodiments, the compound has the structure of Formula (IIIa). In some embodiments, L3 is a bond or substituted or unsubstituted alkylene, and R3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R3 is substituted or unsubstituted phenyl, or substituted or unsubstituted pyridyl. In some embodiments, R3 is unsubstituted phenyl. In some embodiments, R3 is unsubstituted pyridyl. In some embodiments, R3 is substituted or unsubstituted heteroalkyl. In some embodiments, R3 is substituted or unsubstituted cycloalkyl. In some embodiments, R3 is substituted or unsubstituted cyclohexyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cycloheptyl. In some embodiments, R3 is substituted or unsubstituted cycloalkenyl. In some embodiments, R3 is substituted or unsubstituted cyclohexenyl. In some embodiments, R3 is substituted or unsubstituted heterocycloalkyl. In some embodiments, R3 is substituted or unsubstituted piperidinyl. In some embodiments, R3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R3 is substituted or unsubstituted azetidinyl. In some embodiments, R3 is substituted or unsubstituted oxetanyl. In some embodiments, R3 is substituted or unsubstituted oxolanyl. In some embodiments, R3 is substituted or unsubstituted oxanyl.
- In some embodiments, the compound has the structure of Formula (IIIa) wherein L3 is —C(O)O—, and R3 is substituted or unsubstituted alkyl.
- In some embodiments, the compound has the structure of Formula (IIIa) wherein L3 is —C(O)NR6, R6 is hydrogen or alkyl, and R3 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.
- Further to any embodiment above wherein the compound has the structure of Formula (IIIa), in some embodiments, L1 is —S—, —NR5—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, and R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments is an R1 is unsubstituted phenyl. In some embodiments, R1 is a substituted or unsubstituted pyridyl. In some embodiments, R1 is a substituted or unsubstituted pyridazinyl. In some embodiments, R1 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R1 is a substituted or unsubstituted thienyl. In some embodiments, R1 is a substituted or unsubstituted furyl. In some embodiments, R1 is an unsubstituted pyridyl. In some embodiments, R1 is an unsubstituted pyridazinyl. In some embodiments, R1 is an unsubstituted pyrimidinyl. In some embodiments, R1 is an unsubstituted thienyl. In some embodiments, R1 is a chloro-substituted thienyl. In some embodiments, R1 is an unsubstituted furyl. In some embodiments, R1 is a substituted or unsubstituted morpholinyl. In some embodiments, R1 is a substituted or unsubstituted oxanyl. In some embodiments, R1 is a substituted or unsubstituted oxetanyl. In some embodiments, R1 is an unsubstituted morpholinyl. In some embodiments, R1 is an unsubstituted oxanyl. In some embodiments, R1 is an unsubstituted oxetanyl. In some embodiments, R1 is substituted or unsubstituted benzodioxinyl. In some embodiments, R1 is substituted or unsubstituted naphthyl. In some embodiments, R1 is unsubstituted benzodioxinyl. In some embodiments, R1 is unsubstituted naphthyl.
- Further to any embodiment above wherein the compound has the structure of Formula (IIIc), in some embodiments L2 is bond, —S—, —O—, —NR5—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In some embodiments, L2 is —C(O)—. In some embodiments, R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl. In some embodiments, L2 is a bond. In some embodiments, L2 is unsubstituted alkylene. In some embodiments, L2 is substituted alkylene. In some embodiments, L2 is a bond and R2 is hydrogen. In some embodiments, R2 is unsubstituted alkyl. In some embodiments, R2 is unsubstituted aryl. In some embodiments, R2 is substituted alkyl. In some embodiments, R2 is substituted aryl. In some embodiments, R2 is substituted or unsubstituted phenyl. In some embodiments, R2 is unsubstituted phenyl. In some embodiments, R2 is a substituted or unsubstituted pyridyl. In some embodiments, R2 is a substituted or unsubstituted pyridazinyl. In some embodiments, R2 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R2 is a substituted or unsubstituted thienyl. In some embodiments, R2 is a substituted or unsubstituted furyl. In some embodiments, R2 is an unsubstituted pyridyl. In some embodiments, R2 is an unsubstituted pyridazinyl. In some embodiments, R2 is an unsubstituted pyrimidinyl. In some embodiments, R2 is an unsubstituted thienyl. In some embodiments, R2 is a chloro-substituted thienyl. In some embodiments, R2 is an unsubstituted furyl. In some embodiments, R2 is a substituted or unsubstituted morpholinyl. In some embodiments, R2 is a substituted or unsubstituted oxanyl. In some embodiments, R2 is a substituted or unsubstituted oxetanyl. In some embodiments, R2 is an unsubstituted morpholinyl. In some embodiments, R2 is an unsubstituted oxanyl. In some embodiments, R2 is an unsubstituted oxetanyl. In some embodiments, R2 is substituted or unsubstituted benzodioxinyl. In some embodiments, R2 is substituted or unsubstituted naphthyl. In some embodiments, R2 is unsubstituted benzodioxinyl. In some embodiments, R2 is unsubstituted naphthyl.
- In some embodiments, the compound has the structure of Formula (IIIb). In some embodiments, L2 is a bond, substituted or unsubstituted alkylene or —C(O)—. In some embodiments, L2 is a bond. In some embodiments, L2 is unsubstituted alkylene. In some embodiments, L2 is substituted alkylene. In some embodiments, R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. Further to any particular L2, in some embodiments R2 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl. In some embodiments, R2 is unsubstituted alkyl. In some embodiments, R2 is unsubstituted aryl. In some embodiments, R2 is substituted alkyl. In some embodiments, R2 is substituted aryl.
- In some embodiments, the compound has the structure of Formula (IIIc). In some embodiments, L3 is a bond or substituted or unsubstituted alkylene, and R3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R3 is substituted or unsubstituted phenyl, or substituted or unsubstituted pyridyl. In some embodiments, R3 is unsubstituted phenyl. In some embodiments, R3 is unsubstituted pyridyl. In some embodiments, R3 is substituted or unsubstituted heteroalkyl. In some embodiments, R3 is substituted or unsubstituted cycloalkyl. In some embodiments, R3 is substituted or unsubstituted cyclohexyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cycloheptyl. In some embodiments, R3 is substituted or unsubstituted cycloalkenyl. In some embodiments, R3 is substituted or unsubstituted cyclohexenyl. In some embodiments, R3 is substituted or unsubstituted heterocycloalkyl. In some embodiments, R3 is substituted or unsubstituted piperidinyl. In some embodiments, R3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R3 is substituted or unsubstituted azetidinyl. In some embodiments, R3 is substituted or unsubstituted oxetanyl. In some embodiments, R3 is substituted or unsubstituted oxolanyl. In some embodiments, R3 is substituted or unsubstituted oxanyl.
- In some embodiments, the compound has the structure of Formula (IIIc) wherein L3 is —C(O)O—, and R3 is substituted or unsubstituted alkyl.
- In some embodiments, the compound has the structure of Formula (IIIc) wherein L3 is —C(O)NR6, R6 is hydrogen or alkyl, and R3 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.
- Further to any embodiment above wherein the compound has the structure of Formula (IIIc), in some embodiments L1 is —S—, —O—, —NR5—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, where R5 is as described in formula Ia, and R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R1 is substituted or unsubstituted phenyl. In some embodiments is an R1 is unsubstituted phenyl. In some embodiments, R1 is a substituted or unsubstituted pyridyl. In some embodiments, R1 is a substituted or unsubstituted pyridazinyl. In some embodiments, R1 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R1 is a substituted or unsubstituted thienyl. In some embodiments, R1 is a substituted or unsubstituted furyl. In some embodiments, R1 is an unsubstituted pyridyl. In some embodiments, R1 is an unsubstituted pyridazinyl. In some embodiments, R1 is an unsubstituted pyrimidinyl. In some embodiments, R1 is an unsubstituted thienyl. In some embodiments, R1 is a chloro-substituted thienyl. In some embodiments, R1 is an unsubstituted furyl. In some embodiments, R1 is a substituted or unsubstituted morpholinyl. In some embodiments, R1 is a substituted or unsubstituted oxanyl. In some embodiments, R1 is a substituted or unsubstituted oxetanyl. In some embodiments, R1 is an unsubstituted morpholinyl. In some embodiments, R1 is an unsubstituted oxanyl. In some embodiments, R1 is an unsubstituted oxetanyl. In some embodiments, R1 is substituted or unsubstituted benzodioxinyl. In some embodiments, R1 is substituted or unsubstituted naphthyl. In some embodiments, R1 is unsubstituted benzodioxinyl. In some embodiments, R1 is unsubstituted naphthyl.
- Further to any embodiment above wherein the compound has the structure of Formula (IIIc), in some embodiments L2 is bond, —S—, —O—, —NR5—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In some embodiments, L2 is —C(O)—. In some embodiments, R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl. In some embodiments, L2 is a bond. In some embodiments, L2 is a bond and R2 is hydrogen. In some embodiments, R2 is unsubstituted alkyl. In some embodiments, R2 is unsubstituted aryl. In some embodiments, R2 is substituted alkyl. In some embodiments, R2 is substituted aryl. In some embodiments, R2 is substituted or unsubstituted phenyl. In some embodiments, R2 is unsubstituted phenyl. In some embodiments, R2 is a substituted or unsubstituted pyridyl. In some embodiments, R2 is a substituted or unsubstituted pyridazinyl. In some embodiments, R2 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R2 is a substituted or unsubstituted thienyl. In some embodiments, R2 is a substituted or unsubstituted furyl. In some embodiments, R2 is an unsubstituted pyridyl. In some embodiments, R2 is an unsubstituted pyridazinyl. In some embodiments, R2 is an unsubstituted pyrimidinyl. In some embodiments, R2 is an unsubstituted thienyl. In some embodiments, R2 is a chloro-substituted thienyl. In some embodiments, R2 is an unsubstituted furyl. In some embodiments, R2 is a substituted or unsubstituted morpholinyl. In some embodiments, R2 is a substituted or unsubstituted oxanyl. In some embodiments, R2 is a substituted or unsubstituted oxetanyl. In some embodiments, R2 is an unsubstituted morpholinyl. In some embodiments, R2 is an unsubstituted oxanyl. In some embodiments, R2 is an unsubstituted oxetanyl. In some embodiments, R2 is substituted or unsubstituted benzodioxinyl. In some embodiments, R2 is substituted or unsubstituted naphthyl. In some embodiments, R2 is unsubstituted benzodioxinyl. In some embodiments, R2 is unsubstituted naphthyl.
- In some embodiments, there is provided a compound according to Formula (Ib) with structure of Formulae (IV) following.
- In some embodiments, there is provided a compound according with Formula (IV) wherein L3 is a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, and R3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, L3 is a bond, —NH—, —NHCH2— or —NH(CH2)2—.
- Further to any embodiment of a compound with structure of Formula (IV), in some embodiments, L1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —C(O)—, —C(O)—NR6—. In some embodiments, R1 is hydrogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; substituted or unsubstituted heterocycloalkyl. In some embodiments, R6 is hydrogen, or substituted or unsubstituted alkyl.
- In some embodiments, there is provided a compound according to Formula (Ia) with structure of Formulae (Va), (Vb), or (Vc) following.
- In some embodiments, there is provided a compound according to any of Formulae (Va), (Vb), or (Vc) wherein L4 is a bond; and R4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, R4 is halogen. In some embodiments, R4 is unsubstituted alkyl. Further to any embodiment wherein the compound has the structure of Formula (Va), (Vb), or (Vc), in some embodiments L3 is a bond or substituted or unsubstituted alkylene, and R3 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R3 is substituted or unsubstituted heteroalkyl. In some embodiments, R3 is substituted or unsubstituted cycloalkyl. In some embodiments, R3 is substituted or unsubstituted cyclohexyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cycloheptyl. In some embodiments, R3 is substituted or unsubstituted cycloalkenyl. In some embodiments, R3 is substituted or unsubstituted cyclohexenyl. In some embodiments, R3 is substituted or unsubstituted heterocycloalkyl. In some embodiments, R3 is substituted or unsubstituted piperidinyl. In some embodiments, R3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R3 is substituted or unsubstituted azetidinyl. In some embodiments, R3 is substituted or unsubstituted oxetanyl. In some embodiments, R3 is substituted or unsubstituted oxolanyl. In some embodiments, R3 is substituted or unsubstituted oxanyl.
- Further to any embodiment above wherein the compound has the structure of Formulae (Va), (Vb), or (Vc), in some embodiments L1 is —S—, —O—, —NR5—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, where R5 is as described in formula Ia, and R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R1 is substituted or unsubstituted phenyl. In some embodiments is an R1 is unsubstituted phenyl. In some embodiments, R1 is a substituted or unsubstituted pyridyl. In some embodiments, R1 is a substituted or unsubstituted pyridazinyl. In some embodiments, R1 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R1 is a substituted or unsubstituted thienyl. In some embodiments, R1 is a substituted or unsubstituted furyl. In some embodiments, R1 is an unsubstituted pyridyl. In some embodiments, R1 is an unsubstituted pyridazinyl. In some embodiments, R1 is an unsubstituted pyrimidinyl. In some embodiments, R1 is an unsubstituted thienyl. In some embodiments, R1 is a chloro-substituted thienyl. In some embodiments, R1 is an unsubstituted furyl. In some embodiments, R1 is a substituted or unsubstituted morpholinyl. In some embodiments, R1 is a substituted or unsubstituted oxanyl. In some embodiments, R1 is a substituted or unsubstituted oxetanyl. In some embodiments, R1 is an unsubstituted morpholinyl. In some embodiments, R1 is an unsubstituted oxanyl. In some embodiments, R1 is an unsubstituted oxetanyl. In some embodiments, R1 is substituted or unsubstituted benzodioxinyl. In some embodiments, R1 is substituted or unsubstituted naphthyl. In some embodiments, R1 is unsubstituted benzodioxinyl. In some embodiments, R1 is unsubstituted naphthyl. In some embodiments, L2 and R2 are absent. In some embodiments, L2 is a bond. In some embodiments, L2 is a bond and R2 is hydrogen.
- Further to any embodiment above wherein the compound has the structure of Formulae (Va) or (Vb), in some embodiments L2 is bond, —S—, —O—, —NR5—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In some embodiments, L2 is —C(O)—, to give the structure of Formula (Vc). In some embodiments, R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl. In some embodiments, R2 is substituted or unsubstituted phenyl. In some embodiments is an R2 is unsubstituted phenyl. In some embodiments, R2 is a substituted or unsubstituted pyridyl. In some embodiments, R2 is a substituted or unsubstituted pyridazinyl. In some embodiments, R2 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R2 is a substituted or unsubstituted thienyl. In some embodiments, R2 is a substituted or unsubstituted furyl. In some embodiments, R2 is an unsubstituted pyridyl. In some embodiments, R2 is an unsubstituted pyridazinyl. In some embodiments, R2 is an unsubstituted pyrimidinyl. In some embodiments, R2 is an unsubstituted thienyl. In some embodiments, R2 is a chloro-substituted thienyl. In some embodiments, R2 is an unsubstituted furyl. In some embodiments, R2 is a substituted or unsubstituted morpholinyl. In some embodiments, R2 is a substituted or unsubstituted oxanyl. In some embodiments, R2 is a substituted or unsubstituted oxetanyl. In some embodiments, R2 is an unsubstituted morpholinyl. In some embodiments, R2 is an unsubstituted oxanyl. In some embodiments, R2 is an unsubstituted oxetanyl. In some embodiments, R2 is substituted or unsubstituted benzodioxinyl. In some embodiments, R2 is substituted or unsubstituted naphthyl. In some embodiments, R2 is unsubstituted benzodioxinyl. In some embodiments, R2 is unsubstituted naphthyl.
- In some embodiments, there is provided a compound according to Formula (V) with structure of Formula (VI) following:
- In some embodiments, there is provided a compound according to Formula (VI) wherein L4 is a bond; and R4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, R4 is halogen. In some embodiments, R4 is unsubstituted alkyl. Further to any embodiment wherein the compound has the structure of Formula (VI), in some embodiments L3 is a bond or substituted or unsubstituted alkylene, and R3 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R3 is substituted or unsubstituted heteroalkyl. In some embodiments, R3 is substituted or unsubstituted cycloalkyl. In some embodiments, R3 is substituted or unsubstituted cyclohexyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cycloheptyl. In some embodiments, R3 is substituted or unsubstituted cycloalkenyl. In some embodiments, R3 is substituted or unsubstituted cyclohexenyl. In some embodiments, R3 is substituted or unsubstituted heterocycloalkyl. In some embodiments, R3 is substituted or unsubstituted piperidinyl. In some embodiments, R3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R3 is substituted or unsubstituted pyrrolidinyl. In some embodiments, R3 is substituted or unsubstituted azetidinyl. In some embodiments, R3 is substituted or unsubstituted oxetanyl. In some embodiments, R3 is substituted or unsubstituted oxolanyl. In some embodiments, R3 is substituted or unsubstituted oxanyl.
- Further to any embodiment above wherein the compound has the structure of Formula (VI), in some embodiments L1 is —S—, —O—, —NR5—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, where R5 is as described in formula Ia, and R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R1 is substituted or unsubstituted phenyl. In some embodiments is an R1 is unsubstituted phenyl. In some embodiments, R1 is a substituted or unsubstituted pyridyl. In some embodiments, R1 is a substituted or unsubstituted pyridazinyl. In some embodiments, R1 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R1 is a substituted or unsubstituted thienyl. In some embodiments, R1 is a substituted or unsubstituted furyl. In some embodiments, R1 is an unsubstituted pyridyl. In some embodiments, R1 is an unsubstituted pyridazinyl. In some embodiments, R1 is an unsubstituted pyrimidinyl. In some embodiments, R1 is an unsubstituted thienyl. In some embodiments, R1 is a chloro-substituted thienyl. In some embodiments, R1 is an unsubstituted furyl. In some embodiments, R1 is a substituted or unsubstituted morpholinyl. In some embodiments, R1 is a substituted or unsubstituted oxanyl. In some embodiments, R1 is a substituted or unsubstituted oxetanyl. In some embodiments, R1 is an unsubstituted morpholinyl. In some embodiments, R1 is an unsubstituted oxanyl. In some embodiments, R1 is an unsubstituted oxetanyl. In some embodiments, R1 is substituted or unsubstituted benzodioxinyl. In some embodiments, R1 is substituted or unsubstituted naphthyl. In some embodiments, R1 is unsubstituted benzodioxinyl. In some embodiments, R1 is unsubstituted naphthyl. In some embodiments, L2 and R2 are absent. In some embodiments, L2 is a bond. In some embodiments, L2 is a bond and R2 is hydrogen.
- Further to any embodiment above wherein the compound has the structure of Formula (VI), in some embodiments, L2 is bond, and R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl. In some embodiments, R2 is substituted or unsubstituted phenyl. In some embodiments is an R2 is unsubstituted phenyl. In some embodiments, R2 is a substituted or unsubstituted pyridyl. In some embodiments, R2 is a substituted or unsubstituted pyridazinyl. In some embodiments, R2 is a substituted or unsubstituted pyrimidinyl. In some embodiments, R2 is a substituted or unsubstituted thienyl. In some embodiments, R2 is a substituted or unsubstituted furyl. In some embodiments, R2 is an unsubstituted pyridyl. In some embodiments, R2 is an unsubstituted pyridazinyl. In some embodiments, R2 is an unsubstituted pyrimidinyl. In some embodiments, R2 is an unsubstituted thienyl. In some embodiments, R2 is a chloro-substituted thienyl. In some embodiments, R2 is an unsubstituted furyl. In some embodiments, R2 is a substituted or unsubstituted morpholinyl. In some embodiments, R2 is a substituted or unsubstituted oxanyl. In some embodiments, R2 is a substituted or unsubstituted oxetanyl. In some embodiments, R2 is an unsubstituted morpholinyl. In some embodiments, R2 is an unsubstituted oxanyl. In some embodiments, R2 is an unsubstituted oxetanyl. In some embodiments, R2 is substituted or unsubstituted benzodioxinyl. In some embodiments, R2 is substituted or unsubstituted naphthyl. In some embodiments, R2 is unsubstituted benzodioxinyl. In some embodiments, R2 is unsubstituted naphthyl.
- Exemplary compounds, e.g., multisubstituted aromatic compounds, in accordance with the present disclosure are provided herein. In Table A following, compound (Cmpd) number, chemical name (i.e., International Union of Pure and Applied Chemistry [IUPAC] name), molecular weight (MWcalc calculated mass and MWmeas measured mass) and biological activity (i.e., inhibition activity in a thrombin assay) are disclosed.
- Regarding experimental molecular weights obtained by mass spectrometric analysis as described herein including Table A, unless indicated otherwise it is understood that the measured chemical species can be the protonated compound, e.g., [M+H]+, whereby the measured mass is 1 atomic unit greater than the calculated mass of the compound, as well known in the art.
- For Table A following, the disclosed compounds were assayed for inhibition of the protease activity of thrombin as described herein. In Table A, the level of inhibition in the thrombin assay is indicated as follows: a: IC50≦0.1 μM; b: 0.1 μM<IC50<1 μM; c: IC50≧1 μM. Accordingly, in some embodiments, there is provided a compound as expressly set forth in Table A following.
-
TABLE A Cmpd Thrombin No. IUPAC name MWcalc MWmeas Activity 4 N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)-1H-1,2,4- 269 270 c triazol-5-amine 5 N-benzyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 251 252 c 6 N-[(4-fluorophenyl)methyl]-3-(pyridin-2-yl)-1H-1,2,4- 269 270 c triazol-5-amine 7 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 325 326 a 1H-1,2,4-triazol-1-yl)propan-1-one 9 1-(5-[(2-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 325 326 b 1H-1,2,4-triazol-1-yl)propan-1-one 10 4-([1-propanoyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- 332 333 c yl]aminomethyl)benzonitrile 11 N-benzyl-1-[(furan-2-yl)carbonyl]-3-(pyridin-2-yl)-1H- 345 346 a 1,2,4-triazol-5-amine 12 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol- 383 384 a 1-yl]-3-phenylpropan-1-one 13 N-[(4-fluorophenyl)methyl]-3-(pyridin-2-yl)-1- 379 380 a [(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 14 1-benzoyl-N-[(4-fluorophenyl)methyl]-3-(pyridin-4- 373 374 a yl)-1H-1,2,4-triazol-5-amine 15 N-[(4-fluorophenyl)methyl]-3-(pyridin-4-yl)-1- 379 380 a [(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 16 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-4- 365 366 a yl)-1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 17 N-[(4-fluorophenyl)methyl]-1-[(morpholin-4- 382 383 c yl)carbonyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 18 N-(2-fluorophenyl)-5-[(4-fluorophenyl)methyl]amino- 406 407 c 3-(pyridin-3-yl)-1H-1,2,4-triazole-1-carboxamide 19 5-[(4-fluorophenyl)methyl]amino-N-methyl-3-(pyridin- 326 327 c 3-yl)-1H-1,2,4-triazole-1-carboxamide 20 methyl 5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3- 327 328 b yl)-1H-1,2,4-triazole-1-carboxylate 21 2-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 387 388 c 1H-1,2,4-triazol-1-yl)-1-phenylethan-1-one 22 1-5-[(2-phenylethyl)amino]-3-(pyridin-3-yl)-1H-1,2,4- 321 322 c triazol-1-ylpropan-1-one 23 1-(5-[2-(morpholin-4-yl)ethyl]amino-3-(pyridin-3-yl)- 330 331 c 1H-1,2,4-triazol-1-yl)propan-1-one 24 1-[5-(dimethylamino)-3-(pyridin-3-yl)-1H-1,2,4- 245 246 c triazol-1-yl]propan-1-one 26 N-[(4-fluorophenyl)methyl]-3-(furan-2-yl)-1-[(2- 392 393 a methoxyphenyl)carbonyl]-1H-1,2,4-triazol-5-amine 27 N-[(4-fluorophenyl)methyl]-1-[(2- 408 409 b methoxyphenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4- triazol-5-amine 28 3-(5-[(4-fluorophenyl)methyl]sulfanyl-1-[(2- 420 421 a methoxyphenyl)carbonyl]-1H-1,2,4-triazol-3- yl)pyridine 29 1-[(2-methoxyphenyl)carbonyl]-5-(methylsulfanyl)-3- 331 332 a (thiophen-2-yl)-1H-1,2,4-triazole 30 methyl 5-(benzylamino)-1-[(4-chlorophenyl)carbonyl]- 371 371, 373 a 1H-1,2,4-triazole-3-carboxylate 32 methyl 5-amino-1-[(2-chlorophenyl)carbonyl]-1H- 281 281, 283 a 1,2,4-triazole-3-carboxylate 33 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3- 386 387 a (pyrimidin-4-yl)-1H-1,2,4-triazol-5-amine 34 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3- 386 387 a (pyrimidin-5-yl)-1H-1,2,4-triazol-5-amine 35 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3- 386 387 a (pyrimidin-2-yl)-1H-1,2,4-triazol-5-amine 36 1-(5-[(4-fluorophenyl)methyl]amino-3-phenyl-1H- 351 352 c pyrazol-1-yl)-2,2-dimethylpropan-1-one 37 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 352 353 c 1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one 38 1-(5-[(4-fluorophenyl)methyl]amino-4-methyl-3- 365 366 c phenyl-1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one 39 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 352 353 a 1H-pyrazol-1-yl)-2,2-dimethylpropan-1-one 40 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 324 325 b 1H-pyrazol-1-yl)propan-1-one 41 1-[(2-chlorophenyl)carbonyl]-N-[(4- 407 407, 409 b fluorophenyl)methyl]-3-(pyridin-2-yl)-1H-pyrazol-5- amine 42 1-(2-chlorophenyl)-3-(pyridin-2-yl)-1H-pyrazol-5- 271 271, 273 c amine 43 N-[1-(2-chlorophenyl)-3-(pyridin-2-yl)-1H-pyrazol-5- 393 393, 395 c yl]-4-fluorobenzamide 44 1-(2-chlorophenyl)-N,N-bis [(4-fluorophenyl)methyl]- 487 487, 489 c 3-(pyridin-2-yl)-1H-pyrazol-5-amine 45 1-(2-chlorophenyl)-N-[(4-fluorophenyl)methyl]-3- 379 379, 381 c (pyridin-2-yl)-1H-pyrazol-5-amine 46 ethyl 3-[(4-fluorophenyl)methyl]amino-1-(pyridin-2- 340 341 c yl)-1H-pyrazole-4-carboxylate 47 3-[(4-fluorophenyl)methyl]amino-1-(pyridin-2-yl)-1H- 312 313 c pyrazole-4-carboxylic acid 48 3-[(4-fluorophenyl)methyl]amino-N-methoxy-N- 355 356 c methyl-1-(pyridin-2-yl)-1H-pyrazole-4-carboxamide 49 3-[(4-fluorophenyl)methyl]amino-N,N-dimethyl-1- 339 340 c (pyridin-2-yl)-1H-pyrazole-4-carboxamide 50 1-(3-[(4-fluorophenyl)methyl]amino-1-(pyridin-2-yl)- 324 325 c 1H-pyrazol-4-yl)propan-1-one 51 ethyl 1-[2-(4-fluorophenyl)ethyl]-3-(pyridin-2-yl)-1H- 339 340 c pyrazole-5-carboxylate 52 1-[2-(4-fluorophenyl)ethyl]-3-(pyridin-2-yl)-1H- 311 312 c pyrazole-5-carboxylic acid 53 1-[2-(4-fluorophenyl)ethyl]-N-methoxy-N-methyl-3- 354 355 c (pyridin-2-yl)-1H-pyrazole-5-carboxamide 54 2-1-[2-(4-fluorophenyl)ethyl]-5-[(piperidin-1- 378 379 c yl)carbonyl]-1H-pyrazol-3-ylpyridine 55 1-1-[2-(4-fluorophenyl)ethyl]-3-(pyridin-2-yl)-1H- 325 326 c pyrazol-5-ylpropan-1-ol 56 1-1-[2-(4-fluorophenyl)ethyl]-3-(pyridin-2-yl)-1H- 323 324 c pyrazol-5-ylpropan-1-one 57 ethyl 1-[2-(4-fluorophenyl)ethyl]-5-(pyridin-2-yl)-1H- 339 340 c pyrazole-3-carboxylate 58 1-[2-(4-fluorophenyl)ethyl]-5-(pyridin-2-yl)-1H- 311 312 c pyrazole-3-carboxylic acid 59 2-1-[2-(4-fluorophenyl)ethyl]-3-[(piperidin-1- 378 379 c yl)carbonyl]-1H-pyrazol-5-ylpyridine 60 1-(3-[(4-fluorophenyl)methyl]amino-1-(pyridin-2-yl)- 310 311 c 1H-pyrazol-4-yl)ethan-1-one 61 1-(3-[(4-fluorophenyl)methyl]amino-1-phenyl-1H- 309 310 c pyrazol-4-yl)ethan-1-one 62 1-(3-[(4-fluorophenyl)methyl]amino-1-phenyl-1H- 323 324 c pyrazol-4-yl)propan-1-one 63 1-(5-[(4-fluorophenyl)methyl]amino-3-(furan-2-yl)- 314 315 a 1H-1,2,4-triazol-1-yl)propan-1-one 64 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 353 354 a 1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 65 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 339 340 a 1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one 66 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 387 388 a 1H-1,2,4-triazol-1-yl)-2-phenylethan-1-one 67 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 353 354 a 1H-1,2,4-triazol-1-yl)-3-methylbutan-1-one 68 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 401 402 a 1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one 69 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 339 340 a 1H-1,2,4-triazol-1-yl)butan-1-one 70 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-2-yl)- 325 326 a 1H-1,2,4-triazol-1-yl)propan-1-one 71 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 353 354 a 1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 72 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 367 368 c 1H-1,2,4-triazol-1-yl)-3,3-dimethylbutan-2-one 73 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 325 326 c 1H-1,2,4-triazol-1-yl)propan-2-one 74 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)- 324 325 c 1H-pyrazol-1-yl)propan-1-one 75 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 353 354 a 1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 76 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 339 340 a 1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one 77 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 387 388 a 1H-1,2,4-triazol-1-yl)-2-phenylethan-1-one 78 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 353 354 a 1H-1,2,4-triazol-1-yl)-3-methylbutan-1-one 79 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 401 402 a 1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one 80 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 339 340 a 1H-1,2,4-triazol-1-yl)butan-1-one 81 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-4-yl)- 325 326 a 1H-1,2,4-triazol-1-yl)propan-1-one 82 1-(5-[(4-fluorophenyl)methyl]amino-3-(thiophen-2-yl)- 358 359 a 1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 83 1-(5-[(4-fluorophenyl)methyl]amino-3-(thiophen-2-yl)- 330 331 b 1H-1,2,4-triazol-1-yl)propan-1-one 84 1-(5-[(4-fluorophenyl)methyl]amino-3-phenyl-1H- 323 324 c pyrazol-1-yl)propan-1-one 85 1-(5-[(4-fluorophenyl)methyl]amino-4-methyl-3- 337 338 c phenyl-1H-pyrazol-1-yl)propan-1-one 86 1-(5-[(4-fluorophenyl)methyl]sulfanyl-3-(pyridin-3-yl)- 342 343 a 1H-1,2,4-triazol-1-yl)propan-1-one 87 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2- 365 366 a yl)-1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 88 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2- 351 352 a yl)-1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one 89 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2- 399 400 a yl)-1H-1,2,4-triazol-1-yl)-2-phenylethan-1-one 90 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2- 365 366 a yl)-1H-1,2,4-triazol-1-yl)-3-methylbutan-1-one 91 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2- 413 414 b yl)-1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one 92 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2- 351 352 a yl)-1H-1,2,4-triazol-1-yl)butan-1-one 93 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2- 337 338 a yl)-1H-1,2,4-triazol-1-yl)propan-1-one 94 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3- 365 366 a yl)-1H-1,2,4-triazol-1-yl)-2,2-dimethylpropan-1-one 95 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-4- 351 352 a yl)-1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one 96 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-4- 399 400 a yl)-1H-1,2,4-triazol-1-yl)-2-phenylethan-1-one 97 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-4- 365 366 a yl)-1H-1,2,4-triazol-1-yl)-3-methylbutan-1-one 98 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-4- 413 414 c yl)-1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one 99 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-4- 351 352 a yl)-1H-1,2,4-triazol-1-yl)butan-1-one 100 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-4- 337 338 b yl)-1H-1,2,4-triazol-1-yl)propan-1-one 101 1-[(2,2-difluoro-2H-1,3-benzodioxol-4-yl)carbonyl]-N- 452 453 c [(4-fluorophenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5- amine 102 1-[(2,3-dihydro-1,4-benzodioxin-5-yl)carbonyl]-N-[(4- 430 431 a fluorophenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5- amine 103 1-[(2-amino-4-methoxyphenyl)carbonyl]-N-benzyl-3- 416 417 c (2-fluorophenyl)-1H-pyrazol-5-amine 104 1-[(2-amino-4-methoxyphenyl)carbonyl]-N-benzyl-3- 400 401 a (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 105 1-[(2-amino-4-methoxyphenyl)carbonyl]-N-benzyl-3- 399 400 b (pyridin-2-yl)-1H-pyrazol-5-amine 106 1-[(2-amino-4-methylphenyl)carbonyl]-N-benzyl-3-(2- 400 401 c fluorophenyl)-1H-pyrazol-5-amine 107 1-[(2-amino-4-methylphenyl)carbonyl]-N-benzyl-3- 384 385 a (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 108 1-[(2-amino-4-methylphenyl)carbonyl]-N-benzyl-3- 383 384 b (pyridin-2-yl)-1H-pyrazol-5-amine 109 1-[(2-aminophenyl)carbonyl]-N-benzyl-3-(pyridin-2- 370 371 a yl)-1H-1,2,4-triazol-5-amine 110 1-[(2-chlorophenyl)carbonyl]-5-(methylsulfanyl)-3- 336 336, 338 a (thiophen-2-yl)-1H-1,2,4-triazole 111 1-[(2-chlorophenyl)carbonyl]-N-[(4- 408 408, 410 a fluorophenyl)methyl]-3-(pyridin-2-yl)-1H-1,2,4- triazol-5-amine 112 1-[(2-chlorophenyl)carbonyl]-N-[(4-fluorophenyl)methyl]- 408 408, 410 a 3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 113 1-[(2-chlorophenyl)carbonyl]-N-[(4-fluorophenyl)methyl]- 413 413, 415 a 3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 114 1-[(2-chlorophenyl)carbonyl]-N-[(4- 406 406, 408 c fluorophenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 115 1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-N- 391 392 a (thiophen-2-ylmethyl)-1H-1,2,4-triazol-5-amine 116 1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-N- 390 391 b (thiophen-2-ylmethyl)-1H-pyrazol-5-amine 117 1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-N- 391 392 a (thiophen-3-ylmethyl)-1H-1,2,4-triazol-5-amine 118 1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-N- 390 391 b (thiophen-3-ylmethyl)-1H-pyrazol-5-amine 119 1-[(2-methoxyphenyl)carbonyl]-N-(naphthalen-1- 435 436 c ylmethyl)-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 120 1-[(2-methoxyphenyl)carbonyl]-N-(naphthalen-2- 435 436 c ylmethyl)-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 121 1-[(4-chlorophenyl)carbonyl]-N-[(4-fluorophenyl)methyl]- 408 408, 410 a 3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 122 1-[(4-chlorophenyl)carbonyl]-N-[(4-fluorophenyl)methyl]- 408 408, 410 b 3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 123 1-[(furan-2-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]- 375 376 b 3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 124 1-[(furan-2-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]- 375 376 b 3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 125 1-[(furan-3-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]- 375 376 b 3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 126 1-[(furan-3-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]- 375 376 b 3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 127 1-[(furan-3-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]- 375 376 c 3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 128 1-[2-(4-fluorophenyl)ethyl]-N,N-dimethyl-3-(pyridin- 338 339 c 2-yl)-1H-pyrazole-5-carboxamide 129 1-[2-(4-fluorophenyl)ethyl]-N,N-dimethyl-5-(pyridin- 338 339 c 2-yl)-1H-pyrazole-3-carboxamide 130 1-[2-(4-fluorophenyl)ethyl]-N-methyl-N-phenyl-3- 400 401 c (pyridin-2-yl)-1H-pyrazole-5-carboxamide 131 1-[2-(4-fluorophenyl)ethyl]-N-methyl-N-phenyl-5- 400 401 c (pyridin-2-yl)-1H-pyrazole-3-carboxamide 132 1-[5-(benzylamino)-3-(2-fluorophenyl)-1H-1,2,4- 324 325 a triazol-1-yl]propan-1-one 133 1-[5-(benzylamino)-3-(2-fluorophenyl)-1H-pyrazol-1- 351 352 b yl]-2,2-dimethylpropan-1-one 134 1-[5-(benzylamino)-3-(2-fluorophenyl)-1H-pyrazol-1- 351 352 c yl]-3-methylbutan-1-one 135 1-[5-(benzylamino)-3-(3-fluorophenyl)-1H-1,2,4- 324 325 b triazol-1-yl]propan-1-one 136 1-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1- 324 325 a yl]-2,2-dimethylpropan-1-one 137 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol- 335 336 a 1-yl]-2,2-dimethylpropan-1-one 138 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol- 321 322 a 1-yl]-2-methylpropan-1-one 139 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol- 369 370 a 1-yl]-2-phenylethan-1-one 140 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol- 335 336 a 1-yl]-3-methylbutan-1-one 141 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol- 321 322 a 1-yl]butan-1-one 142 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol- 307 308 a 1-yl]propan-1-one 143 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-pyrazol-1-yl]- 334 335 a 2,2-dimethylpropan-1-one 144 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-pyrazol-1-yl]- 334 335 b 3-methylbutan-1-one 145 1-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol- 335 336 a 1-yl]-2,2-dimethylpropan-1-one 146 1-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol- 321 322 a 1-yl]-2-methylpropan-1-one 147 1-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol- 369 370 a 1-yl]-2-phenylethan-1-one 148 1-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol- 335 336 a 1-yl]-3-methylbutan-1-one 149 1-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol- 383 384 b 1-yl]-3-phenylpropan-1-one 150 1-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol- 321 322 a 1-yl]butan-1-one 151 1-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol- 307 308 a 1-yl]propan-1-one 152 1-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol- 340 341 a 1-yl]-2,2-dimethylpropan-1-one 153 1-[5-(methylsulfanyl)-3-(pyridin-3-yl)-1H-1,2,4- 248 249 c triazol-1-yl]propan-1-one 154 1-[5-(methylsulfanyl)-3-(thiophen-2-yl)-1H-1,2,4- 253 254 c triazol-1-yl]propan-1-one 155 1-[5-amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- 217 218 c yl]propan-1-one 156 1-benzoyl-N-[(4-fluorophenyl)methyl]-3-(pyridin-2- 373 374 a yl)-1H-1,2,4-triazol-5-amine 157 1-benzoyl-N-[(4-methoxyphenyl)methyl]-3-(pyridin-2- 385 386 b yl)-1H-1,2,4-triazol-5-amine 158 1-benzoyl-N-[(4-methoxyphenyl)methyl]-3-(pyridin-4- 385 386 c yl)-1H-1,2,4-triazol-5-amine 159 1-benzoyl-N-benzyl-3-(pyridin-2-yl)-1H-1,2,4-triazol- 355 356 a 5-amine 160 1-benzoyl-N-benzyl-3-(pyridin-4-yl)-1H-1,2,4-triazol- 355 356 a 5-amine 161 1-benzyl-N-[(4-fluorophenyl)methyl]-3-(pyridin-2-yl)- 359 360 c 1H-1,2,4-triazol-5-amine 162 1-benzyl-N-[(4-fluorophenyl)methyl]-5-(pyridin-2-yl)- 359 360 c 1H-1,2,4-triazol-3-amine 163 1-1-[2-(4-fluorophenyl)ethyl]-3-(pyridin-2-yl)-1H- 311 312 c pyrazol-5-ylethan-1-ol 164 1-1-[2-(4-fluorophenyl)ethyl]-3-(pyridin-2-yl)-1H- 309 310 c pyrazol-5-ylethan-1-one 165 1-5-[(furan-2-ylmethyl)amino]-3-(pyridin-2-yl)-1H- 324 325 b pyrazol-1-yl-2,2-dimethylpropan-1-one 166 1-5-[(furan-3-ylmethyl)amino]-3-(pyridin-2-yl)-1H- 324 325 b pyrazol-1-yl-2,2-dimethylpropan-1-one 167 2,2-dimethyl-1-[3-(pyridin-2-yl)-5-[(thiophen-2- 340 341 a ylmethyl)amino]-1H-pyrazol-1-yl]propan-1-one 168 2,2-dimethyl-1-[3-(pyridin-2-yl)-5-[(thiophen-3- 340 341 b ylmethyl)amino]-1H-pyrazol-1-yl]propan-1-one 169 2,2-dimethyl-N-3-[(morpholin-4-yl)carbonyl]-1H- 281 282 c 1,2,4-triazol-5-ylpropanamide 170 2-chloro-N-3-[(morpholin-4-yl)carbonyl]-1H-1,2,4- 336 336, 338 c triazol-5-ylbenzamide 171 2-chloro-N-3-[(pyrrolidin-1-yl)carbonyl]-1H-1,2,4- 320 320, 322 c triazol-5-ylbenzamide 172 2-chlorophenyl 5-[(4-fluorophenyl)methyl]amino-3- 424 424, 426 c (pyridin-3-yl)-1H-1,2,4-triazole-1-carboxylate 173 2-fluorophenyl 5-[(4-fluorophenyl)methyl]amino-3- 407 408 c (pyridin-3-yl)-1H-1,2,4-triazole-1-carboxylate 174 2-methoxyphenyl 5-[(4-fluorophenyl)methyl]amino-3- 419 420 c (pyridin-3-yl)-1H-1,2,4-triazole-1-carboxylate 175 2-1-[2-(4-fluorophenyl)ethyl]-5-[(2- 401 402 c methoxyphenyl)carbonyl]-1H-pyrazol-3-ylpyridine 176 2-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol- 380 381 b 1-yl]carbonylbenzonitrile 177 2-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol- 413 414 a 1-yl]carbonylphenyl acetate 178 3-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)-1H-1,2,4- 257 258 c triazol-5-amine 179 3-([1-propanoyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- 332 333 c yl]aminomethyl)benzonitrile 180 3-1-[(2-chlorophenyl)carbonyl]-5-(methylsulfanyl)-1H- 331 331, 333 a 1,2,4-triazol-3-ylpyridine 181 3-1-[(2-chlorophenyl)carbonyl]-5-[(4- 425 425, 427 b fluorophenyl)methyl]sulfanyl-1H-1,2,4-triazol-3- ylpyridine 182 3-1-[(2-methoxyphenyl)carbonyl]-5-(methylsulfanyl)- 326 327 a 1H-1,2,4-triazol-3-ylpyridine 183 3-[(4-fluorophenyl)methyl]amino-N-phenyl-1-(pyridin- 387 388 c 2-yl)-1H-pyrazole-4-carboxamide 184 4-chloro-N-3-[(morpholin-4-yl)carbonyl]-1H-1,2,4- 336 336, 338 c triazol-5-ylbenzamide 185 4-methyl-N-3-[(morpholin-4-yl)carbonyl]-1H-1,2,4- 315 316 c triazol-5-ylbenzamide 186 5-C-(2-chlorobenzene)-3-N,3-N-dimethyl-1H-1,2,4- 294 294, 296 c triazole-3,5-dicarboxamide 187 5-C-(2-chlorobenzene)-3-N-methyl-1H-1,2,4-triazole- 280 280, 282 c 3,5-dicarboxamide 188 5-[(4-fluorophenyl)methyl]amino-N,N-dimethyl-3- 340 341 c (pyridin-3-yl)-1H-1,2,4-triazole-1-carboxamide 189 5-[(4-fluorophenyl)methyl]amino-N-(2- 418 419 c methoxyphenyl)-3-(pyridin-3-yl)-1H-1,2,4-triazole-1- carboxamide 190 5-[(4-fluorophenyl)methyl]amino-N-(propan-2-yl)-3- 354 355 c (pyridin-3-yl)-1H-1,2,4-triazole-1-carboxamide 191 5-[(4-fluorophenyl)methyl]amino-N-phenyl-3-(pyridin- 388 389 c 3-yl)-1H-1,2,4-triazole-1-carboxamide 192 ethyl 5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3- 341 342 b yl)-1H-1,2,4-triazole-1-carboxylate 193 methyl 5-[(2-fluorobenzene)amido]-1H-1,2,4-triazole- 264 265 c 3-carboxylate 194 methyl 5-[(2-methoxybenzene)amido]-1H-1,2,4- 276 277 c triazole-3-carboxylate 195 methyl 5-[(3-chlorobenzene)amido]-1H-1,2,4-triazole- 281 281, 283 c 3-carboxylate 196 methyl 5-[(4-methylbenzene)amido]-1H-1,2,4-triazole- 260 261 c 3-carboxylate 197 methyl 5-amino-1-[(4-chlorophenyl)carbonyl]-1H- 281 281, 283 a 1,2,4-triazole-3-carboxylate 198 N-(1-benzothiophen-2-ylmethyl)-1-[(2- 442 442 c methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4- triazol-5-amine 199 N-(1-benzothiophen-3-ylmethyl)-1-[(2- 442 442 c methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4- triazol-5-amine 200 N-(2-chlorophenyl)-5-[(4-fluorophenyl)methyl]amino- 423 423, 425 c 3-(pyridin-3-yl)-1H-1,2,4-triazole-1-carboxamide 201 N-(furan-2-ylmethyl)-1-[(2-methoxyphenyl)carbonyl]- 374 375 b 3-(pyridin-2-yl)-1H-pyrazol-5-amine 202 N-(furan-3-ylmethyl)-1-[(2-methoxyphenyl)carbonyl]- 374 375 b 3-(pyridin-2-yl)-1H-pyrazol-5-amine 203 N-[(4-fluorophenyl)methyl]-1-(2-phenylethyl)-3- 373 374 c (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 204 N-[(4-fluorophenyl)methyl]-1-(2-phenylethyl)-5- 373 374 c (pyridin-2-yl)-1H-1,2,4-triazol-3-amine 205 N-[(4-fluorophenyl)methyl]-1-[(2-methoxy-4- 416 417 b methylphenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5- amine 206 N-[(4-fluorophenyl)methyl]-1-[(2- 403 404 a methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4- triazol-5-amine 207 N-[(4-fluorophenyl)methyl]-1-[(2- 403 404 a methoxyphenyl)carbonyl]-3-(pyridin-4-yl)-1H-1,2,4- triazol-5-amine 208 N-[(4-fluorophenyl)methyl]-1-[(2-methoxyphenyl)carbonyl]- 401 402 c 3-phenyl-1H-pyrazol-5-amine 209 N-[(4-fluorophenyl)methyl]-1-[(2- 386 387 b methylphenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5- amine 210 N-[(4-fluorophenyl)methyl]-1-[(furan-2-yl)carbonyl]- 363 364 a 3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 211 N-[(4-fluorophenyl)methyl]-1-[(furan-2-yl)carbonyl]- 363 364 a 3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 212 N-[(4-fluorophenyl)methyl]-1-[(furan-3-yl)carbonyl]- 363 364 a 3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 213 N-[(4-fluorophenyl)methyl]-1-[(furan-3-yl)carbonyl]- 363 364 a 3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 214 N-[(4-fluorophenyl)methyl]-1-[(furan-3-yl)carbonyl]- 363 364 a 3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 215 N-[(4-fluorophenyl)methyl]-1-[(piperidin-1- 380 381 c yl)carbonyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 216 N-[(4-fluorophenyl)methyl]-1-propyl-3-(pyridin-2-yl)- 311 312 c 1H-1,2,4-triazol-5-amine 217 N-[(4-fluorophenyl)methyl]-1-propyl-5-(pyridin-2-yl)- 311 312 c 1H-1,2,4-triazol-3-amine 218 N-[(4-fluorophenyl)methyl]-2,2-dimethyl-N-(4-methyl- 365 366 c 3-phenyl-1H-pyrazol-5-yl)propanamide 219 N-[(4-fluorophenyl)methyl]-3-(pyridin-2-yl)-1- 379 380 a [(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 220 N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)-1- 379 380 a [(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 221 N-[(4-fluorophenyl)methyl]-3-(pyridin-4-yl)-1- 379 380 b [(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 222 N-[(4-fluorophenyl)methyl]-3-phenyl-1-[(thiophen-3- 378 379 a yl)carbonyl]-1H-1,2,4-triazol-5-amine 223 N-[(4-fluorophenyl)methyl]-4-[(2- 402 403 c methoxyphenyl)carbonyl]-1-(pyridin-2-yl)-1H-pyrazol- 3-amine 224 N-[(4-fluorophenyl)methyl]-4-[(2-methoxyphenyl)carbonyl]- 401 402 c 1-phenyl-1H-pyrazol-3-amine 225 N-[(4-fluorophenyl)methyl]-4-[(piperidin-1- 379 380 c yl)carbonyl]-1-(pyridin-2-yl)-1H-pyrazol-3-amine 226 N-[(4-methoxyphenyl)methyl]-3-(pyridin-2-yl)-1- 391 392 c [(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 227 N-[(4-methoxyphenyl)methyl]-3-(pyridin-2-yl)-1- 391 392 b [(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 228 N-[(4-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1- 391 392 c [(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 229 N-[(4-methoxyphenyl)methyl]-3-(pyridin-4-yl)-1- 391 392 c [(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 230 N-[(4-methoxyphenyl)methyl]-3-(pyridin-4-yl)-1- 391 392 b [(thiophen-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 231 N-benzyl-1-[(2,2-difluoro-2H-1,3-benzodioxol-4- 435 436 c yl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 232 N-benzyl-1-[(2,3-dihydro-1,4-benzodioxin-5- 413 414 a yl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 233 N-benzyl-1-[(2,3-dimethoxyphenyl)carbonyl]-3- 415 416 a (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 234 N-benzyl-1-[(2,4-dimethoxyphenyl)carbonyl]-3-(2- 431 432 c fluorophenyl)-1H-pyrazol-5-amine 235 N-benzyl-1-[(2,4-dimethoxyphenyl)carbonyl]-3- 415 416 a (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 236 N-benzyl-1-[(2,4-dimethoxyphenyl)carbonyl]-3- 414 415 b (pyridin-2-yl)-1H-pyrazol-5-amine 237 N-benzyl-1-[(2,4-dimethylphenyl)carbonyl]-3-(pyridin- 383 384 b 2-yl)-1H-1,2,4-triazol-5-amine 238 N-benzyl-1-[(2,6-dichlorophenyl)carbonyl]-3-(pyridin- 424 424, 426, c 2-yl)-1H-1,2,4-triazol-5-amine 428 239 N-benzyl-1-[(2,6-difluorophenyl)carbonyl]-3-(pyridin- 391 392 b 2-yl)-1H-1,2,4-triazol-5-amine 240 N-benzyl-1-[(2-bromophenyl)carbonyl]-3-(pyridin-2- 434 434, 436 a yl)-1H-1,2,4-triazol-5-amine 241 N-benzyl-1-[(2-bromophenyl)carbonyl]-3-(pyridin-2- 433 433, 435 b yl)-1H-pyrazol-5-amine 242 N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(2- 406 406, 408 b fluorophenyl)-1H-pyrazol-5-amine 243 N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(pyridin-2- 390 390, 392 a yl)-1H-1,2,4-triazol-5-amine 244 N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(pyridin-2- 389 389, 391 b yl)-1H-pyrazol-5-amine 245 N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(pyridin-4- 390 390, 392 a yl)-1H-1,2,4-triazol-5-amine 246 N-benzyl-1-[(2-ethylphenyl)carbonyl]-3-(pyridin-2-yl)- 383 384 b 1H-1,2,4-triazol-5-amine 247 N-benzyl-1-[(2-ethylphenyl)carbonyl]-3-(pyridin-2-yl)- 382 383 c 1H-pyrazol-5-amine 248 N-benzyl-1-[(2-fluoro-4-methoxyphenyl)carbonyl]-3- 403 404 a (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 249 N-benzyl-1-[(2-fluoro-4-methylphenyl)carbonyl]-3- 387 388 a (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 250 N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-(pyridin-2- 373 374 a yl)-1H-1,2,4-triazol-5-amine 251 N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-(pyridin-2- 372 373 a yl)-1H-pyrazol-5-amine 252 N-benzyl-1-[(2-fluorophenyl)carbonyl]-N-methyl-3- 387 388 b (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 253 N-benzyl-1-[(2-methoxy-4-methylphenyl)carbonyl]-3- 399 400 a (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 254 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3- 386 387 a (pyridazin-3-yl)-1H-1,2,4-triazol-5-amine 255 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2- 385 386 a yl)-1H-1,2,4-triazol-5-amine 256 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2- 384 385 b yl)-1H-pyrazol-5-amine 257 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-4- 385 386 a yl)-1H-1,2,4-triazol-5-amine 258 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(thiophen- 390 391 a 2-yl)-1H-1,2,4-triazol-5-amine 259 N-benzyl-1-[(2-methylphenyl)carbonyl]-3-(pyridin-2- 369 370 a yl)-1H-1,2,4-triazol-5-amine 260 N-benzyl-1-[(2-methylphenyl)carbonyl]-3-(pyridin-2- 368 369 c yl)-1H-pyrazol-5-amine 261 N-benzyl-1-[(3-methoxyphenyl)carbonyl]-3-(pyridin-2- 385 386 a yl)-1H-1,2,4-triazol-5-amine 262 N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-(pyridin-2- 390 390, 392 a yl)-1H-1,2,4-triazol-5-amine 263 N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-(pyridin-4- 390 390, 392 a yl)-1H-1,2,4-triazol-5-amine 264 N-benzyl-1-[(4-methoxy-2-methylphenyl)carbonyl]-3- 399 400 a (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 265 N-benzyl-1-[(4-methoxyphenyl)carbonyl]-3-(pyridin-2- 385 386 a yl)-1H-1,2,4-triazol-5-amine 266 N-benzyl-1-[(furan-2-yl)carbonyl]-3-(pyridin-4-yl)-1H- 345 346 a 1,2,4-triazol-5-amine 267 N-benzyl-1-[(furan-3-yl)carbonyl]-3-(pyridin-2-yl)-1H- 345 346 a 1,2,4-triazol-5-amine 268 N-benzyl-1-[(furan-3-yl)carbonyl]-3-(pyridin-4-yl)-1H- 345 346 a 1,2,4-triazol-5-amine 269 N-benzyl-1-[(naphthalen-1-yl)carbonyl]-3-(pyridin-2- 405 406 a yl)-1H-1,2,4-triazol-5-amine 270 N-benzyl-1-[(naphthalen-1-yl)carbonyl]-3-(pyridin-2- 404 405 c yl)-1H-pyrazol-5-amine 271 N-benzyl-1-[(naphthalen-2-yl)carbonyl]-3-(pyridin-2- 405 406 b yl)-1H-1,2,4-triazol-5-amine 272 N-benzyl-1-[(naphthalen-2-yl)carbonyl]-3-(pyridin-2- 404 405 c yl)-1H-pyrazol-5-amine 273 N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3- 398 399 c (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 274 N-benzyl-1-[2-(methylamino)phenyl]carbonyl-3- 384 385 N/A (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 275 N-benzyl-1-[2-(propan-2-yl)phenyl]carbonyl-3- 397 398 c (pyridin-2-yl)-1H-1,2,4-triazol-5-amine 276 N-benzyl-1-[2-(propan-2-yl)phenyl]carbonyl-3- 396 397 c (pyridin-2-yl)-1H-pyrazol-5-amine 277 N-benzyl-3-(2-fluorophenyl)-1-[(2- 389 390 b fluorophenyl)carbonyl]-1H-pyrazol-5-amine 278 N-benzyl-3-(2-fluorophenyl)-1-[(2- 401 402 c methoxyphenyl)carbonyl]-1H-pyrazol-5-amine 279 N-benzyl-3-(2-fluorophenyl)-1-[(thiophen-3- 377 378 c yl)carbonyl]-1H-pyrazol-5-amine 280 N-benzyl-3-(furan-2-yl)-1-[(2- 374 375 a methoxyphenyl)carbonyl]-1H-1,2,4-triazol-5-amine 281 N-benzyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 240 241 c 282 N-benzyl-3-(pyridin-2-yl)-1-[(thiophen-2-yl)carbonyl]- 361 362 a 1H-1,2,4-triazol-5-amine 283 N-benzyl-3-(pyridin-2-yl)-1-[(thiophen-3-yl)carbonyl]- 361 362 a 1H-1,2,4-triazol-5-amine 284 N-benzyl-3-(pyridin-2-yl)-1-[(thiophen-3-yl)carbonyl]- 360 361 a 1H-pyrazol-5-amine 285 N-benzyl-3-(pyridin-2-yl)-1-[2-(trifluoromethoxy)phenyl]carbonyl- 439 440 a 1H-1,2,4-triazol-5-amine 286 N-benzyl-3-(pyridin-2-yl)-1-[2-(trifluoromethyl)phenyl]carbonyl- 423 424 c 1H-1,2,4-triazol-5-amine 287 N-benzyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 251 252 c 288 N-benzyl-3-(pyridin-4-yl)-1-[(thiophen-2-yl)carbonyl]- 361 362 a 1H-1,2,4-triazol-5-amine 289 N-benzyl-3-(pyridin-4-yl)-1-[(thiophen-3-yl)carbonyl]- 361 362 a 1H-1,2,4-triazol-5-amine 290 N-benzyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 251 252 c 291 N-benzyl-3-(thiophen-2-yl)-1-[(thiophen-3- 366 367 b yl)carbonyl]-1H-1,2,4-triazol-5-amine 292 N-benzyl-N-[3-(2-fluorophenyl)-1H-pyrazol-5-yl]-2- 401 402 c methoxybenzamide 293 N-ethyl-1-[2-(4-fluorophenyl)ethyl]-N-methyl-3- 352 353 c (pyridin-2-yl)-1H-pyrazole-5-carboxamide 294 N-ethyl-1-[2-(4-fluorophenyl)ethyl]-N-methyl-5- 352 353 c (pyridin-2-yl)-1H-pyrazole-3-carboxamide 295 N-ethyl-3-[(4-fluorophenyl)methyl]amino-1-(pyridin- 339 340 c 2-yl)-1H-pyrazole-4-carboxamide 296 N-ethyl-5-[(4-fluorophenyl)methyl]amino-3-(pyridin- 340 341 c 3-yl)-1H-1,2,4-triazole-1-carboxamide 297 N-ethyl-5-[(4-fluorophenyl)methyl]amino-N-methyl-3- 354 355 c (pyridin-3-yl)-1H-1,2,4-triazole-1-carboxamide 298 phenyl 5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3- 389 390 a yl)-1H-1,2,4-triazole-1-carboxylate 299 propan-2-yl 5-[(4-fluorophenyl)methyl]amino-3- 355 356 c (pyridin-3-yl)-1H-1,2,4-triazole-1-carboxylate 300 tert-butyl 5-[(4-fluorophenyl)methyl]amino-3-(pyridin- 369 370 c 3-yl)-1H-1,2,4-triazole-1-carboxylate 301 tert-butyl N-(2-[5-(benzylamino)-3-(pyridin-2-yl)-1H- 471 471 c 1,2,4-triazol-1-yl]carbonylphenyl)carbamate 302 tert-butyl N-(4-acetyl-1-phenyl-1H-pyrazol-3-yl)-N- 409 410 c [(4-fluorophenyl)methyl]carbamate 303 tert-butyl N-[(4-fluorophenyl)methyl]-N-4-[(2- 502 502 c methoxyphenyl)carbonyl]-1-phenyl-1H-pyrazol-3- ylcarbamate 304 1-[2-(4-fluorophenyl)ethyl]-3-(pyridin-2-yl)-1H- 403 404 c pyrazol-5-yl(2-methoxyphenyl)methanol - In some embodiments, there is provided a compound as expressly set forth in Table B following.
-
TABLE B Cmpd No IUPAC name 413 1-[3-(4-chlorophenyl)-5-[(4-fluorophenyl)methyl]amino-1H-1,2,4-triazol-1-yl]-2- methoxyethan-1-one 414 1-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl]-3-methylbutan-1-one 415 1-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl]ethan-1-one 416 1-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl]ethan-1-one 417 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl]ethan-1-one 418 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]-2-methylpropan-1-one 419 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]-2-phenylethan-1-one 420 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]-3-methylbutan-1-one 421 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]-3-phenylpropan-1-one 422 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]butan-1-one 423 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]ethan-1-one 424 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]propan-1-one 425 1-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1-yl]ethan-1-one 426 1-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]-2-methylpropan-1-one 427 1-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]-2-phenylethan-1-one 428 1-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]-3-methylbutan-1-one 429 1-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]-3-phenylpropan-1-one 430 1-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]butan-1-one 431 1-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]ethan-1-one 432 1-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]-2-methylpropan-1-one 433 1-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]-3-methylbutan-1-one 434 1-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]butan-1-one 435 1-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]ethan-1-one 436 1-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]-2-methylpropan-1-one 437 1-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]-2-phenylethan-1-one 438 1-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]-3-methylbutan-1-one 439 1-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]-3-phenylpropan-1-one 440 1-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]butan-1-one 441 1-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]ethan-1-one 442 1-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]propan-1-one 443 1-benzoyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 444 1-benzoyl-3-(furan-2-yl)-N-(pyridin-2-ylmethyl)-1H-1,2,4-triazol-5-amine 445 1-benzoyl-3-(furan-2-yl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine 446 1-benzoyl-3-(furan-2-yl)-N-(pyridin-4-ylmethyl)-1H-1,2,4-triazol-5-amine 447 1-benzoyl-3-(furan-2-yl)-N-[(2-methylphenyl)methyl]-1H-1,2,4-triazol-5-amine 448 1-benzoyl-3-(furan-2-yl)-N-[(3-methoxyphenyl)methyl]-1H-1,2,4-triazol-5-amine 449 1-benzoyl-3-(furan-2-yl)-N-[(3-methylphenyl)methyl]-1H-1,2,4-triazol-5-amine 450 1-benzoyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 451 1-benzoyl-3-(pyridin-2-yl)-N-(pyridin-2-ylmethyl)-1H-1,2,4-triazol-5-amine 452 1-benzoyl-3-(pyridin-2-yl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine 453 1-benzoyl-3-(pyridin-2-yl)-N-(pyridin-4-ylmethyl)-1H-1,2,4-triazol-5-amine 454 1-benzoyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 455 1-benzoyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine 456 1-benzoyl-3-(pyridin-3-yl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine 457 1-benzoyl-3-(pyridin-3-yl)-N-(pyridin-3-ylmethyl)-1H-pyrazol-5-amine 458 1-benzoyl-3-(pyridin-3-yl)-N-(pyridin-4-ylmethyl)-1H-1,2,4-triazol-5-amine 459 1-benzoyl-3-(pyridin-3-yl)-N-(pyridin-4-ylmethyl)-1H-pyrazol-5-amine 460 1-benzoyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 461 1-benzoyl-3-(pyridin-4-yl)-N-(pyridin-4-ylmethyl)-1H-1,2,4-triazol-5-amine 462 1-benzoyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 463 1-benzoyl-3-phenyl-1H-1,2,4-triazol-5-amine 464 1-benzoyl-3-phenyl-1H-pyrazol-5-amine 465 1-benzoyl-3-phenyl-N-(pyridin-2-ylmethyl)-1H-pyrazol-5-amine 466 1-benzoyl-3-phenyl-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine 467 1-benzoyl-3-phenyl-N-(pyridin-3-ylmethyl)-1H-pyrazol-5-amine 468 1-benzoyl-3-phenyl-N-(pyridin-4-ylmethyl)-1H-pyrazol-5-amine 469 1-benzoyl-N-(pyridin-2-ylmethyl)-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 470 1-benzoyl-N-(pyridin-2-ylmethyl)-3-(pyridin-3-yl)-1H-pyrazol-5-amine 471 1-benzoyl-N-(pyridin-2-ylmethyl)-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 472 1-benzoyl-N-(pyridin-2-ylmethyl)-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 473 1-benzoyl-N-(pyridin-3-ylmethyl)-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 474 1-benzoyl-N-(pyridin-3-ylmethyl)-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 475 1-benzoyl-N-(pyridin-4-ylmethyl)-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 476 1-benzoyl-N-[(2-chlorophenyl)methyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 477 1-benzoyl-N-[(2-chlorophenyl)methyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 478 1-benzoyl-N-[(2-chlorophenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 479 1-benzoyl-N-[(2-chlorophenyl)methyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 480 1-benzoyl-N-[(2-chlorophenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 481 1-benzoyl-N-[(2-chlorophenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 482 1-benzoyl-N-[(2-chlorophenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 483 1-benzoyl-N-[(2-fluorophenyl)methyl]-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 484 1-benzoyl-N-[(2-fluorophenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 485 1-benzoyl-N-[(2-fluorophenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 486 1-benzoyl-N-[(2-fluorophenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 487 1-benzoyl-N-[(2-fluorophenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 488 1-benzoyl-N-[(2-methoxyphenyl)methyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 489 1-benzoyl-N-[(2-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 490 1-benzoyl-N-[(2-methoxyphenyl)methyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 491 1-benzoyl-N-[(2-methoxyphenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 492 1-benzoyl-N-[(2-methoxyphenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 493 1-benzoyl-N-[(2-methoxyphenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 494 1-benzoyl-N-[(2-methylphenyl)methyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 495 1-benzoyl-N-[(2-methylphenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 496 1-benzoyl-N-[(2-methylphenyl)methyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 497 1-benzoyl-N-[(2-methylphenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 498 1-benzoyl-N-[(2-methylphenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 499 1-benzoyl-N-[(2-methylphenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 500 1-benzoyl-N-[(3-chlorophenyl)methyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 501 1-benzoyl-N-[(3-chlorophenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 502 1-benzoyl-N-[(3-chlorophenyl)methyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 503 1-benzoyl-N-[(3-chlorophenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 504 1-benzoyl-N-[(3-chlorophenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 505 1-benzoyl-N-[(3-chlorophenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 506 1-benzoyl-N-[(3-fluorophenyl)methyl]-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 507 1-benzoyl-N-[(3-fluorophenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 508 1-benzoyl-N-[(3-fluorophenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 509 1-benzoyl-N-[(3-fluorophenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 510 1-benzoyl-N-[(3-fluorophenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 511 1-benzoyl-N-[(3-methoxyphenyl)methyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 512 1-benzoyl-N-[(3-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 513 1-benzoyl-N-[(3-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 514 1-benzoyl-N-[(3-methoxyphenyl)methyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 515 1-benzoyl-N-[(3-methoxyphenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 516 1-benzoyl-N-[(3-methoxyphenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 517 1-benzoyl-N-[(3-methoxyphenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 518 1-benzoyl-N-[(3-methylphenyl)methyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 519 1-benzoyl-N-[(3-methylphenyl)methyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 520 1-benzoyl-N-[(3-methylphenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 521 1-benzoyl-N-[(3-methylphenyl)methyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 522 1-benzoyl-N-[(3-methylphenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 523 1-benzoyl-N-[(3-methylphenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 524 1-benzoyl-N-[(3-methylphenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 525 1-benzoyl-N-[(4-chlorophenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 526 1-benzoyl-N-[(4-chlorophenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 527 1-benzoyl-N-[(4-chlorophenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 528 1-benzoyl-N-[(4-chlorophenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 529 1-benzoyl-N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 530 1-benzoyl-N-[(4-fluorophenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 531 1-benzoyl-N-[(4-fluorophenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 532 1-benzoyl-N-[(4-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 533 1-benzoyl-N-[(4-methoxyphenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 534 1-benzoyl-N-[(4-methoxyphenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 535 1-benzoyl-N-[(4-methylphenyl)methyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 536 1-benzoyl-N-[(4-methylphenyl)methyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 537 1-benzoyl-N-[(4-methylphenyl)methyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 538 1-benzoyl-N-[(4-methylphenyl)methyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 539 1-benzoyl-N-[(4-methylphenyl)methyl]-3-phenyl-1H-1,2,4-triazol-5-amine 540 1-benzoyl-N-[(4-methylphenyl)methyl]-3-phenyl-1H-pyrazol-5-amine 541 1-benzoyl-N-benzyl-3-(2-fluorophenyl)-1H-1,2,4-triazol-5-amine 542 1-benzoyl-N-benzyl-3-(2-methylphenyl)-1H-1,2,4-triazol-5-amine 543 1-benzoyl-N-benzyl-3-(3-fluorophenyl)-1H-1,2,4-triazol-5-amine 544 1-benzoyl-N-benzyl-3-(3-methylphenyl)-1H-1,2,4-triazol-5-amine 545 1-benzoyl-N-benzyl-3-(4-fluorophenyl)-1H-1,2,4-triazol-5-amine 546 1-benzoyl-N-benzyl-3-(4-methylphenyl)-1H-1,2,4-triazol-5-amine 547 1-benzoyl-N-benzyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine 548 1-benzoyl-N-benzyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 549 1-benzoyl-N-benzyl-3-phenyl-1H-pyrazol-5-amine 550 1-benzoyl-N-[2-(dimethylamino)phenyl]methyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 551 1-benzoyl-N-[2-(dimethylamino)phenyl]methyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5- amine 552 1-benzoyl-N-[2-(dimethylamino)phenyl]methyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- amine 553 1-benzoyl-N-[2-(dimethylamino)phenyl]methyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine 554 1-benzoyl-N-[2-(dimethylamino)phenyl]methyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5- amine 555 1-benzoyl-N-[2-(dimethylamino)phenyl]methyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5- amine 556 1-benzoyl-N-[2-(dimethylamino)phenyl]methyl-3-phenyl-1H-1,2,4-triazol-5-amine 557 1-benzoyl-N-[2-(dimethylamino)phenyl]methyl-3-phenyl-1H-pyrazol-5-amine 558 1-benzoyl-N-[3-(dimethylamino)phenyl]methyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 559 1-benzoyl-N-[3-(dimethylamino)phenyl]methyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5- amine 560 1-benzoyl-N-[3-(dimethylamino)phenyl]methyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- amine 561 1-benzoyl-N-[3-(dimethylamino)phenyl]methyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine 562 1-benzoyl-N-[3-(dimethylamino)phenyl]methyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5- amine 563 1-benzoyl-N-[3-(dimethylamino)phenyl]methyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5- amine 564 1-benzoyl-N-[3-(dimethylamino)phenyl]methyl-3-phenyl-1H-1,2,4-triazol-5-amine 565 1-benzoyl-N-[3-(dimethylamino)phenyl]methyl-3-phenyl-1H-pyrazol-5-amine 566 1-benzoyl-N-[4-(dimethylamino)phenyl]methyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5- amine 567 1-benzoyl-N-[4-(dimethylamino)phenyl]methyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- amine 568 1-benzoyl-N-[4-(dimethylamino)phenyl]methyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine 569 1-benzoyl-N-[4-(dimethylamino)phenyl]methyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5- amine 570 1-benzoyl-N-[4-(dimethylamino)phenyl]methyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5- amine 571 1-benzoyl-N-[4-(dimethylamino)phenyl]methyl-3-phenyl-1H-pyrazol-5-amine 572 2-([1-benzoyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 573 2-([1-benzoyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 574 2-([1-benzoyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl]aminomethyl)benzonitrile 575 2-([1-benzoyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 576 2-([1-benzoyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 577 2-[(1-benzoyl-3-phenyl-1H-1,2,4-triazol-5-yl)amino]methylbenzonitrile 578 2-[(1-benzoyl-3-phenyl-1H-pyrazol-5-yl)amino]methylbenzonitrile 579 2-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 580 2-[5-(benzylamino)-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 581 2-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]carbonylbenzonitrile 582 2-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 583 2-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 584 2-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 585 2-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]carbonylbenzonitrile 586 3-([1-benzoyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 587 3-([1-benzoyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 588 3-([1-benzoyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 589 3-([1-benzoyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl]aminomethyl)benzonitrile 590 3-([1-benzoyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 591 3-([1-benzoyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 592 3-[(1-benzoyl-3-phenyl-1H-1,2,4-triazol-5-yl)amino]methylbenzonitrile 593 3-[(1-benzoyl-3-phenyl-1H-pyrazol-5-yl)amino]methylbenzonitrile 594 3-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 595 3-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 596 3-[5-(benzylamino)-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 597 3-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]carbonylbenzonitrile 598 3-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 599 3-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 600 3-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 601 3-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]carbonylbenzonitrile 602 4-([1-benzoyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 603 4-([1-benzoyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 604 4-([1-benzoyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 605 4-([1-benzoyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl]aminomethyl)benzonitrile 606 4-([1-benzoyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 607 4-([1-benzoyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-yl]aminomethyl)benzonitrile 608 4-[(1-benzoyl-3-phenyl-1H-1,2,4-triazol-5-yl)amino]methylbenzonitrile 609 4-[(1-benzoyl-3-phenyl-1H-pyrazol-5-yl)amino]methylbenzonitrile 610 4-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 611 4-[5-(benzylamino)-3-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 612 4-[5-(benzylamino)-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 613 4-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]carbonylbenzonitrile 614 4-[5-(benzylamino)-3-(pyridin-4-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 615 4-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 616 4-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]carbonylbenzonitrile 617 4-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]carbonylbenzonitrile 618 ethyl 5-[(E)-(pyridin-3-ylmethylidene)amino]-1H-1,2,4-triazole-3-carboxylate 619 N-(2,4-dichlorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-3-carboxamide 620 N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 621 N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine 622 N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 623 N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 624 N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 625 N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 626 N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine 627 N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 628 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 629 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 630 N-benzyl-1-[(2-methylphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 631 N-benzyl-1-[(2-methylphenyl)carbonyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 632 N-benzyl-1-[(2-methylphenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 633 N-benzyl-1-[(2-methylphenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine 634 N-benzyl-1-[(2-methylphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 635 N-benzyl-1-[(3-chlorophenyl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 636 N-benzyl-1-[(3-chlorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 637 N-benzyl-1-[(3-chlorophenyl)carbonyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 638 N-benzyl-1-[(3-chlorophenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 639 N-benzyl-1-[(3-chlorophenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine 640 N-benzyl-1-[(3-chlorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 641 N-benzyl-1-[(3-fluorophenyl)carbonyl]-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 642 N-benzyl-1-[(3-fluorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 643 N-benzyl-1-[(3-fluorophenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 644 N-benzyl-1-[(3-fluorophenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine 645 N-benzyl-1-[(3-fluorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 646 N-benzyl-1-[(3-methoxyphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 647 N-benzyl-1-[(3-methoxyphenyl)carbonyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 648 N-benzyl-1-[(3-methoxyphenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 649 N-benzyl-1-[(3-methoxyphenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine 650 N-benzyl-1-[(3-methoxyphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 651 N-benzyl-1-[(3-methylphenyl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 652 N-benzyl-1-[(3-methylphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 653 N-benzyl-1-[(3-methylphenyl)carbonyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 654 N-benzyl-1-[(3-methylphenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 655 N-benzyl-1-[(3-methylphenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine 656 N-benzyl-1-[(3-methylphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 657 N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 658 N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 659 N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 660 N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine 661 N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 662 N-benzyl-1-[(4-fluorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 663 N-benzyl-1-[(4-fluorophenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 664 N-benzyl-1-[(4-fluorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 665 N-benzyl-1-[(4-methoxyphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 666 N-benzyl-1-[(4-methoxyphenyl)carbonyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 667 N-benzyl-1-[(4-methoxyphenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 668 N-benzyl-1-[(4-methoxyphenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine 669 N-benzyl-1-[(4-methoxyphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 670 N-benzyl-1-[(4-methylphenyl)carbonyl]-3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine 671 N-benzyl-1-[(4-methylphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 672 N-benzyl-1-[(4-methylphenyl)carbonyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 673 N-benzyl-1-[(4-methylphenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 674 N-benzyl-1-[(4-methylphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 675 N-benzyl-1-[(furan-2-yl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 676 N-benzyl-1-[(furan-2-yl)carbonyl]-3-phenyl-1H-pyrazol-5-amine 677 N-benzyl-1-[(pyridin-2-yl)carbonyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine 678 N-benzyl-1-[(pyridin-2-yl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine 679 N-benzyl-1-[(pyridin-2-yl)carbonyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 680 N-benzyl-1-[(pyridin-2-yl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 681 N-benzyl-1-[(pyridin-3-yl)carbonyl]-3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 682 N-benzyl-1-[(pyridin-3-yl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 683 N-benzyl-1-[(pyridin-4-yl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine 684 N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 685 N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- amine 686 N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine 687 N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5- amine 688 N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5- amine 689 N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3-phenyl-1H-1,2,4-triazol-5-amine 690 N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3-phenyl-1H-pyrazol-5-amine 691 N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 692 N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5- amine 693 N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- amine 694 N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine 695 N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5- amine 696 N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5- amine 697 N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-phenyl-1H-1,2,4-triazol-5-amine 698 N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-phenyl-1H-pyrazol-5-amine 699 N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine 700 N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-(pyridin-2-yl)-1H-1,2,4-triazol-5- amine 701 N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- amine 702 N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine 703 N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-(pyridin-4-yl)-1H-1,2,4-triazol-5- amine 704 N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-(thiophen-2-yl)-1H-1,2,4-triazol-5- amine 705 N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-phenyl-1H-1,2,4-triazol-5-amine 706 N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-phenyl-1H-pyrazol-5-amine 707 N-benzyl-3-(furan-2-yl)-1-[(3-methoxyphenyl)carbonyl]-1H-1,2,4-triazol-5-amine 708 N-benzyl-3-(furan-2-yl)-1-[(4-methoxyphenyl)carbonyl]-1H-1,2,4-triazol-5-amine 709 N-benzyl-3-(furan-2-yl)-1-[(pyridin-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 710 N-benzyl-3-(furan-2-yl)-1-[(pyridin-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 711 N-benzyl-3-(furan-2-yl)-1-[(pyridin-4-yl)carbonyl]-1H-1,2,4-triazol-5-amine 712 N-benzyl-3-(pyridin-2-yl)-1-[(pyridin-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 713 N-benzyl-3-(pyridin-2-yl)-1-[(pyridin-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 714 N-benzyl-3-(pyridin-2-yl)-1-[(pyridin-4-yl)carbonyl]-1H-1,2,4-triazol-5-amine 715 N-benzyl-3-(pyridin-3-yl)-1-[(pyridin-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 716 N-benzyl-3-(pyridin-3-yl)-1-[(pyridin-3-yl)carbonyl]-1H-pyrazol-5-amine 717 N-benzyl-3-(pyridin-3-yl)-1-[(pyridin-4-yl)carbonyl]-1H-1,2,4-triazol-5-amine 718 N-benzyl-3-(pyridin-3-yl)-1-[(pyridin-4-yl)carbonyl]-1H-pyrazol-5-amine 719 N-benzyl-3-(pyridin-3-yl)-1-[(thiophen-2-yl)carbonyl]-1H-pyrazol-5-amine 720 N-benzyl-3-(pyridin-4-yl)-1-[(pyridin-4-yl)carbonyl]-1H-1,2,4-triazol-5-amine 721 N-benzyl-3-phenyl-1-[(pyridin-2-yl)carbonyl]-1H-1,2,4-triazol-5-amine 722 N-benzyl-3-phenyl-1-[(pyridin-2-yl)carbonyl]-1H-pyrazol-5-amine 723 N-benzyl-3-phenyl-1-[(pyridin-3-yl)carbonyl]-1H-1,2,4-triazol-5-amine 724 N-benzyl-3-phenyl-1-[(pyridin-3-yl)carbonyl]-1H-pyrazol-5-amine 725 N-benzyl-3-phenyl-1-[(pyridin-4-yl)carbonyl]-1H-1,2,4-triazol-5-amine 726 N-benzyl-3-phenyl-1-[(pyridin-4-yl)carbonyl]-1H-pyrazol-5-amine 727 N-benzyl-3-phenyl-1-[(thiophen-2-yl)carbonyl]-1H-pyrazol-5-amine - Compounds disclosed herein also include racemic mixtures, stereoisomers and mixtures of the compounds, including isotopically-labeled and radio-labeled compounds. See e.g., Goding, 1986, M
ONOCLONAL ANTIBODIES PRINCIPLES AND PRACTICE ; Academic Press, p. 104. Such isomers can be isolated by standard resolution techniques, including e.g., fractional crystallization, chiral chromatography, and the like. See e.g., Eliel, E. L. & Wilen S. H., 1993, STEREOCHEMISTRY IN ORGANIC COMPOUNDS ; John Wiley & Sons, New York. - In some embodiments, compounds disclosed herein have asymmetric centers and may occur as racemates, racemic mixtures, and as individual enantiomers or diastereoisomers, with all isomeric forms as well as mixtures thereof being contemplated for use in the compounds and methods described herein. The compounds contemplated for use in the compounds and methods described herein do not include those that are known in the art to be too unstable to synthesize and/or isolate.
- The compounds disclosed herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I), or carbon-14 (14C). All isotopic variations of the compounds disclosed herein, whether radioactive or not, are encompassed within the contemplated scope.
- In some embodiments, metabolites of the compounds disclosed herein are useful for the methods disclosed herein.
- In some embodiments, compounds contemplated herein are provided in the form of a prodrug. The term “prodrug” refers to a compound that can be converted into a compound (e.g., a biologically active compound) described herein in vivo. Prodrugs can be useful for a variety of reason known in the art, including e.g., ease of administration due e.g., to enhanced bioavailability in oral administration, and the like. The prodrug may also have improved solubility in pharmaceutical compositions over the biologically active compounds. An example, without limitation, of a prodrug is a compound which is administered as an ester (i.e., the “prodrug”) to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in DESIGN OF PRODRUGS, (ed. H. Bundgaard, Elsevier, 1985), which is hereby incorporated herein by reference for the limited purpose describing procedures and preparation of suitable prodrug derivatives.
- Accordingly, in some embodiments, compounds contemplated herein are provided in the form of a prodrug ester. The term “prodrug ester” refers to derivatives of the compounds disclosed herein formed by the addition of any of a variety of ester-forming groups, e.g., groups known in the art, that are hydrolyzed under physiological conditions. Examples of prodrug ester groups include pivaloyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art, including a (5-R-2-oxo-1,3-dioxolen-4-yl)methyl group. Other examples of prodrug ester groups can be found in, for example, T. Higuchi and V. Stella, in “Pro-drugs as Novel Delivery Systems”, Vol. 14, A.C.S. Symposium Series, American Chemical Society (1975); and B
IOREVERSIBLE CARRIERS IN DRUG DESIGN : THEORY AND APPLICATION , edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987) (providing examples of esters useful as prodrugs for compounds containing carboxyl groups). Each of the above-mentioned references is herein incorporated by reference for the limited purpose of disclosing ester-forming groups that can form prodrug esters. - In some embodiments, prodrugs can be slowly converted to the compounds described herein useful for the methods described herein when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Certain compounds disclosed herein can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of contemplated compounds. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the compounds and methods contemplated herein and are intended to be within the scope disclosed herein.
- In some embodiments, compounds described herein exhibit inhibitory activity against thrombin with activities 1 μM, e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 μM, or even greater. In some embodiments, the compounds exhibit inhibitory activity against thrombin with activities between 0.1 μM and 1 μM, e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 μM. In some embodiments, compounds described herein exhibit inhibitory activity against thrombin with activities 0.1 μM, e.g., about 1, 2, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nM. Ranges of values using a combination of any of the values recited herein as upper and/or lower limits are also contemplated, for example, but not limited to, 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM, 100-200 μM, 200-500 μM, or even 500-1000 μM. In some embodiments, the inhibitory activity is in the range of about 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM, 100-200 μM, 200-500 μM, or even 500-1000 μM. It is understood that for purposes of quantification, the terms “activity,” “inhibitory activity,” “biological activity,” “thrombin activity” and the like in the context of an inhibitory compound disclosed herein can be quantified in a variety of ways known in the art. Unless indicated otherwise, as used herein such terms refer to IC50 in the customary sense (i.e., concentration to achieve half-maximal inhibition).
- Inhibitory activity against thrombin in turn inhibits the blood coagulation process. Accordingly, compounds disclosed herein are indicated in the treatment or management of thrombotic disorders. In some embodiments, a dose or a therapeutically effective dose of a compound disclosed herein will be that which is sufficient to achieve a plasma concentration of the compound or its active metabolite(s) within a range set forth herein, e.g., about 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM, 100-200 μM, 200-500 μM, or even 500-1000 μM, preferably about 1-10 nM, 10-100 nM, or 0.1-1 Without wishing to be bound by any theory, it is believe that such compounds are indicated in the treatment or management of thrombotic disorders.
- Accordingly, compounds disclosed herein are indicated in the treatment or management of a variety of diseases or disorders. In some embodiments, a dose or a therapeutically effective dose of a compound disclosed herein will be that which is sufficient to achieve a plasma concentration of the compound or its active metabolite(s) within a range set forth herein, e.g., about 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM, 100-200 μM, 200-500 μM, or even 500-1000 μM, preferably about 1-10 nM, 10-100 nM, or 0.1-1 μM. Without wishing to be bound by any theory, it is believe that such compounds are indicated in the treatment or management of diseases associated with thrombin.
- In some embodiments, the compounds selectively inhibit thrombin over related serine proteases such as trypsin, chymotrypsin, factor XIIa, factor XIa, factor Xa, and factor VIIa. In some embodiments, the compounds inhibit chymotrypsin with an IC50 greater than 1 uM. In some embodiments, the compounds inhibit chymotrypsin with an IC50 greater than 10 uM. In some embodiments, the compounds inhibit chymotrypsin with an IC50 greater than 100 uM. In some embodiments, the compounds inhibit Factor XIa with an IC50 greater than 1 uM. In some embodiments, the compounds inhibit Factor XIa with an IC50 greater than 10 uM. In some embodiments, the compounds inhibit Factor XIa with an IC50 greater than 100 uM.
- In some embodiments, the compounds persist in the blood plasma after intravenous infusion. In some embodiments, greater than 50% of the initial compound concentration persists in the blood plasma of mice 1 hour after intravenous injection. In some embodiments, greater than 50% of the initial compound concentration persists in the blood plasma of mice 3 hours or longer after intravenous injection.
- Thrombin-Related Diseases and Conditions (e.g. Thrombosis).
- Thrombotic diseases are the primary indications for thrombin inhibition, because of thrombin's location in the coagulation cascade and, in turn, the importance of the coagulation cascade in the progression of blood clotting processes. However, without wishing to be bound by any theory, it is believed the coagulation cascade in general, and thrombin in particular, is important in a variety other disease states.
- It has been discovered that compounds described herein, e.g., multisubstituted aromatic compounds, exhibit inhibitory action against thrombin (activated blood-coagulation factor II; EC 3.4.21.5). This, in turn inhibits the blood coagulation process.
- This inhibitory action is useful in the treatment of a variety of thrombotic disorders, such as, but not limited to, acute vascular diseases such as acute coronary syndromes; venous-, arterial- and cardiogenic thromboembolisms; the prevention of other states such as disseminated intravascular coagulation, or other conditions that involve the presence or the potential formation of a blood clot thrombus. Other indications for methods described herein include the following.
- Cancer.
- It has long been recognized that cancer progression is accompanied by venous thrombosis, but it has not been understood how each disease is related. From several clinical trials studying the treatment of VTE, meta-analyses have shown that low molecular weight heparins (LMWHs) improve overall survival in subgroups of cancer patients. See e.g., Zacharski, L. R. & Lee, A. Y., 2008, Expert Opin Investig Drugs, 17:1029-1037; Falanga, A. & Piccioli, A., 2005, Current Opinion in Pulmonary Medicine, 11:403-407; Smorenburg, S. M., et al., 1999, Thromb Haemost, 82:1600-1604; Hettiarachchi, R. J., et al., 1999, Thromb Haemost, 82:947-952. This finding was substantiated in later clinical trials that measured specifically the survival of cancer patients. See e.g., Lee, A. Y. et al., 2005, J Clin Oncol, 23:2123-2129; Klerk, C. P. et al., J Clin Oncol 2005, 23:2130-2135; Kakkar, A. K., et al., 2004, J Clin Oncol, 22:1944-1948; Altinbas, M., et al., 2004, J Thromb Haemost, 2:1266-1271.
- More recently, researchers have focused on the specific anticancer effect of DTIs. For example, it was shown that heparin significantly prolonged the survival of patients with limited small cell lung cancer. See e.g., Akl, E. A., et al., 2008, J Exp Clin Cancer Res, 27:4. Other investigators found that systemic use of argatroban reduced tumor mass and prolonged survival time in rat glioma models leading to the conclusion that argatroban should be considered as a novel therapeutic for glioma, a notoriously difficult to treat cancer type. See e.g., Hua, Y., et al., 2005, Acta Neurochir, Suppl 2005, 95:403-406; Hua, Y., et al., 2005, J Thromb Haemost, 3:1917-1923. Very recently, it was demonstrated that dabigatran etexilate, a DTI recently FDA-approved (see e.g., Hughes, B., 2010, Nat Rev Drug Discov, 9:903-906) for DVT indications, inhibited both the invasion and metastasis of malignant breast tumors. See e.g., DeFeo, K., et al., 2010, Thrombosis Research, 125 (Supplement 2): 5188; Defeo, K., et al., 2010, Cancer Biol Ther, 10:1001-1008. Thus, dabigatran etexilate treatment led to a 50% reduction in tumor volume at 4 weeks with no weight loss in treated mice. Dabigatran etexilate also reduced tumor cells in the blood and liver micrometastases by 50-60%. These investigators concluded that dabigatran etexilate may be beneficial in not only preventing thrombotic events in cancer patients, but also as adjunct therapy to treat malignant tumors.
- Further, hirudin and the LMWH nadroparin dramatically reduced the number of lung metastases when administered prior to cancer cell inoculation. See e.g., Hu, L., et al., 2004, Blood, 104:2746-51.
- The de novo thrombin inhibitor d-Arg-Oic-Pro-d-Ala-Phe(p-Me) has been found to block thrombin-stimulated invasion of prostate cancer cell line PC-3 in a concentration dependent manner. See e.g., Nieman, M. T., et al., 2008, J Thromb Haemost, 6:837-845. A reduced rate of tumor growth was observed in mice dosed with the pentapeptide through their drinking water. The mice also showed reduced fold rate in tumor size and reduced overall tumor weight compared to untreated mice. Microscopic examination of treated tumors showed reduced number of large blood vessels thus concluding that the pentapeptide interfered with tumor angiogenesis. Nieman, M. T., et al., Thromb Haemost, 104:1044-8.
- In view of these and related studies, it is suggested that anticoagulants affect tumor metastasis; that is, angiogenesis, cancer cell adhesion, migration and invasion processes. See e.g., Van Noorden, C. J., et al., 2010, Thromb Res, 125 Suppl 2:S77-79.
- Fibrosis. Several studies have shown the utility of anticoagulant therapy in fibrotic disorders. For example, in a rat model of CCl4-induced chronic liver injury, the DTI SSR182289 decreased liver fibrogenesis significantly after 7 weeks of administration. Similar observations were made in other studies using the LMWHs nadroparin, tinzaparin, enoxaparin, and dalteparin sodium. See e.g., Duplantier, J. G., et al., 2004, Gut, 53:1682-1687; Abdel-Salam, O. M., et al., 2005, Pharmacol Res, 51:59-67; Assy, N., et al., 2007, Dig Dis Sci, 52:1187-1193; Abe, W., et al., 2007, J Hepatol, 46:286-294. Thus a thrombin inhibitor as an anticoagulant can be useful in the treatment of fibrinolytic diseases.
- In another example, the DTI melagatran greatly reduced ischemia reperfusion injury in a kidney transplant model in the large white pig. This led to a drastically improved kidney graft survival at 3 months. See e.g., Favreau, F., et al., 2010, Am J Transplant, 10:30-39.
- Recent studies have shown that in a bleomycin-induced mouse model of pulmonary fibrosis, dabigatran etexilate treatment reduced important profibrotic events in lung fibroblasts, including the production of collagen and connective tissue growth factor. See e.g., Silver, R. M., et al., 2010, Am. J Respir. Crit. Care Med., 181:A6780; Bogatkevich, G. S., et al., 2009, Arthritis Rheum, 60:3455-3464.
- The above experimental evidence points to a close relationship between thrombin and fibrosis and suggests novel therapeutic opportunities for fibrosis using thrombin inhibitors. See e.g., Calvaruso, V., et al., 2008, Gut, 57:1722-1727; Chambers, R. C., 2008, Br J Pharmacol, 153 Suppl 1:S367-378; Chambers, R. C. & Laurent, G. J., 2002, Biochem Soc Trans, 30:194-200; Howell, D. C., et al., 2001, Am J Pathol, 159:1383-1395.
- Alzheimer's Disease.
- Very recent experiments confirm higher thrombin levels in brain endothelial cells of patients with Alzheimer's disease. While ‘normal’ thrombin levels are connected to regulatory CNS functions, thrombin accumulation in the brain is toxic. It has also been found that the neural thrombin inhibitor Protease Nexin 1 (PN-1) is significantly reduced in the Alzheimer's disease brain, despite the fact that PN-1 mRNA levels are unchanged. These observations have led some investigators to suggest that reduction of CNS-resident thrombin will prove useful in Alzheimer's Disease (AD) treatment. See e.g., Vaughan, P. J., et al., 1994, Brain Res, 668:160-170; Yin, X., et al., 2010, Am J Pathol, 176:1600-1606; Akiyama, H., et al., 1992, Neurosci Lett, 146:152-154.
- Multiple Sclerosis.
- Investigators found that hirudin treatment in an animal model of Multiple Sclerosis (MS) showed a dramatic improvement in disease severity. See e.g., Han, M. H., et al., 2008, Nature, 451:1076-1081. Similar results were obtained following treatment with heparin (a DTI) and dermatan sulfate (another coagulation inhibitor). See e.g., Chelmicka-Szorc, E. & Amason, B. G., 1972, Arch Neurol, 27:153-158; Inaba, Y., et al., 1999, Cell Immunol, 198:96-102. Other evidence shows that naturally occurring antithrombin III has anti-inflammatory effects in diseases such as endotoxemia and other sepsis-related conditions. See e.g., Wiedermann, C. J. & Romisch, J., 2002, Acta Med Austriaca, 29:89-92. Naturally occurring thrombin inhibitors are presumably synthesized in situ and have protective roles in CNS inflammation. Therefore, therapeutic thrombin inhibition has been proposed as a potential MS treatment. See e.g., Luo, W., et al., 2009, In: T
HROMBIN , Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer New York: 2009; pp 133-159. - Pain.
- In a rat pain model with partial lesion of the sciatic nerve, intrathecal hirudin prevented the development of neuropathic pain and curbed pain responses for 7 days. The investigators found that following injury, neuropathic pain was mediated by thrombin generation, which in turn activated PAR-1 receptor in the spinal cord. Hirudin inhibited thrombin generation and ultimately led to pain relief. See e.g., Garcia, P. S., et al., 2010, Thromb Haemost, 103:1145-1151; Narita, M., et al., 2005, J Neurosci, 25:10000-10009. Researchers hypothesize that thrombin and the PARs are involved not just as part of the coagulation cascade, but in inflammation, nociception and neurodevelopment. Development of a DTI to intersect an unexploited pharmacology will lead to pain therapeutics distinct from opioids and NSAIDs, whose shortcomings are well documented. See e.g., Garcia 2010, Id.
- Thrombin-Related Cardiac, Pulmonary, and Venous Conditions.
- Known thrombin inhibitors have been reported to be useful in preventing stroke in individuals with atrial fibrillation. The selective thrombin inhibitor ximelagatran was studied in two phase III clinical trials ((SPORTIF III and SPORTIF V), which compared ximelagatran to warfarin for the prevention of cardioembolic events in patients with non-valvular atrial fibrillation. The investigators for the SPORTIF III clinical trial found that ximelagatran, administered in a fixed dose without coagulation monitoring, protects high-risk patients with atrial fibrillation against thromboembolism at least as effectively as well-controlled warfarin, and is associated with less bleeding. When the results of SPORTIF III and V were combined, ximelagatran was associated with a 16% relative risk reduction in the composite outcome measure of all strokes (ischemic or hemorrhagic), systemic embolic events, major bleeding, and death. (Olsson, S. B. Lancet 2003, 362 (9397), 1691-1698; Hirsh, J. et al. Blood 2005, 105 (2), 453-463; Clemens, A. et al. WIPO Patent Application WO/2008/009638). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful in preventing stroke in individuals with atrial fibrillation.
- Known thrombin inhibitors have been reported to be useful in the treatment and prevention of acute coronary syndrome (Clemens, A. et al. WIPO Patent Application WO/2008/009638). ACS is a group of symptoms that are caused by myocardial ischemia. The drug could be used as a prophylaxis for myocardial infarction, or at a certain time after the event (e.g. after myocardial infarction, post-MI; i.e. chronic therapy, secondary prevention). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful in treating and preventing acute coronary syndrome.
- Known thrombin inhibitors have been reported to be useful in the prevention of recurrent cardiac events after myocardial infarction. The selective thrombin inhibitor ximelagatran was studied in a phase II clinical trial entitled ESTEEM, measuring the efficacy and safety of ximelagatran in patients with recent myocardial damage. The result of the ESTEEM trial supports the notion that long-term treatment with an oral direct thrombin inhibitor reduces arterial thrombotic events. Oral ximelagatran in combination with acetylsalicylic acid was more effective than acetylsalicylic acid alone in reducing the frequency of major cardiovascular events during 6 months of treatment in patients with a recent myocardial infarction. (Hirsh, J. et al. Blood 2005, 105 (2), 453-463.). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful in preventing recurrent cardiac events after myocardial infarction.
- Known thrombin inhibitors have been reported to be useful in post-operative prophylaxis of deep vein thrombosis. The selective thrombin inhibitor ximelagatran was found to be efficacious for the prevention of venous thromboembolism following a medical procedure like total hip or knee replacement (Francis, C. W. et al. Ann Intern Med 2002; 137:648-55; Heit, J. A. et al. Arch Intern Med 2001; 161: 2215-21; Eriksson B I et al. Thromb Haemost 2003; 89: 288-96). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful in post-operative prophylaxis of deep vein thrombosis.
- Known thrombin inhibitors, such as, for example, dabigatran have been reported to be useful in long-term treatment of pulmonary embolism. (Robertson L, Kesteven P, McCaslin J E. Cochrane Database Syst Rev. 2015 Dec. 4; 12). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful in treating pulmonary embolism.
- Known thrombin inhibitors have been reported to be useful for the prevention of coagulation in patients undergoing percutaneous coronary intervention. Percutaneous coronary intervention (PCI) requires aggressive anticoagulation therapy, and was historically achieved with unfractionated heparin. However, in many patients heparin is contraindicated, especially in patients with heparin-induced thrombocytopenia (HIT). In such instances, the endovascular disruption and the hypercoagulable state that characterized HIT means patients are put at risk of thrombosis during PCI. (Lewis, B. E. et al. Catheterization and cardiovascular interventions 2002, 57 (2), 177-184; Kokolis, S et al. Progress in cardiovascular diseases 2004, 46 (6), 506-523.) Dabigatran, which had already been claimed as a thrombin inhibitor and a useful anticoagulant in the clinical setting, was also published as a secondary medication in percutaneous interventional cardiac catherization. (Reilly et al. WIPO Patent Application WO/2010/020602). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful in preventing coagulation in patients undergoing percutaneous coronary intervention.
- Known thrombin inhibitors have been reported to be useful for the treatment of pulmonary-arterial hypertension. Dabigatran, a selective thrombin inhibitor, has been published as a useful drug for the treatment of pulmonary-arterial hypertension (PAH). Furthermore, dabigatran had found use as a treatment of: (i); pulmonary hypertension caused by left heart disorders, (ii); pulmonary hypertension associated with lung diseases such as pulmonary fibroses, particularly idiopathic pulmonary fibrosis, and/or hypoxia, (iii); pulmonary hypertension caused by chronic thromboembolic diseases. (Feuring, M. WIPO Patent Application WO/2010/020600). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of pulmonary-arterial hypertension.
- Known thrombin inhibitors have been reported to be useful for the treatment of pulmonary-arterial hypertension caused by left heart disorders (Feuring, M. WIPO Patent Application WO/2010/020600). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of pulmonary-arterial hypertension caused by left heart disorders.
- Known thrombin inhibitors have been reported to be useful for the treatment of pulmonary-arterial hypertension associated with lung diseases such as pulmonary fibroses, particularly idiopathic pulmonary fibrosis, and/or hypoxia (Feuring, M. WIPO Patent Application WO/2010/020600). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of pulmonary-arterial hypertension associated with lung diseases.
- Known thrombin inhibitors have been reported to be useful for the treatment of pulmonary hypertension caused by chronic thromboembolic diseases (Feuring, M. WIPO Patent Application WO/2010/020600). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of pulmonary hypertension caused by chronic thromboembolic diseases.
- Non-valvular atrial fibrillation is a sustained cardiac disturbance often associated with heart disease. Known thrombin inhibitors like ximelagatran have been reported to be useful for stroke prevention in patients with non-valvular atrial fibrillation (Diener H.-C. Cerebrovasc Dis 2006; 21:279-293). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for stroke prevention in patients with non-valvular atrial fibrillation.
- A Transient Ischemic Attack (TIA) is an acute episode of temporary neurologic dysfunction that typically lasts less than an hour; results from focal cerebral, spinal cord, or retinal ischemia; and is not associated with acute tissue infarction. In people who have a TIA, the incidence of subsequent stroke is as high as 11% over the next 7 days and 24-29% over the following 5 years. In view of the high short-term risk of stroke after TIA, many physicians believe antithrombotic therapy should be initiated as soon as intracranial hemorrhage has been ruled out. Stroke prevention medication typically recommended for cardioembolic TIA is as follows: For patients with atrial fibrillation after TIA, long-term anticoagulation with warfarin (aspirin 325 mg/day for those unable to take oral anticoagulants); In acute myocardial infarction (MI) with left ventricular thrombus, oral anticoagulation with warfarin; concurrent aspirin up to 162 mg/day for ischemic coronary artery disease [CAD]); In dilated cardiomyopathy, oral anticoagulation with warfarin or antiplatelet therapy; In rheumatic mitral valve disease, oral anticoagulation with warfarin. For patients with TIA and ischaemic stroke of cardiac origin due to atrial fibrillation, vitamin K antagonists (VKAs) are highly effective in preventing recurrent ischaemic stroke but have important limitations and are thus underused. Antiplatelet therapy is much less effective than VKAs. The direct thrombin inhibitor, dabigatran etexilate, has shown efficacy over warfarin in a recent trial. Other new anticoagulants, including the oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, the parenteral factor Xa inhibitor, idrabiotaparinux, and the novel VKA, tecarfarin, were being assessed in 2010. (Hankey, G. J.; Eikelboom, J. W. ‘Antithrombotic Drugs for Patients with Ischaemic Stroke and Transient Ischaemic Attack to Prevent Recurrent Major Vascular Events.’ The Lancet Neurology 2010, 9 (3), 273-284.)
- Known thrombin inhibitors have been reported to be useful for the treatment of venous thromboembolism due to formation of a thrombus within a vein (venous thrombosis) associated with acquired (prolonged bedrest, surgery, injury, malignancy, pregnancy and postpartum states) or inherited (deficiency of natural coagulation inhibitors) risk factors (Marsic, L. P. et al. WIPO Patent Application WO/2003/048155). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of venous thromboembolism due to formation of a thrombus within a vein associated with acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus. An example of an acquired risk factor would be a previous venous thromboembolism and/or embolism of peripheral veins caused by a detached thrombus. An example of an acquired risk factor would be a previous venous thromboembolism.
- Known thrombin inhibitors have been reported to be useful for the treatment of cardiogenic thromboembolism due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, embolism of peripheral arteries caused by a detached thrombus, most commonly in the brain (ischemic stroke). See Marsic, L. P. et al. WIPO Patent Application WO/2003/048155. Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of cardiogenic thromboembolism.
- Known thrombin inhibitors have been reported to be useful for the treatment of arterial thrombosis due to underlying atherosclerotic processes in the arteries which obstructs or occludes an artery and causes myocardial ischemia (angina pectoris, acute coronary syndrome) or myocardial infarction, obstructs or occludes a peripheral artery (ischemic peripheral artery disease) and obstructs or occludes the artery after a procedure on the blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries). See Marsic, L. P. et al. WIPO Patent Application WO/2003/048155. Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of arterial thrombosis.
- Known thrombin inhibitors have been reported to be useful for the treatment of disseminated intravascular coagulation in a number of states (e.g., in complications in pregnancy, in metastasing malignant diseases, after extensive injuries, in bacterial sepsis) when thrombogenic activation causes dysfunctional coagulation with widespread formation of thrombi within the vascular system. See Marsic, L. P. et al. WIPO Patent Application WO/2003/048155. Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of disseminated intravascular coagulation.
- Known thrombin inhibitors have been reported to be useful as an adjunct therapy in conjunction with thrombolytic therapy in recent myocardial infarction, in combination with aspirin in patients with unstable angina pectoris designed to undergo percutaneous transluminal angioplasty and in the treatment of patients with thrombosis and with heparin-induced thrombocytopenia (Marsic, L. P. et al. WIPO Patent Application WO/2003/048155). Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful as an adjunct therapy with other antithrombotic therapies.
- Known thrombin inhibitors have been reported to be useful for the treatment of inflammation (Kirk, I. WIPO Patent Application WO/2000/041716), type I diabetes mellitus (Korsgren, O.; Nillson, B. WIPO Patent Application WO/2003/061682), cancer (Kakkar, A. K. et al. J Clin Oncol 2004, 22, (10), 1944-8; Hua, Y. et al. Acta Neurochir Suppl 2005, 95, 403-6; Nieman, M. T. et al. J Thromb Haemost, 6 (2008), 837-845; Van Ryn, J.; Clemens, A. WIPO Patent Application WO/2010/020601), fibrosis (Duplantier, J. G. et al. Gut, 2004, 53:1682-1687; Seijo, S. et al. J Hepatol, 2007, 46:286-294; Assy, N. et al. Dig Dis Sci, 2007, 52:1187-1193; Bogatkevich, G. S. et al. Arthritis Rheum, 2009, 60:3455-3464), and pain (Garcia, P. S. et al. Thromb Haemost, 103:1145-1151; Narita, M. et al. J Neurosci, 2005, 25:10000-10009). Metaanalyses of clinical trials that studied the use of anticoagulants in oncology patients showed that low molecular weight heparins (LMWHs), selective thrombin inhibitors, improve overall survival in subgroups of cancer patients. This finding was substantiated in later clinical trials, in particular the FAMOUS clinical trials, that measured specifically the survival of cancer patients.
- Without further wishing to be bound by any theory, it is reasonable to believe that thrombin inhibition in general can be useful for the treatment of thrombotic diseases or disorders and/or diseases or disorders which involve a blood clot thrombus or the potential formation of a blood clot thrombus and/or further involves stroke and/or one or more transient ischemic attacks (TIA) and/or pulmonary hypertension. Such conditions include, for example, acute coronary syndrome, thromboembolism, thrombosis, inflammation, diabetes mellitus, cancer, fibrosis, Alzheimer's Disease, multiple sclerosis, pain, recurrent cardiac events after myocardial infarction, or the like.
- Accordingly, in a further aspect, there is provided a method for treating a disease or disorder in a subject in need thereof. The method includes administering a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, a compound as set forth in any of Tables A, B or C, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical composition thereof, to a subject in need thereof in an amount effective to treat the disease or disorder. The terms “therapeutically effective amount,” “amount effective to treat,” “amount effective to prevent” and the like refer to that amount of drug or pharmaceutical agent (e.g., compound or pharmaceutical composition disclosed herein) that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- Compounds useful for methods disclosed herein include the compounds set forth for Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), and (VI), and for the compounds set forth in Tables A and B above. Additionally, compounds useful for methods disclosed herein include the compounds set forth in Table C following. For Table C, the compounds were assayed for inhibition of the protease activity of thrombin as described for Table A.
-
TABLE C Cmpd Thrombin No IUPAC name Activity 1 3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine c 2 3-(pyridin-2-yl)-1H-1,2,4-triazol-5-amine c 3 3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine c 8 1-(5-[(3-fluorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- b yl)propan-1-one 25 3-(furan-2-yl)-1H-1,2,4-triazol-5-amine c 31 methyl 5-[(2-chlorobenzene)amido]-1H-1,2,4-triazole-3-carboxylate c 305 1-(5-[(2-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)- c 2-methylpropan-1-one 306 1-(5-[(4-chlorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)-2- a methylpropan-1-one 307 1-(5-[(4-chlorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- a yl)ethan-1-one 308 1-(5-[(4-chlorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- a yl)propan-1-one 309 1-(5-[(4-fluorophenyl)methyl]amino-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl)-2,2- a dimethylpropan-1-one 310 1-(5-[(4-fluorophenyl)methyl]amino-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl)-2- a methylpropan-1-one 311 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)-2- c methoxyethan-1-one 312 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)-2- a methylpropan-1-one 313 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)-2- a phenylethan-1-one 314 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)-3- a methylbutan-1-one 315 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)-3- a phenylpropan-1-one 316 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- a yl)butan-1-one 317 1-(5-[(4-fluorophenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- a yl)ethan-1-one 318 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)- a 2-methylpropan-1-one 319 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)- a 2-phenylethan-1-one 320 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)- a 3-methylbutan-1-one 321 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)- b 3-phenylpropan-1-one 322 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- a yl)butan-1-one 323 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- b yl)ethan-1-one 324 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- b yl)propan-1-one 325 1-(5-[(4-methylphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1- a yl)ethan-1-one 326 1-(benzenesulfonyl)-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine c 327 1-(benzenesulfonyl)-3-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)-1H-1,2,4- c triazol-5-amine 328 1-(benzenesulfonyl)-3-[(morpholin-4-yl)carbonyl]-1H-1,2,4-triazol-5-amine c 329 1-(ethanesulfonyl)-3-[(morpholin-4-yl)carbonyl]-1H-1,2,4-triazol-5-amine c 330 1-[(2-chlorophenyl)carbonyl]-3-(furan-2-yl)-5-(methylsulfanyl)-1H-1,2,4- a triazole 331 1-[(2-chlorophenyl)carbonyl]-N-[(4-fluorophenyl)methyl]-3-(furan-2-yl)-1H- a 1,2,4-triazol-5-amine 332 1-[(2-chlorophenyl)carbonyl]-N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)- a 1H-1,2,4-triazol-5-amine 333 1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine b 334 1-[(2-methoxyphenyl)carbonyl]-3-phenyl-1H-1,2,4-triazol-5-amine c 335 1-[(2-methoxyphenyl)carbonyl]-3-phenyl-N-(thiophen-2-ylmethyl)-1H-1,2,4- a triazol-5-amine 336 1-[(4-chlorobenzene)sulfonyl]-3-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)-1H- c 1,2,4-triazol-5-amine 337 1-[(4-chlorobenzene)sulfonyl]-3-[(morpholin-4-yl)carbonyl]-1H-1,2,4-triazol- c 5-amine 338 1-[(4-chlorophenyl)carbonyl]-N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)- a 1H-1,2,4-triazol-5-amine 339 1-[(4-methylphenyl)carbonyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5-amine b 340 1-[(furan-2-yl)carbonyl]-N-[(4-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1H- b 1,2,4-triazol-5-amine 341 1-[3-(furan-2-yl)-5-(methylsulfanyl)-1H-1,2,4-triazol-1-yl]propan-1-one c 342 1-[3-(pyridin-3-yl)-5-[(thiophen-2-ylmethyl)amino]-1H-1,2,4-triazol-1- a yl]butan-1-one 343 1-[3-(pyridin-3-yl)-5-[(thiophen-2-ylmethyl)amino]-1H-1,2,4-triazol-1- a yl]ethan-1-one 344 1-[3-(pyridin-3-yl)-5-[(thiophen-2-ylmethyl)amino]-1H-1,2,4-triazol-1- a yl]propan-1-one 345 1-[5-(benzylamino)-3-(4-fluorophenyl)-1H-1,2,4-triazol-1-yl]propan-1-one c 346 1-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl]-2-phenylethan-1-one a 347 1-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl]-3-phenylpropan-1- a one 348 1-[5-(benzylamino)-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl]propan-1-one a 349 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl]-2-methylpropan-1- a one 350 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl]-3-methylbutan-1- a one 351 1-[5-(benzylamino)-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl]propan-1-one a 352 1-[5-(benzylamino)-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl]propan-1-one a 353 1-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]-2-phenylethan-1-one a 354 1-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]-3-phenylpropan-1-one c 355 1-[5-(benzylamino)-3-phenyl-1H-1,2,4-triazol-1-yl]propan-1-one b 356 1-benzoyl-N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- a amine 357 1-benzoyl-N-[(4-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- b amine 358 1-benzoyl-N-benzyl-3-(furan-2-yl)-1H-1,2,4-triazol-5-amine a 359 1-benzoyl-N-benzyl-3-phenyl-1H-1,2,4-triazol-5-amine a 360 1-methanesulfonyl-3-[(morpholin-4-yl)carbonyl]-1H-1,2,4-triazol-5-amine c 361 1-5-[(furan-2-ylmethyl)amino]-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl-2- a methylpropan-1-one 362 1-5-[(furan-2-ylmethyl)amino]-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-ylbutan-1- a one 363 1-5-[(furan-2-ylmethyl)amino]-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-ylethan-1- a one 364 1-5-[(furan-2-ylmethyl)amino]-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-ylpropan-1- b one 365 2-fluoro-N-[5-(furan-2-yl)-1H-1,2,4-triazol-3-yl]benzamide c 366 2-methyl-1-(5-[(4-methylphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4- a triazol-1-yl)propan-1-one 367 3-(furan-2-yl)-1-[(2-methoxyphenyl)carbonyl]-5-(methylsulfanyl)-1H-1,2,4- a triazole 368 3-(furan-2-yl)-1-[(pyridin-3-yl)carbonyl]-N-(thiophen-2-ylmethyl)-1H-1,2,4- a triazol-5-amine 369 3-(furan-2-yl)-1-methanesulfonyl-N-(thiophen-2-ylmethyl)-1H-1,2,4-triazol-5- c amine 370 3-(furan-2-yl)-N-[(2-methoxyphenyl)methyl]-1-[(4-methylphenyl)carbonyl]- b 1H-1,2,4-triazol-5-amine 371 3-(furan-2-yl)-N-[(4-methoxyphenyl)methyl]-1-[(4-methylphenyl)carbonyl]- b 1H-1,2,4-triazol-5-amine 372 3-(pyridin-3-yl)-1-[(pyridin-3-yl)carbonyl]-N-(thiophen-2-ylmethyl)-1H-1,2,4- b triazol-5-amine 373 3-(thiophen-2-yl)-1H-1,2,4-triazol-5-amine c 374 3-methyl-1-(5-[(4-methylphenyl)methyl]amino-3-(pyridin-3-yl)-1H-1,2,4- a triazol-1-yl)butan-1-one 375 3-methyl-1-[3-(pyridin-3-yl)-5-[(thiophen-2-ylmethyl)amino]-1H-1,2,4- a triazol-1-yl]butan-1-one 376 ethyl 5-amino-3-(4-chlorophenyl)-1H-pyrazole-1-carboxylate c 377 methyl 3-[(2,4-dichlorobenzene)amido]-1H-1,2,4-triazole-5-carboxylate c 378 methyl 5-(2,2-dimethylpropanamido)-1H-1,2,4-triazole-3-carboxylate c 379 methyl 5-(2-methylfuran-3-amido)-1H-1,2,4-triazole-3-carboxylate c 380 methyl 5-[(2-methylbenzene)amido]-1H-1,2,4-triazole-3-carboxylate c 381 methyl 5-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]-1H-1,2,4-triazole-3- c carboxylate 382 methyl 5-[(3-methylbenzene)amido]-1H-1,2,4-triazole-3-carboxylate c 383 methyl 5-[(4-bromobenzene)amido]-1H-1,2,4-triazole-3-carboxylate c 384 methyl 5-[(4-chlorobenzene)amido]-1H-1,2,4-triazole-3-carboxylate c 385 methyl 5-[(4-fluorobenzene)amido]-4H-1,2,4-triazole-3-carboxylate b 386 methyl 5-[(4-tert-butylbenzene)amido]-1H-1,2,4-triazole-3-carboxylate b 387 methyl 5-[(pyridin-3-ylmethylidene)amino]-1H-1,2,4-triazole-3-carboxylate c 388 methyl 5-[3-(4-methylphenyl)propanamido]-1H-1,2,4-triazole-3-carboxylate c 389 methyl 5-amino-1H-1,2,4-triazole-3-carboxylate c 390 N-(2,4-dichlorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)-4H-1,2,4-triazole-3- c carboxamide 391 N-(2-chlorophenyl)-3-(4H-1,2,4-triazol-4-yl)-1H-1,2,4-triazole-5-carboxamide c 392 N-(4-bromophenyl)-3-(4H-1,2,4-triazol-4-yl)-1H-1,2,4-triazole-5-carboxamide c 393 N-(4-ethoxyphenyl)-3-(4H-1,2,4-triazol-4-yl)-1H-1,2,4-triazole-5- c carboxamide 394 N-(furan-2-ylmethyl)-1-[(2-methoxyphenyl)carbonyl]-3-phenyl-1H-1,2,4- a triazol-5-amine 395 N-(furan-2-ylmethyl)-1-methanesulfonyl-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- c amine 396 N-(furan-2-ylmethyl)-3-(pyridin-3-yl)-1-[(pyridin-3-yl)carbonyl]-1H-1,2,4- c triazol-5-amine 397 N-[(2-chlorophenyl)methyl]-3-(furan-2-yl)-1-[(pyridin-3-yl)carbonyl]-1H- b 1,2,4-triazol-5-amine 398 N-[(2-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1-[(pyridin-3-yl)carbonyl]-1H- c 1,2,4-triazol-5-amine 399 N-[(4-fluorophenyl)methyl]-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-3-yl)- a 1H-1,2,4-triazol-5-amine 400 N-[(4-fluorophenyl)methyl]-1-[(2-methoxyphenyl)carbonyl]-3-phenyl-1H- a 1,2,4-triazol-5-amine 401 N-[(4-fluorophenyl)methyl]-1-[(4-methylphenyl)carbonyl]-3-(pyridin-3-yl)- a 1H-1,2,4-triazol-5-amine 402 N-[(4-fluorophenyl)methyl]-1-[(furan-2-yl)carbonyl]-3-(pyridin-3-yl)-1H- a 1,2,4-triazol-5-amine 403 N-[(4-fluorophenyl)methyl]-3-(pyridin-3-yl)-1-[(thiophen-2-yl)carbonyl]-1H- a 1,2,4-triazol-5-amine 404 N-[(4-methoxyphenyl)methyl]-1-[(4-methylphenyl)carbonyl]-3-(pyridin-3-yl)- b 1H-1,2,4-triazol-5-amine 405 N-[(4-methoxyphenyl)methyl]-3-(pyridin-3-yl)-1-[(thiophen-2-yl)carbonyl]- c 1H-1,2,4-triazol-5-amine 406 N-[5-(benzylamino)-1H-1,2,4-triazol-3-yl]acetamide c 407 N-[5-(furan-2-yl)-1H-1,2,4-triazol-3-yl]benzamide c 408 N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(furan-2-yl)-1H-1,2,4-triazol-5- a amine 409 N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(thiophen-2-yl)-1H-1,2,4-triazol-5- a amine 410 N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- a amine 411 N-benzyl-1-[(4-methylphenyl)carbonyl]-3-(pyridin-3-yl)-1H-1,2,4-triazol-5- a amine 412 N-benzyl-3-(thiophen-2-yl)-1-[(thiophen-2-yl)carbonyl]-1H-1,2,4-triazol-5- c amine - In some embodiments of the methods, compounds, or pharmaceutical compositions described herein, the disease or disorder to be treated can include one or more thrombotic diseases or disorders and/or can involve a blood clot thrombus or the potential formation of a blood clot thrombus. In some embodiments, the thrombotic disease or disorder can be acute coronary syndrome, thromboembolism, and/or thrombosis. In some embodiments, the thromboembolism can be venous thromboembolism, arterial thromboembolism and/or cardiogenic thromboembolism. In some embodiments, the venous thromboembolism can include deep vein thrombosis and/or pulmonary embolism. In some embodiments, the deep vein thrombosis and/or pulmonary embolism can occur following a medical procedure. In some embodiments, the thrombotic disease or disorder can involve dysfunctional coagulation or disseminated intravascular coagulation. In some embodiments, the subject with dysfunctional coagulation can be undergoing percutaneous coronary intervention (PCI). In some embodiments, the thrombotic disease or disorder can involve a blood clot thrombus or the potential formation of a blood clot thrombus and further can involve stroke and/or one or more transient ischemic attacks (TIA). In some embodiments, the thrombotic disease or disorder involving a blood clot thrombus or the potential formation of a blood clot thrombus can further involve stroke, wherein the subject can have non-valvular atrial fibrillation. In some embodiments, the thrombotic disease or disorder can involve a blood clot thrombus or the potential formation of a blood clot thrombus and further can involve pulmonary hypertension. In some embodiments, the pulmonary hypertension can be caused by one or more left heart disorder and/or chronic thromboembolic disease. In some embodiments, the pulmonary hypertension can be associated with one or more lung disease, including pulmonary fibrosis (idiopathic or otherwise), and/or hypoxia.
- In some embodiments, the venous thromboembolism can be associated with formation of a thrombus within a vein associated with one or more acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus. In some embodiments, the one or more risk factors can include a previous venous thromboembolism. In some embodiments, the cardiogenic thromboembolism can be due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, and/or embolism of peripheral arteries caused by a detached thrombus. In some embodiments, the detached thrombus can be in the brain (ischemic stroke). In some embodiments, the detached thrombus can cause a transient ischemic attack (TIA). In some embodiments, the cardiogenic thromboembolism can be due to non-valvular atrial fibrillation. In some embodiments, the thrombosis can be arterial thrombosis. In some embodiments, the arterial thrombosis can be due to one or more underlying atherosclerotic processes in the arteries. In some embodiments, the one or more underlying atherosclerotic processes in the arteries can obstruct or occlude an artery, cause myocardial ischemia (angina pectoris, acute coronary syndrome), cause myocardial infarction, obstruct or occlude a peripheral artery (ischemic peripheral artery disease), and/or obstruct or occlude the artery after a procedure on a blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries).
- In some embodiments, the disease or disorder can include fibrosis, Alzheimer's Disease, multiple sclerosis, pain, cancer, inflammation, and/or Type I diabetes mellitus. In some embodiments, the disease or disorder can involve recurrent cardiac events after myocardial infarction.
- In some embodiments, the treatment or prevention can include an adjunct therapy. In some embodiments, the subject can have myocardial infarction, and the adjunct therapy can be in conjunction with thrombolytic therapy. In some embodiments, the subject can have unstable angina pectoris, thrombosis, and/or heparin-induced thrombocytopenia, and the adjunct therapy can be in combination with antiplatelet therapy. In some embodiments, the subject can have non-valvular atrial fibrillation, and the adjunct therapy can be in conjunction with one or more other therapies.
- In some embodiments, the disease or disorder can be fibrosis. In some embodiments contemplating fibrosis, the method is directed to treating chronic liver injury. In some embodiments, the disease or disorder can be ischemia reperfusion injury. In some embodiments, the disease or disorder can be pulmonary fibrosis.
- In some embodiments, the disease or disorder can be pain. In some embodiments, the pain can be neuropathic pain.
- In some embodiments, the disease or disorder is cancer. In some embodiments, said type of cancer can be cervical-, testicular-, or non-small-cell lung adenocarcinoma. In some embodiments, the cancer can be limited small cell lung cancer. In some embodiments, the cancer can be a glioma. In some embodiments, the cancer can be malignant breast cancer. In some embodiments, the cancer can be a micrometastasis. In some embodiments, the micrometastasis can be of the blood or liver. In some embodiments, the cancer can be a lung metastasis. In some embodiments, the cancer can be prostatic cancer.
- In some embodiments wherein the disease or disorder can be an inflammatory condition, said inflammatory condition can be sepsis, inflammatory bowel disease, systemic inflammatory response syndrome, inflammatory arthritis, or rheumatoid arthritis.
- In another aspect, there is provided a method for preventing a disease or disorder in a subject. The method includes administering a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, compound as set forth in any of Tables A, B or C herein, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, or pharmaceutical composition thereof, to a subject in need thereof in an amount effective to prevent the disease or disorder.
- Compounds described herein can be assayed, by a variety of methods known in the art and described herein, for inhibition of biological activity, e.g., protease activity, of a variety of proteins, e.g., thrombin. For example, the protease activity of such proteins, e.g., thrombin, can be monitored using a chromophoric substrate, e.g., a p-nitroanilide peptide substrate, which upon hydrolysis releases p-nitroanilide, which in turn gives rise to a color change which can be determined spectrophotometrically. See e.g., Lottenberg, R, et al, 1983, Biochemica et Biophysica Acta, 752:539-557. Accordingly, the change in color can be monitored with a spectrophotometer at e.g., 405 nm to provide a signal which is directly proportional to the proteolytic activity of the enzyme.
- The thrombin activity reported herein (e.g., Table A) was obtained as follows. Human thrombin was obtained from Haematologic Technologies Inc. The chromogenic substrate S-2238 was obtained from DiaPharma. Thrombin was assayed in buffer containing 0.05 M Tris (pH 7.4), 0.015 M NaCl and 0.01% PEG-8000. The final concentration of enzyme used was 3 nM thrombin. The final concentration of substrate used was 125 μM S-2238 for thrombin. All assays were performed in 96-well microtiter plates at room temperature (RT). The enzyme and inhibitor were pre-incubated for 10 minutes then substrate was added and read at 405 nm in a SpectraMax Plus Spectrophotometer (Molecular Devices). Inhibitor IC50 values were determined by adding test compound as ten point, three-fold serial dilutions in buffer solution, as known in the art. The plate was read at 10 minutes after substrate addition. The IC50 was calculated by plotting the percent (%) inhibition against compound concentration and fitting the data to a constrained four parameter sigmoidal curve, as known in the art.
- In another aspect, there is provided a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient. The compound is a compound of any of Formulae (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IIIc), (IV), (Va), (Vb), (Vc), or (VI) as disclosed herein, a compound as set forth in any of Tables A, B or C herein, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof. In some embodiments, the compound is set forth in Table A herein. In some embodiments, the compound is set forth in Table B herein. In some embodiments, the compound is set forth in Table C herein.
- The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds disclosed herein contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds disclosed herein contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galacturonic acids and the like (see, for example, Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds disclosed herein contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- Compounds disclosed herein may exist as salts, such as with pharmaceutically acceptable acids. Accordingly, the compounds contemplated herein include such salts. Examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, (−)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in the art.
- The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
- Pharmaceutically acceptable salts of the compounds above, where a basic or acidic group is present in the structure, are also included within the scope of compounds contemplated herein. When an acidic substituent is present, such as —NHSO3H, —COOH and —P(O)(OH)2, there can be formed the ammonium, sodium, potassium, calcium salt, and the like, for use as the dosage form. Basic groups, such as amino or basic heteroaryl radicals, or pyridyl and acidic salts, such as hydrochloride, hydrobromide, acetate, maleate, palmoate, methanesulfonate, p-toluenesulfonate, and the like, can be used as the dosage form.
- Also, in the embodiments in which R—COOH is present, pharmaceutically acceptable esters can be employed, e. g., methyl, ethyl, tert-butyl, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
- A. Formulations
- The compounds disclosed herein can be prepared and administered in a wide variety of oral, parenteral, and topical dosage forms. Thus, the compounds described herein can be administered by injection (e.g. intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally). Also, the compounds described herein can be administered by inhalation, for example, intranasally. Additionally, the compounds disclosed herein can be administered transdermally. It is also envisioned that multiple routes of administration (e.g., intramuscular, oral, transdermal) can be used to administer the compounds disclosed herein. In some embodiments, the compounds disclosed herein may be administered orally as tablets, aqueous or oily suspensions, lozenges, troches, powders, granules, emulsions, capsules, syrups or elixirs. The composition for oral use may contain one or more agents selected from the group of sweetening agents, flavoring agents, coloring agents and preserving agents in order to produce pharmaceutically elegant and palatable preparations. Accordingly, there are also provided pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and one or more compounds disclosed herein.
- In some embodiments, tablets contain the acting ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate, carboxymethylcellulose, or sodium phosphate; (2) granulating and disintegrating agents, such as corn starch or alginic acid; (3) binding agents, such as starch, gelatin or acacia; and (4) lubricating agents, such as magnesium stearate, stearic acid or talc. These tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. A coating may also be performed using techniques known in the art.
- For preparing pharmaceutical compositions from the compounds disclosed herein, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substance that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- A compound disclosed herein, in the form of a free compound or a pharmaceutically-acceptable pro-drug, metabolite, analogue, derivative, solvate or salt, can be administered, for in vivo application, parenterally by injection or by gradual perfusion over time. Administration may be intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally. For in vitro studies the compounds may be added or dissolved in an appropriate biologically acceptable buffer and added to a cell or tissue.
- In powders, the carrier is a finely divided solid in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- The powders and tablets preferably contain from 5% to 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
- For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- When parenteral application is needed or desired, particularly suitable admixtures for the compounds disclosed herein are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories. In particular, carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like. Ampoules are convenient unit dosages. The compounds disclosed herein can also be incorporated into liposomes or administered via transdermal pumps or patches. Pharmaceutical admixtures suitable for use in the pharmaceuticals compositions and methods disclosed herein include those described, for example, in P
HARMACEUTICAL SCIENCES (17th Ed., Mack Pub. Co., Easton, Pa.) and WO 96/05309, the teachings of both of which are hereby incorporated by reference. - In some embodiments, preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, growth factors and inert gases and the like.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.
- Some compounds may have limited solubility in water and therefore may require a surfactant or other appropriate co-solvent in the composition. Such co-solvents include: Polysorbate 20, 60, and 80; Pluronic F-68, F-84, and P-103; cyclodextrin; and polyoxyl 35 castor oil. Such co-solvents are typically employed at a level between about 0.01% and about 2% by weight.
- Viscosity greater than that of simple aqueous solutions may be desirable to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation, and/or otherwise to improve the formulation. Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose, chondroitin sulfate and salts thereof, hyaluronic acid and salts thereof, and combinations of the foregoing. Such agents are typically employed at a level between about 0.01% and about 2% by weight.
- The compositions disclosed herein may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides, and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
- By the present, there are provided methods for ameliorating wound healing and for mediating tissue repair (including but not limited to treatment of peripheral and coronary vascular disease). According to these methods, a subject having a wound or in need of tissue repair, is treated at the site of the wound or damaged tissue or treated systemically, with a compound disclosed herein in the form of a free compound or a pharmaceutically-acceptable prodrug, metabolite, analogue, derivative, solvate or salt.
- Generally, the terms “treating”, “treatment” and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or disorder or sign or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure for a disorder and/or adverse effect attributable to it, e.g. pulmonary embolism following a medical procedure. “Treating” as used herein covers any treatment of, or prevention of a disease or disorder in a vertebrate, a mammal, particularly a human, and includes: (a) preventing the disease or disorder from occurring in a subject that may be predisposed to the disease or disorder, but has not yet been diagnosed as having it; (b) inhibiting the disease or disorder, i. e., arresting its development; or (c) relieving or ameliorating the disease or disorder, i. e., cause regression of the disease or disorder.
- There are provided various pharmaceutical compositions useful for ameliorating certain diseases and disorders, as set forth above. The pharmaceutical compositions according to one embodiment are prepared by formulating a compound disclosed herein in the form of a free compound or a pharmaceutically-acceptable pro-drug, metabolite, analogue, derivative, solvate or salt, either alone or together with other pharmaceutical agents, suitable for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers.
- Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing Co., 1405-1412, 1461-1487 (1975) and The National Formulary XIV., 14th ed. Washington: American Pharmaceutical Association (1975), the contents of which are hereby incorporated by reference. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See e.g., Goodman and Gilman (eds.), 1990, T
HE PHARMACOLOGICAL BASIS FOR THERAPEUTICS (7th ed.). - The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories. For treatment of a subject, depending on activity of the compound, manner of administration, nature and severity of the disease or disorder, age and body weight of the subject, different daily doses can be used.
- Under certain circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administrations of subdivided doses at specific intervals.
- The pharmaceutical compositions contemplated herein may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease or disorder and the weight and general state of the subject. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders.
- Various considerations are described, e. g., in Langer, 1990, Science, 249: 1527; Goodman and Gilman's (eds.), 1990, Id., each of which is herein incorporated by reference and for all purposes. Dosages for parenteral administration of active pharmaceutical agents can be converted into corresponding dosages for oral administration by multiplying parenteral dosages by appropriate conversion factors. As to general applications, the parenteral dosage in mg/mL times 1.8=the corresponding oral dosage in milligrams (“mg”). As to oncology applications, the parenteral dosage in mg/mL times 1.6=the corresponding oral dosage in mg. An average adult weighs about 70 kg. See e.g., Miller-Keane, 1992, E
NCYCLOPEDIA & DICTIONARY OF MEDICINE , NURSING & ALLIED HEALTH , 5th Ed., (W. B. Saunders Co.), pp. 1708 and 1651. - The method by which the compound disclosed herein may be administered for oral use would be, for example, in a hard gelatin capsule wherein the active ingredient is mixed with an inert solid diluent, or soft gelatin capsule, wherein the active ingredient is mixed with a co-solvent mixture, such as PEG 400 containing Tween-20. A compound disclosed herein may also be administered in the form of a sterile injectable aqueous or oleaginous solution or suspension. The compound can generally be administered intravenously or as an oral dose of 0.1 μg to 20 mg/kg given, for example, every 3-24 hours.
- Formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspension. Such excipients may be (1) suspending agent such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; (2) dispersing or wetting agents which may be (a) naturally occurring phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; (c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylenoxycetanol; (d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as polyoxyethylene sorbitol monooleate, or (e) a condensation product of ethylene oxide with a partial ester derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate.
- The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation may also a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
- A compound disclosed herein may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.
- The compounds disclosed herein as used in the methods disclosed herein may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
- For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds disclosed herein, are employed.
- In addition, some of the compounds disclosed herein may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the methods contemplated herein.
- B. Effective Dosages
- Pharmaceutical compositions provided herein include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose. The actual amount effective for a particular application will depend, inter alia, on the condition being treated. For example, when administered in methods to treat thrombosis, such compositions will contain an amount of active ingredient effective to achieve the desired result (such as, e.g., decreasing the extent of the thrombosis).
- The dosage and frequency (single or multiple doses) of compound administered can vary depending upon a variety of factors, including route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated (e.g., the disease responsive to inhibition of thrombin); presence of other diseases or other health-related problems; kind of concurrent treatment; and complications from any disease or treatment regimen. Other therapeutic regimens or agents can be used in conjunction with the methods and compounds disclosed herein.
- For any compound described herein, the therapeutically effective amount can be initially determined from a variety of techniques known in the art, e.g., biochemical characterization of inhibition of thrombin, cell culture assays, and the like. Target concentrations will be those concentrations of active compound(s) that are capable of decreasing thrombin enzymatic activity as measured, for example, using the methods described.
- Therapeutically effective amounts for use in humans may be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring thrombin inhibition and adjusting the dosage upwards or downwards, as described above.
- Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the methods disclosed herein, should be sufficient to affect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side effects. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. In some embodiments of a method disclosed herein, the dosage range is 0.001% to 10% w/v. In some embodiments, the dosage range is 0.1% to 5% w/v.
- Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
- Utilizing the teachings provided herein, an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is entirely effective to treat the clinical symptoms demonstrated by the particular patient. This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration, and the toxicity profile of the selected agent.
- Accordingly, in some embodiments, dosage levels of the compounds disclosed herein as used in the present methods are of the order of e.g., about 0.1 mg to about 1 mg, about 1 mg to about 10 mg, about 0.5 mg to about 20 mg per kilogram body weight, an average adult weighing 70 kilograms, with a preferred dosage range between about 0.1 mg to about 20 mg per kilogram body weight per day (from about 7.0 mg to about 1.4 gm per patient per day). The amount of the compound disclosed herein that may be combined with the carrier materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for oral administration to humans may contain about 5 μg to 1 g of a compound disclosed herein with an appropriate and convenient amount of carrier material that may vary from about 5 to 95 percent of the total composition. Dosage unit forms will generally contain between from about 0.1 mg to 500 mg of a compound disclosed herein.
- It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
- C. Toxicity
- The ratio between toxicity and therapeutic effect for a particular compound is its therapeutic index and can be expressed as the ratio between LD50 (the amount of compound lethal in 50% of the population) and ED50 (the amount of compound effective in 50% of the population). Compounds that exhibit high therapeutic indices are preferred. Therapeutic index data obtained from in vitro assays, cell culture assays and/or animal studies can be used in formulating a range of dosages for use in humans. The dosage of such compounds preferably lies within a range of plasma concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. See, e.g. Fingl et al., In: T
HE PHARMACOLOGICAL BASIS OF THERAPEUTICS , Ch. 1, p. 1, 1975. The exact formulation, route of administration, and dosage can be chosen by the individual practitioner in view of the patient's condition and the particular method in which the compound is used. For in vitro formulations, the exact formulation and dosage can be chosen by the individual practitioner in view of the patient's condition and the particular method in which the compound is used. - The examples below are meant to illustrate certain embodiments of the invention and not to limit the scope of the invention. Abbreviations used herein have their conventional meaning in the art, unless indicated otherwise. Specific abbreviations include the following: Å=Angstrom; Ac2O=acetic anhydride; AcOH=acetic acid; aq=aqueous; Bt=benzotriazole; BOC=N-tert-butoxycarbonyl; br=broad; t-BuOH=tert-butanol; ° C.=degree Celsius; d=doublet; DABCO=1,4-diazabicyclo[2.2.2]octane; DCE=1,2-dichloroethane; DCM=dichloromethane; dd=doublet of doublets; DIEA=diethylisopropylamine; DMAP=4-dimethylaminopyridine; DMF=N,N-dimethylformamide; DMSO=dimethylsulfoxide; 6=chemical shift (given in ppm, unless otherwise indicated); EDCI=1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; eq=equivalent; Et2O=diethyl ether; Et3N=triethylamine; EtOAc=ethyl acetate; EtOH=ethanol; g=gram; h (or hr)=hour; HOBt=hydroxybenzotriazole; HPLC=high performance liquid chromatography; Hz=Hertz; IC50=inhibitory concentration at 50% inhibition; J=coupling constant (given in Hz, unless otherwise indicated); LC=liquid chromatography; LHMDS=lithium hexamethyldisilazide; m=multiplet; M=molar; [M+H]+=parent mass spectrum peak plus H+; MS=mass spectrum; ms=molecular sieves; MP=melting point; Me2NH=dimethylamine; MeOH=methanol; mg=milligram; mL=milliliter; mM=millimolar; mmol=millimole; min=minute; μL=microliter; μM=micromolar; ng=nanogram; nM=nanomolar; NMR=nuclear magnetic resonance; ppm=parts per million; q=quartet; Rf=retention factor; RT=room temperature; s=singlet; t=triplet; TFA=trifluoroacetic acid; THF=tetrahydrofuran; TLC=thin layer chromatography.
- General Scheme I.
- A synthetic scheme useful for synthesis of compounds described herein is disclosed in General Scheme I following, wherein the term “Ar” in General Scheme I refers to substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, and the terms “R1” and “R2” are as defined above.
- The synthesis of Cmpd 1 followed General Procedure 1 following.
- A solution of nicotinic acid (9.9 g, 80.9 mmol) in water (30 mL) was added slowly portion-wise to a previously stirred mixture of aminoguanidine sulfate (10 g, 73.5 mmol) in concentrated H2SO4 (8.8 mL, 162 mmol), and the reaction mixture was stirred at 140° C. for 72 h. The reaction mixture was diluted with water (50 mL) and neutralized with saturated aqueous K2CO3 (30 mL), and the resultant solid was filtered. The residue was washed with water (2×30 mL), Et2O (2×30 mL) and dried under vacuum to afford Cmpd 1 (4.6 g, 39%) as an off-white solid. 1H NMR: (DMSO-d6) δ 12.23 (s, 1H), 9.05 (s, 1H), 8.54 (d, J=2.8 Hz, 1H), 8.17 (d, J=7.4 Hz, 1H), 7.42-7.52 (m, 1H), 6.19 (s, 2H); MS: 162 [M+H]+; MP: 234-236° C.; TLC: 20% MeOH/NH3 in CHCl3: Rf: 0.40.
-
- General Procedure 1 was followed to obtain Cmpd 2 (8.5 g, 46%). 1H NMR: (DMSO-d6) δ 8.60 (d, J=4.4 Hz, 1H), 7.86-7.91 (m, 2H), 7.37 (br s, 1H), 5.79 (br s, 2H); MS: 162 [M+H]+; MP: 218-220° C.; TLC: 20% MeOH/NH3 in CHCl3: Rf: 0.40.
-
- General Procedure 1 was followed to obtain Cmpd 3 (12 g, 67%). 1H NMR: (DMSO-d6) δ 12.35 (br s, 1H), 8.59 (d, J=5.5 Hz, 2H), 7.76-7.78 (m, 2H), 6.23 (s, 2H); MS: 162 [M+H]+; TLC: 20% MeOH/NH3 in CHCl3: Rf: 0.40.
- The synthesis of Cmpd 4 followed the procedure of General Procedure 2 following.
- 4-Fluorobenzaldehyde (3.1 g, 24.8 mmol, 2 eq) and molecular sieves (4 Å powder) were added to a solution of Cmpd 1 (2 g, 12.4 mmol) in EtOH (20 mL) at RT and refluxed for 8 h. Then was added a catalytic quantity of AcOH, NaCNBH3 (1.6 g, 24.8 mmol, 2 eq) at 0° C. and with stirring for 15 h at RT. The solvent was distilled off, and the residue was dissolved in EtOAc (200 mL) and filtered through a Celite® pad to remove inorganic materials. The filtrate was washed with saturated aqueous NaHCO3 (2×20 mL), water (20 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The resultant compound was purified by column chromatography over silica gel (100-200 mesh) by using a solvent gradient of 0-10% MeOH—CHCl3 as the eluent to afford Cmpd 4 (1.7 g, 51%). 1H NMR: (DMSO-d6) δ 12.50 (s, 1H), 9.06 (d, J=1.4 Hz, 1H), 8.53-8.55 (m, 1H), 8.17-8.20 (m, 1H), 7.33-7.45 (m, 4H), 7.12-7.19 (m, 2H), 4.40 (d, J=6.4 Hz, 2H); MS: 270 [M+H]+; MP: 185-186° C.; TLC: 10% MeOH in CHCl3: Rf: 0.25.
-
- General Procedure 2 was followed to obtain Intermediate 1 (80 mg). 1H NMR: (DMSO-d6) δ 12.53 (s, 1H), 9.05 (d, J=1.3 Hz, 1H), 8.50-8.54 (m, 1H), 8.18-8.20 (m, 1H), 7.01-7.62 (m, 6H), 4.44 (d, J=6.2 Hz, 2H); TLC: 10% MeOH in CHCl3: Rf: 0.25.
-
- General Procedure 2 was followed to obtain Intermediate 2 (75 mg). 1H NMR: (DMSO-d6) δ 12.51 (s, 1H), 9.06 (d, J=1.8 Hz, 1H), 8.54-8.55 (m, 1H), 8.17-8.20 (m, 1H), 7.15-7.45 (m, 6H), 4.49 (d, J=6.2 Hz, 2H); TLC: 10% MeOH in CHCl3: Rf: 0.25.
-
- General Procedure 2 was followed to obtain Intermediate 3 (180 mg). 1H NMR: (DMSO-d6) δ 12.57 (s, 1H), 9.05 (s, 1H), 8.54-8.55 (m, 1H), 8.16-8.18 (m, 1H), 7.41-7.95 (m, 6H), 4.52 (d, J=6.6 Hz, 2H); TLC: 10% MeOH in CHCl3: Rf: 0.25.
-
- General Procedure 2 was followed to obtain Cmpd 5 (2.8 g, 60%). MS: 252 [M+H]+; MP: 226-228° C.; TLC: 10% MeOH in CHCl3: Rf: 0.30.
-
- General Procedure 2 was followed to obtain Cmpd 6 (1.6 g, 48%). 1H NMR: (DMSO-d6) δ 13.15 (br s, 1H), 8.60 (d, J=4.0 Hz, 1H), 7.86-7.93 (m, 2H), 7.30-7.42 (m, 3H), 7.02-7.15 (m, 2H), 6.84 (br s, 1H), 4.37 (d, J=6.2 Hz, 2H); MS: 270 [M+H]+; MP: 219-220° C.; TLC: 10% MeOH in CHCl3: Rf: 0.25.
-
- General Procedure 2 was followed to obtain Intermediate 4 (1.4 g, 42%). MS: 270 [M+H]+; TLC: 10% MeOH in CHCl3: Rf: 0.25.
-
- General Procedure 2 was followed to obtain Intermediate 5 (1.3 g, 38%). MS: 282 [M+H]+; TLC: 10% MeOH in CHCl3: Rf: 0.30.
- The synthesis of Cmpd 7 followed General Procedure 3 following.
- Propionyl chloride (39 μL, 0.44 mmol, 1.2 eq) was added to a solution of Cmpd 4 (100 mg, 0.37 mmol) in triethylamine (3 mL) at RT and stirred for 5 h. The reaction mixture was diluted with water (5 mL) and extracted with EtOAc (20 mL). The organic layer washed with water (2×5 mL), saturated aqueous NaHCO3 (5 mL), brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Cmpd 7 (40 mg, 33%). 1H NMR: (DMSO-d6) δ 9.14 (d, J=1.8 Hz, 1H), 8.66-8.67 (m, 1H), 8.28-8.34 (m, 2H), 7.47-7.53 (m, 3H), 7.13-7.17 (m, 2H), 4.63 (d, J=6.2 Hz, 2H), 3.05 (q, J=7.5 Hz, 2H), 1.16 (t, J=7.5 Hz, 3H); MS: 326 [M+H]+; TLC: 50% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 3 was followed to obtain Cmpd 8 (50 mg, 51%). 1H NMR: (DMSO-d6) δ 9.13 (d, J=1.8 Hz, 1H), 8.65-8.67 (m, 1H), 8.42 (t, J=6.4 Hz, 1H), 8.27-8.29 (m, 1H), 7.50-7.53 (m, 1H), 7.24-7.41 (m, 3H), 7.06-7.10 (m, 1H), 4.67 (d, J=6.6 Hz, 2H), 3.06 (q, J=7.3 Hz, 2H), 1.16 (t, J=7.3 Hz, 3H); MS: 326 [M+H]+; MP: 140-142° C.; TLC: 50% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 3 was followed to obtain Cmpd 9 (35 mg, 38%). 1H NMR: (DMSO-d6) δ 9.12 (d, J=1.3 Hz, 1H), 8.65-8.67 (m, 1H), 8.26-8.32 (m, 2H), 7.45-7.52 (m, 2H), 7.15-7.33 (m, 3H), 4.73 (d, J=6.2 Hz, 2H), 3.07 (q, J=7.5 Hz, 2H), 1.16 (t, J=7.3 Hz, 3H); MS: 326 [M+H]+; MP: 142-144° C.; TLC: 50% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 3 was followed to obtain Cmpd 10 (25 mg, 20%). 1H NMR: (DMSO-d6) δ 9.11 (s, 1H), 8.50-8.67 (m, 2H), 8.26 (d, J=7.8 Hz, 1H), 7.81 (d, J=7.8 Hz, 2H), 7.49-7.62 (m, 3H), 4.73 (d, J=6.3 Hz, 2H), 3.06 (q, J=7.1 Hz, 2H), 1.16 (t, J=7.3 Hz, 3H); MS: 333 [M+H]+; MP: 143-145° C.; TLC: 50% EtOAc in hexane: Rf: 0.65.
-
- General Procedure 3 was followed to obtain Cmpd 11 (48 mg, 35%). 1H NMR: (DMSO-d6) δ 8.71 (d, J=4.0 Hz, 1H), 8.46 (br s, 1H), 8.13-8.23 (m, 3H), 7.92-7.96 (m, 1H), 7.24-7.52 (m, 6H), 6.88-6.89 (m, 1H), 4.74 (d, J=6.2 Hz, 2H); MS: 346 [M+H]+; MP: 143-145° C.; TLC: 50% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 3 was followed to obtain Cmpd 12 (25 mg, 16%). 1H NMR: (DMSO-d6) δ 8.65 (d, J=4.0 Hz, 1H), 8.26 (br s, 1H), 8.03 (d, J=8.1 Hz, 1H), 7.90 (t, J=7.7 Hz, 1H), 7.19-7.48 (m, 11H), 4.67 (d, J=6.0 Hz, 2H), 3.30-3.41 (m, 2H), 2.99-3.03 (m, 2H); MS: 384 [M+H]+; MP: 118-120° C.; TLC: 50% EtOAc in hexane: Rf: 0.40.
-
- General Procedure 3 was followed to obtain Cmpd 13 (40 mg, 28%). 1H NMR: (DMSO-d6) δ 8.72 (d, J=4.6 Hz, 1H), 8.47-8.54 (m, 2H), 8.12-8.23 (m, 2H), 7.94-7.98 (m, 1H), 7.48-7.52 (m, 3H), 7.34-7.36 (m, 1H), 7.16 (t, J=9.0 Hz, 2H), 4.71 (d, J=6.1 Hz, 2H); MS: 380 [M+H]+; MP: 159-160° C.; TLC: 50% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 3 was followed to obtain Cmpd 14 (48 mg, 46%). 1H NMR: (DMSO-d6) δ 8.68-8.70 (m, 3H), 8.14-8.16 (m, 2H), 7.85-7.87 (m, 2H), 7.53-7.73 (m, 5H), 7.18 (t, J=8.9 Hz, 2H), 4.70 (d, J=6.2 Hz, 2H); MS: 374 [M+H]+; MP: 174-178° C.; TLC: 50% EtOAc in hexane: Rf: 0.50.
-
- General Procedure 3 was followed to obtain Cmpd 15 (20 mg, 14%). 1H NMR: (DMSO-d6) δ 9.19 (d, J=1.3 Hz, 1H), 8.63-8.73 (m, 3H), 8.00 (d, J=5.7 Hz, 2H), 7.72-7.88 (m, 2H), 7.50-7.54 (m, 2H), 7.17 (t, J=8.8 Hz, 2H), 4.70 (d, J=6.2 Hz, 2H); MS: 380 [M+H]+; MP: 187-188° C.; TLC: 50% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 3 was followed to obtain Cmpd 16 (35 mg, 36%). 1H NMR: (DMSO-d6) δ 8.71 (d, J=6.2 Hz, 2H), 8.38 (t, J=6.2 Hz, 1H), 7.90 (d, J=5.7 Hz, 2H), 7.38 (d, J=8.3 Hz, 2H), 6.90 (d, J=8.8 Hz, 2H), 4.58 (d, J=6.2 Hz, 2H), 3.72 (s, 3H), 1.46 (s, 9H); MS: 366 [M+H]+; MP: 143-146° C.; TLC: 50% EtOAc in hexane: Rf: 0.60.
- The synthesis of Cmpd 17 followed General Procedure 4 following.
- A solution of Cmpd 4 (100 mg, 0.37 mmol) in dry DMF (2 mL) was added to a solution of morpholinecarbonyl chloride (86 μL, 0.74 mmol, 2 eq), DABCO (124 mg, 1.11 mmol, 3 eq) in DMF (3 mL) at RT and stirred for 2 h. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (30 mL). The organic layer washed with water (2×5 mL), saturated aqueous NaHCO3 (2×5 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo to get a crude residue. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-50% EtOAc-hexane as the eluent to afford Cmpd 17 (33 mg, 23%). 1H NMR: (DMSO-d6) δ 9.11 (s, 1H), 8.64 (d, J=4.8 Hz, 1H), 8.25 (d, J=7.9 Hz, 1H), 7.90 (s, 1H), 7.46-7.52 (m, 3H), 7.16 (t, J=8.8, 2H), 4.59 (d, J=6.2 Hz, 2H), 3.70-3.99 (m, 8H); MS: 383 [M+H]+; TLC: 50% EtOAc in hexane: Rf: 0.40.
- The synthesis of Cmpd 18 followed General Procedure 5 following.
- 2-Fluorophenyl isocyanate (29 μL, 0.26 mmol, 0.7 eq) was added to a solution of Cmpd 4 (100 mg, 0.37 mmol) in DMF (5 mL) at 0° C. and stirred at RT for 6 h. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (30 mL). The organic layer washed with water (2×5 mL), saturated aqueous NaHCO3 (2×5 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo to get crude a residue. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Cmpd 18 (60 mg, 39%). 1H NMR: (DMSO-d6) δ 9.94 (s, 1H), 9.23 (s, 1H), 8.68 (d, J=4.4 Hz, 1H), 8.34-8.36 (m, 1H), 8.11-8.14 (m, 1H), 7.48-7.67 (m, 4H), 7.14-7.38 (m, 5H), 4.64 (d, J=5.7 Hz, 2H); MS: 407 [M+H]+; MP: 157-159° C.; TLC: 40% EtOAc in hexane: Rf: 0.50.
-
- A solution of Cmpd 4 (200 mg, 0.74 mmol) in dry THF (5 mL) was added to a solution of triphosgene (100 mg, 0.37 mmol, 0.5 eq) in THF (3 mL) at 0° C. and stirred at RT for 1 h. The reaction re-cooled to 0° C., added methylamine (2.47 mL, 3M solution in THF, 7.43 mmol, 10 eq), sealed the reaction vessel, and stirred at RT for 16 h. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2×30 mL). The combined organic layer was washed with water (2×30 mL), saturated aqueous NaHCO3 (20 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-50% EtOAc-hexane as eluent to afford Cmpd 19 (70 mg, 34%). 1H NMR: (DMSO-d6) δ 9.16 (d, J=1.3 Hz, 1H), 8.64-8.66 (m, 1H), 8.24-8.29 (m, 2H), 8.01 (t, J=6.2 Hz, 1H), 7.46-7.54 (m, 3H), 7.16 (t, J=9.0 Hz, 2H), 4.61 (d, J=6.2 Hz, 2H), 2.81 (d, J=4.4 Hz, 3H); MS: 327 [M+H]+; MP: 154-158° C.; TLC: 50% EtOAc in hexane: Rf: 0.50.
-
- General Procedure 3 was followed to obtain Cmpd 20 (44 mg, 40%). 1H NMR: (DMSO-d6) δ 9.14 (d, J=1.3 Hz, 1H), 8.65-8.67 (m, 1H), 8.26-8.29 (m, 1H), 8.13 (t, J=6.2, 1H), 7.47-7.52 (m, 3H), 7.14-7.18 (m, 2H), 4.63 (d, J=6.2 Hz, 2H), 3.99 (s, 3H); MS: 328 [M+H]+; MP: 134-137° C.; TLC: 60% EtOAc in hexane: Rf: 0.50.
- General Scheme II. A synthetic scheme useful for synthesis of compounds described herein is disclosed in General Scheme II following, wherein the term “X” in General Scheme II refers to halogen, e.g., Cl, Br, “base” is a base known in the art, e.g., K2CO3, Et3N, and the like, and “R” is a substituent as disclosed herein, e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- Synthesis of Cmpd 21 followed General Procedure 6 following.
- 2-Bromoacetophenone (44 mg, 0.22 mmol) was added to a solution of Cmpd 4 (100 mg, 0.37 mmol), K2CO3 (102 mg, 0.74 mmol) in DMF (4 mL) at RT and stirred for 5 h. The reaction mixture was diluted with water (10 mL), and extracted with EtOAc (30 mL). The organic layer washed with water (2×5 mL), saturated aqueous NaHCO3 (5 mL), brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-5% MeOH/CHCl3 as the eluent to afford Cmpd 21 (25 mg, 17%). 1H NMR: (DMSO-d6) δ 9.06 (d, J=1.3 Hz, 1H), 8.55-8.57 (m, 1H), 8.19 (d, J=7.9 Hz, 1H), 8.06 (d, J=7.0, 2H), 7.59-7.75 (m, 3H), 7.41-7.46 (m, 3H), 7.15-7.29 (m, 3H), 5.74 (s, 2H), 4.52 (d, J=5.7, 2H); MS: 388 [M+H]+; TLC: 10% MeOH in CHCl3: Rf: 0.50.
- A useful scheme for the preparation of compounds of the type of Cmpd 22 is Provided in Scheme 1 following.
- A detailed description of the preparation of Intermediate 6 and Cmpd 22 follows.
- Phenylacetaldehyde (0.29 mL, 2.48 mmol, 2 eq), molecular sieves (4 Å powder), AcOH (0.1 mL, 2.48 mmol, 2 eq), and Na(OAc)3BH (655 mg, 7.71 mmol, 6.2 eq) at 0° C. were added to a solution of Cmpd 1 (200 mg, 1.24 mmol) in DCE (10 mL) and stirred at RT for 18 h. The solvent was distilled-off and the residue was diluted with EtOAc (150 mL). The organic layer was washed with saturated aqueous NaHCO3 (50 mL), brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo to obtain crude Intermediate 6 (220 mg) which was used without additional purification. TLC: 10% MeOH in CHCl3: Rf: 0.40.
- General Procedure 3 was followed to obtain Cmpd 22 (13 mg, 5%). 1H NMR: (DMSO-d6) δ 9.17 (s, 1H), 8.68 (d, J=4.4 Hz, 1H), 8.33 (d, J=7.9 Hz, 1H), 7.83 (t, J=5.7 Hz, 1H), 7.52-7.55 (m, 1H), 7.21-7.34 (m, 5H), 3.70 (q, J=6.6 Hz, 2H), 2.95-3.07 (m, 4H), 1.14 (t, J=7.3 Hz, 3H); MS: 322 [M+H]+; MP: 98-100° C.; TLC: 60% EtOAc in hexane: Rf: 0.60.
- A useful scheme for the preparation of compounds of the type of Cmpd 23 is provided in Scheme 2 following.
- A detailed description of the preparation of Intermediates 7-9 and Cmpd 23 follows.
- A mixture of 2-bromoacetaldehyde diethyl acetal (4.5 g, 22.9 mmol), morpholine (2.0 g, 22.9 mmol) and K2CO3 (6.34 g, 45.9 mmol, 2 eq) was stirred at 120° C. for 16 h. The reaction mixture was cooled to RT, diluted with water (50 mL) and extracted with DCM (3×50 mL). The organic layer was washed with saturated aqueous NaHCO3 (50 mL), brine (50 mL), dried over Na2SO4, filtered and concentrated to get crude a residue. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-50% EtOAc-hexane as the eluent to afford Intermediate 7 (2.6 g, 56%) as a pale yellow liquid. 1H NMR: (CDCl3) δ 4.64 (t, J=5.3 Hz, 1H), 3.63-3.70 (m, 6H), 3.50-3.58 (m, 2H), 2.52-2.55 (m, 6H), 1.20 (t, J=7.0 Hz, 6H); TLC: 60% EtOAc in hexane: Rf: 0.50.
- A solution of Intermediate 7 (600 mg, 2.95 mmol) dissolved in concentrated aqueous HCl (4 mL) was stirred at 80° C. for 2 h. The reaction mixture was cooled to RT, made alkaline (pH ˜10) with saturated aqueous NaHCO3 (20 mL) and the resulting solution was extracted with DCM (3×50 mL). The combined organic layers were washed with water (50 mL), brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo to obtain crude Intermediate 8 (340 mg) as a colorless oil which was used without additional purification. TLC: 60% EtOAc in hexane: Rf: 0.30.
- Intermediate 8 (320 mg, 2.48 mmol, 2 eq) and molecular sieves (4 Å powder) were added to a solution of Cmpd 1 (200 mg, 1.24 mmol) in MeOH (10 mL) at −20° C. and the resulting solution was stirred at RT. After 16 h, added AcOH (1 mL) and NaCNBH3 (156 mg, 2.48 mmol, 2 eq) at 0° C. and the reaction mixture was stirred for 3 h at RT. The solvent was evaporated and the residue was dissolved in EtOAc (75 mL) and filtered through a Celite pad to remove inorganic materials. The filtrate was washed with saturated aqueous NaHCO3 (2×10 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a solvent gradient of 0-80% EtOAc-hexane as the eluent to afford Intermediate 9 (210 mg). TLC: 10% MeOH in CHCl3: Rf: 0.40.
- General Procedure 3 was followed to obtain Cmpd 23 (10 mg, 4%). 1H NMR: (DMSO-d6) δ 9.15 (s, 1H), 8.67 (d, J=4.8 Hz, 1H), 8.30 (d, J=7.9 Hz, 1H), 7.83 (br s, 1H), 7.51-7.54 (m, 1H), 3.58 (d, J=4.4 Hz, 6H), 3.02-3.08 (m, 2H), 2.44-2.59 (m, 6H), 1.15 (t, J=7.3 Hz, 3H); MS: 331 [M+H]+; TLC: 50% EtOAc in hexane: Rf: 0.50.
- A useful scheme for the preparation of compounds of the type of Cmpd 24 is provided in Scheme 3 following.
- A detailed description of the preparation of Intermediates 10-13 and Cmpd 24 follows.
- A solution of cyanogen bromide (1.3 g, 12.6 mmol) in acetone (5 mL) was added portion-wise slowly to a mixture of benzotriazole (3 g, 25.2 mmol, 2 eq) in EtOH (50 mL) followed by 10% aqueous NaOH (6 mL, 12.6 mmol, 1 eq) at 0° C. The reaction mixture was then stirred at RT for 30 min. Solid formation was observed. The solid was filtered and washed with cold EtOH. The resulting material was recrystallized from benzene to afford Intermediate 10 (2.2 g, 33%) as a white solid. 1H NMR: (DMSO-d6) δ 11.76 (s, 1H), 8.29-8.39 (m, 2H), 7.86-8.09 (m, 2H), 7.44-7.72 (m, 4H), MS: 264 [M+H]+; TLC: 30% EtOAc in hexane: Rf: 0.50.
- Dimethylamine (1.59 mL, 7.60 mmol, 1 eq) was added to Intermediate 10 (2 g, 7.60 mmol) in THF (30 mL) at RT and the resulting mixture was allowed to stir for 24 h. The solvent was evaporated and the residue was dissolved in DCM (100 mL). The organic layer was washed with 10% Na2CO3 (3×5 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford Intermediate 11 (1.2 g, 71%) as a light yellow liquid which was used without additional purification. 1H NMR: (DMSO-d6) δ 8.17 (d, J=8.4 Hz, 1H), 7.65-7.80 (m, 3H), 7.49-7.53 (m, 1H), 2.87 (s, 6H); MS: 190 [M+H]+; TLC: 30% EtOAc in hexane: Rf: 0.30.
- Oxalyl chloride (2 mL, 23.3 mmol, 1.4 eq) was added to a solution of nicotinic acid (2 g, 16.3 mmol) in DCM followed by catalytic amount of DMF (0.5 mL) at 0° C. and stirred for 5 h at RT. The solvent was then evaporated to afford nicotinic acid chloride as a yellow solid. Nicotinic acid chloride (1.1 g, 7.93 mmol, 1.5 eq) was then added to a solution of Intermediate 11 (1 g, 5.29 mmol) in CHCl3 (30 mL) followed by Et3N (0.7 mL, 5.29 mmol, 1 eq) at 0° C. The reaction mixture was allowed to warm to RT for stir for 18 h. The mixture was then diluted with CHCl3 (20 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The resulting compound was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-50% EtOAc-hexane as the eluent to afford Intermediate 12 (900 mg, 60%) as a white solid. MS: 295 [M+H]+; TLC: 50% EtOAc in DCM: Rf: 0.40.
- Hydrazine hydrate (5 mL) was added solution of Intermediate 12 (900 mg, 25.2 mmol) in chloroform (20 mL) at RT and the resulting mixture was allowed to stir for 24 h. The mixture was diluted with excess CHCl3 (20 mL). The organic layer was then washed with water (15 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was partially purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-50% EtOAc-hexane as the eluent to afford Intermediate 13 (150 mg) as a thick brown mass. MS: 190 [M+H]+; TLC: 10% MeOH in CHCl3: Rf: 0.30.
- General Procedure 3 was followed to obtain Cmpd 24 (13 mg, 6%). 1H NMR: (DMSO-d6) δ 9.15 (s, 1H), 8.68 (d, J=3.5 Hz, 1H), 8.31 (d, J=7.9 Hz, 1H), 7.53 (dd, J=7.9, 4.8 Hz, 1H), 3.04-3.14 (m, 8H), 1.15 (t, J=7.3 Hz, 3H); MS: 246 [M+H]+; TLC: 50% EtOAc in DCM: Rf: 0.50.
- A general chemical scheme which includes the formation of the triazolyl ring is provided in General Scheme III following, wherein “Ar,” “R1” and “R2” are as defined in Example 1.
- Synthesis of Cmpd 25 followed General Procedure 7 following.
- 2-Furoyl chloride (7.9 mL, 75.2 mmol) was added to a solution of aminoguanidine sulfate (10 g, 75.2 mmol, 1 eq) in pyridine (50 mL) at 0° C. The reaction mixture was then allowed to stir at RT for 14 h before being neutralized with saturated aqueous NaHCO3 (20 mL), extracted with t-BuOH (3×100 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was then dissolved in water (150 mL) and stirred at 100° C. for 6 h. The reaction mixture was cooled to 0° C. and extracted with EtOAc (5×100 mL), dried over Na2SO4, filtered and concentrated to afford Cmpd 25 (3.5 g, 31%) as an off-white solid. 1H NMR: (DMSO-d6) δ 12.17 (br s, 1H), 7.69 (s, 1H), 6.69 (d, J=2.5 Hz, 1H), 6.55 (dd, J=2.9, 1.8 Hz, 1H), 6.05 (br s, 2H); MS: 151 [M+H]+; MP: 202-204° C.; TLC: 20% MeOH/NH3 in CHCl3: Rf: 0.40.
-
- General Procedure 7 was followed to obtain crude Intermediate 14 (2.2 g). 1H NMR: (DMSO-d6) δ 12.07 (br s, 1H), 7.39-7.46 (m, 2H), 7.07 (s, 1H), 6.09 (br s, 2H); MS: 167 [M+H]+; MP: 206-208° C.; TLC: 20% MeOH/NH3 in CHCl3: Rf: 0.40.
-
- General Procedure 2 was followed to obtain Intermediate 15 (350 mg, 25%). MS: 259 [M+H]+; TLC: 10% MeOH in CHCl3: Rf: 0.25.
-
- General Procedure 2 was followed to obtain Intermediate 16 (500 mg, 38%). 1H NMR: (DMSO-d6) δ 12.27 (s, 1H), 7.38-7.47 (m, 4H), 7.07-22 (m, 4H), 4.37 (d, J=6.2 Hz, 2H); MS: 275 [M+H]+; TLC: 10% MeOH in CHCl3: Rf: 0.25.
-
- General Procedure 3 was followed to obtain Cmpd 26 (20 mg, 17%). 1H NMR: (DMSO-d6) δ 8.51 (t, J=6.2 Hz, 1H), 7.76 (s, 1H), 7.49-7.57 (m, 4H), 7.06-7.21 (m, 4H), 6.94 (d, J=3.5 Hz, 1H), 6.59 (m, 1H), 4.64 (d, J=6.2 Hz, 2H), 3.77 (s, 3H); MS: 393 [M+H]+; MP: 150-152° C.; TLC: 50% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 3 was followed to obtain Cmpd 27 (25 mg, 21%). 1H NMR: (DMSO-d6) δ 8.47 (t, J=6.2 Hz, 1H), 7.50-7.63 (m, 6H), 7.06-7.22 (m, 5H), 4.65 (d, J=6.2 Hz, 2H), 3.77 (s, 3H); MS: 409 [M+H]+; MP: 151-152° C.; TLC: 50% EtOAc in hexane: Rf: 0.60.
- A general chemical scheme for the formation of compounds of the type of Cmpd 28 is provided in General Scheme IV following, wherein “Ar,” “R1” and “R2” are as defined in Example 1.
- A detailed description of the preparation of Intermediates 17, 18 and Cmpd 28 follows.
- Oxalyl chloride (5.4 mL, 61.0 mmol, 1.5 eq) and DMF (3 mL) was added sequentially to a solution of nicotinic acid (5 g, 40.7 mmol) in dry DCM (300 mL) at RT. The reaction mixture was allowed to stir at RT for 2 h. The solvent was removed and co-distilled with dry toluene (2×50 mL) and to afford 5 g of crude nicotinic acid chloride (5 g, 35.5 mmol). This material was added slowly portion-wise to a solution of thiosemicarbazide (5 g, 54.9 mmol, 1.5 eq) in pyridine (50 mL) at 0° C. over a period of 1 h and then allowed to stir at RT for 14 h. The reaction mixture was neutralized with saturated aqueous NaHCO3 (30 mL) and extracted with t-BuOH (3×100 mL) and dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was dissolved in water (20 mL) along with 10% aqueous KOH (50 mL) and the resulting mixture was allowed to stir at 100° C. for 3 h. The reaction mixture was then cooled to 0° C. and neutralized with 10% aqueous AcOH (60 mL), extracted with EtOAc (2×150 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford crude Intermediate 17 (1.2 g) as an off-white solid. MS: 179 [M+H]+; TLC: 20% MeOH/NH3 in CHCl3: Rf: 0.30.
- 4-Flourobenzyl bromide (0.12 mL, 1.01 mmol, 0.6 eq) was added to a solution of Intermediate 17 (300 mg, 1.68 mmol) in water (5 mL) and THF (15 mL) at −10° C. and the reaction mixture was allowed to stir at −10° C. for 8 h. The solvent was removed and the residue was diluted with water (10 mL) and extracted with EtOAc (50 mL). The organic layer was washed with water (15 mL), saturated aqueous NaHCO3 (10 mL), brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a solvent gradient mixture of 0-10% MeOH—CHCl3 as the eluent to afford Intermediate 18 (110 mg, 23%) as an off-white solid. MS: 287 [M+H]+; TLC: EtOAc: Rf: 0.40.
- General Procedure 3 was followed to obtain Cmpd 28 (20 mg, 30%). 1H NMR: (DMSO-d6) δ 9.13 (s, 1H), 8.71 (d, J=4.0 Hz, 1H), 8.26 (d, J=7.9 Hz, 1H), 7.53-7.67 (m, 5H), 7.09-7.25 (m, 4H), 4.64 (s, 2H), 3.75 (s, 3H); MS: 421 [M+H]+; MP: 108-112° C.; TLC: 30% EtOAc in hexane: Rf: 0.40.
-
- 2-Thiophene carboxylic acid chloride (6.5 mL, 60.4 mmol) was added slowly portion-wise to a solution of thiosemicarbazide (5 g, 54.9 mmol, 1.1 eq) in pyridine (50 mL) at 0° C. over a period of 1 h and then allowed to stir at RT for 14 h. The reaction mixture was neutralized with saturated aqueous NaHCO3 (50 mL) and extracted with t-BuOH (3×100 mL) and dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was dissolved in water (30 mL) along with 10% aqueous KOH (60 mL) and the resulting mixture was allowed to stir at 100° C. for 3 h. The reaction mixture was then cooled to 0° C. and neutralized with 10% aqueous AcOH, extracted with EtOAc (2×150 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford crude Intermediate 19 (1.2 g) as an off-white solid. MS: 184 [M+H]+; TLC: 10% MeOH/NH3 in CHCl3: Rf: 0.60.
-
- A solution of methyl iodide (65 μL, 1.04 mmol, 1.6 eq) in EtOH (2 mL) was added to a solution of Intermediate 19 (120 mg, 0.66 mmol) in 1M aqueous NaOH (3 mL) at RT and the resulting mixture was allowed to stir for 3 h. The reaction mixture was then neutralized with 10% aqueous AcOH (5 mL) and extracted with EtOAc (30 mL). The organic layer was washed with water (10 mL), saturated aqueous NaHCO3 (5 mL), brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a solvent gradient mixture of 0-10% MeOH—CHCl3 as the eluent to afford Intermediate 20 (90 mg, 70%) as an off-white solid. 1H NMR: (DMSO-d6) δ 14.19 (br s, 1H), 7.62-7.67 (m, 2H), 7.16-7.18 (m, 1H), 2.60 (s, 3H); MS: 198 [M+H]+; TLC: 50% EtOAc in hexane: Rf: 0.50.
-
- General Procedure 3 was followed to obtain Cmpd 29 (30 mg, 29%). 1H NMR: (DMSO-d6) δ 7.72 (d, J=4.8 Hz, 1H), 7.56-7.65 (m, 3H), 7.25 (d, J=8.8 Hz, 1H), 7.09-7.24 (m, 2H), 3.77 (s, 3H), 2.73 (s, 3H); MS: 332 [M+H]+; MP: 165-167° C.; TLC: 30% EtOAc in hexane: Rf: 0.40.
- A general chemical scheme for the formation of compounds of the type of Cmpd 30 is provided in General Scheme V following, wherein “R1” and “R2” are as defined in Example 1.
- A detailed description of the preparation of Intermediates 21, 22 and Cmpd 30 follows.
- Thionyl chloride (5.43 mL, 74.9 mmol, 3.2 eq) was added to a cold solution of 5-amino-[1,2,4]triazole-3-carboxylic acid (3 g, 23.4 mmol) in MeOH (21 mL) at RT and the resulting mixture was allowed to stir for 24 h. The solvent was then removed and the crude residue was recrystallized from a mixture of MeOH-Et2O to afford Intermediate 21 (3.5 g, 98%) as an HCl salt. 1H NMR: (DMSO-d6) δ 12.62 (s, 1H), 6.23 (s, 2H), 3.76 (s, 3H); MS: 143 [M+H]+; MP: 240-241° C.; TLC: 15% MeOH in CHCl3: Rf: 0.50.
- Benzaldehyde (0.7 mL, 6.74 mmol, 2 eq) was added to a solution of Intermediate 21 (600 mg, 3.37 mmol) in EtOH (10 mL) and the resulting solution was allowed to stir for 6 h at 75° C. NaCNBH3 (424 mg, 6.74 mmol, 2 eq) was then added and the mixture was allowed to stir for 16 h at RT. The reaction mixture was then diluted with water (20 mL) and extracted with EtOAc (2×100 mL). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by column chromatography over silica (100-200 mesh) using a gradient mixture of 10-40% of EtOAc-hexane as the eluent to afford Intermediate 22 (120 mg, 15%) as a yellow solid. 1H NMR: (DMSO-d6) δ 12.87 (s, 1H), 7.23-7.38 (m, 7H), 4.39 (d, J=6.6 Hz, 2H), 3.76 (s, 3H), 3.08-3.10 (m, 1H); MS: 233 [M+H]+; TLC: EtOAc: Rf: 0.70.
- General Procedure 3 was followed to obtain Cmpd 30 (25 mg, 47%). 1H NMR: (DMSO-d6) δ 8.56 (t, J=6.4 Hz, 1H), 8.06 (d, J=8.3 Hz, 2H), 7.67 (d, J=8.8 Hz, 2H), 7.24-7.41 (m, 5H), 4.67 (d, J=6.2 Hz, 2H), 3.82 (s, 3H); MS: 371 [M+H]+; TLC: 20% EtOAc in hexane: Rf: 0.50.
-
- 2-Chlorobenzoyl chloride (0.33 mL, 2.46 mmol, 1.1 eq) was added to a solution of Intermediate 21 (400 mg, 2.24 mmol) in Et3N (6 mL) at 0° C. The resulting mixture was heated to 80° C. and allowed to stir for 4 h. The reaction mixture was diluted with saturated aqueous NaHCO3 and extracted with DCM (3×40 mL). The combined organic layers were washed with water (40 mL), brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by column chromatography over silica gel (100-200 mesh) using a gradient mixture of 0-6% MeOH—CHCl3 as the eluent to afford Cmpd 31 (80 mg, 12%). 1H NMR: (DMSO-d6) δ 14.36 (s, 1H), 12.37 (s, 1H), 7.46-7.67 (m, 4H), 3.84 (s, 3H); MS: 281 [M+H]+; MP: 100-101° C.; TLC: 10% MeOH in CHCl3: Rf: 0.60.
-
- 2-Chlorobenzoyl chloride (0.24 mL, 1.80 mmol, 1.1 eq) was added to a solution of Intermediate 21 (300 mg, 1.68 mmol) in pyridine (6 mL) at 0° C. The resulting solution was warmed to RT and allowed to stir for 2 h. The reaction mixture was diluted with saturated aqueous NaHCO3 and extracted with CHCl3 (3×40 mL). The combined organic layers were washed with water (40 mL), brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by column chromatography over silica gel (100-200 mesh) using a gradient mixture of 0-6% MeOH—CHCl3 as the eluent to afford Cmpd 32 (99 mg, 21%). 1H NMR: (DMSO-d6) δ 8.00 (s, 2H), 7.73 (d, J=7.5 Hz, 1H), 7.49-7.64 (m, 3H), 3.77 (s, 3H); MS: 281 [M+H]+; TLC: 10% MeOH in CHCl3: Rf: 0.60.
- General Scheme VI.
- A synthetic scheme useful for synthesis of compounds described herein including Cmpd 33 is disclosed in General Scheme VI following, wherein the terms “Ar,” “R1” and “R2” are as defined in Example 1.
- A description of the synthesis of Intermediates 23-28 and Cmpd 33 follows. Synthesis of Intermediate 23 followed General Procedure 8 following.
- General procedure 8 was followed in the preparation of Intermediate 23.
- Thionyl chloride (3.55 mL, 48.4 mmol, 3 eq) was added drop-wise to a solution of pyrimidine-4-carboxylic acid (2 g, 16.1 mmol) in EtOH (15 mL) and the resulting mixture was heated to reflux for 14 h. The mixture was then cooled to RT and made alkaline with saturated aqueous NaHCO3 to pH 8. The basic solution was then extracted with EtOAc (4×50 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford Intermediate 23 (1.7 g, 77%). 1H NMR: (DMSO-d6) δ 9.40 (d, J=1.0 Hz, 1H), 9.10 (d, J=5.1 Hz, 1H), 8.05 (dd, J=5.1, 1.3 Hz, 1H), 4.39 (q, J=7.1 Hz, 2H), 1.35 (t, J=7.1 Hz, 3H); MS: 153 [M+H]+; TLC: 40% hexane in EtOAc: Rf: 0.40.
- General Procedure 8 was followed to obtain crude Intermediate 24 (950 mg, 86%). 1H NMR: (DMSO-d6) δ 9.43 (s, 1H), 9.26 (s, 2H), 4.39 (q, J=7.1 Hz, 2H), 1.35 (t, J=7.1 Hz, 3H); TLC: 40% EtOAc in hexane: Rf: 0.50.
- General Procedure 9 was followed in the preparation of Intermediate 25.
- Intermediate 23 (1.6 g, 10.5 mmol) was added drop-wise to a vigorously stirring mixture of aminoguanidine sulfate (10.3 g, 42.1 mmol, 4 eq) in freshly prepared NaOMe (using 968 mg, 42.1 mmol of Na in 28 mL of dry MeOH) at 0° C. The resulting mixture was heated to reflux for 20 h. The mixture was then cooled to RT, carefully poured over ice cold water (20 mL) and concentrated in vacuo. The crude residue was purified over neutral alumina using 4-10% MeOH—CHCl3 as the eluent to give Intermediate 25 (500 mg, 26%). MS: 163 [M+H]+; TLC: 20% MeOH in CHCl3: Rf: 0.20.
- General Procedure 9 was followed to obtain Intermediate 26 (500 mg, 45%). 1H NMR: (DMSO-d6) δ 12.44 (br s, 1H), 9.17-9.18 (m, 3H), 6.32 (s, 2H); TLC: 20% MeOH in CHCl3: Rf: 0.20.
- General Procedure 2 was followed to obtain Intermediate 27 (210 mg, 34%). 1H NMR: (DMSO-d6) δ 12.80 (s, 1H), 9.18 (s, 1H), 8.83 (s, 1H), 7.92 (d, J=4.4 Hz, 1H), 7.25-7.40 (m, 5H), 4.44 (d, J=5.7 Hz, 2H); TLC: EtOAc: Rf: 0.30.
- General Procedure 2 was followed to obtain Intermediate 28 (160 mg, 20%). MS: 253 [M+H]+; TLC: EtOAc: Rf: 0.30.
- General Procedure 10 was followed in the preparation of Cmpd 33.
- 2-Methoxybenzoyl chloride (72 μL, 0.54 mmol, 2 eq) was added to a solution of Intermediate 27 (70 mg, 0.27 mmol) in Et3N (0.18 mL, 1.35 mmol) and DCM (3 mL) at 0° C. The resulting mixture was allowed to stir at RT for 2 h. The reaction mixture was then diluted with water (5 mL) and extracted with DCM (3×15 mL). The combined organic layers were washed with saturated aqueous NaHCO3 (10 mL), water (2×5 mL), brine (15 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) using a gradient mixture of 0-70% EtOAc-hexane as the eluent to afford Cmpd 33 (45 mg, 29%). 1H NMR: (DMSO-d6) δ 9.21 (s, 1H), 8.90 (d, J=5.1 Hz, 1H), 8.59 (t, J=6.0 Hz, 1H), 7.93 (d, J=5.1 Hz, 1H), 7.08-7.60 (m, 10H), 4.72 (d, J=5.7 Hz, 2H), 3.77 (s, 3H); MS: 387 [M+H]+; MP: 192-195° C.; TLC: 40% hexane in EtOAc: Rf: 0.30.
-
- General Procedure 10 was followed by preparative HPLC purification to obtain Cmpd 34 (30 mg, 16%). 1H NMR: (DMSO-d6) δ 9.26 (s, 1H), 9.11 (s, 2H), 8.64 (t, J=6.3 Hz, 1H), 7.07-7.60 (m, 9H), 4.71 (d, J=6.3 Hz, 2H), 3.78 (s, 3H); MS: 387 [M+H]+; MP: 154-157° C.; TLC: 40% EtOAc in hexane: Rf: 0.20.
- General Scheme VII. A synthetic scheme useful for synthesis of compounds described herein including Cmpd 35 is disclosed in General Scheme VII following, wherein the terms “Ar,” “R1” and “R2” are as defined in Example 1.
- A description of the synthesis of Intermediates 29, 30 and Cmpd 35 follows.
- Oxalyl chloride (2.36 mL, 24.2 mmol, 1.5 eq) and a catalytic quantity of DMF were added to a solution of pyrimidine-2-carboxylic acid (2 g, 16.1 mmol) in dry DCM (30 mL) at 0° C. The resulting mixture was allowed to warm to RT and stir for 3 h. The volatiles were removed in vacuo and the residue was thoroughly dried to afford pyrimidine-2-carboxylic acid chloride (2.1 g, 14.8 mmol) as a black solid. The crude material was added portion-wise to a solution of aminoguanidine sulfate (5.5 g, 22.2 mmol, 1.5 eq) in pyridine (20 mL) at 0° C. The resulting mixture was allowed to warm to RT and stir for 14 h. The mixture was then neutralized with saturated aqueous NaHCO3, extracted with t-BuOH (5×50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was dissolved in water (45 mL) and the resulting solution was heated to 100° C. for 24 h. The reaction mixture was then cooled to RT, extracted with t-BuOH (5×30 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford Intermediate 29 (650 mg, 25%) as off-white solid. TLC: 30% MeOH in CHCl3: Rf: 0.20.
- General Procedure 2 was followed to obtain Intermediate 30 (120 mg, 17%). MS: 253 [M+H]+; TLC: EtOAc: Rf: 0.30.
- General Procedure 10 was followed to obtain Cmpd 35 (32 mg, 21%). 1H NMR: (DMSO-d6) δ 8.86 (d, J=5.1 Hz, 2H), 8.44 (t, J=6.0 Hz, 1H), 7.08-7.59 (m, 10H), 4.73 (d, J=6.3 Hz, 2H), 3.77 (s, 3H); MS: 387 [M+H]+; MP: 203-205° C.; TLC: 40% hexane in EtOAc: Rf: 0.40.
- General Scheme VIII. A synthetic scheme useful for synthesis of compounds described herein including Cmpd 36 is disclosed in General Scheme VII following, wherein the terms “Ar,” “R1” and “R2” are as defined in Example 1.
- General Procedure 11 was followed in the preparation of Intermediate 31.
- 4-Fluorobenzaldehyde (0.54 mL, 5.03 mmol, 2 eq) and molecular sieves (4 Å powder) were added to a solution of 3-amino-5-phenylpyrazole (400 mg, 2.51 mmol) in EtOH (20 mL) at RT and the resulting mixture was heated to reflux. After 8 h, the reaction mixture was cooled to 0° C. and AcOH (0.4 mL) and NaCNBH3 (316 mg, 5.03 mmol, 2 eq) were added. The mixture was then allowed to warm to RT and stir for 15 h. The solvent was evaporated and the residue was dissolved in EtOAc (100 mL) and filtered through a Celite pad to remove inorganic materials. The filtrate was then washed with saturated aqueous NaHCO3 (2×20 mL), water (20 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a solvent gradient of 0-50% EtOAc-petroleum ether as the eluent to afford Intermediate 31 (240 mg, 36%) as an off white solid. MS: 268 [M+H]+; TLC: EtOAc: Rf: 0.60.
- General Procedure 12 was followed in the preparation of Cmpd 36.
- Pivaloyl chloride (32 μL, 0.26 mmol, 1.2 eq) was added to a solution of Intermediate 31 (60 mg, 0.22 mmol) in triethylamine (3 mL) at RT and stirred for 3 h. The reaction mixture was diluted with water (5 mL) and extracted with EtOAc (20 mL). The organic layer was washed with water (2×5 mL), saturated aqueous NaHCO3 (5 mL), brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude compound was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-10% EtOAc-hexane as the eluent to afford Cmpd 36 (23 mg, 29%). 1H NMR: (DMSO-d6) δ 7.79-7.84 (m, 3H), 7.37-7.49 (m, 5H), 7.17 (t, J=8.8 Hz, 2H), 5.89 (s, 1H), 4.38 (d, J=6.2 Hz, 2H), 1.49 (s, 9H); MS: 352 [M+H]+; TLC: 20% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 11 was followed to afford Intermediate 32 (200 mg, 24%). MS: 269 [M+H]+; TLC: EtOAc: Rf: 0.40.
-
- General Procedure 12 was followed to afford Cmpd 37 (10 mg, 15%). 1H NMR: (DMSO-d6) δ 8.99 (d, J=1.5 Hz, 1H), 8.58 (dd, J=4.9, 1.3 Hz, 1H), 8.14-8.16 (m, 1H), 7.83 (t, J=6.4 Hz, 1H), 7.45-7.48 (m, 3H), 7.16 (t, J=8.7 Hz, 2H), 6.01 (s, 1H), 4.38 (d, J=6.1 Hz, 2H), 1.49 (s, 9H); MS: 353 [M+H]+; TLC: 30% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 11 was followed to afford Intermediate 33 (35 mg, 44%). MS: 282 [M+H]+; TLC: 50% EtOAc in hexane: Rf: 0.50.
-
- General Procedure 12 was followed to afford Cmpd 38 (6 mg, 7%). 1H NMR: (DMSO-d6) δ 7.56-7.59 (m, 2H), 7.34-7.49 (m, 6H), 7.18 (t, J=9.0 Hz, 2H), 4.52 (d, J=6.8 Hz, 2H), 2.04 (s, 3H), 1.43 (s, 9H); MS: 366 [M+H]+; TLC: 20% EtOAc in hexane: Rf: 0.70.
- General Scheme IX.
- A synthetic scheme useful for synthesis of compounds described herein including Cmpd 39 is disclosed in General Scheme IX following, wherein the terms “Ar,” “R1” and “R2” are as defined in Example 1.
- A description of the syntheses of Intermediates 34-37 and Cmpd 39 follows.
- General Procedure 13 was followed in the preparation of Intermediate 34.
- Thionyl chloride (5.4 mL, 73.2 mmol, 3 eq) was added to a solution of picolinic acid (3 g, 24.4 mmol) in EtOH (50 mL) at 0° C. The resulting mixture was heated to reflux and allowed to stir for 2 h. The mixture was then cooled and the solvent was evaporated. The resulting residue was poured into saturated aqueous NaHCO3 and extracted with EtOAc (2×50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using DCM as the eluent to afford Intermediate 34 (3 g, 81%) as a colorless liquid. MS: 152 [M+H]+; TLC: 10% MeOH/NH3 in CHCl3: Rf: 0.70.
- General Procedure 14 was followed in the preparation of Intermediate 35.
- A solution of Intermediate 34 (3 g, 19.6 mmol) and CH3CN (0.8 mL, 19.6 mmol, 1 eq) in dry toluene (10 mL) was slowly added to a mixture of NaH (784 mg, 19.6 mmol, 1 eq, 60% in mineral oil) in toluene (50 mL) at 65° C. The resulting mixture was allowed to stir at 65° C. for 16 h. The reaction mixture was then cooled to RT and quenched with ice cold water (20 mL). The resulting solid was filtered to afford Intermediate 35 (1.5 g, 53%) as a brown solid. 1H NMR: (CDCl3) δ 8.70 (d, J=4.8 Hz, 1H), 8.12 (d, J=7.5 Hz, 1H), 7.90-7.94 (m, 1H), 7.56-7.60 (m, 1H), 4.41 (s, 2H); MS: 147 [M+H]+; TLC: EtOAc: Rf: 0.40.
- General Procedure 15 was followed in the preparation of Intermediate 36.
- Hydrazine hydrate (0.34 mL, 6.8 mmol, 1 eq) was added to a solution of Intermediate 35 (1 g, 6.8 mmol) in EtOH (30 mL) at RT. The mixture was then heated to reflux and allowed to stir for 20 h. The solvent was then evaporated. The resulting crude material was triturated with Et2O (2×20 mL) and dried under vacuum to afford Intermediate 36 (700 mg, 64%) as a brown liquid. 1H NMR: (DMSO-d6) δ 8.53 (d, J=4.4 Hz, 1H), 7.78 (d, J=4.4 Hz, 2H), 7.23-7.26 (m, 1H), 5.95 (s, 1H), 4.84 (br s, 2H); MS: 161 [M+H]+; TLC: EtOAc: Rf: 0.20.
- General Procedure 11 was followed to afford Intermediate 37 (450 mg). MS: 269 [M+H]+; TLC: EtOAc: Rf: 0.40.
- General Procedure 12 was followed to afford Cmpd 39 (40 mg, 30%). 1H NMR: (DMSO-d6) δ 8.58 (d, J=4.4 Hz, 1H), 7.86-7.98 (m, 3H), 7.38-7.46 (m, 3H), 7.18 (t, J=8.8 Hz, 2H), 5.84 (s, 1H), 4.40 (d, J=6.2 Hz, 2H), 1.50 (s, 9H); MS: 353 [M+H]+; MP: 102-103° C.; TLC: 20% EtOAc in hexane: Rf: 0.60.
-
- General Procedure 12 was followed to afford Cmpd 40 (38 mg, 29%). 1H NMR: (DMSO-d6) δ 8.58 (d, J=4.4 Hz, 1H), 7.97 (d, J=7.9 Hz, 1H), 7.79-7.88 (m, 2H), 7.37-7.46 (m, 3H), 7.17 (t, J=8.8 Hz, 2H), 5.87 (s, 1H), 4.42 (d, J=6.2 Hz, 2H), 3.13 (q, J=7.3 Hz, 2H), 1.17 (t, J=7.3 Hz, 3H); MS: 325 [M+H]+; MP: 106-108° C.; TLC: 20% EtOAc in hexane: Rf: 0.50.
-
- General Procedure 12 was followed to afford Cmpd 41 (30 mg, 20%). 1H NMR: (DMSO-d6) δ 8.55 (d, J=4.4 Hz, 1H), 7.97 (t, J=5.9 Hz, 1H), 7.71-7.78 (m, 2H), 7.49-7.63 (m, 6H), 7.34-7.37 (m, 1H), 7.20 (t, J=8.8 Hz, 2H), 5.94 (s, 1H), 4.49 (d, J=6.2 Hz, 2H); MS: 407 [M+H]+, 409 [M+2+H]+; MP: 137-136° C.; TLC: 20% EtOAc in hexane: Rf: 0.30.
- A synthetic scheme useful for synthesis of compounds described herein is disclosed in General Scheme X following, wherein the term “R” is each occurrence is independently “R1” and “R2” as defined in Example 1, and “Ar1” and “Ar2” are defined as “Ar” in Example 1.
- General Procedure 16 was followed in the preparation of Cmpd 42.
- 2-Chlorophenylhydrazine hydrochloride (122 mg, 0.68 mmol, 1 eq) and Et3N (95 μL, 0.68 mmol, 1 eq) was added to a solution of Intermediate 35 (100 mg, 0.68 mmol) in EtOH (3 mL). The resulting solution was heated to reflux and allowed to stir for 2 h. The solvent was then evaporated. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-70% EtOAc-hexane as the eluent to afford Cmpd 42 (70 mg, 37%). 1H NMR: (DMSO-d6) δ 8.56 (d, J=4.4 Hz, 1H), 7.64-7.84 (m, 3H), 7.28-7.29 (m, 1H), 6.00 (s, 1H), 5.31 (s, 2H); MS: 271 [M+H]+, 273 [M+2+H]+; MP: 134-137° C.; TLC: EtOAc: Rf: 0.20.
- General Procedure 17 was followed in the preparation of Cmpd 43.
- Oxalyl chloride (7.2 mL, 5.37 mmol, 1.5 eq) and DMF (0.5 mL) was added to a solution of 4-fluorobenzoic acid in DCM (20 mL) at 0° C. The resulting mixture was allowed to warm to RT and stir for 1 h. The volatiles were evaporated and the mixture was co-distilled with toluene (30 mL). The resulting material was dried under vacuum to afford crude 4-fluorobenzoyl chloride (500 mg) as a colorless liquid, which was used without additional purification. 4-Fluorobenzoyl chloride (49 mg, 0.31 mmol, 1.2 eq) and Et3N (0.36 mL, 2.59 mmol, 10 eq) were added to a solution of Cmpd 42 (70 mg, 0.26 mmol) in DCM (4 mL) at RT and the resulting mixture was allowed to stir for 3 h. The mixture was diluted with water (10 mL) and extracted into EtOAc (30 mL). The organic layer washed with water (2×5 mL), saturated aqueous NaHCO3 (2×5 mL) brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-60% EtOAc-hexane as the eluent to afford Cmpd 43 (25 mg, 25%). 1H NMR: (DMSO-d6) δ 10.57 (s, 1H), 8.64 (d, J=4.4 Hz, 1H), 7.97 (d, J=7.9 Hz, 1H), 7.82-7.88 (m, 3H), 7.49-7.68 (m, 4H), 7.31-7.39 (m, 3H), 7.06 (s, 1H); MS: 393 [M+H]+, 395 [M+2+H]+; MP: 186-188° C.; TLC: EtOAc: Rf: 0.40.
- General Procedure 18 was followed in the preparation of Cmpd 44.
- Sodium hydride (17.7 mg, 0.37 mmol, 1 eq, 60% in mineral oil) was added to a solution of Cmpd 42 (100 mg, 0.37 mmol) and 4-fluorobenzyl bromide (30 μL, 0.22 mmol, 0.6 eq) in DMF (4 mL) at 0° C. The resulting mixture was allowed to warm to RT and stir for 1 h. The mixture was diluted with water (10 mL) and extracted into EtOAc (30 mL). The organic layer washed with water (2×5 mL), saturated aqueous NaHCO3 (2×5 mL) brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-20% EtOAc-hexane as the eluent to afford Cmpd 44 (25 mg, 13%). 1H NMR: (DMSO-d6) δ 8.57 (d, J=4.4 Hz, 1H), 7.73-7.88 (m, 3H), 7.49-7.62 (m, 3H), 7.30-7.33 (m, 1H), 7.06-7.15 (m, 8H), 6.63 (s, 1H), 3.96 (s, 4H); MS: 487 [M+H]+, 489 [M+2+H]+; MP: 113-117° C.; TLC: EtOAc: Rf: 0.60.
- General Procedure 19 was followed in the preparation of Cmpd 45.
- 4-Fluorobenzyl bromide (126 mg, 0.67 mmol, 0.6 eq) and K2CO3 (310 mg, 2.24 mmol, 2 eq) were added to a solution of Cmpd 42 (300 mg, 1.11 mmol) in DMF (8 mL) at RT. The resulting mixture was heated to 70° C. and allowed to stir for 8 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (30 mL). The organic layer was washed with water (2×5 mL), saturated aqueous NaHCO3 (2×5 mL) brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was partially purified by preparative-TLC using 40% EtOAc-hexane and subsequently by preparative-HPLC to afford Cmpd 45 (16 mg, 4%) as an off-white solid. 1H NMR: (DMSO-d6) δ 8.51 (d, J=4.4 Hz, 1H), 7.70-7.83 (m, 3H), 7.54-7.60 (m, 3H), 7.40-7.43 (m, 2H), 7.12-7.27 (m, 3H), 6.13 (t, J=5.7 Hz, 1H), 5.87 (s, 1H), 4.24 (d, J=5.7 Hz, 2H); MS: 379 [M+H]+, 381 [M+2+H]+; MP: 159-162° C.; TLC: EtOAc: Rf: 0.30.
- A synthetic scheme useful for synthesis of compounds described herein is disclosed in General Scheme XI following, wherein the terms “Ar,” “R1” and “R2” are as defined in Example 1.
-
- A solution of ethyl cyanoacetate (20 g, 176.8 mmol) and triethyl orthoformate (29.4 mL, 176.8 mmol) in acetic anhydride (100 mL) was heated to 140° C. and allowed to stir for 5 h. The solvent was then evaporated to afford crude Intermediate 38 (23 g, 76%) as low melting solid. MS: 170 [M+H]+; TLC: 30% EtOAc in hexane: Rf: 0.40.
-
- Sodium acetate (8.2 g, 100 mmol, 2 eq) was added to a solution of Intermediate 38 (8.45 g, 50.0 mmol) and 2-hydrazinopyridine (5 g, 45.5 mmol, 0.9 eq) in AcOH (100 mL) and water (20 mL). The resulting mixture was heated at 110° C. and allowed to stir for 16 h. The mixture was then allowed to cool and ice-cold water was added. The precipitate was collected by filtration and washed with Et2O and dried under vacuum to afford Intermediate 39 (4 g, 38%) as a pale yellow solid. 1H NMR: (DMSO-d6) δ 8.48-8.49 (m, 1H), 8.00-8.04 (m, 1H), 7.87 (d, J=8.3 Hz, 1H), 7.79 (s, 1H), 7.65 (br s, 2H), 7.33-7.36 (m, 1H), 4.22 (q, J=7.0 Hz, 2H), 1.28 (t, J=7.0 Hz, 3H); MS: 233 [M+H]+; TLC: 15% EtOAc in hexane: Rf: 0.50.
-
- Sodium hydride (603 mg, 15.1 mmol, 1 eq, 60% in mineral oil) was added to a solution of Intermediate 39 (3.5 g, 15.1 mmol) in DMF (300 mL) at 0° C. After 30 minutes, a solution of 4-fluorobenzyl bromide (2.85 g, 15.1 mmol, 1 eq) in DMF (50 mL) was added and the resulting mixture was allowed to warm to RT. After 5 h, the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with water (5×50 mL), brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-5% EtOAc-hexane as the eluent to afford a partially pure product. The material was then recrystallized from Et2O and pentane to afford Cmpd 46 (2.8 g, 55%) as a pale yellow solid. 1H NMR: (DMSO-d6) δ 9.50 (t, J=6.6 Hz, 1H), 8.45-8.46 (m, 1H), 8.00-8.05 (m, 1H), 7.82-7.89 (m, 2H), 7.24-7.38 (m, 3H), 7.11 (t, J=8.8 Hz, 2H), 4.88 (d, J=6.6 Hz, 2H), 4.17 (q, J=7.0 Hz, 2H), 1.24 (t, J=7.0 Hz, 3H); MS: 341 [M+H]+; MP: 99-100° C.; TLC: 15% EtOAc in hexane: Rf: 0.40.
-
- Potassium hydroxide (922 mg, 16.5 mmol) was added to a solution of Cmpd 46 (2.8 g, 8.23 mmol) in THF (10 mL) and MeOH (10 mL). The resulting mixture was heated to 70° C. and allowed to stir for 16 h. The reaction mixture was then neutralized with aqueous HCl (2/V) and the resulting precipitate was collected by filtration, washed with water (50 mL) and dried thoroughly to afford Cmpd 47 (2.1 g, 84%) as an off-white solid. MS: 313 [M+H]+; TLC: 50% EtOAc in hexane: Rf: 0.30.
- General Procedure 20 was followed in the preparation of Cmpd 48.
- N,O-Dimethylhydroxylamine hydrochloride (979 mg, 10.1 mmol, 1.5 eq) was added to a mixture of EDCI (2.0 g, 10.1 mmol, 1.5 eq), HOBt (3.1 g, 21.2 mmol, 3.2 eq), DIEA (3.5 mL, 20.2 mmol, 3 eq) and Cmpd 47 (2.1 g, 6.73 mmol) in DMF (30 mL). The resulting mixture was allowed to stir at RT for 16 h. The mixture was then diluted with water (50 mL) and extracted with EtOAc (100 mL). The organic layer was washed with water (2×50 mL), saturated aqueous NaHCO3 (50 mL), brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Cmpd 48 (1.5 g, 65%). 1H NMR: (DMSO-d6) δ 9.29 (t, J=6.6 Hz, 1H), 8.49 (d, J=4.9 Hz, 1H), 7.98-8.04 (m, 1H), 7.82-7.85 (m, 1H), 7.69 (s, 1H), 7.34-7.38 (m, 1H), 7.06-7.19 (m, 4H), 4.54 (d, J=7.0 Hz, 2H), 3.28 (s, 3H), 3.14 (s, 3H); MS: 356 [M+H]+; MP: 88-99° C.; TLC: 50% EtOAc in hexane: Rf: 0.30.
-
- General Procedure 20 was followed to afford Cmpd 49 (31 mg, 32%). 1H NMR: (DMSO-d6) δ 9.23 (t, J=6.6 Hz, 1H), 8.48 (d, J=3.5 Hz, 1H), 7.99-8.03 (m, 1H), 7.88-7.91 (m, 1H), 7.49 (s, 1H), 7.32-7.35 (m, 1H), 7.09-7.20 (m, 4H), 4.50 (d, J=6.6 Hz, 2H), 2.57-2.89 (m, 6H); MS: 340 [M+H]+; MP: 107-109° C.; TLC: 50% EtOAc in hexane: Rf: 0.30.
-
- Lithium aluminum hydride (642 mg, 16.9 mmol) was added to a solution of Cmpd 48 (1.5 g, 4.22 mmol) in THF (20 mL) at −40° C. The resulting mixture was allowed to warm to 0° C. and stir for 5 h. The mixture was then quenched with saturated aqueous NH4Cl (20 mL) and extracted with EtOAc (30 mL). The organic layer washed with water (2×50 mL), saturated aqueous NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-10% EtOAc-hexane as the eluent to afford Intermediate 40 (1 g, 80%). 1H NMR: (DMSO-d6) δ 10.09 (s, 1H), 9.53 (s, 1H), 8.47 (d, J=5.1 Hz, 1H), 8.05 (t, J=7.9 Hz, 1H), 7.99 (s, 1H), 7.92 (d, J=8.2 Hz, 1H), 7.34-7.37 (m, 3H), 7.15-7.20 (m, 2H), 4.96 (d, J=6.3 Hz, 2H); MS: 297 [M+H]+; TLC: 20% EtOAc in hexane: Rf: 0.30.
-
- Triethylamine (4.6 mL, 33.7 mmol, 10 eq), DMAP (410 mg, 3.36 mmol, 1 eq) and (BOC)2O (5 mL, 20.5 mmol, 6.1 eq) was added to a solution of Intermediate 40 (1 g, 3.36 mmol) in THF (3 mL). The resulting mixture was allowed to stir at RT for 16 h. The mixture was then diluted with water (75 mL) and extracted with EtOAc (150 mL). The organic layer was washed with water (2×75 mL), brine (75 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-15% EtOAc-hexane as the eluent to afford Intermediate 41 (1 g, 76%) as a pale yellow liquid. MS: 397 [M+H]+; TLC: 30% EtOAc in hexane: Rf: 0.50.
-
- Ethyl magnesium chloride (0.75 mL, 1.5 mmol, 3 eq, 2M in THF) was added to a solution of Intermediate 41 (200 mg, 0.50 mmol) in THF (10 mL) at −78° C. The resulting mixture was warmed to 0° C. and allowed to stir for 4 h. The reaction was then quenched with saturated aqueous NH4Cl (20 mL) and extracted with EtOAc (30 mL). The organic layer washed with water (10 mL), saturated aqueous NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Intermediate 42 (140 mg, 65%) as a yellow solid. MS: 427 [M+H]+; TLC: 50% EtOAc in hexane: Rf: 0.50.
-
- Manganese dioxide (245 mg, 2.81 mmol) was added to a solution of Intermediate 42 (120 mg, 0.28 mmol) in THF (10 mL) and the resulting mixture was allowed to stir at RT for 48 h. The mixture was then filtered through Celite and washed with EtOAc (20 mL). The organic phase was washed with water (10 mL), saturated aqueous NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Intermediate 43 (90 mg, 75%). MS: 425 [M+H]+; TLC: 40% EtOAc in hexane: Rf: 0.50.
-
- Trifluoroacetic acid (2 mL) was added to a solution of Intermediate 43 (90 mg, 0.21 mmol) in DCM (2 mL) at 0° C. The resulting mixture was allowed to warm to RT and stir for 2 h. The reaction mixture was then neutralized with saturated aqueous NaHCO3 and extracted with EtOAc (30 mL). The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-20% EtOAc-hexane as the eluent to afford Cmpd 50 (50 mg, 73%). 1H NMR: (DMSO-d6) δ 9.40-9.43 (m, 1H), 8.46 (d, J=3.2 Hz, 1H), 7.97-8.08 (m, 2H), 7.79 (d, J=8.2 Hz, 1H), 7.35-7.38 (m, 1H), 7.03-7.14 (m, 4H), 4.72 (d, J=6.7 Hz, 2H), 2.70 (q, J=7.3 Hz, 2H), 1.00 (t, J=7.5 Hz, 3H); MS: 325 [M+H]+; MP: 108-110° C.; TLC: 50% EtOAc in hexane: Rf: 0.40.
- A synthetic scheme useful for synthesis of compounds described herein is disclosed in General Scheme XII following, wherein the terms “Ar,” “R1” and “R2” are as defined in Example 1, and the term “X” refers to halogen, e.g., Cl, Br.
-
- Lithium hexamethyldisilazide (24.8 mL, 24.8 mmol, 1 eq, 1M in THF) was diluted with anhydrous Et2O (100 mL) and cooled to −78° C. under an argon atmosphere. After 15 min, 2-acetylpyridine (3 g, 24.8 mmol) in Et2O (20 mL) was added to the cold mixture. After 30 min at −78° C., diethyl oxalate (3.61 g, 24.8 mmol, 1 eq) in Et2O (25 mL) was added in a single portion and the resulting mixture was allowed to warm to RT and stir for 20 h. The resulting precipitate was collected by filtration and dried to afford Intermediate 44 (4 g, 74%) as the lithium salt. MS: 222 [M+H]+; TLC: EtOAc: Rf: 0.10.
-
- Hydrazine hydrate (602 mg, 13.3 mmol, 15 eq) was added to a solution of Intermediate 44 (200 mg, 0.90 mmol) in AcOH (5 mL). The resulting mixture was heated to 100° C. and allowed to stir for 12 h. The reaction mixture was then neutralized with saturated aqueous NaHCO3 (20 mL) and extracted with EtOAc (40 mL). The organic layer was washed with saturated aqueous NaHCO3 (2×10 mL), water (20 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was washed with pentane (2×10 mL) and dried under vacuum to afford Intermediate 45 (120 mg, 66%) as a viscous liquid. MS: 218 [M+H]+; TLC: EtOAc: Rf: 0.40.
-
- Anhydrous K2CO3 (1.27 g, 9.21 mmol, 2.5 eq) and 4-fluorophenethyl bromide (1 g, 4.61 mmol, 1.25 eq) was added to a solution of Intermediate 45 (744 mg, 3.68 mmol) in DMF (30 mL) and the resulting mixture was allowed to stir at RT for 8 h. The mixture was then diluted with water (30 mL) and extracted with EtOAc (100 mL). The organic layer was washed with water (2×10 mL), saturated aqueous NaHCO3 (2×15 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-10% EtOAc-hexane as the eluent to afford Cmpd 51 (700 mg, 58%). 1H NMR: (DMSO-d6) δ 8.61 (d, J=4.3 Hz, 1H), 7.85-7.96 (m, 2H), 7.31-7.38 (m, 2H), 7.07-7.19 (m, 4H), 4.78 (t, J=7.2 Hz, 2H), 4.27 (q, J=7.2 Hz, 2H), 3.12 (t, J=7.2 Hz, 2H), 1.29 (t, J=7.0 Hz, 3H); MS: 340 [M+H]+; MP: 94-95° C.; TLC: 30% EtOAc in hexane: Rf: 0.40.
- General Procedure 21 was followed in the preparation of Cmpd 52.
- To a solution of Cmpd 51 (300 mg, 0.88 mmol) in THF (3 mL) was added LiOH.H2O (185 mg, 4.42 mmol, 5 eq) in water (3 mL) and MeOH (3 mL). The mixture was heated to 50° C. and allowed to stir for 3 h. The reaction mixture was then neutralized with aqueous HCl (2/V) and the precipitate was collected by filtration, washed with water (20 mL) and dried thoroughly to afford Cmpd 52 (220 mg, 83%) as a pale pink solid. 1H NMR: (DMSO-d6) δ 8.74 (d, J=4.5 Hz, 1H), 8.29-8.33 (m, 2H), 7.72 (br s, 2H), 7.08-7.19 (m, 4H), 4.84 (t, J=6.7 Hz, 2H), 3.16 (t, J=7.0 Hz, 2H); MS: 312 [M+H]+; MP: 256-258° C.; TLC: EtOAc: Rf: 0.10.
-
- General Procedure 20 was followed to afford Cmpd 53 (190 mg, 55%). 1H NMR: (DMSO-d6) δ 8.60 (d, J=4.4 Hz, 1H), 7.95 (d, J=7.9 Hz, 1H), 7.86-7.88 (m, 1H), 7.34-7.37 (m, 1H), 7.07-7.21 (m, 5H), 4.67 (t, J=7.1 Hz, 2H), 3.57 (s, 3H), 3.25 (s, 3H), 3.12 (t, J=7.1 Hz, 2H); MS: 355 [M+H]+; MP: 110-111° C.; TLC: 50% EtOAc in hexane: Rf: 0.30.
-
- General Procedure 20 was followed to afford Cmpd 54 (25 mg, 21%). 1H NMR: (DMSO-d6) δ 8.57 (d, J=4.4 Hz, 1H), 7.82-7.94 (m, 2H), 7.31-7.34 (m, 1H), 7.04-7.14 (m, 4H), 6.84 (s, 1H), 4.56 (t, J=7.0 Hz, 2H), 3.52 (br s, 2H), 3.25 (br s, 2H), 3.10 (t, J=7.0 Hz, 2H), 1.41-1.58 (m, 6H); MS: 379 [M+H]+; MP: 88-90° C.; TLC: EtOAc: Rf: 0.50.
-
- Lithium aluminum hydride (11 mg, 0.28 mmol) was added to a solution of Cmpd 53 (100 mg, 0.28 mmol) in THF (4 mL) at −40° C. The resulting mixture was allowed to slowly warm to 0° C. and stir for 2 h. The mixture was then quenched with saturated aqueous NH4Cl (20 mL) and extracted with EtOAc (30 mL). The organic layer washed with water (10 mL), saturated aqueous NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was washed with pentane (2×5 mL) and dried under vacuum to afford Intermediate 46 (65 mg, 79%). 1H NMR: (DMSO-d6) δ 9.82 (s, 1H), 8.63 (d, J=3.5 Hz, 1H), 7.86-7.97 (m, 2H), 7.54 (s, 1H), 7.36-7.39 (m, 1H), 7.07-7.19 (m, 4H), 4.75-4.78 (m, 2H), 3.11-3.14 (m, 2H); TLC: 30% EtOAc in hexane: Rf: 0.50.
-
- Ethyl magnesium chloride (0.33 mL, 0.66 mmol, 3 eq, 2M in THF) was added to a solution of Intermediate 46 (65 mg, 0.22 mmol) in THF (4 mL) at −78° C. The resulting mixture was warmed to 0° C. and allowed to stir for 4 h. The reaction was then quenched with saturated aqueous NH4Cl (20 mL) and extracted with EtOAc (30 mL). The organic layer washed with water (10 mL), saturated aqueous NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Cmpd 55 (60 mg, 84%) as an off-white solid. 1H NMR: (DMSO-d6) δ 8.55 (d, J=3.8 Hz, 1H), 7.79-7.93 (m, 2H), 7.10-7.30 (m, 5H), 6.65 (s, 1H), 5.31 (d, J=6.0 Hz, 1H), 4.25-4.39 (m, 3H), 3.14-3.16 (m, 2H), 1.58-1.69 (m, 2H), 0.81 (t, J=7.3 Hz, 3H); MS: 326 [M+H]+; MP: 91-96° C.; TLC: 50% EtOAc in hexane: Rf: 0.20.
-
- Manganese dioxide (83 mg, 0.96 mmol, 3 eq) was added to a solution of Cmpd 55 (100 mg, 0.32 mmol) in THF (4 mL) and the resulting mixture was allowed to stir at RT for 14 h. The mixture was then filtered through Celite and washed with EtOAc (20 mL). The organic phase was washed with water (10 mL), saturated aqueous NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a gradient mixture of 0-30% EtOAc-hexane as the eluent to afford Cmpd 56 (22 mg, 21%). 1H NMR: (DMSO-d6) δ 8.61 (d, J=5.1 Hz, 1H), 7.85-7.95 (m, 2H), 7.60 (s, 1H), 7.35-7.38 (m, 1H), 7.08-7.21 (m, 4H), 4.74 (t, J=7.6 Hz, 2H), 3.06 (t, J=7.3 Hz, 2H), 2.94 (q, J=7.2 Hz, 2H), 1.03 (t, J=7.3 Hz, 3H); MS: 324 [M+H]+; MP: 129-130° C.; TLC: 50% EtOAc in hexane: Rf: 0.50.
- A synthetic scheme useful for synthesis of compounds described herein is disclosed in General Scheme XII following, wherein the terms “Ar,” “R1” and “R2” are as defined in Example 1.
-
- [2-(4-Fluorophenyl)-ethyl]-hydrazine (348 mg, 2.26 mmol, 2 eq) was added to a solution of Intermediate 44 (500 mg, 2.26 mmol) in EtOH (30 mL) and the resulting mixture was allowed to stir for 12 h. The solvent was evaporated and the residue was dissolved in EtOAc (100 mL) and filtered through Celite to remove any residual inorganic material. The filtrate was washed with saturated aqueous NaHCO3 (2×10 mL), water (20 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by column chromatography over silica gel (100-200 mesh) by using a solvent gradient of 0-15% EtOAc-hexane as the eluent to afford Cmpd 57 (400 mg, 52%). 1H NMR: (DMSO-d6) δ 8.72-8.73 (m, 1H), 7.87-7.91 (m, 1H), 7.75-7.77 (m, 1H), 7.41-7.44 (m, 1H), 7.29 (s, 1H), 6.99-7.15 (m, 4H), 4.91 (t, J=7.6 Hz, 2H), 4.31 (q, J=7.1 Hz, 2H), 3.06 (t, J=7.6 Hz, 2H), 1.3 (t, J=7.0 Hz, 3H); MS: 340 [M+H]+; MP: 91-92° C.; TLC: 30% EtOAc in hexane: Rf: 0.30.
-
- General Procedure 21 was followed to afford Cmpd 58 (230 mg, 84%) as an off-white solid. 1H NMR: (DMSO-d6) δ 12.84 (s, 1H), 8.71 (d, J=4.4 Hz, 1H), 7.73-7.90 (m, 2H), 7.40-7.43 (m, 1H), 6.99-7.22 (m, 5H), 4.88 (t, J=7.3 Hz, 2H), 3.06 (t, J=7.6 Hz, 2H); MS: 312 [M+H]+; MP: 132-134° C.; TLC: EtOAc: Rf: 0.10.
-
- General Procedure 20 was followed to afford Cmpd 59 (25 mg, 21%). 1H NMR: (DMSO-d6) δ 8.69 (d, J=4.4 Hz, 1H), 7.85-7.89 (m, 1H), 7.73 (d, J=7.6 Hz, 1H), 7.38-7.41 (m, 1H), 6.95-7.06 (m, 5H), 4.86 (t, J=7.0 Hz, 2H), 3.54-3.95 (m, 4H), 3.01 (t, J=7.0 Hz, 2H), 1.42-1.60 (m, 6H); MS: 379 [M+H]+; TLC: EtOAc: Rf: 0.50.
- The contents of all references, patents, and published applications cited herein are hereby incorporated by reference in their entirety and for all purposes.
- While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.
Claims (29)
1. A method for treating and/or preventing a disease or disorder in a subject, comprising administering a compound to a subject in need thereof in an amount effective to treat or prevent said disease or disorder, wherein the compound has the following formula:
or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;
wherein
ring A is substituted or unsubstituted pyrazolyl, or substituted or unsubstituted triazolyl;
L1, L2 and L3 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
L4 is absent, a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
R1, R2 and R3 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R4 is absent, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, provided that when L4 is absent, then R4 is absent; and
R5 is independently hydrogen, or substituted or unsubstituted alkyl.
2. The method according to claim 1 , wherein the compound has the following formula:
wherein
L1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —NHSO2—, or —NR5—;
L2 is a bond;
L3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
L4 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
R1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl having at least one heteroatom selected from the group consisting of N, P, Si, and S, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl has a substituent group selected from the group consisting of —OH, —NH2, —SH, —CN, —CF3, —NO2, oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted fused ring aryl, or substituted heteroaryl has a substituent group selected from the group consisting of oxo, —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;
R3 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted aryl, or substituted or unsubstituted heteroaryl, and
R5 is independently hydrogen, or substituted or unsubstituted alkyl.
3. The method according to claim 1 , wherein said disease or disorder is a thrombotic disorder and/or involves a blood clot thrombus or the potential formation of a blood clot thrombus.
4. The method according to claim 3 , wherein said thrombotic disorder comprises acute coronary syndrome, thromboembolism, and/or thrombosis.
5. The method according to claim 4 , wherein the thromboembolism comprises venous thromboembolism, arterial thromboembolism, and/or cardiogenic thromboembolism.
6. The method according to claim 5 , wherein the venous thromboembolism comprises deep vein thrombosis and/or pulmonary embolism.
7. The method according to claim 6 , wherein the deep vein thrombosis and/or pulmonary embolism occurs following a medical procedure.
8. The method according to claim 3 , wherein said thrombotic disorder involves dysfunctional coagulation or disseminated intravascular coagulation.
9. The method according to claim 8 , wherein the subject is undergoing percutaneous coronary intervention (PCI).
10. The method according to claim 3 , wherein said thrombotic disease or disorder involves a blood clot thrombus or the potential formation of a blood clot thrombus and further involves stroke and/or one or more transient ischemic attacks (TIA).
11. The method according to claim 10 , wherein said thrombotic disease or disorder involving a blood clot thrombus or the potential formation of a blood clot thrombus further involves stroke and wherein the subject has non-valvular atrial fibrillation.
12. The method according to claim 3 , wherein said thrombotic disease or disorder involves a blood clot thrombus or the potential formation of a blood clot thrombus and further involves pulmonary hypertension.
13. The method according to claim 12 , wherein the pulmonary hypertension is caused by one or more left heart disorder and/or chronic thromboembolic disease.
14. The method according to claim 12 , wherein the pulmonary hypertension is associated with one or more lung disease, including pulmonary fibrosis (idiopathic or otherwise), and/or hypoxia.
15. The method according to claim 1 , wherein said disease or disorder comprises fibrosis, Alzheimer's Disease, multiple sclerosis, pain, cancer, inflammation, and/or Type I diabetes mellitus.
16. The method according to claim 1 , wherein the disease or disorder involves recurrent cardiac events after myocardial infarction.
17. The method according to claim 5 , wherein the venous thromboembolism is associated with formation of a thrombus within a vein associated with one or more acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus.
18. The method according to claim 17 , wherein the one or more risk factors comprise a previous venous thromboembolism.
19. The method according to claim 5 , wherein the cardiogenic thromboembolism is due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, and/or embolism of peripheral arteries caused by a detached thrombus.
20. The method according to claim 19 , wherein the detached thrombus is in the brain (ischemic stroke).
21. The method according to claim 20 , wherein the detached thrombus causes a transient ischemic attack (TIA).
22. The method according to claim 19 , wherein the cardiogenic thromboembolism is due to non-valvular atrial fibrillation.
23. The method according to claim 4 , wherein the thrombosis is arterial thrombosis.
24. The method according to claim 23 , wherein the arterial thrombosis is due to one or more underlying atherosclerotic processes in the arteries.
25. The method according to claim 24 , wherein the one or more underlying atherosclerotic processes in the arteries obstruct or occlude an artery, cause myocardial ischemia (angina pectoris, acute coronary syndrome), cause myocardial infarction, obstruct or occlude a peripheral artery (ischemic peripheral artery disease), and/or obstruct or occlude the artery after a procedure on a blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries).
26. The method according to claim 1 , wherein the treatment or prevention comprises an adjunct therapy.
27. The method according to claim 26 , wherein the subject has myocardial infarction, and the adjunct therapy is in conjunction with thrombolytic therapy.
28. The method according to claim 26 , wherein the subject has unstable angina pectoris, thrombosis, and/or heparin-induced thrombocytopenia, and the adjunct therapy is in combination with antiplatelet therapy.
29. The method according to claim 26 , wherein the subject has non-valvular atrial fibrillation, and the adjunct therapy is in conjunction with other therapies.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/155,954 US20160256440A1 (en) | 2010-03-30 | 2016-05-16 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US15/937,475 US10653674B2 (en) | 2010-03-30 | 2018-03-27 | Multisubstituted aromatic compounds as inhibitors of thrombin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31917510P | 2010-03-30 | 2010-03-30 | |
PCT/US2011/030585 WO2011126903A2 (en) | 2010-03-30 | 2011-03-30 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US13/630,201 US9533967B2 (en) | 2010-03-30 | 2012-09-28 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US15/155,954 US20160256440A1 (en) | 2010-03-30 | 2016-05-16 | Multisubstituted aromatic compounds as inhibitors of thrombin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/630,201 Continuation-In-Part US9533967B2 (en) | 2010-03-30 | 2012-09-28 | Multisubstituted aromatic compounds as inhibitors of thrombin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/937,475 Division US10653674B2 (en) | 2010-03-30 | 2018-03-27 | Multisubstituted aromatic compounds as inhibitors of thrombin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160256440A1 true US20160256440A1 (en) | 2016-09-08 |
Family
ID=44763506
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/630,201 Active - Reinstated US9533967B2 (en) | 2010-03-30 | 2012-09-28 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US14/989,742 Abandoned US20160122333A1 (en) | 2010-03-30 | 2016-01-06 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US15/004,789 Active US9963440B2 (en) | 2010-03-30 | 2016-01-22 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US15/155,954 Abandoned US20160256440A1 (en) | 2010-03-30 | 2016-05-16 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US15/937,475 Active US10653674B2 (en) | 2010-03-30 | 2018-03-27 | Multisubstituted aromatic compounds as inhibitors of thrombin |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/630,201 Active - Reinstated US9533967B2 (en) | 2010-03-30 | 2012-09-28 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US14/989,742 Abandoned US20160122333A1 (en) | 2010-03-30 | 2016-01-06 | Multisubstituted aromatic compounds as inhibitors of thrombin |
US15/004,789 Active US9963440B2 (en) | 2010-03-30 | 2016-01-22 | Multisubstituted aromatic compounds as inhibitors of thrombin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/937,475 Active US10653674B2 (en) | 2010-03-30 | 2018-03-27 | Multisubstituted aromatic compounds as inhibitors of thrombin |
Country Status (15)
Country | Link |
---|---|
US (5) | US9533967B2 (en) |
EP (1) | EP2560966B1 (en) |
JP (3) | JP6155187B2 (en) |
KR (3) | KR102113960B1 (en) |
CN (3) | CN104940200B (en) |
AU (3) | AU2011238616B2 (en) |
BR (1) | BR112012024678A2 (en) |
CA (1) | CA2829790C (en) |
IL (3) | IL222019A (en) |
MX (1) | MX355038B (en) |
NZ (3) | NZ603156A (en) |
RU (2) | RU2017144535A (en) |
SG (2) | SG10201502484SA (en) |
WO (1) | WO2011126903A2 (en) |
ZA (2) | ZA201507923B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9687479B2 (en) | 2013-03-15 | 2017-06-27 | Verseon Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
US9951025B2 (en) | 2013-03-15 | 2018-04-24 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
US10988462B2 (en) | 2018-04-04 | 2021-04-27 | Japan Tobacco Inc. | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof |
US11014910B2 (en) | 2018-03-01 | 2021-05-25 | Japan Tobacco Inc. | Methyllactam ring compound and pharmaceutical use thereof |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077975A1 (en) | 2009-08-28 | 2011-10-05 | Irm Llc | PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
RU2017144535A (en) * | 2010-03-30 | 2019-02-18 | Версеон Корпорейшн | MULTI-DISPLACED AROMATIC COMPOUNDS AS THROMBINE INHIBITORS |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
AU2011277426B2 (en) | 2010-07-15 | 2015-04-23 | Sumitomo Pharma Co., Ltd. | Pyrazole compound |
RU2576316C2 (en) | 2010-11-03 | 2016-02-27 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Pesticidal composition, method of pest control, method of controlling endoparasites, ectoparasites or both and method of plant health enhancement |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
US9371292B2 (en) | 2011-07-27 | 2016-06-21 | Shanghai Pharmaceuticals Holdings Co., Ltd. | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof |
AR087701A1 (en) | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | PIRAZOL DERIVATIVES WITH SGLT1 INHIBITING ACTIVITY |
UA111754C2 (en) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | SUBSTITUTED BENZILINDASOLS FOR THE APPLICATION OF BUB1-KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES |
KR102006039B1 (en) | 2011-10-26 | 2019-07-31 | 다우 아그로사이언시즈 엘엘씨 | Pesticidal compositions and processes related thereto |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
RU2622015C2 (en) | 2011-11-11 | 2017-06-08 | Новартис Аг | Method for proliferative disease treatment |
CA2856406C (en) | 2011-11-23 | 2020-06-23 | Novartis Ag | Pharmaceutical formulations |
CA2859779A1 (en) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
RU2623233C2 (en) | 2012-04-27 | 2017-06-23 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Pesticidal compositions and methods related thereto |
US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
US9309235B2 (en) * | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
JP2016501203A (en) | 2012-11-20 | 2016-01-18 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
CA2894281C (en) | 2012-12-20 | 2021-04-20 | Inception 2, Inc. | Triazolone compounds and uses thereof |
EP2948447B1 (en) | 2013-01-23 | 2016-09-21 | Astrazeneca AB | Chemical compounds |
US8921401B2 (en) * | 2013-02-07 | 2014-12-30 | Musc Foundation For Research Development | Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
JP2016525076A (en) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | Substituted benzylpyrazoles |
CA2916194A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
PE20160880A1 (en) | 2013-09-06 | 2016-09-22 | Inception 2 Inc | TRIAZOLONE COMPOUNDS AND USES OF THEM |
CA2925914A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
CN105636445B (en) | 2013-10-17 | 2018-12-07 | 美国陶氏益农公司 | The method for preparing Pesticidal compound |
CN105636441B (en) | 2013-10-17 | 2018-06-15 | 美国陶氏益农公司 | The method for preparing Pesticidal compound |
JP2016536295A (en) | 2013-10-17 | 2016-11-24 | ダウ アグロサイエンシィズ エルエルシー | Method for producing pest control compound |
MX2016004946A (en) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds. |
KR20160072155A (en) | 2013-10-17 | 2016-06-22 | 다우 아그로사이언시즈 엘엘씨 | Processes for the preparation of pesticidal compounds |
MX2016004948A (en) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds. |
JP2016535022A (en) | 2013-10-22 | 2016-11-10 | ダウ アグロサイエンシィズ エルエルシー | Agrochemical compositions and related methods |
AR098092A1 (en) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | SYNERGIC PESTICIDE COMPOSITIONS AND RELATED METHODS |
TWI651049B (en) | 2013-10-22 | 2019-02-21 | 陶氏農業科學公司 | Insecticidal composition and related methods |
MX2016005319A (en) | 2013-10-22 | 2016-08-12 | Dow Agrosciences Llc | Pesticidal compositions and related methods. |
US9788546B2 (en) | 2013-10-22 | 2017-10-17 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
RU2656391C2 (en) | 2013-10-22 | 2018-06-05 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Pesticide compositions and related methods |
RU2656888C2 (en) | 2013-10-22 | 2018-06-07 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Pesticide compositions and related methods |
AR098105A1 (en) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | PESTICIATED COMPOSITIONS AND RELATED METHODS |
NZ720113A (en) | 2013-10-22 | 2017-06-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
JP2016538265A (en) | 2013-10-22 | 2016-12-08 | ダウ アグロサイエンシィズ エルエルシー | Synergistic pest control compositions and related methods |
AR098091A1 (en) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | SYNERGIC PESTICIDE COMPOSITIONS AND RELATED METHODS |
MX2016005308A (en) | 2013-10-22 | 2016-08-08 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods. |
CA2927206A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
KR20160074621A (en) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | Synergistic pesticidal compositions and related methods |
CN105828611A (en) | 2013-10-22 | 2016-08-03 | 美国陶氏益农公司 | Synergistic pesticidal compositions and related methods |
US9155304B2 (en) | 2013-10-22 | 2015-10-13 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
AU2014340407B2 (en) | 2013-10-22 | 2017-05-04 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
MX367576B (en) | 2014-01-29 | 2019-08-27 | Toray Industries | THERAPEUTIC or PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS. |
GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
DK3122359T3 (en) | 2014-03-26 | 2021-03-08 | Astex Therapeutics Ltd | COMBINATIONS OF AN FGFR INHIBITOR AND AN IGF1R INHIBITOR |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
LT3122358T (en) | 2014-03-26 | 2021-04-12 | Astex Therapeutics Ltd. | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer |
JP6545199B2 (en) | 2014-06-17 | 2019-07-17 | バイエル ファーマ アクチエンゲゼルシャフト | 3-Amino-1,5,6,7-tetrahydro-4H-indol-4-ones |
EP3186229A4 (en) | 2014-07-31 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
CA2954345A1 (en) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
US9249122B1 (en) | 2014-07-31 | 2016-02-02 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
WO2016028328A1 (en) | 2014-08-19 | 2016-02-25 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
BR112017003918B1 (en) * | 2014-08-29 | 2022-05-03 | Fmc Corporation | Compost, compositions and herbicide mixture and method for controlling vegetation growth |
AR098113A1 (en) | 2014-09-12 | 2016-05-04 | Dow Agrosciences Llc | PROCESS FOR THE PREPARATION OF 3- (3-CHLORINE-1H-PIRAZOL-1-IL) PIRIDINE |
KR20170048410A (en) | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
AU2015316796A1 (en) | 2014-09-19 | 2017-03-30 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as Bub1 inhibitors |
HUE053443T2 (en) | 2014-10-24 | 2021-06-28 | Takeda Pharmaceuticals Co | Heteroaryl compounds for the treatment of ophthalmic diseases |
WO2016108249A1 (en) * | 2014-12-29 | 2016-07-07 | Council Of Scientific & Industrial Research | 1,2,4-triazole, 1,3,4-oxadiazole, and 1,3,4-thiadiazole derivatives and their antimycobacterial activity |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
MX2017011000A (en) * | 2015-02-27 | 2017-10-20 | Verseon Corp | Substituted pyrazole compounds as serine protease inhibitors. |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
AU2016263564B2 (en) | 2015-05-20 | 2019-12-05 | Amgen Inc. | Triazole agonists of the APJ receptor |
WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
WO2017050865A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
BR112018005637B1 (en) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | COMPOUNDS DERIVED FROM QUINOXALINE, QUINOLINE AND QUINAZOLINONE, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND USE OF SAID COMPOUNDS |
WO2017063966A1 (en) | 2015-10-13 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds |
CN105218436B (en) * | 2015-10-21 | 2019-02-05 | 济南诚汇双达化工有限公司 | A method of preparing 4- Chloro-2-Pyridyle methyl formate |
WO2017123518A1 (en) * | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
WO2017152842A1 (en) * | 2016-03-10 | 2017-09-14 | National Institute Of Biological Sciences, Beijing | Kinase inhibitors |
EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
KR102282673B1 (en) * | 2016-05-23 | 2021-07-27 | 더 락커펠러 유니버시티 | Aminoacylindazole Immunomodulators for the Treatment of Autoimmune Diseases |
JP6691221B2 (en) | 2016-08-08 | 2020-04-28 | 旭化成株式会社 | Coating composition dispersion, aqueous composite particle dispersion, and method for producing aqueous composite particle dispersion |
US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
EP3541810B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
EP3541804A1 (en) | 2016-11-16 | 2019-09-25 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
US10233155B2 (en) | 2016-12-29 | 2019-03-19 | Dow Agrosciences Llc | Processes for the preparation of pesticide compounds |
WO2018125815A1 (en) | 2016-12-29 | 2018-07-05 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
JP7108680B2 (en) | 2017-03-24 | 2022-07-28 | ピクサイ インコーポレイテッド | Fused triazolo-pyrimidine compounds with useful pharmaceutical uses |
ES2951809T3 (en) | 2017-05-17 | 2023-10-25 | Arcus Biosciences Inc | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
KR20200067850A (en) | 2017-10-06 | 2020-06-12 | 포르마 세라퓨틱스 인크. | Inhibition of ubiquitin-specific peptidase 30 |
US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
EP3788037A1 (en) | 2018-05-01 | 2021-03-10 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
RS64321B1 (en) | 2018-10-05 | 2023-08-31 | Forma Therapeutics Inc | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
EP3927702A4 (en) | 2019-04-11 | 2022-05-11 | Angion Biomedica Corp. | Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole |
CN112062692A (en) * | 2019-06-11 | 2020-12-11 | 太仓市茜泾化工有限公司 | Preparation method of ethyl ethoxymethylene cyanoacetate |
WO2023064458A1 (en) * | 2021-10-13 | 2023-04-20 | Yale University | Selective jak2 inhibitors and methods of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058721A2 (en) * | 2002-12-21 | 2004-07-15 | Angion Biomedica Corp. | Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE627393A (en) | 1962-01-23 | |||
BE793955A (en) * | 1972-01-15 | 1973-07-12 | Merck Patent Gmbh | ARYLPIPERAZINES AND THEIR PREPARATION PROCESS |
DE2409753A1 (en) * | 1974-03-01 | 1975-09-11 | Basf Ag | SUBSTITUTED PYRAZOLES |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
IL82542A0 (en) | 1986-05-23 | 1987-11-30 | Smithkline Beckman Corp | Triazole derivatives,their preparation and pharmaceutical compositions containing them |
JPH089541B2 (en) | 1988-03-07 | 1996-01-31 | 三井東圧化学株式会社 | Brain edema inhibitor containing pyrazoles as the main component |
JP2784925B2 (en) | 1988-09-07 | 1998-08-13 | 日本農薬株式会社 | 3 or 5-phenylpyrazoles or salts thereof and herbicides |
DE69212850T2 (en) | 1991-01-15 | 1997-03-06 | Alcon Lab Inc | Use of carrageenan in topical ophthalmic compositions |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US5604294A (en) | 1991-09-05 | 1997-02-18 | Luly; Jay R. | Macrocyclic immunomodulators |
DE4309213A1 (en) * | 1992-09-11 | 1994-09-29 | Thomae Gmbh Dr K | Cyclic urea derivatives, medicaments containing these compounds and processes for their preparation |
JP3810097B2 (en) | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | Pyrrolidin-2-ylcarbonyl heterocyclic compound derivative |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
ES2172959T3 (en) | 1993-11-30 | 2002-10-01 | Searle & Co | PIRAZOLIL-BENCENOSULFONAMIDAS TRICICLICAS, REPLACED AND ITS USE AS INHIBITORS OF CYCLOOXYGENASE II. |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
AU700964B2 (en) | 1994-11-10 | 1999-01-14 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
US5733955A (en) | 1995-02-10 | 1998-03-31 | The Goodyear Tire & Rubber Company | Asphalt cement modification |
JP3663522B2 (en) | 1995-08-12 | 2005-06-22 | 日本農薬株式会社 | Composition for controlling plant growth and method of using the same |
US5756529A (en) | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
WO1997013756A1 (en) * | 1995-10-13 | 1997-04-17 | Otsuka Kagaku Kabushiki Kaisha | Pyrazole derivatives and insecticidal compositions containing the same as active ingredient |
US5792761A (en) * | 1996-08-12 | 1998-08-11 | Merck & Co., Inc. | Thrombin inhibitors |
DE19632773A1 (en) | 1996-08-14 | 1998-02-19 | Basf Ag | New thrombin inhibitors |
GB9622370D0 (en) | 1996-10-28 | 1997-01-08 | Merck Sharp & Dohme | Therapeutic agents |
US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
PL334250A1 (en) | 1996-12-23 | 2000-02-14 | Du Pont Pharm Co | Nitrogen containing hetero-aromatic compounds and inhibitors of xa factor |
AR012117A1 (en) | 1997-03-21 | 2000-09-27 | Novartis Ag | HERBICIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATE COMPOUNDS FOR YOUR EXCLUSIVE USE IN SUCH PROCESS, HERBICIDAE COMPOSITION INHIBITING PLANT GROWTH, METHOD FOR CONTROLLING THE INDISPENDED GROWTH OF PLANTS AND USE OF SUCH COMPOSITION CONTROL |
KR20010071975A (en) * | 1998-08-11 | 2001-07-31 | 해슬러 요세 | Nematicidal pyrazoles |
KR20000047461A (en) * | 1998-12-29 | 2000-07-25 | 성재갑 | Thrombin inhibitors |
SE9900070D0 (en) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
AR023510A1 (en) * | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | A TEAM OF PARTS, PHARMACEUTICAL FORMULATION AND USE OF A THROMBIN INHIBITOR. |
WO2000071536A1 (en) | 1999-05-20 | 2000-11-30 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
CA2383555C (en) * | 1999-08-12 | 2009-02-17 | Paolo Pevarello | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
BR0014078A (en) | 1999-09-17 | 2002-12-31 | Millennium Pharm Inc | Xa factor inhibitors |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
JP2003515608A (en) | 1999-12-02 | 2003-05-07 | ノバルティス アクチエンゲゼルシャフト | Aminoheterocyclylamides as insecticides and anthelmintics |
US6188045B1 (en) | 2000-04-03 | 2001-02-13 | Alto-Shaam, Inc. | Combination oven with three-stage water atomizer |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
WO2002092573A2 (en) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
SI21097A (en) | 2001-12-04 | 2003-06-30 | Univerza V Ljubljani | Thrombine inhibitors |
EP1509505A2 (en) | 2002-01-23 | 2005-03-02 | Arena Pharmaceuticals, Inc. | SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO |
SE0200198D0 (en) | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
JP2003313103A (en) | 2002-02-20 | 2003-11-06 | Sankyo Agro Kk | Agrochemical comprising 4-acylaminopyrazole derivative as active ingredient |
GB0214139D0 (en) * | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
DE10229070A1 (en) | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenyl derivatives 5 |
US20040132726A1 (en) | 2002-08-09 | 2004-07-08 | Astrazeneca Ab And Nps Pharmaceuticals, Inc. | New compounds |
WO2004035564A1 (en) | 2002-10-17 | 2004-04-29 | Syngenta Participations Ag | Pyridine derivatives useful as herbicides |
JP4585448B2 (en) | 2002-12-23 | 2010-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Pyrazole derivatives as factor Xa inhibitors |
US20060229335A1 (en) | 2002-12-24 | 2006-10-12 | Bradley Teegarden | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
US20040147561A1 (en) | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
JP2004231528A (en) | 2003-01-28 | 2004-08-19 | Sankyo Agro Kk | Amide derivative |
GB0308318D0 (en) * | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
BRPI0409949A (en) | 2003-05-01 | 2006-04-25 | Bristol Myers Squibb Co | aryl-substituted amide pyrazole compounds useful as kinase inhibitors |
JP2006526015A (en) | 2003-05-02 | 2006-11-16 | エラン ファーマシューティカルズ,インコーポレイテッド | 4-Bromo-5- (2-chloro-benzoylamino) -1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases |
EP1479679A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
US7223780B2 (en) * | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
EP1697342A2 (en) | 2003-09-08 | 2006-09-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
MXPA06002853A (en) * | 2003-09-11 | 2006-06-14 | Kemia Inc | Cytokine inhibitors. |
JP2007506741A (en) | 2003-09-23 | 2007-03-22 | メルク エンド カムパニー インコーポレーテッド | Pyrazole modulators of metabotropic glutamate receptors |
TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
WO2005066162A1 (en) | 2003-12-23 | 2005-07-21 | Human Biomolecular Research Institute | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer |
EP1735319B1 (en) | 2004-03-26 | 2017-05-03 | MethylGene Inc. | Inhibitors of histone deacetylase |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
CN101137414A (en) * | 2004-12-31 | 2008-03-05 | 欧兰拓制药股份有限公司 | Multicyclic bis-amide mmp inhibitors |
US8084451B2 (en) | 2005-01-10 | 2011-12-27 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
WO2006109846A1 (en) * | 2005-04-06 | 2006-10-19 | Takeda Pharmaceutical Company Limited | Triazole derivative and the use thereof |
CN100427481C (en) | 2005-05-26 | 2008-10-22 | 沈阳化工研究院 | An arylether kind compound and its preparation and application |
US20090227588A1 (en) | 2005-12-05 | 2009-09-10 | Roman Wolfgang Fleck | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors |
US20090118336A1 (en) | 2006-05-03 | 2009-05-07 | Laurent David | Pyrazole derivatives and their use as pi3k inhibitors |
CA2691214A1 (en) * | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
EP2044063A1 (en) | 2006-06-30 | 2009-04-08 | Astra Zeneca AB | Pyrimidine derivatives useful in the treatment of cancer |
DE102006032824A1 (en) | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituted indazoles |
WO2008009638A2 (en) | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors in the cardiovascular field |
AU2007281220B2 (en) | 2006-07-31 | 2013-08-15 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
WO2008023235A1 (en) | 2006-08-25 | 2008-02-28 | Pfizer Products Inc. | Pyrazole derivatives as anti-platelet and anti-thrombotic agents |
WO2008062739A1 (en) | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
EP2121619A2 (en) | 2006-11-24 | 2009-11-25 | AC Immune S.A. | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
EP2125778A1 (en) | 2006-12-22 | 2009-12-02 | Millennium Pharmaceuticals, Inc. | Certain pyrazoline derivatives with kinase inhibitory activity |
UY30892A1 (en) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | AKT ACTIVITY INHIBITORS |
WO2008105383A1 (en) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | Pyrazole derivative and use thereof for medical purposes |
GB0714129D0 (en) | 2007-07-19 | 2007-08-29 | Smithkline Beecham Corp | compounds |
BRPI0815112A2 (en) | 2007-08-06 | 2015-08-25 | Dainippon Sumitomo Pharma Co | Aminopyrazole Amide Derivative |
JP5379690B2 (en) * | 2007-09-28 | 2013-12-25 | 武田薬品工業株式会社 | 5-membered heterocyclic compounds |
EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | Method for altering the lifespan of eukaryotic organisms |
US8658685B2 (en) | 2008-01-31 | 2014-02-25 | Activesite Pharmaceuticals, Inc. | Methods for treatment of kallikrein-related disorders |
WO2009100438A2 (en) | 2008-02-07 | 2009-08-13 | Massachusetts Eye & Ear Infirmary | Compounds that enhance atoh-1 expression |
WO2009140621A2 (en) | 2008-05-15 | 2009-11-19 | Duke University | Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
PE20091972A1 (en) | 2008-05-19 | 2010-01-15 | Schering Corp | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF IXA FACTOR |
JP5775452B2 (en) | 2008-07-10 | 2015-09-09 | アンジオン バイオメディカ コーポレイション | Compositions and methods of small molecule modulators of hepatocyte growth factor (dispersion factor) activity |
TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
MX2011001601A (en) | 2008-08-14 | 2011-03-29 | Bayer Cropscience Ag | Insecticidal 4-phenyl-1h-pyrazoles. |
EP2328581A1 (en) | 2008-08-19 | 2011-06-08 | Boehringer Ingelheim International GmbH | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
JP2012500244A (en) | 2008-08-19 | 2012-01-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dabigatran in tumor therapy |
EA201100358A1 (en) | 2008-08-19 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | DABIGATRAN FOR INTERTEGUAL SURGICAL CATHETERIZATION OF THE HEART |
AR076753A1 (en) * | 2009-05-07 | 2011-07-06 | Gruenenthal Chemie | DERIVATIVES OF CARBOXAMIDE AND UREA AROMATICS REPLACED AS LIGANDOS OF THE VANILLOID RECEIVER. |
RU2017144535A (en) * | 2010-03-30 | 2019-02-18 | Версеон Корпорейшн | MULTI-DISPLACED AROMATIC COMPOUNDS AS THROMBINE INHIBITORS |
CN101851207B (en) | 2010-06-11 | 2012-01-25 | 扬州康伊尔医药科技有限公司 | Antiviral compound intermediate 1-acyl-pyrazol-3-carboxylic acid and preparation method thereof |
RU2576316C2 (en) | 2010-11-03 | 2016-02-27 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Pesticidal composition, method of pest control, method of controlling endoparasites, ectoparasites or both and method of plant health enhancement |
WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
EP2748159A1 (en) | 2011-08-25 | 2014-07-02 | F.Hoffmann-La Roche Ag | Serine/threonine pak1 inhibitors |
KR20150132148A (en) * | 2013-03-15 | 2015-11-25 | 베르선 코포레이션 | Multisubstituted aromatic compounds as serine protease inhibitors |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
-
2011
- 2011-03-30 RU RU2017144535A patent/RU2017144535A/en not_active Application Discontinuation
- 2011-03-30 WO PCT/US2011/030585 patent/WO2011126903A2/en active Application Filing
- 2011-03-30 MX MX2012011380A patent/MX355038B/en active IP Right Grant
- 2011-03-30 EP EP11766507.5A patent/EP2560966B1/en active Active
- 2011-03-30 AU AU2011238616A patent/AU2011238616B2/en active Active
- 2011-03-30 KR KR1020197006283A patent/KR102113960B1/en active IP Right Grant
- 2011-03-30 RU RU2012146194A patent/RU2639876C2/en not_active IP Right Cessation
- 2011-03-30 NZ NZ603156A patent/NZ603156A/en unknown
- 2011-03-30 BR BR112012024678A patent/BR112012024678A2/en not_active Application Discontinuation
- 2011-03-30 CN CN201510237933.7A patent/CN104940200B/en not_active Expired - Fee Related
- 2011-03-30 NZ NZ700332A patent/NZ700332A/en not_active IP Right Cessation
- 2011-03-30 KR KR1020127028509A patent/KR20130053404A/en not_active Application Discontinuation
- 2011-03-30 NZ NZ718622A patent/NZ718622A/en not_active IP Right Cessation
- 2011-03-30 SG SG10201502484SA patent/SG10201502484SA/en unknown
- 2011-03-30 KR KR1020187005952A patent/KR101955691B1/en active IP Right Grant
- 2011-03-30 CN CN201910477649.5A patent/CN110269856A/en active Pending
- 2011-03-30 JP JP2013502815A patent/JP6155187B2/en active Active
- 2011-03-30 SG SG2012070892A patent/SG184243A1/en unknown
- 2011-03-30 CN CN201180026731.8A patent/CN102918034B/en active Active
- 2011-03-30 CA CA2829790A patent/CA2829790C/en active Active
-
2012
- 2012-09-20 IL IL222019A patent/IL222019A/en not_active IP Right Cessation
- 2012-09-28 US US13/630,201 patent/US9533967B2/en active Active - Reinstated
-
2015
- 2015-10-23 ZA ZA2015/07923A patent/ZA201507923B/en unknown
-
2016
- 2016-01-06 US US14/989,742 patent/US20160122333A1/en not_active Abandoned
- 2016-01-22 US US15/004,789 patent/US9963440B2/en active Active
- 2016-02-07 IL IL243989A patent/IL243989B/en not_active IP Right Cessation
- 2016-02-07 IL IL243990A patent/IL243990B/en not_active IP Right Cessation
- 2016-02-08 JP JP2016021856A patent/JP6411390B2/en not_active Expired - Fee Related
- 2016-05-16 US US15/155,954 patent/US20160256440A1/en not_active Abandoned
- 2016-07-19 AU AU2016206247A patent/AU2016206247B2/en not_active Ceased
-
2017
- 2017-10-20 ZA ZA2017/07157A patent/ZA201707157B/en unknown
-
2018
- 2018-03-27 US US15/937,475 patent/US10653674B2/en active Active
- 2018-09-26 JP JP2018180211A patent/JP6650983B2/en active Active
-
2019
- 2019-01-03 AU AU2019200013A patent/AU2019200013A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058721A2 (en) * | 2002-12-21 | 2004-07-15 | Angion Biomedica Corp. | Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity |
Non-Patent Citations (7)
Title |
---|
A New Era of Anticoagulation (US Pharmacist, published March 21, 2007). * |
Calabresi and Chabner (Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed, 2001). * |
Calabresi and Chabner (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Edition, Published 2001.) * |
Hallett et al., Acute Peripheral Arterial Occlusion. Merck Manual. Published 2014. * |
Journal of Neuroscience Research Vol. 59, pages 351-359 (2005). * |
Medication guide of Dabigatran etexilate (published 2010). * |
Nature, Vol. 451 pages 1076-1081 (2008). * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9687479B2 (en) | 2013-03-15 | 2017-06-27 | Verseon Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
US9951025B2 (en) | 2013-03-15 | 2018-04-24 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
US11014910B2 (en) | 2018-03-01 | 2021-05-25 | Japan Tobacco Inc. | Methyllactam ring compound and pharmaceutical use thereof |
US10988462B2 (en) | 2018-04-04 | 2021-04-27 | Japan Tobacco Inc. | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10653674B2 (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
US10251872B2 (en) | Multisubstituted aromatic compounds as serine protease inhibitors | |
US20180186751A1 (en) | Halogenopyrazoles as inhibitors of thrombin | |
US20160251341A1 (en) | Substituted triazole compounds as serine protease inhibitors | |
US20170326125A1 (en) | Multisubstituted aromatic compounds as inhibitors of thrombin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VERSEONCORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHORT, KEVIN MICHAEL;PHAM, SON MINH;WILLIAMS, DAVID CHARLES;AND OTHERS;SIGNING DATES FROM 20161205 TO 20170125;REEL/FRAME:041170/0654 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: VERSEON INTERNATIONAL CORPORATION, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VERSEON CORPORATION;REEL/FRAME:054145/0363 Effective date: 20201021 |